

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
4 November 2004 (04.11.2004)

PCT

(10) International Publication Number  
**WO 2004/094671 A2**

(51) International Patent Classification<sup>7</sup>: C12Q 1/68

(21) International Application Number:  
PCT/US2004/012788

(22) International Filing Date: 22 April 2004 (22.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/464,586 22 April 2003 (22.04.2003) US  
60/464,588 22 April 2003 (22.04.2003) US

(71) Applicants (for all designated States except US): COLEY PHARMACEUTICAL GmbH [DE/DE]; Elisabeth-Selbert-Strasse 9, D-40764 Langenfeld (DE). COLEY PHARMACEUTICAL GROUP, INC. [US/US]; 93 Worcester Street, Suite 101, Wellesley, MA 02481 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): VOLLMER, Jörg [DE/DE]; Kohlrauschweg 24, D-40591 Duesseldorf (DE).

JURK, Marion [DE/DE]; Klosterstr. 4, D-41540 Dornagel (DE). LIPFORD, Grayson, B. [GB/US]; 38 Bates Road, Watertown, MA 02472 (US). SCHETTER, Christian [DE/DE]; Oerkhaushof 35, D-40723 Hilden (DE). FORSBACH, Alexandra [DE/DE]; Raiffeisenstrasse N°1, D-40764 Rantingen (DE). KRIEG, Arthur, M. [US/US]; 173 Winding River Road, Wellesley, MA 02482 (US).


(74) Agent: TREVISAN, Maria, A.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

(54) Title: METHODS AND PRODUCTS FOR IDENTIFICATION AND ASSESSMENT OF TLR LIGANDS



(57) Abstract: The invention provides in part novel screening methods and compositions for identifying and distinguishing between candidate immunomodulatory compounds. The invention further provides methods for assessing biological activity of composition containing a known TLR ligand. These latter methods can be used for quality assessment and selection of various lots of test compositions, including pharmaceutical products for clinical use.



GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**METHODS AND PRODUCTS FOR IDENTIFICATION AND ASSESSMENT  
OF TLR LIGANDS**

**Background of the Invention**

5           Nucleic acids with immunostimulatory activity have been identified. The first recognized immunostimulatory motif was the CpG motif in which at least the C of the dinucleotide was unmethylated. It has been postulated that mammalian subjects recognize the unmethylated dinucleotide as being of bacterial origin, and thus mount a heightened immune response following exposure. The ensuing immune response includes both cell mediated and  
10   humoral aspects. Since the discovery of the CpG immunostimulatory motif, other immunostimulatory motifs have also been identified including the poly-T and T-rich motifs, the TG motif and the poly-G motif. In some instances, immunostimulation has also been observed in response to exposure to methylated CpG motifs and motif-less nucleic acids having phosphorothioate backbone linkages.

15           The responses induced by immunostimulatory nucleic acids are varied and can include production and secretion of cytokines, chemokines, and other growth factors. The nucleic acids can induce a heightened immune stimulation regardless of whether an antigen is also introduced to the subject. Identification of new motifs as well as of subtle differences between response profiles of different nucleic acids oftentimes can be laborious, and a high  
20   throughput system for screening nucleic acids for their ability to be immunostimulatory as well as to determine the profile of responses they induce would be useful.

**Summary of the Invention**

          The invention provides in its broadest sense screening methods and tools for  
25   identification and discrimination of immunomodulatory molecules and assessment and standardization of samples containing known immunomodulatory molecules. The immunomodulatory molecules can be immunostimulatory or immunoinhibitory, and most preferably are Toll-like receptor (TLR) ligands.

          In one aspect, the invention provides a screening method for identifying TLR agonists.  
30   The method comprises contacting a cell line endogenously expressing at least one TLR with a test compound and measuring a test level of TLR signaling activity, wherein a positive test level is indicative of a TLR agonist (i.e., an immunostimulatory compound). The positive test

- 2 -

level may be apparent without referring to a control. Preferably, however, it is determined relative to a control (i.e., the TLR signaling activity from a reference compound).

In some embodiments, the reference compound is a compound that induces no response (i.e., a zero response) or a minimal response. In this case, a test level that is greater  
5 than the reference level is indicative of a compound with TLR signaling activity. More preferably, the reference compound is a compound that induces a positive response (i.e., a non-zero response) and that is immunostimulatory. These reference compounds are referred to herein as negative and positive reference compounds, respectively. If the reference compound is immunostimulatory (i.e., a positive reference compound), a non-zero test level  
10 that is lower than the reference level is still indicative of an immunostimulatory test compound. In this latter embodiment, the test compound is less immunostimulatory than the reference compound (for that particular readout), but it is nonetheless immunostimulatory given the non-zero response induced. There may be one or more concurrent or consecutive assays with a negative reference compound, a positive reference compound, or both. The  
15 reference may also be a standard curve or data generated previously.

In a related aspect, the screening method involves exposing the same cell to a positive reference compound and a test compound in order to identify a test compound that inhibits the immunostimulatory response of the positive reference compound (i.e., a TLR antagonist or an immunoinhibitory compound).

20 In still a related aspect, the screening method involves exposing the same cells to a positive reference compound and a test compound in order to identify a test compound that enhances the immunostimulatory response of the positive reference compound (i.e., an enhancer).

In both of these latter aspects, the assay requires a co-incubation of the positive  
25 reference compound, the test compound and the cells. Separate assays with positive reference compound alone and optionally negative reference compound alone are usually also performed.

The positive reference compound is a known TLR ligand. Non-limiting examples include but are not limited to TLR3 ligands, TLR7 ligands, TLR8 ligands and TLR9 ligands.  
30 In some embodiments, the positive reference compound is an immunostimulatory nucleic acid. In some embodiments, the positive reference compound is a CpG nucleic acid, a poly-T nucleic acid, a T-rich nucleic acid or a poly-G nucleic acid. Another example of a positive



- 3 -

reference compound is a nucleic acid comprising a backbone that contains at least one phosphorothioate linkage.

It has been further discovered according to the invention that the RPMI 8226 cell line expresses TLR7 and responds to the imidazoquinoline compound R-848 (Resiquimod) which is known to signal through TLR7 and TLR8. Accordingly, the screening method can be performed using RPMI 8226, Raji or RAMOS cells and an imidazoquinoline compound such as R-848 or R-847 (Imiquimod) as the positive reference compound.

In one embodiment, the test compound is a nucleic acid such as but not limited to a DNA, an RNA and a DNA/RNA hybrid. The test compound may be a nucleic acid that does not comprise motif selected from the group consisting of a CpG motif, a poly-T motif, a T-rich motif and a poly-G motif. The test compound may be a nucleic acid that comprises a phosphorothioate backbone linkage. In another embodiment, the test compound is a non-nucleic acid small molecule. The non-nucleic acid small molecule may be derived from a molecular library. In other embodiments, the test compound comprises amino acids, carbohydrates such as polysaccharides. It may be a hormone or a lipid or contain moieties derived therefrom. In other embodiments, the test compounds are putative ligands for TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10 or TLR11.

In one embodiment, the cell is a RPMI 8226 cell, a Raji cell, a RAMOS cell, a THP-1 cells, a Nalm cell or a KG-1 cell and the TLR is TLR9. In another embodiment, the cell is a RPMI 8226 cell, a Raji cell or a RAMOS cell and the TLR is TLR7. In yet another embodiment, the cell is a KG-1 cell, a Nalm cell, a Raji cell, a RAMOS cell, a Jurkat cell, a Hela cell, a Hep-2 cell, a Hep-2 cells, a A549 cell, a Bewo cell, an NK-92 cell or an NK-92 MI cell and the TLR is TLR3.

In another embodiment, the cell is an RPMI 8226 cell and the TLR is TLR7 or TLR9. In still another embodiment, the cell is a Raji cell and the TLR is TLR9, TLR7 or TLR3.

Depending upon the embodiment, the TLR signaling activity may be measured or detected in a number of ways. In one embodiment, the TLR signaling activity is measured by cytokine, chemokine, or growth factor secretion. The cytokine secretion may be selected from the group consisting of IL-6 secretion, IL-10 secretion, IL-12 secretion, IFN- $\alpha$  secretion and TNF- $\alpha$  secretion, but is not so limited. The chemokine secretion may be IP-10 secretion or IL-8 secretion, but is not so limited.

In another embodiment, the TLR signaling activity is measured by antibody secretion. The antibody secretion may be IgM secretion, but is not limited to this antibody subtype.

- 4 -

In another embodiment, the TLR signaling activity is measured by phosphorylation. The total level of phosphorylation in the cell or the level of phosphorylation of particular factors in the cell may be measured. These factors are preferably signaling factors and can be selected from the group consisting of IRAK, ERK, MyD88, TRAF6, p38, Jun, c-fos, and  
5 subunits of NF- $\kappa$ B, but are not so limited.

In still a further embodiment, the TLR signaling activity is measured by cell surface marker expression. In one embodiment, the TLR signaling activity is measured by an increase in cell surface marker expression. Examples of cell surface markers to be analyzed include CD71, CD86, HLA-DR, CD80, HLA Class I, CD54 and CD69. In other  
10 embodiments, the TLR signaling activity is measured by a decrease in cell surface marker expression. Cell surface marker expression can be determined using flow cytometry. TLR signaling activity can also be measured by protein production (e.g., by Western blot).

In another embodiment, the TLR signaling activity is measured by gene expression. Gene expression profiles may be determined using Northern blot analysis or RT-PCR that  
15 uses mRNA or total RNA as a starting material. The gene expression of interest may be that of the chemokines and cytokines and cell surface molecules recited above. Gene expression analysis can be performed using microarray techniques.

In yet another embodiment, the TLR signaling activity is measured by cell proliferation. Cell proliferation assays can be measured in a number of ways including but  
20 not limited to  $^3$ H-thymidine incorporation.

In one embodiment, the cell is an RPMI 8226 cell and TLR signaling is indicated by expression of a marker such as CD71, CD86 and/or HLA-DR or by expression, production or secretion of a factor such as IL-8, IL-10, IP-10 and/or TNF- $\alpha$ . Preferably, in this latter  
25 embodiment, the RPMI 8226 cell is unmodified. In another embodiment, the cell is a Raji cell and the TLR signaling is indicated by IL-6 or IFN- $\alpha$ 2 expression, production or secretion. In yet another embodiment, the cell is a RAMOS cell and the TLR signaling is indicated by CD80 cell surface expression.

TLR signaling activity can be measured via a native readout or an artificial readout or both. A native readout is one that does not rely on introduction of a reporter construct into the  
30 cell of interest.

The cell line may be used in a modified or unmodified form. In one embodiment, the cell line is transfected with a reporter construct. The transfection may be transient or stable. The reporter construct generally comprises a promoter, a coding sequence and a

- 5 -

polyadenylation signal. The coding sequence may comprise a reporter sequence selected from the group consisting of an enzyme (e.g., luciferase, alkaline phosphatase,  $\beta$ -galactosidase, chloramphenicol acetyltransferase (CAT), secreted alkaline phosphatase, etc.), a bioluminescence marker (e.g., green fluorescent protein (GFP, U.S. Patent No. 5,491,084), etc.), a surface-expressed molecule (e.g., CD25), a secreted molecule (e.g., IL-8, IL-12 p40, TNF- $\alpha$ , etc.), and other detectable protein sequences known to those of skill in the art. Preferably, the coding sequence encodes a protein, the level or activity of which can be quantified, with preferably a wide linear range.

In some embodiments, the promoter is a promoter that is responsive to TLR signaling pathways (i.e., a "TLR responsive promoter"). In some embodiments, the promoter contains a binding site for a transcription factor activated upon CpG nucleic acid exposure, such as for example NF- $\kappa$ B. In other embodiments, the promoter contains a binding site for a transcription factor that is activated by a positive reference compound other than CpG nucleic acids. The transcription factor binding site may be selected from the group consisting of a NF- $\kappa$ B binding site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding site, and a TARE, as well as others known to those of skill in the art.

In another embodiment, the promoter contains a functional promoter element from an IL-1 gene, an IL-6 gene, an IL-8 gene, an IL-10 gene, an IL-12 p40 gene, an IFN- $\alpha$ 1 gene, an IFN- $\alpha$ 4 gene, an IFN- $\beta$  gene, an IFN- $\gamma$  gene, a TNF- $\alpha$  gene, a TNF- $\beta$  gene, an IP-9 gene, an IP-10 gene, a RANTES gene, an ITAC gene, a MCP-1 gene, an IGFBP4 gene, a CD54 gene, a CD69 gene, a CD71 gene, a CD80 gene, a CD86 gene, a HLA-DR gene, and a HLA class I gene.

The TLR responsive promoter may be a TLR1 responsive promoter, a TLR2 responsive promoter, a TLR3 responsive promoter, a TLR4 responsive promoter, a TLR5 responsive promoter, a TLR6 responsive promoter, a TLR7 responsive promoter, a TLR8 responsive promoter, a TLR9 responsive promoter, a TLR10 responsive promoter or a TLR11 responsive promoter.

In these latter embodiments, the cell line may be transfected with a reporter construct having a promoter derived from a particular cytokine, chemokine, or cell surface marker, and a unique reporter coding sequence conjugated thereto. In this way, the readout from a particular reporter construct is a surrogate readout for cytokine, chemokine, or cell surface marker readout. Measuring readout from the reporter coding sequences described herein is in

- 6 -

some instances easier than measuring cytokine or chemokine secretion, or upregulation of a cell surface marker.

In these latter embodiments, the cell line may be transfected with a number of reporter constructs each having a promoter derived from a particular cytokine, chemokine, or cell surface marker, and a unique distinguishable coding sequence conjugated thereto. In these  
5       embodiments, multiple readouts are possible from one screen. In other embodiments, multiple native readouts are also possible from one screen.

In a related embodiment, the cell may be further transfected with a nucleic acid that codes for a TLR polypeptide or a fragment thereof. Preferably, the TLR is one that is not  
10       endogenously expressed by the cell. As an example, if the cell is an RPMI 8226 cell which has been shown to express TLR7 and TLR9 according to the invention, then it may be modified to express TLRs other than these (e.g., TLR8) in some embodiments. In this aspect, the RPMI 8226 cell is responsive to TLR8 ligands. In preferred embodiments, the TLR is a human TLR (i.e., hTLR).

15       In another aspect, the invention provides an RPMI 8226 cell transfected with a TLR nucleic acid. In still another embodiment, the TLR nucleic acid is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR8, TLR10 and TLR11. The encoded TLRs nucleic acids can derive from human or non-human sources. Examples of non-human sources include, but are not limited to, murine, bovine, canine, feline, ovine,  
20       porcine, and equine species. Other species include chicken and fish, e.g., aquaculture species. The TLR nucleic acids can also include chimeric sequences consisting of domains originating from different species. In preferred embodiments, the TLR is a human TLR.

In still another aspect, the invention provides kits including the cells lines (e.g., the RPMI 8226 cell line), the reporter constructs and/or expression constructs described above,  
25       and instructions for use.

Other aspects of the invention provide methods for analyzing the biological activity of individual lots of material containing previously identified specific TLR ligands (i.e., specific compounds which are ligands for a particular TLR) intended for use as, or for use in the preparation of, pharmaceutical compositions. The methods permit a qualitative and,  
30       importantly, a quantitative assessment of biological activity of individual lots of TLR ligands, pre-formulation as well as post-formulation. Such methods are useful in the manufacture and validation of pharmaceutical compositions containing, as an active agent, at least one specific ligand of at least one specific TLR. The specific TLR can be any known TLR, including

- 7 -

without limitation TLR3, TLR7, TLR8 and TLR9. The specific TLR ligand is an isolated TLR ligand, either found in nature or synthetic (not found in nature), including in particular certain nucleic acid molecules and small molecules. Nucleic acid molecules that are specific TLR ligands include synthetic and naturally-occurring oligonucleotides having specific base sequence motifs. Furthermore, specific TLR ligands include both agonists and antagonists of specific TLR.

These methods are to be distinguished from test procedures and acceptance criteria for new drug substances and new drug products which are classified as chemical substances. Unlike the afore-mentioned test procedures and acceptance criteria, the methods of the instant invention deal specifically with characterizing drug substances and drug products which are classified as oligonucleotides. Oligonucleotides are explicitly excluded in ICH Topic Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, Step 4 – Consensus Guideline: 6 October 1999, § 1.3.

Further still, the methods of the instant invention are to be distinguished from test procedures and acceptance criteria for biotechnological/biological products. Unlike the afore-mentioned test procedures and acceptance criteria, the methods of the invention deal specifically with characterizing biotechnological/biological products which are classified as DNA products. DNA products are explicitly excluded in ICH Harmonised Tripartite Guideline Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products, Step 4 – 10 March 1999, § 1.3.

In one aspect, the invention provides a method for quality assessment of a test composition containing a known TLR ligand. The method according to this aspect of the invention involves measuring a reference activity of a reference composition comprising a known TLR ligand, wherein the known TLR ligand is a nucleic acid molecule; measuring a test activity of a test composition comprising the known TLR ligand; and comparing the test activity to the reference activity. In one embodiment the method further involves the step of selecting the test composition if the test activity falls within a predetermined range of variance about the reference activity.

In one embodiment, the reference composition is a first production lot of a pharmaceutical composition comprising the known TLR ligand, and the test composition is a second production lot of a pharmaceutical composition comprising the known TLR ligand. This embodiment is particularly useful as a method for developing and applying acceptance criteria for finished pharmaceutical products containing a known TLR ligand.

In another embodiment, the reference composition is a first in-process lot of a composition comprising the known TLR ligand, and the test composition is a second in-process lot of a composition comprising the known TLR ligand. This embodiment is particularly useful as a method for developing and applying acceptance criteria for raw materials and/or other in-process materials containing a known TLR ligand bound for use in a pharmaceutical product.

In one embodiment according to this aspect of the invention, measuring the reference activity involves contacting the reference composition with an isolated cell expressing a TLR responsive to the known TLR ligand, and measuring the test activity involves contacting the test composition with the isolated cell expressing the TLR responsive to the known TLR ligand. Further, in one embodiment the isolated cell expressing the TLR responsive to the known TLR ligand includes an expression vector for the TLR responsive to the known TLR ligand. Such expression vector, and likewise for any expression vector according to the instant invention, can be introduced into the cell using any suitable method.

In one embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand naturally expresses the TLR responsive to the known TLR ligand. Such a cell can be naturally occurring or it can be a cell line, provided the cell does not include an expression vector introduced into the cell for the purpose of artificially inducing the cell to express or overexpress the TLR.

In one particular embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand is RPMI 8226. In another embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand is Raji, RAMOS, Nalm, THP-1 or KG-1 and the TLR is TLR9. In another embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand is RPMI 8226, Raji or RAMOS and the TLR is TLR7. In yet another embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand is a KG-1 cell, a Nalm cell, a Raji cell, a RAMOS cell, a Jurkat cell, a HeLa cell, a Hep-2 cell, a Hep-2 cells, a A549 cell, a Bewo cell, an NK-92 cell or an NK-92 MI cell and the TLR is TLR3.

Further according to this aspect of the invention, in one embodiment measuring the reference activity and measuring the test activity each comprises measuring signaling activity mediated by a TLR responsive to the known TLR ligand. As described in greater detail elsewhere herein, TLR signaling involves a series of intracellular signaling events. These signaling events give rise to various downstream products, including certain transcription

factors (e.g., NF- $\kappa$ B and AP-1), cytokines, chemokines, etc., which can affect the activity of certain gene promoters. For example, in one embodiment the signaling activity is activity of a reporter gene or reporter construct under the control of a NF- $\kappa$ B response element.

In other embodiments, the signaling activity is activity of a reporter gene or reporter  
5 construct under the control of an interferon-stimulated response element (ISRE); an IFN- $\alpha$  promoter; an IFN- $\beta$  promoter; an IL-6 promoter; an IL-8 promoter; an IL-12 p40 promoter; a RANTES promoter; an IL-10 promoter or an IP-10 promoter.

In one embodiment, the known TLR ligand is an immunostimulatory nucleic acid. An immunostimulatory nucleic acid can include, without limitation, a CpG nucleic acid. In  
10 another embodiment, the known TLR ligand is an immunoinhibitory nucleic acid. When the known TLR ligand is a TLR antagonist (e.g., an immunoinhibitory oligonucleotide), the method according to this aspect of the invention can further involve measuring the reference activity of the reference composition and measuring the test activity of the test composition, each performed in the presence of a known immunostimulatory TLR ligand.

15 In various embodiments, the known TLR ligand is a ligand for a particular TLR. Thus in one embodiment the known TLR ligand is a TLR9 ligand. More specifically, in one embodiment the known TLR ligand is a CpG nucleic acid.

In one embodiment, the known TLR ligand is a TLR3 ligand. Such a ligand can include, for example, a double-stranded RNA or a homolog thereof.

20 In one embodiment, the known TLR ligand is a TLR7 ligand. In one embodiment the known TLR ligand is a TLR8 ligand.

The invention provides in another aspect a method for quality assessment of a test lot of a pharmaceutical product containing a known TLR9 ligand. The method according to this aspect of the invention involves measuring a reference activity of a reference lot of a  
25 pharmaceutical product comprising a known TLR9 ligand, wherein the known TLR9 ligand is a nucleic acid molecule; measuring a test activity of a test lot of a pharmaceutical product comprising the known TLR9 ligand; comparing the test activity to the reference activity; and rejecting the test lot if the test activity falls outside of a predetermined range of variance about the reference activity.

30 In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TGT CGT TTT GTC GTT-3' (SEQ ID NO:1).

- 10 -

In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TGA CGT TTT GTC GTT-3' (SEQ ID NO:139).

5 In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TGT CGT TTT TTT CGA-3' (SEQ ID NO:140).

In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT CGT CGT TTC GTC GTT-3' (SEQ ID NO:141).

10 In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT CGT CGT TTT GTC GTT-3' (SEQ ID NO:142).

In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TTC GGT CGT  
15 TTT-3' (SEQ ID NO:143).

In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TTC GTG CGT TTT T-3' (SEQ ID NO:144).

In one embodiment according to this aspect of the invention, the known TLR9 ligand  
20 is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TCG GCG GCC GCC G-3' (SEQ ID NO:145).

In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TC\_G TTT TAC\_GGC  
GCC\_GTG CCG-3' (SEQ ID NO:146), wherein every internucleoside linkage is  
25 phosphorothioate except for those indicated by “\_”, which are phosphodiester.

Each of the limitations of the invention can encompass various embodiments of the invention. It is, therefore, anticipated that each of the limitations of the invention involving any one element or combinations of elements can be included in each aspect of the invention.

30

### **Brief Description of the Figures**



Fig. 1 is a bar graph showing cell surface expression of various markers by RPMI 8226 24 hours and 48 hours following stimulation with CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), LPS and IL-1.

Fig. 2 is a bar graph showing IL-8 production by RPMI 8226 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), R-848 and LPS.

Fig. 3 is a bar graph showing IL-6 production by RPMI 8226 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), R-848 and LPS.

Fig. 4 is a bar graph showing IP-10 production by RPMI 8226 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), R-848 and LPS.

Fig. 5 is a bar graph showing IL-10 production by RPMI 8226 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), R-848 and LPS.

Fig. 6 is a dose response curve showing fold induction of IL-8 production 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1) and non-CpG nucleic acid (SEQ ID NO: 2). The  $EC_{50}$  for CpG nucleic acid is 19 nM and the  $EC_{50}$  for non-CpG nucleic acid is 263 nM.

Fig. 7 is a bar graph showing NF- $\kappa$ B activation in RPMI 8226 transfected transiently with a NF- $\kappa$ B-luciferase reporter gene construct as a function of cell density and nucleic acid amount transfected, following exposure to CpG nucleic acid (SEQ ID NO: 1), LPS and TNF- $\alpha$ . NF- $\kappa$ B activation is measured by luciferase activity.

Fig. 8 is a bar graph showing RT-PCR results from RNA isolated from RPMI 8226 using gene specific primers for TLR7, TLR8 and TLR9 genes.

Fig. 9 is a dose response curve showing IP-10 production induced by SEQ ID NO: 1, and inhibition thereof in the presence of SEQ ID NO: 151, a immunoinhibitory nucleic acid.

Fig. 10 is a bar graph showing the results of a TLR9 RT-PCR analysis of a number of cell lines.

Fig. 11 is a bar graph showing the results of a TLR7 RT-PCR analysis of a number of cell lines.

Fig. 12 is a bar graph showing the results of a TLR3 RT-PCR analysis of a number of cell lines.

Fig. 13 is a bar graph showing the results of a TLR3, TLR7, TLR8 and TLR9 RT-PCR analysis of the Raji cell line.

Fig. 14 is a graph showing IL-6 production by the Raji cell line upon stimulation with various ODN (SEQ ID NO:1; SEQ ID NO:154; SEQ ID NO:158; SEQ ID NO:160; SEQ ID  
5 NO:159; SEQ ID NO:161).

Fig. 15 is a bar graph showing IL-6 production of the Raji cell line upon stimulation with poly I:C and R-848.

Fig. 16 is a bar graph showing IFN- $\alpha$ 2 production by the Raji cell line upon stimulation with CpG ODN (SEQ ID NO: 1), R-848 and poly I:C.

10 Fig. 17 is a bar graph showing CD80 expression (by flow cytometry) by the RAMOS cell line upon stimulation with CpG ODN (SEQ ID NO: 1) and non-CpG ODN (SEQ ID NO: 2).

Fig. 18A is a bar graph showing the induction of NF- $\kappa$ B by 293 fibroblast cells transfected with human TLR9 in response to exposure to various stimuli, including CpG-  
15 ODN, GpC-ODN, LPS, and medium.

Fig. 18B is a bar graph showing the amount of IL-8 produced by 293 fibroblast cells transfected with human TLR9 in response to exposure to various stimuli, including CpG-ODN, GpC-ODN, LPS, and medium.

Fig. 19 is a bar graph showing the induction of NF- $\kappa$ B-luc produced by stably  
20 transfected 293-mTLR9 cells in response to exposure to various stimuli, including CpG-ODN, methylated CpG-ODN (Me-CpG-ODN), GpC-ODN, LPS and medium.

Fig. 20 is a bar graph showing the induction of NF- $\kappa$ B-luc produced by stably transfected 293-hTLR9 cells in response to exposure to various stimuli, including CpG-ODN, methylated CpG-ODN (Me-CpG-ODN), GpC-ODN, LPS and medium.

25 Fig. 21 is a series of gel images depicting the results of reverse transcriptase-polymerase chain reaction (RT-PCR) assays for murine TLR9 (mTLR9), human TLR9 (hTLR9), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in untransfected control 293 cells, 293 cells transfected with mTLR9 (293-mTLR9), and 293 cells transfected with hTLR9 (293-hTLR9).

30

It is to be understood that the Figures are not required for enablement of the invention.

#### **Brief Description of Sequences**

SEQ ID NO:1 is the nucleotide sequence of an immunostimulatory nucleic acid (TLR9 ligand).

SEQ ID NO:2 is the nucleotide sequence of a non-CpG nucleic acid.

SEQ ID NO:3 is the nucleotide sequence of human TLR2 cDNA (U88878).

5 SEQ ID NO:4 is the amino acid sequence of human TLR2 protein (AAC34133).

SEQ ID NO:5 is the nucleotide sequence of murine TLR2 cDNA (AF165189).

SEQ ID NO:6 is the amino acid sequence of murine TLR2 protein (NP\_036035).

SEQ ID NO:7 is the nucleotide sequence of human TLR3 cDNA (NM\_003265).

SEQ ID NO:8 is the amino acid sequence of human TLR3 protein (NP\_003256).

10 SEQ ID NO:9 is the nucleotide sequence of murine TLR3 cDNA (AF355152).

SEQ ID NO:10 is the amino acid sequence of murine TLR3 protein (AAK26117).

SEQ ID NO:11 is the nucleotide sequence of human TLR4 cDNA (U88880).

SEQ ID NO:12 is the nucleotide sequence of human TLR4 cDNA transcript variant 4 (NM\_138557).

15 SEQ ID NO:13 is the nucleotide sequence of human TLR4 cDNA transcript variant 2 (NM\_138556).

SEQ ID NO:14 is the nucleotide sequence of human TLR4 cDNA transcript variant 1 (NM\_138554).

20 SEQ ID NO:15 is the nucleotide sequence of human TLR4 cDNA transcript variant 3 (NM\_003266).

SEQ ID NO:16 is the amino acid sequence of human TLR4 protein isoform A (NP\_612564).

SEQ ID NO:17 is the amino acid sequence of human TLR4 protein isoform B (NP\_612566).

25 SEQ ID NO:18 is the amino acid sequence of human TLR4 protein isoform C (NP\_003257).

SEQ ID NO:19 is the amino acid sequence of human TLR4 protein isoform D (NP\_612567).

30 SEQ ID NO:20 is the nucleotide sequence of murine TLR4 cDNA (NM\_021297).

SEQ ID NO:21 is the nucleotide sequence of murine TLR4 mRNA (AF185285).

SEQ ID NO:22 is the nucleotide sequence of murine TLR4 mRNA (AF110133).

SEQ ID NO:23 is the amino acid sequence of murine TLR4 protein (AAD29272).

SEQ ID NO:24 is the amino acid sequence of murine TLR4 protein (AAF04278).

- 14 -

- SEQ ID NO:25 is the nucleotide sequence of human TLR5 cDNA (AB060695).  
SEQ ID NO:26 is the amino acid sequence of human TLR5 protein (BAB43558).  
SEQ ID NO:27 is the amino acid sequence of human TLR5 protein (O60602).  
SEQ ID NO:28 is the amino acid sequence of human TLR5 protein (AAC34136).  
5 SEQ ID NO:29 is the nucleotide sequence of murine TLR5 cDNA (AF186107).  
SEQ ID NO:30 is the amino acid sequence of murine TLR5 protein (AAF65625).  
SEQ ID NO:31 is the nucleotide sequence of human TLR7 cDNA (AF240467).  
SEQ ID NO:32 is the nucleotide sequence of human TLR7 cDNA (AF245702).  
SEQ ID NO:33 is the nucleotide sequence of human TLR7 cDNA (NM\_016562).  
10 SEQ ID NO:34 is the amino acid sequence of human TLR7 protein (AAF60188).  
SEQ ID NO:35 is the amino acid sequence of human TLR7 protein (AAF78035).  
SEQ ID NO:36 is the amino acid sequence of human TLR7 protein (NP\_057646).  
SEQ ID NO:37 is the amino acid sequence of human TLR7 protein (Q9NYK1).  
SEQ ID NO:38 is the nucleotide sequence of murine TLR7 cDNA (AY035889).  
15 SEQ ID NO:39 is the nucleotide sequence of murine TLR7 splice variant  
(NM\_133211).  
SEQ ID NO:40 is the nucleotide sequence of murine TLR7 splice variant (AF334942).  
SEQ ID NO:41 is the amino acid sequence of murine TLR7 protein (AAK62676).  
SEQ ID NO:42 is the amino acid sequence of murine TLR7 protein (AAL73191).  
20 SEQ ID NO:43 is the amino acid sequence of murine TLR7 protein (AAL73192).  
SEQ ID NO:44 is the amino acid sequence of murine TLR7 protein (NP\_573474).  
SEQ ID NO:45 is the amino acid sequence of murine TLR7 protein (P58681).  
SEQ ID NO:46 is the nucleotide sequence of human TLR8 cDNA (AF245703).  
SEQ ID NO:47 is the nucleotide sequence of human TLR8 cDNA (AF246971).  
25 SEQ ID NO:48 is the nucleotide sequence of human TLR8 cDNA (NM\_138636).  
SEQ ID NO:49 is the nucleotide sequence of human TLR8 cDNA (NM\_016610).  
SEQ ID NO:50 is the amino acid sequence of human TLR8 protein (AAF78036).  
SEQ ID NO:51 is the amino acid sequence of human TLR8 protein (AAF64061).  
SEQ ID NO:52 is the amino acid sequence of human TLR8 protein (Q9NR97).  
30 SEQ ID NO:53 is the amino acid sequence of human TLR8 protein (NP\_619542).  
SEQ ID NO:54 is the amino acid sequence of human TLR8 protein (NP\_057694).  
SEQ ID NO:55 is the nucleotide sequence of murine TLR8 cDNA (AY035890).  
SEQ ID NO:56 is the nucleotide sequence of murine TLR8 cDNA (NM\_133212).

- 15 -

- SEQ ID NO:57 is the amino acid sequence of murine TLR8 protein (AAK62677).  
SEQ ID NO:58 is the amino acid sequence of murine TLR8 protein (NP\_573475).  
SEQ ID NO:59 is the amino acid sequence of murine TLR8 protein (P58682).  
SEQ ID NO:60 is the nucleotide sequence of human TLR9 cDNA (AF245704).  
5 SEQ ID NO:61 is the nucleotide sequence of human TLR9 cDNA (AB045180).  
SEQ ID NO:62 is the amino acid sequence of human TLR9 protein (AAF78037).  
SEQ ID NO:63 is the amino acid sequence of human TLR9 protein (AAF72189).  
SEQ ID NO:64 is the amino acid sequence of human TLR9 protein (AAG01734).  
SEQ ID NO:65 is the amino acid sequence of human TLR9 protein (AAG01735).  
10 SEQ ID NO:66 is the amino acid sequence of human TLR9 protein (AAG01736).  
SEQ ID NO:67 is the amino acid sequence of human TLR9 protein (BAB19259).  
SEQ ID NO:68 is the nucleotide sequence of murine TLR9 cDNA (AF348140).  
SEQ ID NO:69 is the nucleotide sequence of murine TLR9 cDNA (AB045181).  
SEQ ID NO:70 is the nucleotide sequence of murine TLR9 cDNA (AF314224).  
15 SEQ ID NO:71 is the nucleotide sequence of murine TLR9 cDNA (NM\_031178).  
SEQ ID NO:72 is the amino acid sequence of murine TLR9 protein (AAK29625).  
SEQ ID NO:73 is the amino acid sequence of murine TLR9 protein (AAK28488).  
SEQ ID NO:74 is the amino acid sequence of murine TLR9 protein (BAB19260).  
SEQ ID NO:75 is the amino acid sequence of murine TLR9 protein (NP\_112455).  
20 SEQ ID NO:76 is the nucleotide sequence of human TLR10 cDNA (AF296673).  
SEQ ID NO:77 is the amino acid sequence of human TLR10 protein (AAK26744).  
SEQ ID NO:78 is the nucleotide sequence of human TLR6 cDNA (AB020807).  
SEQ ID NO:79 is the nucleotide sequence of human TLR6 mRNA (NM\_006068).  
SEQ ID NO:80 is the amino acid sequence of human TLR6 protein (BAA78631).  
25 SEQ ID NO:81 is the amino acid sequence of human TLR6 protein (NP\_006059).  
SEQ ID NO:82 is the amino acid sequence of human TLR6 protein (Q9Y2C9).  
SEQ ID NO:83 is the nucleotide sequence of murine TLR6 cDNA (AB020808).  
SEQ ID NO:84 is the nucleotide sequence of murine TLR6 cDNA (NM\_011604).  
SEQ ID NO:85 is the nucleotide sequence of murine TLR6 cDNA (AF314636).  
30 SEQ ID NO:86 is the amino acid sequence of murine TLR6 protein (BAA78632).  
SEQ ID NO:87 is the amino acid sequence of murine TLR6 protein (AAG38563).  
SEQ ID NO:88 is the amino acid sequence of murine TLR6 protein (NP\_035734).  
SEQ ID NO:89 is the amino acid sequence of murine TLR6 protein (Q9EPW9).

- 16 -

SEQ ID NO:90 is the nucleotide sequence of a consensus sequence for NF- $\kappa$ B p50 subunit.

SEQ ID NO:91 is the nucleotide sequence of a consensus sequence for NF- $\kappa$ B p65 subunit.

5        SEQ ID NO:92 is the nucleotide sequence of an example of an NF- $\kappa$ B p65 subunit binding site.

SEQ ID NO:93 is the nucleotide sequence of an example of a murine CREB binding site.

10       SEQ ID NO:94 is the nucleotide sequence of an example of a murine AP-1 binding site.

SEQ ID NO:95 is the nucleotide sequence of an example of a murine AP-1 binding site.

SEQ ID NO:96 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:97 is the nucleotide sequence of an example of an ISRE.

15       SEQ ID NO:98 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:99 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:100 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:101 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:102 is the nucleotide sequence of an example of an ISRE.

20       SEQ ID NO:103 is the nucleotide sequence of an example of an SRE.

SEQ ID NO:104 is the nucleotide sequence of an example of an SRE.

SEQ ID NO:105 is the nucleotide sequence of an example of an SRE.

SEQ ID NO:106 is the nucleotide sequence of an example of an NFAT binding site.

SEQ ID NO:107 is the nucleotide sequence of an example of an NFAT binding site.

25       SEQ ID NO:108 is the nucleotide sequence of an example of an NFAT binding site.

SEQ ID NO:109 is the nucleotide sequence of an example of an NFAT binding site.

SEQ ID NO:110 is the nucleotide sequence of an example of a GAS.

SEQ ID NO:111 is the nucleotide sequence of a p53 binding site consensus sequence.

SEQ ID NO:112 is the nucleotide sequence of an example of a p53 binding site.

30       SEQ ID NO:113 is the nucleotide sequence of an example of a p53 binding site.

SEQ ID NO:114 is the nucleotide sequence of an example of a p53 binding site.

SEQ ID NO:115 is the nucleotide sequence of an example of a p53 binding site.

SEQ ID NO:116 is the nucleotide sequence of an example of a p53 binding site.

- 17 -

SEQ ID NO:117 is the nucleotide sequence of an example of a p53 binding site.

SEQ ID NO:118 is the nucleotide sequence of an example of a TARE (TNF- $\alpha$  response element).

SEQ ID NO:119 is the nucleotide sequence of an example of an SRF binding site.

5 SEQ ID NO:120 is the nucleotide sequence of an example of an SRF binding site.

SEQ ID NO:121 is the nucleotide sequence of the -620 to +50 promoter region of IFN- $\alpha$ 4.

SEQ ID NO:122 is the nucleotide sequence of the -140 to +9 promoter region of IFN- $\alpha$ 1.

10 SEQ ID NO:123 is the nucleotide sequence of the -140 to +9 promoter region of IFN- $\alpha$ 1 (point mutation, AL353732).

SEQ ID NO:124 is the nucleotide sequence of the -280 to +20 promoter region of IFN- $\beta$ .

15 SEQ ID NO:125 is the nucleotide sequence of the -397 to +5 promoter region of human RANTES (AB023652).

SEQ ID NO:126 is the nucleotide sequence of the -751 to +30 promoter region of human IL-12 p40.

SEQ ID NO:127 is the nucleotide sequence of the -250 to +30 promoter region of human IL-12 p40.

20 SEQ ID NO:128 is the nucleotide sequence of the -288 to +7 promoter region of human IL-6.

SEQ ID NO:129 is the nucleotide sequence of the IL-6 gene promoter from -1174 to +7 (M22111).

25 SEQ ID NO:130 is the nucleotide sequence of the -734 to +44 promoter region derived from human IL-8.

SEQ ID NO:131 is the nucleotide sequence of the -162 to 44 promoter region of human IL-8.

SEQ ID NO:132 is the nucleotide sequence of the -615 to +30 promoter region of human TNF- $\alpha$ .

30 SEQ ID NO:133 is the nucleotide sequence of a promoter region of human TNF- $\beta$ .

SEQ ID NO:134 is the nucleotide sequence of the -875 to +97 promoter region of human IP-10.

SEQ ID NO:135 is the nucleotide sequence of the -219 to +114 promoter region of human CXCL11 (IP-9).

SEQ ID NO:136 is the nucleotide sequence of the full length promoter region of human CXCL11 (IP-9).

5 SEQ ID NO:137 is the nucleotide sequence of the -289 to +217 promoter region of IGFBP4 (Insulin growth factor binding protein 4).

SEQ ID NO:138 is the nucleotide sequence of the full length promoter region of IGFBP4.

10 SEQ ID NO:139 is the nucleotide sequence of an immunostimulatory nucleic acid.  
SEQ ID NO:140 is the nucleotide sequence of an immunostimulatory nucleic acid.  
SEQ ID NO:141 is the nucleotide sequence of an immunostimulatory nucleic acid.  
SEQ ID NO:142 is the nucleotide sequence of an immunostimulatory nucleic acid.  
SEQ ID NO:143 is the nucleotide sequence of an immunostimulatory nucleic acid.  
SEQ ID NO:144 is the nucleotide sequence of an immunostimulatory nucleic acid.  
15 SEQ ID NO:145 is the nucleotide sequence of an immunostimulatory nucleic acid.  
SEQ ID NO:146 is the nucleotide sequence of an immunostimulatory nucleic acid.  
SEQ ID NO:147 is the nucleotide sequence of an immunostimulatory methylated CpG nucleic acid.

20 SEQ ID NO:148 is the nucleotide sequence of an immunostimulatory methylated CpG nucleic acid.

SEQ ID NO:149 is the nucleotide sequence of an immunostimulatory methylated CpG nucleic acid.

SEQ ID NO:150 is the nucleotide sequence of an immunostimulatory methylated CpG nucleic acid.

25 SEQ ID NO:151 is the nucleotide sequence of an immunoinhibitory nucleic acid.  
SEQ ID NO:152 is the nucleotide sequence of a sense primer for human TLR3.  
SEQ ID NO:153 is the nucleotide sequence of an antisense primer for human TLR3.  
SEQ ID NO:154 is the nucleotide sequence of a GpC nucleic acid.  
SEQ ID NO:155 is the nucleotide sequence of a CpG ODN.  
30 SEQ ID NO:156 is the nucleotide sequence of a GpC ODN.  
SEQ ID NO:157 is the nucleotide sequence of a Me-CpG ODN.  
SEQ ID NO:158 is the nucleotide sequence of a TLR9 ligand.  
SEQ ID NO:159 is the nucleotide sequence of a TLR9 ligand.



- 19 -

SEQ ID NO:160 is the nucleotide sequence of a TLR9 ligand.

SEQ ID NO:161 is the nucleotide sequence of a TLR9 ligand.

### **Detailed Description of the Invention**

5 In its broadest sense, the invention relates to screening methods and tools to be used to identify and discriminate between newly discovered immunomodulatory molecules and to compare and standardize compositions of known immunomodulatory molecules. The immunomodulatory molecules are preferably TLR ligands.

Thus, the invention is based in part on the discovery that cell lines expressing  
10 endogenous TLR respond to TLR ligands in a manner similar to the response of peripheral blood mononuclear cells (PBMC). PBMC respond to immunomodulatory TLR ligands by modulating one or more parameters including gene expression, cell surface marker expression, cytokine and/or chemokine production and secretion, cell cycle status, phosphorylation status, and the like. TLR ligands can be categorized and distinguished based  
15 on the cellular changes they induce (i.e., their induction profiles). The ability of a TLR ligand to provide therapeutic or prophylactic benefit to a subject depends on its induction profile. The ability to screen new TLR ligands for a panel of response indicators or parameters allows for rapid discrimination and categorization of TLR ligands. Moreover, the similarity between the cell line responses and those observed after in vivo administration of the TLR ligand  
20 indicates that the cell lines are suitable predictors of in vivo activity. The use of in vitro propagated cell lines additionally overcomes the variability encountered when using freshly isolated PBMC.

The TLR ligands identified according to the invention therefore can be used therapeutically or prophylactically in a more patient- or disorder-specific manner. The  
25 invention allows for the tailoring of TLR ligands for particular patients or disorders.

The invention identifies a number of cell lines that can be used to identify TLR ligands based on endogenous TLR expression such as TLR3, TLR7 and TLR9 expression. As an example, the invention is premised in part on the discovery of TLR9 expression in a number of cell lines including RPMI 8226, Raji, RAMOS, THP-1, Nalm-6 and KG-1. Cell lines  
30 RPMI 8226, Raji and RAMOS have been determined to express TLR7 according to the invention. Cell lines KG-1 cell, a Nalm cell, a Raji cell, a RAMOS cell, a Jurkat cell, a HeLa cell, a Hep-2 cell, a Hep-2 cells, a A549 cell, a Bewo cell, an NK-92 cell or an NK-92 MI cell have been discovered to express TLR3 according to the invention.

It is further premised in part on the discovery that RPMI 8226 cells respond to the imidazoquinoline compound R-848. Consistent with this latter finding, it was also discovered that RPMI 8226 cells express TLR7.

The invention in other aspects provides for screening methods and tools for verifying and standardizing compositions containing known TLR ligands. These compositions may be for example commercial production lots to be used in a clinical setting. Accordingly, the invention provides methods for standardizing lots of known TLR ligands prior to distribution and use clinically. In this way, production processes can be observed and controlled and substandard production lots can be identified and eliminated prior to shipment.

The methods of the instant invention can be used at any step in the preparation and production of clinical material, i.e., pharmaceutical product. In particular, the methods will find use in characterizing or validating raw materials, in-process materials, finished product materials (e.g., pre-release materials), and post-production materials (e.g., post-release materials). The methods can also be used to validate existing process methods, as well as to validate new or changed process methods used in the production of the pharmaceutical product.

## Screening Assays Generally

The screening assays provided herein may be used to identify immunomodulatory agents. Immunomodulatory agents are agents that either stimulate or inhibit immune responses in a subject. Accordingly, as used herein, immunomodulation embraces both immunostimulation and immunoinhibition.

The screening methods are used to identify TLR agonists and antagonists. The methods can also be used to identify compounds that enhance the immunostimulation induced by a TLR agonist. This latter set of compounds is referred to herein as "enhancers". A TLR agonist is a compound that stimulates TLR signaling activity. A TLR antagonist is a compound that inhibits TLR signaling activity. Agonists are generally referred to herein as immunostimulatory compounds because stimulation of TLR is associated with immune stimulation. Antagonists are generally referred to herein as immunoinhibitory compounds because inhibition of TLR is associated with immune inhibition. TLR antagonists include compounds that reduce (or eliminate completely) the immunostimulation induced by a TLR

- 21 -

agonist. In some embodiments, the agonists, antagonists and enhancers are TLR ligands (i.e., they bind to a TLR). In other embodiments, the test compounds with agonist, antagonist or enhancer activity may act downstream or upstream of the TLR-TLR ligand interaction.

An "immunostimulatory compound" as used herein refers to a natural or synthetic  
 5 compound that characteristically induces a TLR-mediated response when contacted with a suitable functional TLR polypeptide. In one embodiment the immunostimulatory compound is a natural or synthetic compound that induces a TLR-mediated response when contacted with a cell that naturally or artificially expresses a suitable functional TLR polypeptide. Depending on the aspect of the invention, the cell may be an experimental cell or a primary  
 10 cell such as a PBMC.

Examples of immunostimulatory compounds include the following immunostimulatory nucleic acids, which are discussed in further detail below:

	5'-TCGTCGTTTTGTCGTTTTGTCGTT-3'	(SEQ ID NO:1)
	5'-TCGTCGTTTTGACGTTTTGTCGTT-3'	(SEQ ID NO:139)
15	5'-TCGTCGTTTTGTCGTTTTTTTCGA-3'	(SEQ ID NO:140)
	5'-TCGTCGTTTCGTCGTTTCGTCGTT-3'	(SEQ ID NO:141)
	5'-TCGTCGTTTCGTCGTTTGTGCGTT-3'	(SEQ ID NO:142)
	5'-TCGTCGTTTTTCGGTCGTTTT-3'	(SEQ ID NO:143)
	5'-TCGTCGTTTTTCGTGCGTTTTT-3'	(SEQ ID NO:144)
20	5'-TCGTCGTTTTCGGCGGCCGCCG-3'	(SEQ ID NO:145)
	5'-TCGTC_GTTTTAC_GGCGCC_GTGCCG-3'	(SEQ ID NO:146)

Imidazoquinolines are immune response modifiers thought to induce expression of several cytokines including interferons (e.g., IFN- $\alpha$  and IFN- $\beta$ ), TNF- $\alpha$  and some interleukins  
 25 (e.g., IL-1, IL-6 and IL-12) as well as chemokines (e.g., IP-10 and IL-8). Imidazoquinolines are capable of stimulating a Th1 immune response, as evidenced in part by their ability to induce increases in IgG2a levels. Imidazoquinoline agents reportedly are also capable of inhibiting production of Th2 cytokines such as IL-4, IL-5, and IL-13. Some of the cytokines induced by imidazoquinolines are produced by macrophages and dendritic cells. Some  
 30 species of imidazoquinolines have been reported to increase NK cell lytic activity and to stimulate B cells proliferation and differentiation, thereby inducing antibody production and secretion. Imidazoquinoline mimics can also be tested using the screening methods.

An "immunoinhibitory compound" as used herein refers to a natural or synthetic compound that characteristically inhibits a TLR-mediated response when contacted with a suitable functional TLR polypeptide. In one embodiment the immunoinhibitory compound is a natural or synthetic compound that inhibits a TLR-mediated response when contacted with a cell that naturally or artificially expresses a suitable functional TLR polypeptide.

In addition to the immunoinhibitory nucleic acids disclosed elsewhere herein, immunoinhibitory compounds and TLR antagonists encompass certain small molecules (chloroquine, quinacrine, 9-aminoacridines and 4-aminoquinolines, and derivatives thereof) described by Macfarlane and colleagues in U.S. Pat. 6,221,882; U.S. Pat. 6,399,630; U.S. Pat. 6,479,504; U.S. Pat. 6,521,637; and published U.S. Pat. application 2002/0151564, the contents of all of which are hereby incorporated by reference in their entirety.

The invention provides in part methods and tools that utilize cell lines, in modified or unmodified form, as surrogates for PBMC. Immunomodulation by TLR ligands can be assessed using one or preferably more parameters including but not limited to cytokine and chemokine secretion, upregulation of cell surface markers, changes in cell proliferation, phosphorylation changes, and the like. These parameters may be native readouts or artificial readouts as described herein.

The cellular response to immunostimulatory nucleic acids by the cell lines described herein (e.g., RPMI 8226, Raji, RAMOS, and the like) so resembles that of PBMC that these cells can be used to identify and differentiate between immunomodulatory compounds based on the extent of the induced response and the particular profile of that response. The invention provides a number of cell lines each with a particular endogenous TLR expression profile, as described herein.

The cell lines can be used to identify immunomodulatory compounds with particular response profiles. As an example, the cell lines can be used to identify molecules that are mimics to known TLR ligands. The cell lines can also be used to identify TLR ligands that trigger some but not necessarily all of the responses induced by known TLR ligands. For example, the cell line can be used to distinguish between compounds based on individual or group cytokine or chemokine secretion, or based on upregulation of one, a subset or all cell surface markers. As an example, in some therapeutic instances, it may be desirable to use a compound that induces the secretion of relatively high levels of chemokine such as IP-10, yet induces only relatively low levels of one or more other factors. The screening methods of the invention allow for the identification of such a compound with this type of induction profile.

It is to be understood that the screening method also can be used to determine effective amounts of known and newly identified immunomodulatory compounds. For example, the EC<sub>50</sub> value of a TLR ligand for the production of a particular cytokine or chemokine can be determined, thereby facilitating comparison between different nucleic acids.

5           Generally, these assays require the incubation of cells with a reference compound and a test compound, and an analysis of the readout. Depending on the embodiment, the same cells are exposed to the reference compound and the test compound. An example of this latter embodiment is a screening assay for compounds that enhance the immunostimulatory effects of a TLR agonist. Another example is a screening assay for compounds that inhibit the  
10 immunostimulatory effects of a TLR agonist. In both examples, the reference compound is a positive reference compound (i.e., it is itself immunostimulatory).

          In other embodiments, particularly those directed at identifying immunostimulatory compounds, separate aliquots from the same cell line (or from the same freshly harvested cell population) are exposed to either the reference compound or the test compound, and the  
15 readouts from each are measured and compared to the other. If the reference compound is a negative reference compound (i.e., it is inert and neither immunostimulatory nor immunoinhibitory), then any test level that is greater than the reference level is indicative of a test compound that has at least some immunostimulatory capacity. Generally, the negative reference compound is used to set background levels of immunostimulation or  
20 immunoinhibition observed in the absence of the test compound. If the reference compound is a positive reference compound (i.e., it is immunostimulatory), then it is possible to compare and contrast the induction profile of the test compound to that of the reference compound.

          In some instances, separate reference assays individually containing a positive and a negative reference compound are performed alongside the test assay. For example, if the test  
25 assay is a screen for an immunostimulatory TLR ligand, then reference assays can be a positive reference assay (in which the reference compound is immunostimulatory), a negative reference assay (in which the reference compounds is immunologically inert or neutral), or both. A test compound is defined as immunostimulatory if it induces a response greater than that of the negative reference compound. The level and profile of the immunostimulatory  
30 response can be compared to the level and profile induced by the positive reference compound. It is to be understood that a test compound that induces a level of immunostimulation less than that of the positive reference compound may still be considered immunostimulatory according to the invention. Modifications to these screening assays for a

- 24 -

desired readout will be apparent to those of ordinary skill in the art based on the teachings provided herein.

If the test assay is a screen for an immunoinhibitory TLR ligand, then the assay may generally involve co-incubation of the test compound and a positive reference compound.

5 The control assay may include co-incubation of the negative and positive reference compounds. As used herein, co-incubation embraces simultaneous or consecutive addition of the reference and test compounds. The test compound may be added before or after the positive reference compound. An immunoinhibitory test compound may be identified by a diminution of the immunostimulatory response induced by the positive reference compound  
10 when in the presence of the test compound. If the level of the response is less in the presence of the test compound, this indicates that the test compound is capable of interfering with the immunostimulatory effects of the positive reference compound. As an example, simultaneous or consecutive addition of a putative immunoinhibitory test compound can reduce the amount of cytokines or chemokines secreted by cells in response to the positive reference compound  
15 alone, indicating an inhibition of the immunostimulatory effects of the positive reference compound.

The reference immunoinhibitory compound can be used at one or more concentrations in conjunction with a selected or constant concentration of reference immunostimulatory compound. Under proper conditions, the immunostimulatory effect of the reference  
20 immunostimulatory compound will be less in the presence of the immunoinhibitory substance than in the absence of the immunoinhibitory substance. Furthermore, under proper conditions, the immunostimulatory effect of the reference immunostimulatory compound will decrease with increasing concentration of the immunoinhibitory substance.

The breadth of response by the cell line to immunomodulatory compounds, and its  
25 facile manipulation, allows for the identification of novel compounds. The cell line allows the rapid discovery of such compounds given that it lends itself to high throughput screening methods such as those provided herein. These methods and compositions are described in greater detail below. The invention therefore provides screening methods that utilize cell lines that either endogenous express TLRs such as the RPMI 8226 cell line as well as cell  
30 lines that have been modified to express TLRs. The invention further provides compositions that comprise such cell lines.

The verification and standardization methods of the invention generally involve assays in which an isolated cell expressing a functional TLR is contacted with each of two

- 25 -

compositions, each composition containing a known ligand for the TLR. One composition is a reference composition, and the assay using the reference composition yields a reference activity. The second composition is a test composition, and the assay using the test composition yields a test activity. The two contacting steps can be performed on separate cells that are alike, and typically will be performed on separate populations of cells that are alike. For example, the separate cells or the separate populations of cells can be drawn from a single population of cells. In typical usage according to this embodiment, the reference and test activities are measured essentially concurrently, although the use of historical reference activity is also contemplated by the methods of the invention. As an alternative, the two contacting steps can be performed on a single cell or on a single population of cells, usually in an essentially concurrent manner when it is desirable to have competition between reference and test compositions. In one embodiment the known TLR ligand is a nucleic acid molecule.

The assays of the invention are performed under specific conditions so that comparison can be made between reference and test activities or levels. The results of the comparison can be used as a basis upon which to accept or reject the test material as suitable for its intended use.

The biological characterization of the reference composition will generally entail a series of biological activity measurements of the reference composition using a single assay under defined conditions in order to define a range of inter-test variance. The range of inter-test variance so obtained using reference composition can be used to define an acceptable range of variance within which a subsequent test measurement must fall in order to satisfy quality standards. Such a range of acceptable variance can serve as a basis for developing predetermined range of variance about the reference activity, i.e., acceptance criteria for a particular test composition or test lot. For example, a particular reference composition can be assayed under defined conditions in a number of independent measurements and found to yield a result expressed as  $100 \pm 5$  units of activity. Under this same example, a subsequent test measurement of a test composition performed using the same assay and defined conditions is found to yield 97 units of activity. The activity of the test composition under this example thus yielded a result that falls within the normal range of inter-test variance observed for the reference composition. Accordingly, the test material under this example could be selected on the basis of the test activity falling within a predetermined range of variance about the reference activity. In short, the test material can be deemed acceptable

- 26 -

provided the test activity falls within a predetermined range of activity that is related to the activity of the reference material.

In one embodiment, the methods of the invention provide for comparison between a reference lot of a particular TLR ligand and a test lot of the same particular TLR ligand. Such comparison is useful for quality control assessment of the test lot of material, also referred to  
5 herein as validation, e.g., product validation. Such comparison is also useful for process validation.

In another embodiment, the methods of the invention provide for comparison between a reference lot of a particular TLR ligand and a test lot of a different TLR ligand. In a simple example, where a test TLR ligand (T) is expected to have little or no activity characteristic of reference TLR ligand (R), comparison can be made between T and R to confirm the lack of R-like activity possessed by T. In a more complex example, where a test TLR ligand (C) is capable of exerting two different effects, wherein each effect is characteristic of one of two different classes of TLR ligand and is best characterized by one of two different reference  
10 TLR ligands (A and B), the test TLR ligand (C) can be compared with either of the two reference TLR ligands (A or B). In this second example, test composition C could be found, for example, to possess 50 percent A-like activity compared with reference A and 70 percent B-like activity compared with reference B. Test composition C could thus independently meet or fail to meet predetermined standards for each of A-like activity and B-like activity.  
15 Such comparison is also useful for quality control assessment of the test lot of material, e.g., product validation. Of course test TLR ligand C can alternatively or additionally be compared against reference TLR ligand C, as described in the preceding paragraph.

To facilitate the methods of the invention, certain conditions for carrying out the assays are standardized and used for measurements of both reference activity and test activity.  
25 In this way direct comparison between reference activity and test activity can be made readily. Conditions that can be standardized and used in this manner can include, without limitation, readout, temperature, media characteristics, duration (time between introduction of reference composition or test composition and activity measurement), methods of sampling, etc. In some embodiments the methods of the invention can be at least partially automated in order to  
30 increase throughput and/or to reduce inter-test variability. For example, robotic devices and workstations with the capacity to dispense and/or sample fluids in a set or programmable fashion are now well known in the art and can be used in performing the methods of the instant invention.



In one embodiment a standard curve of reference composition activity is employed. Typically the standard curve is generated by selecting conditions including concentration of the reference composition such that the dose-response curve is essentially linear (and the slope is non-zero) over a range of concentrations that includes the effective concentration at which activity is 50 percent of maximum (EC50). In one embodiment the standard curve spans a range of concentrations defined by  $EC50 \pm 1 \log$  concentration, e.g.,  $1 \times 10^{-7} \text{ M} - 1 \times 10^{-5} \text{ M}$ , where EC50 is  $1 \times 10^{-6} \text{ M}$ . In another embodiment the standard curve spans a broader range of concentrations defined by  $EC50 \pm 2 \log$  concentration, e.g.,  $1 \times 10^{-8} \text{ M} - 1 \times 10^{-4} \text{ M}$ , where EC50 is  $1 \times 10^{-6} \text{ M}$ . In yet another embodiment the standard curve spans a narrower range of concentrations defined by  $EC50 \pm 0.5 \log$  concentration, e.g.,  $3.16 \times 10^{-7} \text{ M} - 3.16 \times 10^{-6} \text{ M}$ , where EC50 is  $1 \times 10^{-6} \text{ M}$ . The foregoing embodiments are intended to be exemplary and not limiting in any way. One of skill in the art will be able to select, for a given reference composition and without undue experimentation, an appropriate range of concentrations about some middle value in order to generate an essentially linear standard curve with a non-zero slope.

In one embodiment a non-linear standard curve of reference and test composition activity is employed. The standard curve can be generated by selecting conditions including concentrations of the reference composition such that the dose-response curve is sigmoidal and the EC50 value can be determined. Comparison of reference and test activity can be done by comparing, e.g., the EC50 values of both curves. Concentration range is chosen to yield a complete sigmoidal response, e.g., concentration should include  $EC50 \pm 3 \log$  concentration or  $EC50 \pm 4 \log$  concentration. In the case of testing an inhibitory compound the value determined would be the IC50, i.e., concentration where inhibition of the stimulatory signal is half-maximal.

The methods of the invention can be adapted to be automated or at least partially automated methods, as well as to parallel array or high throughput format methods. For example, the assays can be set up using multiwell plates in which cells are dispensed in individual wells and reagents are added in a systematic manner using a multiwell delivery device suited to the geometry of the multiwell plate. Manual and robotic multiwell delivery devices suitable for use in a high throughput screening assay are known by those skilled in the art. Each well or array element can be mapped in a one-to-one manner to a particular test condition, such as the test compound. Readouts can also be performed in this multiwell array, preferably using a multiwell plate reader device or the like. Examples of such devices are

known in the art and are available through commercial sources. Sample and reagent handling can be automated to further enhance the throughput capacity of the screening assay, such that dozens, hundreds, thousands, or even millions of parallel assays can be performed in a day or in a week. Fully robotic systems are known in the art for applications such as generation and analysis of combinatorial libraries of synthetic compounds. See, for example, U.S. Pat. Nos. 5,443,791 and 5,708,158.

#### Cell lines

The screening methods may use experimental cells. As used herein, an experimental cell is a non-primary cell (i.e., it is not a cell that has been recently harvested from a subject). It excludes, for example, freshly harvested PBMCs. An experimental cell includes a cell from a cell line such as the RPMI 8226 cell line.

In certain embodiments, the cell naturally expresses a functional TLR. In one embodiment relating to the verification and standardization aspects of the invention, the cell may be a PBMC, preferably a PBMC freshly harvested from a subject.

Cells that would be suitable for identification of TLR agonists, antagonists or enhancers according to the invention may possess one or more particular attributes. These attributes include but are not limited to being of human origin, being an immortalized stable cell line, endogenously expressing at least one functional TLR or a combination of functional TLRs, having intact signaling mechanisms, having intact uptake mechanisms, being able to upregulate cytokines, chemokines or cell surface markers, deriving from normal human B cells or from myeloma or B cell leukemia, deriving from human plasmacytoid and myeloid dendritic cells, and readily activatable by TLR ligands such as TLR7 ligands, TLR8 ligands or TLR9 ligands such as CpG nucleic acids or nucleic acids having other immunostimulatory sequence motifs or small molecules such as imidazoquinoline compounds.

In some embodiments, the cell line is the Raji cell line which expresses TLR3, TLR7 and TLR9. This latter cell line secretes, for example, IL-6 and IFN- $\alpha$ 2 upon CpG nucleic acid exposure. In other embodiments, the cell line is RPMI 8226 which expresses TLR7 and TLR9. Upon CpG nucleic acid exposure, this cell line expresses, produces and/or secretes IL-8, IL-10, IP-10 and TNF- $\alpha$ . It also expresses at its cell surface CD86, HLA-DR and CD71. In yet other embodiments, the cell line is the RAMOS cell line which expresses TLR3, TLR7 and TLR9. This cell line at least induces CD80 cell surface expression in response to CpG nucleic acid exposure.

- 29 -

The cell lines have been observed to respond in a concentration dependent manner to TLR ligands such as but not limited to CpG nucleic acids and some non-CpG nucleic acids including T-rich nucleic acids, poly-T nucleic acids and poly-G nucleic acids. The highest responses have been observed using CpG nucleic acids.

5           The screening methods employ a variety of cell lines as shown in the Examples. These include A549 (human lung carcinoma, ATCC CCL-185), BeWo (human choriocarcinoma, ATCC CCL-98), HeLa (human cervix carcinoma, ATCC CCL-2), Hep-2 (human cervix carcinoma, ATCC CCL-23), KG-1 (human acute myeloid leukemia, ATCC CCL-246), MUTZ-3 (human acute myelomonocytic leukemia, German Collection of Cell  
10 lines and Microorganisms (DSZM) ACC-295), Nalm-6 (human B cell precursor leukemia, DSZM ACC-128), NK-92 (human Natural killer cell line, ATCC CRL-2407), NK-92 MI (IL-2 independent human Natural killer cell line, ATCC CRL-2408), Raji (human B lymphocyte Burkitt's lymphoma, ATCC CCL-86), RAMOS (B lymphocyte Burkitt's lymphoma, ATCC CRL-1596), RPMI 8226 (human B lymphocyte multiple myeloma, ATCC CCL-155), THP-1  
15 (human acute monocytic leukemia, ATCC TIB 202), U937 (human lymphoma, ATCC CRL-1593.2) and Jurkat (human T cell leukemia, ATCC TIB 152).

As shown in the Examples, each of the afore-mentioned cell lines has a particular endogenous TLR expression profile which dictates its suitability in a particular screening assay.

20           A cell that artificially expresses a functional TLR can be a cell that does not express the functional TLR but for a transfected TLR expression vector. For example, human 293 fibroblasts (ATCC CRL-1573) do not express TLR7, TLR8 or TLR9, and they express very little TLR3. As described in the examples below, such cells can be transiently or stably transfected with suitable expression vector (or vectors) so as to yield cells that do express  
25 TLR3, TLR7, TLR8, TLR9, or any combination thereof. Alternatively, a cell that artificially expresses a functional TLR can be a cell that expresses the functional TLR at a significantly higher level with the TLR expression vector than it does without the TLR expression vector. Transfected cells are considered modified cells, as used herein.

30           A cell that artificially expresses an expression or reporter construct is preferably stably transfected.

RPMI

The RPMI 8226 cell line is a human multiple myeloma cell line. The cell line was established from the peripheral blood of a 61 year old man at the time of diagnosis for multiple myeloma (IgG lambda type). RPMI 8226 was previously reported as responsive to CpG nucleic acids as evidenced by the production and secretion of IL-6 protein and  
5 production of IL-12p40 mRNA. (Takeshita et al. (2000), *Eur. J. Immunol.* 30, 108-116, and Takeshita et al. (2000) *Ibid.* 30, 1967-1976) Takeshita et al. however used the cell line solely to study promoter constructs in order to identify transcription factor binding sites important for CpG nucleic acid signaling. It is now known according to the invention that the cell line produces a number of other chemokines and cytokines including IL-8, IL-10 and IP-10. It has  
10 also been discovered according to the invention that the cell line responds to immunostimulatory nucleic acids by upregulating cell surface expression of particular markers. Many of these markers, including CD71, CD86 and HLA-DR, are similarly upregulated in PBMCs exposed to immunostimulatory nucleic acids. This has been observed using flow cytometric analysis of the cell line following CpG nucleic acid exposure. In other  
15 aspects of the invention, the cell line can be used in similar screening assays that involve secretion of IL-6, IL-12 and/or TNF- $\alpha$ .

It has recently been discovered that R-848 mediates its immunostimulatory effects via other TLR family members, namely TLR7 and TLR8. TLR7 has previously been found expressed on human B cells. It has now also been discovered according to the invention that  
20 RPMI 8226 expresses TLR9 as well as TLR7, thus making it a suitable cell line for identifying immunostimulatory nucleic acid and/or imidazoquinoline (e.g., R-848) mimics or other small molecules that also signal through TLR7 and/or TLR9. Incubation of RPMI 8226 cells with the imidazoquinoline R-848 (Resiquimod) induces for example IL-8, IL-10 and IP-10 production.

25

#### Known TLR Ligands

Ligands for many but not all of the TLRs have been described. For instance, it has been reported that TLR1 and TLR2 signals in response to peptidoglycan and lipopeptides. Yoshimura A et al. (1999) *J Immunol* 163:1-5; Brightbill HD et al. (1999) *Science* 285:732-6;  
30 Aliprantis AO et al. (1999) *Science* 285:736-9; Takeuchi O et al. (1999) *Immunity* 11:443-51; Underhill DM et al. (1999) *Nature* 401:811-5. TLR4 has been reported to signal in response to lipopolysaccharide (LPS). Hoshino K et al. (1999) *J Immunol* 162:3749-52; Poltorak A et al. (1998) *Science* 282:2085-8; Medzhitov R et al. (1997) *Nature* 388:394-7. Bacterial

flagellin has been reported to be a natural ligand for TLR5. Hayashi F et al. (2001) *Nature* 410:1099-1103. TLR6, in conjunction with TLR2, has been reported to signal in response to proteoglycan. Ozinsky A et al. (2000) *Proc Natl Acad Sci USA* 97:13766-71; Takeuchi O et al. (2001) *Int Immunol* 13:933-40.

5 TLR9 is a receptor for CpG DNA. Hemmi H et al. (2000) *Nature* 408:740-5. Other TLR9 ligands are described herein under "Immunostimulatory Nucleic Acids". Certain imidazoquinoline compounds having antiviral activity are ligands of TLR7 and TLR8. Imidazoquinolines are potent synthetic activators of immune cells with antiviral and antitumor properties. R-848 is a ligand for human TLR7 and TLR8. Jurk M et al. (2002) *Nat Immunol*  
10 3:499. Ligands of TLR3 include poly(I:C) and double-stranded RNA (dsRNA). Alexopoulou et al. (2001) *Nature* 413:732-738. For purposes of this invention, poly(I:C) and double-stranded RNA (dsRNA) are classified as oligonucleotide molecules. TLR3 may have a role in host defense against viruses.

#### 15 Reference and Test Compounds

A test and/or reference compound can be a nucleic acid such as an oligonucleotide or a polynucleotide, an oligopeptide, a polypeptide, a lipid such as a lipopolysaccharide, a carbohydrate such as an oligosaccharide or a polysaccharide, or a small molecule. Alternatively, these compounds may also comprise or be synthesized from elements such as  
20 amino acids, carbohydrates, hormones, lipids, organic molecules, and the like.

Small molecules in general include naturally occurring, synthetic, and semisynthetic organic and organometallic compounds with molecular weight less than about 2.5 kDa. Examples of small molecules include most drugs, subunits of polymeric materials, and analogs and derivatives thereof.

25 Some specific examples of small molecules include the imidazoquinolines. As used herein, an imidazoquinoline includes imidazoquinoline amines (imidazoquinolinamines), imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2 bridged imidazoquinoline amines. These compounds have been described in U.S. Pat. Nos. 4,689,338; 4,929,624; 5,238,944; 5,266,575; 5,268,376; 5,346,905; 5,352,784; 5,389,640;  
30 5,395,937; 5,482,936; 5,494,916; 5,525,612; 6,039,969 and 6,110,929. Particular species of imidazoquinoline agents include resiquimod (R-848; S-28463; 4-amino-2 ethoxymethyl- $\alpha,\alpha$ -dimethyl-1*H*-imidazo[4,5-*c*]quinoline-1-ethanol); and imiquimod (R-837; S-26308; 1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*]quinoline-4-amine). Further examples of specific small

molecules include 4-aminoquinoline and derivatives thereof, 9-aminoacridine and derivatives thereof, and additional compounds disclosed in U.S. Pat. Nos. 6,221,882; 6,399,630; 6,479,504; and 6,521,637; and published U.S. Pat. Application No. 2002/0151564 A1, the entire contents of which are hereby incorporated by reference.

5           The test and reference compounds may be formulated for pharmaceutical use or not. For example, a test compound not formulated for pharmaceutical use can be a compound (e.g., a lot or batch of the compound) under evaluation for possible use in preparing a pharmaceutical formulation of the compound.

10           A reference compound, as used herein, is a compound having a known activity in the presence of a TLR. The reference compound may stimulate TLR signaling (and is therefore regarded as a positive reference compound), or it may be inert in the presence of a TLR (and is therefore regarded as a negative reference compound). If it is a positive reference compound, it need not be the best known stimulator of TLR signaling (i.e., it is possible that other reference compounds and even test compounds will stimulate TLR signaling to a greater  
15           extent). The readout of the screening assay may simply be stated relative to the level of signaling that occurs in the presence of the reference compound. Preferably, the reference compound is analyzed prior to the screening assay in order to determine its level of activity on a TLR. In some aspects of the invention, the reference compound and the test compound will be assayed separately (i.e., in separate wells); in other aspects, the reference compound and  
20           the test compound will be assayed together (i.e., in the same well). These latter aspects are designed to measure the ability of a test compound to modulate the activity of the reference compound. The activity of the test compound and the reference compound combined (i.e., when assayed together in the same well) may be the same as that of the positive reference compound alone, indicating at a minimum that the test compound is not inhibitory; or it may  
25           be less than that of the positive reference compound, indicating at a minimum that it is inhibitory to the effect of the reference compound; or it may be additive or synergistic possibly indicating that the test compound is an enhancer. The effect of an enhance may be due to its ability to stimulate TLR signaling independently of the positive reference compound.

30           A "reference composition" as used herein refers to a composition that includes a reference compound and optionally another agent, e.g., a pharmaceutically acceptable carrier and/or another biologically active agent. A reference compound may be an immunostimulatory compound or it may be an immunoinhibitory compound.

As discussed further below, in some aspects of the invention the reference compositions include both finished products, e.g., finished pharmaceutical products, as well as raw materials and other in-process materials used for the preparation of such finished products, all of which contain a known TLR ligand. As used herein, a "production lot" shall refer to a batch or lot of a completed product prepared for release as clinical material, e.g., a pharmaceutical product. As used herein, an "in-process lot" shall refer to a batch or lot of unfinished product that is prepared in the course of making a production lot; an "in-process lot" shall also refer to a batch or lot of raw material provided for use in the production of a production lot.

In some aspects of the invention, the reference compositions of the invention are highly characterized in terms of their chemical, physical, and biological properties. A reference composition will be a specific composition previously determined to have a specific activity, or range of specific activity, of the particular known TLR ligand present in the composition. As used herein, "specific activity" refers to an amount of activity per unit mass or per unit volume of the reference composition as a whole, as determined using a defined assay under defined conditions. In one embodiment the reference composition is a representative sample of a particular lot or batch of a specific TLR ligand. In one embodiment the reference composition is a representative sample of a particular lot or batch of a specific TLR ligand formulated for pharmaceutical use, e.g., a sterile solution of the TLR ligand at a determined concentration or activity.

At least the following parameters are typically very well defined for a given reference composition: chemical formula of the active ingredient TLR ligand (e.g., nucleobase sequence and type of backbone of a nucleic acid; structural formula of a small molecule); concentration; diluent composition; and purity. Such parameters as purity and concentration can be determined using any appropriate physicochemical method, e.g., optical spectroscopy including absorbance at one or more specified wavelengths; nuclear magnetic resonance (NMR) spectroscopy; mass spectrometry (MS), including matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS); melting point; specific gravity; chromatography including as appropriate high pressure liquid chromatography (HPLC), one- and two-dimensional polyacrylamide gel electrophoresis (PAGE), capillary electrophoresis, and the like; as well as other methods known to those of skill in the art.

Reference compositions can also be very well characterized in terms of their biological activity, independent of the methods of the invention, although the methods of the

invention generally include such characterization, at least in part. A reference composition can be very well characterized in terms of its biological activity by characterizing, both qualitatively and quantitatively, the response by sensitive cells to the reference composition under defined conditions. For example, a reference composition can be a specific CpG oligonucleotide such as SEQ ID NO:1 which in a specific assay and under specific conditions of temperature, concentration, duration of contact between the CpG oligonucleotide and a population of TLR9-expressing cells, and particular readout, reliably yields a specific result or range of results. Results can be expressed in any suitable manner, but can include results expressed on a per-cell basis, e.g., picograms of particular cytokine per cell per hour of contact with the reference composition. Reference compositions can be very well characterized in terms of their biological activity according to one or more parameters, for example, according to their capacity to induce each of a plurality of cytokines.

The methods of the invention also involve measurement of a test activity of a test composition containing a known TLR ligand. A "test composition" as used herein refers to a composition that includes a test compound and optionally another agent, e.g., a pharmaceutically acceptable carrier and/or another biologically active agent. A test compound can be an immunostimulatory compound or it can be an immunoinhibitory compound. In some aspects of the invention, the test compound is a known TLR ligand. Test compositions of the invention may comprise known TLR agonist or TLR antagonist compounds, generally but not necessarily nominally the same as the reference compositions against which comparison is to be made according to some aspects of the invention. Thus test compositions may encompass immunostimulatory compounds, immunoinhibitory compounds, known TLR ligands, finished pharmaceutical products, and raw materials and other in-process materials used for the preparation of such finished products.

Unlike a reference composition, a test composition is not characterized at all, or is only partially characterized, or is not as well characterized as the reference composition, in terms of its chemical, physical, or (most particularly) biological properties. The methods of the invention permit further characterization of the test composition by comparison with a reference composition. In some aspects, a test composition will be a specific composition previously determined to be a ligand of a specific TLR. In one embodiment the test composition is a representative sample of a particular lot or batch of a specific TLR ligand. In one embodiment the test composition is a representative sample of a particular lot or batch of



- 35 -

a specific TLR ligand formulated for pharmaceutical use, e.g., a sterile solution of the TLR ligand at a determined concentration or activity.

#### Immunostimulatory and Immunoinhibitory Nucleic Acids

5 Nucleic acids useful as reference compounds and as test compounds in the methods of the invention include single- and double-stranded natural and synthetic nucleic acids, including those with phosphodiester, stabilized, and chimeric backbones. Also encompassed are at least the following classes of nucleic acids, which are described in detail below: immunostimulatory CpG nucleic acids (CpG nucleic acids), including but not limited to types  
10 A, B, and C; immunostimulatory non-CpG nucleic acids, including without limitation methylated CpG nucleic acids, T-rich nucleic acids, TG-motif nucleic acids, CpI motif nucleic acids, and poly-G nucleic acids; and immunoinhibitory nucleic acids. Nucleic acids useful as reference compounds and as test compounds in the methods of the invention also include nucleic acids with modified backbones, including "soft" and "semi-soft" oligonucleotides as  
15 described herein. As will be appreciated from the descriptions below, certain of these various classes of nucleic acids can coexist in a given nucleic acid molecule.

A "nucleic acid" as used herein with respect to test compounds and reference compounds used in the methods of the invention, shall refer to any polymer of two or more individual nucleoside or nucleotide units. Typically individual nucleoside or nucleotide units  
20 will include any one or combination of deoxyribonucleosides, ribonucleosides, deoxyribonucleotides, and ribonucleotides. The individual nucleotide or nucleoside units of the nucleic acid can be naturally occurring or not naturally occurring. For example, the individual nucleotide units can include deoxyadenosine, deoxycytidine, deoxyguanosine, thymidine, and uracil. In addition to naturally occurring 2'-deoxy and 2'-hydroxyl forms,  
25 individual nucleosides also include synthetic nucleosides having modified base moieties and/or modified sugar moieties, e.g., as described in Uhlmann E et al. (1990) *Chem Rev* 90:543-84. The linkages between individual nucleotide or nucleoside units can be naturally occurring or not naturally occurring. For example, the linkages can be phosphodiester, phosphorothioate, phosphorodithioate, phosphoramidate, as well as peptide linkages and other  
30 covalent linkages, known in the art, suitable for joining adjacent nucleoside or nucleotide units. The linkages can also be mixed in a single polymer (e.g., a semi-soft backbone). The nucleic acid test compounds and nucleic acid reference compounds typically range in size from 3-4 units to a few tens of units, e.g., 18-40 units.

In some embodiments the nucleic acids are oligonucleotides made up of 2 to about 100 nucleotides, and more typically 4 to about 40 nucleotides. Oligonucleotides composed exclusively of deoxynucleotides are termed oligodeoxyribonucleotides or, equivalently, oligodeoxynucleotides (ODN).

5 A CpG nucleic acid is an immunostimulatory nucleic acid which contains a cytosine-guanine (CG) dinucleotide, the C residue of which is unmethylated. The effects of CpG nucleic acids on immune modulation have been described extensively in U.S. Pat. Nos. 6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116; and 6,339,068; and published patent applications, such as PCT/US95/01570 (WO 96/02555); PCT/US98/04703 (WO 98/40100);  
10 and PCT/US99/09863 (WO 99/56755). The entire contents of each of these patents and published patent applications is hereby incorporated by reference. The entire immunostimulatory nucleic acid can be unmethylated or portions can be unmethylated, but at least the C of the 5'-CG-3' must be unmethylated. The CpG nucleic acid sequences of the invention include, without limitation, those broadly described above as well as those disclosed  
15 in U.S. Pat. Nos. 6,207,646 and 6,239,116.

In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTTGTCGTTTTGTCGTT-3' (SEQ ID NO:1).

In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTTGACGTTTTGTCGTT-3' (SEQ ID NO:139).

20 In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTTGTCGTTTTTTTCGA-3' (SEQ ID NO:140).

In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTCGTCGTTTCGTCGTT-3' (SEQ ID NO:141).

25 In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTCGTCGTTTTGTCGTT-3' (SEQ ID NO:142).

In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTTTCGGTCGTTTT-3' (SEQ ID NO:143).

In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTTTCGTGCGTTTTT-3' (SEQ ID NO:144).

30 In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTTCGGCGGCCGCCG-3' (SEQ ID NO:145).

In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTC\_GTTTTAC\_GGCGCC\_GTGCCG-3' (SEQ ID NO:146).

The oligonucleotides described by SEQ ID NOs: 1, 139-145 are fully stabilized phosphorothioate backbone ODN. The oligonucleotide of SEQ ID NO:146 has a chimeric backbone in which all internucleoside linkages are phosphorothioate except for those indicated by “\_”, which are phosphodiester.

5 CpG nucleic acids have been further classified by structure and function into at least the following three types, all of which are intended to be encompassed within the methods of the instant invention: Type B CpG nucleic acids such as SEQ ID NO:1 include the earliest described CpG nucleic acids and characteristically activate B cells but do not induce or only weakly induce expression of IFN- $\alpha$ . Type B nucleic acids are described in U.S. Patents  
10 6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116; and 6,339,068. Type A CpG nucleic acids, described in published international application PCT/US00/26527 (WO 01/22990), incorporate a CpG motif, include a hybrid phosphodiester/phosphorothioate backbone, and characteristically induce plasmacytoid dendritic cells to express large amounts of IFN- $\alpha$  but do not activate or only weakly activate B cells. Type C oligonucleotides incorporate a CpG,  
15 include a chimeric backbone, include a GC-rich palindromic or nearly-palindromic region, and are capable of both activating B cells and inducing expression of IFN- $\alpha$ . These have been described, for example, in copending U.S. Pat. application Ser. No. 10/224,523, filed August 19, 2002. Exemplary sequences of A, B and C class nucleic acids are described in the afore-mentioned references, patents and patent applications, the entire contents of which are  
20 hereby incorporated by reference herein.

In other embodiments of the invention, a non-CpG nucleic acid is used. A non-CpG nucleic acid is an immunostimulatory nucleic acid which either does not have a CpG motif in its sequence, or has a CpG motif which contains a methylated C residue. In some instances, the non-CpG nucleic acid may still be immunostimulatory by virtue of its having other  
25 immunostimulatory motifs such as those described herein and known in the art. In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid. In some instances the non-CpG nucleic acid is still immunostimulatory despite methylation of the C of the CpG motif, even without having another non-CpG immunostimulatory motif described herein and known in the art.

30 In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid having a base sequence provided by 5'-TZGTZGTTTTGTZGTTTTGTZGTT-3' (SEQ ID NO:147), wherein Z represents 5-methylcytosine.

In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid having a base sequence provided by 5'-TZGTZGZTGTZTZZGZTTZTTZTTGZZ-3' (SEQ ID NO:148), wherein Z represents 5-methylcytosine.

In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid having  
5 a base sequence provided by 5'-GZGTTTGZTZZTTZTTZTTGZG-3' (SEQ ID NO:149), wherein Z represents 5-methylcytosine.

In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid having a base sequence provided by 5'-GZZZAAGZTGGZATZZGTZA-3' (SEQ ID NO:150), wherein Z represents 5-methylcytosine.

10 Non-CpG nucleic acids include T-rich immunostimulatory nucleic acids. The T-rich immunostimulatory nucleic acids include those disclosed in published PCT patent application PCT/US00/26383 (WO 01/22972), the entire contents of which are incorporated herein by reference. In some embodiments, T-rich nucleic acids 24 bases in length are used. A T-rich nucleic acid is a nucleic acid which includes at least one poly T sequence and/or which has a  
15 nucleotide composition of greater than 25% T nucleotide residues. A nucleic acid having a poly-T sequence includes at least four Ts in a row, such as 5'-TTTT-3'. In some embodiments the T-rich nucleic acid includes more than one poly T sequence. In important embodiments, the T-rich nucleic acid may have 2, 3, 4, or more poly T sequences, such as SEQ ID NO:1.

Non-CpG nucleic acids also include poly-G immunostimulatory nucleic acids. A  
20 variety of references describe the immunostimulatory properties of poly-G nucleic acids. Pisetsky DS et al. (1993) *Mol Biol Reports* 18:217-221; Krieger M et al. (1994) *Ann Rev Biochem* 63:601-637; Macaya RF et al. (1993) *Proc Natl Acad Sci USA* 90:3745-3749; Wyatt JR et al. (1994) *Proc Natl Acad Sci USA* 91:1356-1360; Rando and Hogan, 1998, In *Applied Antisense Oligonucleotide Technology*, Krieg and Stein, eds., pp. 335-352; Kimura Y et al.  
25 (1994) *J Biochem (Tokyo)* 116:991-994.

The immunostimulatory nucleic acids of the invention can also be those which do not possess CpG, methylated CpG, T-rich, or poly-G motifs.

Exemplary immunostimulatory nucleic acid sequences include but are not limited to those immunostimulatory sequences described and listed in U.S. Non-Provisional Pat.  
30 Application No. 09/669,187, filed on September 25, 2000, and in corresponding published PCT patent application PCT/US00/26383 (WO 01/22972).

Immunoinhibitory nucleic acids have been described in Lenert P et al. (2001) *Antisense Nucleic Acid Drug Dev* 11:247-56 and in Stunz L et al. (2002) *Eur J Immunol*

32:1212-22. These inhibitory phosphorothioate ODN (S-ODN) differ from stimulatory S-ODN by having 2-3 G substitutions in the central motif. As inhibitory S-ODN did not directly interfere with the NF- $\kappa$ B DNA binding but prevented CpG-induced NF- $\kappa$ B nuclear translocation of p50, p65, and c-Rel and blocked p105, I $\kappa$ B $\alpha$ , and I $\kappa$ B $\beta$  degradation, Lenert et al. suggested that the putative target of immunoinhibitory ODN would lie upstream of inhibitory kinase (IKK) activation. Stunz et al. reported that replacing GCGTT or ACGTT with GCGGG or ACGGG converted a stimulatory 15-mer ODN into an inhibitory ODN. All inhibitory ODN had three consecutive G, and a fourth G increased inhibitory activity, but a deazaguanosine substitution to prevent planar stacking did not affect activity. Inhibitory ODN blocked apoptosis protection and cell-cycle entry induced by stimulatory ODN, but not that induced by lipopolysaccharide, anti-CD40 or anti-IgM+IL-4. ODN-driven up-regulation of cyclin D(2), c-Myc, c-Fos, c-Jun and Bcl(XL) and down-regulation of cyclin kinase inhibitor p27(kip1) were all blocked by inhibitory ODN. Stunz et al. also reported that interference with uptake of stimulatory ODN did not account for the inhibitory effects of the immunoinhibitory nucleic acids.

In one embodiment the immunoinhibitory nucleic acid has a base sequence provided by 5'-TCCTGGCGGGGAAGT-3' (SEQ ID NO:151).

Immunoinhibitory nucleic acids have also been described in U.S. Pat. No. 6,194,388, issued to Krieg et al. The immunoinhibitory oligonucleotides disclosed by Krieg et al. are oligonucleotides with GCG trinucleotides at or near the ends of the oligonucleotide and are represented by the formula 5' GCGX<sub>n</sub>GCG 3' in which X is a nucleotide and n is an integer between 0 and 50.

The nucleic acids used as either test or reference compounds can be double-stranded or single-stranded. They can be deoxyribonucleotide (DNA) or ribonucleotide (RNA) molecules. Generally, double-stranded molecules are more stable in vivo, while single-stranded molecules have increased immune activity. Thus in some the nucleic acid is single-stranded and in other embodiments the nucleic acid is double-stranded. In certain embodiments, while the nucleic acid is single-stranded, it is capable of forming secondary and tertiary structures (e.g., by folding back on itself, or by hybridizing with itself either throughout its entirety or at select segments along its length). Accordingly, while the primary structure of such a nucleic acid may be single-stranded, its higher order structures may be double- or triple-stranded.

- 40 -

For facilitating uptake into cells, the nucleic acids are preferably in the range of 6 to 100 bases in length. However, nucleic acids of any size equal to or greater than 6 nucleotides (even many kb long) are capable of inducing an immune response. Preferably the nucleic acid is in the range of between 8 and 100 and in some embodiments between 8 and 50 or 8 and 30 nucleotides in size.

The terms "nucleic acid" and "oligonucleotide" are used interchangeably to mean multiple nucleotides (i.e., molecules comprising a sugar (e.g., ribose or deoxyribose) linked to a phosphate group and to an exchangeable organic base, which is either a substituted pyrimidine (e.g., cytosine (C), thymine (T) or uracil (U)) or a substituted purine (e.g., adenine (A) or guanine (G)). As used herein, the terms "nucleic acid" and "oligonucleotide" refer to oligoribonucleotides as well as oligodeoxyribonucleotides. The terms "nucleic acid" and "oligonucleotide" shall also include polynucleosides (i.e., a polynucleotide minus the phosphate) and any other organic base containing polymer. Nucleic acid molecules can be obtained from existing nucleic acid sources (e.g., genomic or cDNA), but are preferably synthetic (e.g., produced by nucleic acid synthesis).

The terms "nucleic acid" and "oligonucleotide" also encompass nucleic acids or oligonucleotides with substitutions or modifications, such as in the bases and/or sugars. For example, they include nucleic acids having backbone sugars that are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 2' position and other than a phosphate group or hydroxy group at the 5' position. Thus modified nucleic acids may include a 2'-O-alkylated ribose group. In addition, modified nucleic acids may include sugars such as arabinose or 2'-fluoroarabinose instead of ribose. Thus the nucleic acids may be heterogeneous in backbone composition thereby containing any possible combination of polymer units linked together such as peptide-nucleic acids (which have an amino acid backbone with nucleic acid bases). Other examples are described in more detail below.

The immunostimulatory and immunoinhibitory nucleic acids can encompass various chemical modifications and substitutions, in comparison to natural RNA and DNA, involving a phosphodiester internucleoside bridge, a  $\beta$ -D-ribose unit and/or a natural nucleoside base (adenine, guanine, cytosine, thymine, uracil). Examples of chemical modifications are known to the skilled person and are described, for example, in Uhlmann E et al. (1990) *Chem Rev* 90:543; "Protocols for Oligonucleotides and Analogs" Synthesis and Properties & Synthesis and Analytical Techniques, S. Agrawal, Ed, Humana Press, Totowa, USA 1993; Crooke ST et al. (1996) *Annu Rev Pharmacol Toxicol* 36:107-129; and Hunziker J et al. (1995) *Mod Synth*

*Methods 7:331-417.* An oligonucleotide according to the invention may have one or more modifications, wherein each modification is located at a particular phosphodiester internucleoside bridge and/or at a particular  $\beta$ -D-ribose unit and/or at a particular natural nucleoside base position in comparison to an oligonucleotide of the same sequence which is composed of natural DNA or RNA.

For example, the oligonucleotides may comprise one or more modifications and wherein each modification is independently selected from:

- a) the replacement of a phosphodiester internucleoside bridge located at the 3' and/or the 5' end of a nucleoside by a modified internucleoside bridge,
- 10 b) the replacement of phosphodiester bridge located at the 3' and/or the 5' end of a nucleoside by a dephospho bridge,
- c) the replacement of a sugar phosphate unit from the sugar phosphate backbone by another unit,
- d) the replacement of a  $\beta$ -D-ribose unit by a modified sugar unit, and
- 15 e) the replacement of a natural nucleoside base by a modified nucleoside base.

More detailed examples for the chemical modification of an oligonucleotide are as follows.

The oligonucleotides may include modified internucleotide linkages, such as those described in (a) or (b) above. These modified linkages may be partially resistant to degradation (e.g., are stabilized). A "stabilized oligonucleotide molecule" shall mean an oligonucleotide that is relatively resistant to *in vivo* degradation (e.g., via an exo- or endonuclease) resulting from such modifications. Oligonucleotides having phosphorothioate linkages, in some embodiments, may provide maximal activity and protect the oligonucleotide from degradation by intracellular exo- and endo-nucleases.

25 A phosphodiester internucleoside bridge located at the 3' and/or the 5' end of a nucleoside can be replaced by a modified internucleoside bridge, wherein the modified internucleoside bridge is for example selected from phosphorothioate, phosphorodithioate,  $\text{NR}^1\text{R}^2$ -phosphoramidate, boranophosphate,  $\alpha$ -hydroxybenzyl phosphonate, phosphate-( $\text{C}_1$ - $\text{C}_{21}$ )-O-alkyl ester, phosphate-[( $\text{C}_6$ - $\text{C}_{12}$ )aryl-( $\text{C}_1$ - $\text{C}_{21}$ )-O-alkyl]ester, ( $\text{C}_1$ - $\text{C}_8$ )alkylphosphonate and/or ( $\text{C}_6$ - $\text{C}_{12}$ )arylphosphonate bridges, ( $\text{C}_7$ - $\text{C}_{12}$ )- $\alpha$ -hydroxymethyl-aryl (e.g., disclosed in WO 95/01363), wherein ( $\text{C}_6$ - $\text{C}_{12}$ )aryl, ( $\text{C}_6$ - $\text{C}_{20}$ )aryl and ( $\text{C}_6$ - $\text{C}_{14}$ )aryl are optionally substituted by halogen, alkyl, alkoxy, nitro, cyano, and where  $\text{R}^1$  and  $\text{R}^2$  are, independently of each other, hydrogen, ( $\text{C}_1$ - $\text{C}_{18}$ )-alkyl, ( $\text{C}_6$ - $\text{C}_{20}$ )-aryl, ( $\text{C}_6$ - $\text{C}_{14}$ )-aryl-( $\text{C}_1$ - $\text{C}_8$ )-alkyl, preferably hydrogen,

(C<sub>1</sub>-C<sub>8</sub>)-alkyl, preferably (C<sub>1</sub>-C<sub>4</sub>)-alkyl and/or methoxyethyl, or R<sup>1</sup> and R<sup>2</sup> form, together with the nitrogen atom carrying them, a 5-6-membered heterocyclic ring which can additionally contain a further heteroatom from the group O, S and N.

The replacement of a phosphodiester bridge located at the 3' and/or the 5' end of a nucleoside by a dephospho bridge (dephospho bridges are described, for example, in Uhlmann E and Peyman A in "Methods in Molecular Biology", Vol. 20, "Protocols for Oligonucleotides and Analogs", S. Agrawal, Ed., Humana Press, Totowa, 1993, Chapter 16, pp. 355 ff), wherein a dephospho bridge is for example selected from the dephospho bridges formacetal, 3'-thioformacetal, methylhydroxylamine, oxime, methylenedimethyl-hydrazo, dimethylenesulfone and/or silyl groups.

A sugar phosphate unit (i.e., a  $\beta$ -D-ribose and phosphodiester internucleoside bridge together forming a sugar phosphate unit) from the sugar phosphate backbone (i.e., a sugar phosphate backbone is composed of sugar phosphate units) can be replaced by another unit, wherein the other unit is for example suitable to build up a "morpholino-derivative" oligomer (as described, for example, in Stirchak EP et al. (1989) *Nucleic Acids Res* 17:6129-41), that is, e.g., the replacement by a morpholino-derivative unit; or to build up a polyamide nucleic acid ("PNA"; as described for example, in Nielsen PE et al. (1994) *Bioconjug Chem* 5:3-7), that is, e.g., the replacement by a PNA backbone unit, e.g., by 2-aminoethylglycine. The oligonucleotide may have other carbohydrate backbone modifications and replacements, such as peptide nucleic acids with phosphate groups (PHONA), locked nucleic acids (LNA), and oligonucleotides having backbone sections with alkyl linkers or amino linkers. The alkyl linker may be branched or unbranched, substituted or unsubstituted, and chirally pure or a racemic mixture.

A  $\beta$ -ribose unit or a  $\beta$ -D-2'-deoxyribose unit can be replaced by a modified sugar unit, wherein the modified sugar unit is for example selected from  $\beta$ -D-ribose,  $\alpha$ -D-2'-deoxyribose, L-2'-deoxyribose, 2'-F-2'-deoxyribose, 2'-F-arabinose, 2'-O-(C<sub>1</sub>-C<sub>6</sub>)alkyl-ribose, preferably 2'-O-(C<sub>1</sub>-C<sub>6</sub>)alkyl-ribose is 2'-O-methylribose, 2'-O-(C<sub>2</sub>-C<sub>6</sub>)alkenyl-ribose, 2'-[O-(C<sub>1</sub>-C<sub>6</sub>)alkyl-O-(C<sub>1</sub>-C<sub>6</sub>)alkyl]-ribose, 2'-NH<sub>2</sub>-2'-deoxyribose,  $\beta$ -D-xylo-furanose,  $\alpha$ -arabinofuranose, 2,4-dideoxy- $\beta$ -D-erythro-hexo-pyranose, and carbocyclic (described, for example, in Froehler J (1992) *Am Chem Soc* 114:8320) and/or open-chain sugar analogs (described, for example, in Vandendriessche et al. (1993) *Tetrahedron* 49:7223) and/or bicyclosugar analogs (described, for example, in Tarkov M et al. (1993) *Helv Chim Acta* 76:481).



- 43 -

In some embodiments the sugar is 2'-O-methylribose, particularly for one or both nucleotides linked by a phosphodiester or phosphodiester-like internucleoside linkage.

In some embodiments, the nucleic acids may be soft or semi-soft nucleic acids. A soft nucleic acid is an immunostimulatory nucleic acid having a partially stabilized backbone, in which phosphodiester or phosphodiester-like internucleotide linkages occur only within and immediately adjacent to at least one internal pyrimidine-purine dinucleotide (YZ). Preferably YZ is YG, a pyrimidine-guanosine (YG) dinucleotide. The at least one internal YZ dinucleotide itself has a phosphodiester or phosphodiester-like internucleotide linkage. A phosphodiester or phosphodiester-like internucleotide linkage occurring immediately adjacent to the at least one internal YZ dinucleotide can be 5', 3', or both 5' and 3' to the at least one internal YZ dinucleotide.

In particular, phosphodiester or phosphodiester-like internucleotide linkages involve "internal dinucleotides". An internal dinucleotide in general shall mean any pair of adjacent nucleotides connected by an internucleotide linkage, in which neither nucleotide in the pair of nucleotides is a terminal nucleotide, i.e., neither nucleotide in the pair of nucleotides is a nucleotide defining the 5' or 3' end of the nucleic acid. Thus a linear nucleic acid that is n nucleotides long has a total of n-1 dinucleotides and only n-3 internal dinucleotides. Each internucleotide linkage in an internal dinucleotide is an internal internucleotide linkage. Thus a linear nucleic acid that is n nucleotides long has a total of n-1 internucleotide linkages and only n-3 internal internucleotide linkages. The strategically placed phosphodiester or phosphodiester-like internucleotide linkages, therefore, refer to phosphodiester or phosphodiester-like internucleotide linkages positioned between any pair of nucleotides in the nucleic acid sequence. In some embodiments the phosphodiester or phosphodiester-like internucleotide linkages are not positioned between either pair of nucleotides closest to the 5' or 3' end.

Preferably a phosphodiester or phosphodiester-like internucleotide linkage occurring immediately adjacent to the at least one internal YZ dinucleotide is itself an internal internucleotide linkage. Thus for a sequence  $N_1$  YZ  $N_2$ , wherein  $N_1$  and  $N_2$  are each, independent of the other, any single nucleotide, the YZ dinucleotide has a phosphodiester or phosphodiester-like internucleotide linkage, and in addition (a)  $N_1$  and Y are linked by a phosphodiester or phosphodiester-like internucleotide linkage when  $N_1$  is an internal nucleotide, (b) Z and  $N_2$  are linked by a phosphodiester or phosphodiester-like internucleotide linkage when  $N_2$  is an internal nucleotide, or (c)  $N_1$  and Y are linked by a phosphodiester or

- 44 -

phosphodiester-like internucleotide linkage when  $N_1$  is an internal nucleotide and Z and  $N_2$  are linked by a phosphodiester or phosphodiester-like internucleotide linkage when  $N_2$  is an internal nucleotide.

Soft nucleic acids according to the instant invention are believed to be relatively  
5 susceptible to nuclease cleavage compared to completely stabilized nucleic acids. Without  
meaning to be bound to a particular theory or mechanism, it is believed that soft nucleic acids  
of the invention are cleavable to fragments with reduced or no immunostimulatory activity  
relative to full-length soft nucleic acids. Incorporation of at least one nuclease-sensitive  
internucleotide linkage, particularly near the middle of the nucleic acid, is believed to provide  
10 an "off switch" which alters the pharmacokinetics of the nucleic acid so as to reduce the  
duration of maximal immunostimulatory activity of the nucleic acid. This can be of particular  
value in tissues and in clinical applications in which it is desirable to avoid injury related to  
chronic local inflammation or immunostimulation, e.g., the kidney.

A semi-soft nucleic acid is an immunostimulatory nucleic acid having a partially  
15 stabilized backbone, in which phosphodiester or phosphodiester-like internucleotide linkages  
occur only within at least one internal pyrimidine-purine (YZ) dinucleotide. Semi-soft  
nucleic acids generally possess increased immunostimulatory potency relative to  
corresponding fully stabilized immunostimulatory nucleic acids. Due to the greater potency  
of semi-soft nucleic acids, semi-soft nucleic acids may be used, in some instances, at lower  
20 effective concentrations and have lower effective doses than conventional fully stabilized  
immunostimulatory nucleic acids in order to achieve a desired biological effect.

It is believed that the foregoing properties of semi-soft nucleic acids generally increase  
with increasing "dose" of phosphodiester or phosphodiester-like internucleotide linkages  
involving internal YZ dinucleotides. Thus it is believed, for example, that generally for a  
25 given nucleic acid sequence with five internal YZ dinucleotides, an nucleic acid with five  
internal phosphodiester or phosphodiester-like YZ internucleotide linkages is more  
immunostimulatory than an nucleic acid with four internal phosphodiester or phosphodiester-  
like YG internucleotide linkages, which in turn is more immunostimulatory than an nucleic  
acid with three internal phosphodiester or phosphodiester-like YZ internucleotide linkages,  
30 which in turn is more immunostimulatory than an nucleic acid with two internal  
phosphodiester or phosphodiester-like YZ internucleotide linkages, which in turn is more  
immunostimulatory than an nucleic acid with one internal phosphodiester or phosphodiester-  
like YZ internucleotide linkage. Importantly, inclusion of even one internal phosphodiester or

phosphodiester-like YZ internucleotide linkage is believed to be advantageous over no internal phosphodiester or phosphodiester-like YZ internucleotide linkage. In addition to the number of phosphodiester or phosphodiester-like internucleotide linkages, the position along the length of the nucleic acid can also affect potency.

5       The soft and semi-soft nucleic acids will generally include, in addition to the phosphodiester or phosphodiester-like internucleotide linkages at preferred internal positions, 5' and 3' ends that are resistant to degradation. Such degradation-resistant ends can involve any suitable modification that results in an increased resistance against exonuclease digestion over corresponding unmodified ends. For instance, the 5' and 3' ends can be stabilized by the  
10       inclusion thereof at least one phosphate modification of the backbone. In a preferred embodiment, the at least one phosphate modification of the backbone at each end is independently a phosphorothioate, phosphorodithioate, methylphosphonate, or methylphosphorothioate internucleotide linkage. In another embodiment, the degradation-resistant end includes one or more nucleotide units connected by peptide or amide linkages at  
15       the 3' end.

A phosphodiester internucleotide linkage is the type of linkage characteristic of nucleic acids found in nature. The phosphodiester internucleotide linkage includes a phosphorus atom flanked by two bridging oxygen atoms and bound also by two additional oxygen atoms, one charged and the other uncharged. Phosphodiester internucleotide linkage  
20       is particularly preferred when it is important to reduce the tissue half-life of the nucleic acid.

A phosphodiester-like internucleotide linkage is a phosphorus-containing bridging group that is chemically and/or diastereomerically similar to phosphodiester. Measures of similarity to phosphodiester include susceptibility to nuclease digestion and ability to activate RNase H. Thus for example phosphodiester, but not phosphorothioate, nucleic acids are  
25       susceptible to nuclease digestion, while both phosphodiester and phosphorothioate nucleic acids activate RNase H. In a preferred embodiment the phosphodiester-like internucleotide linkage is boranophosphate (or equivalently, boranophosphonate) linkage. U.S. Patent No. 5,177,198; U.S. Patent No. 5,859,231; U.S. Patent No. 6,160,109; U.S. Patent No. 6,207,819; Sergueev et al., (1998) *J Am Chem Soc* 120:9417-27. In another preferred embodiment the  
30       phosphodiester-like internucleotide linkage is diastereomerically pure Rp phosphorothioate. It is believed that diastereomerically pure Rp phosphorothioate is more susceptible to nuclease digestion and is better at activating RNase H than mixed or diastereomerically pure Sp phosphorothioate. Stereoisomers of CpG nucleic acids are the subject of co-pending U.S.

patent application 09/361,575 filed July 27, 1999, and published PCT application PCT/US99/17100 (WO 00/06588). It is to be noted that for purposes of the instant invention, the term "phosphodiester-like internucleotide linkage" specifically excludes phosphorodithioate and methylphosphonate internucleotide linkages.

5 As described above the soft and semi-soft nucleic acids of the invention may have phosphodiester like linkages between C and G. One example of a phosphodiester-like linkage is a phosphorothioate linkage in an  $R_p$  conformation. Nucleic acid p-chirality can have apparently opposite effects on the immune activity of a CpG nucleic acid, depending upon the time point at which activity is measured. At an early time point of 40 minutes, the  $R_p$  but not  
10 the  $S_p$  stereoisomer of phosphorothioate CpG nucleic acid induces JNK phosphorylation in mouse spleen cells. In contrast, when assayed at a late time point of 44 hr, the  $S_p$  but not the  $R_p$  stereoisomer is active in stimulating spleen cell proliferation. This difference in the kinetics and bioactivity of the  $R_p$  and  $S_p$  stereoisomers does not result from any difference in cell uptake, but rather most likely is due to two opposing biologic roles of the p-chirality.  
15 First, the enhanced activity of the  $R_p$  stereoisomer compared to the  $S_p$  for stimulating immune cells at early time points indicates that the  $R_p$  may be more effective at interacting with the CpG receptor, TLR9, or inducing the downstream signaling pathways. On the other hand, the faster degradation of the  $R_p$  PS-nucleic acids compared to the  $S_p$  results in a much shorter duration of signaling, so that the  $S_p$  PS-nucleic acids appear to be more biologically  
20 active when tested at later time points.

A surprisingly strong effect is achieved by the p-chirality at the CpG dinucleotide itself. In comparison to a stereo-random CpG nucleic acid the congener in which the single CpG dinucleotide was linked in  $R_p$  was slightly more active, while the congener containing an  $S_p$  linkage was nearly inactive for inducing spleen cell proliferation.

25 Nucleic acids also include substituted purines and pyrimidines such as C-5 propyne pyrimidine and 7-deaza-7-substituted purine modified bases. Wagner RW et al. (1996) *Nat Biotechnol* 14:840-4. Purines and pyrimidines include but are not limited to adenine, cytosine, guanine, and thymine, and other naturally and non-naturally occurring nucleobases, substituted and unsubstituted aromatic moieties.

30 A modified base is any base which is chemically distinct from the naturally occurring bases typically found in DNA and RNA such as T, C, G, A, and U, but which share basic chemical structures with these naturally occurring bases. The modified nucleoside base may be, for example, selected from hypoxanthine, uracil, dihydrouracil, pseudouracil, 2-thiouracil,

- 47 -

4-thiouracil, 5-aminouracil, 5-(C<sub>1</sub>-C<sub>6</sub>)-alkyluracil, 5-(C<sub>2</sub>-C<sub>6</sub>)-alkenyluracil, 5-(C<sub>2</sub>-C<sub>6</sub>)-alkynyluracil, 5-(hydroxymethyl)uracil, 5-chlorouracil, 5-fluorouracil, 5-bromouracil, 5-hydroxycytosine, 5-(C<sub>1</sub>-C<sub>6</sub>)-alkylcytosine, 5-(C<sub>2</sub>-C<sub>6</sub>)-alkenylcytosine, 5-(C<sub>2</sub>-C<sub>6</sub>)-alkynylcytosine, 5-chlorocytosine, 5-fluorocytosine, 5-bromocytosine, N<sup>2</sup>-dimethylguanine, 2,4-diamino-purine, 8-azapurine, a substituted 7-deazapurine, preferably 7-deaza-7-substituted and/or 7-deaza-8-substituted purine, 5-hydroxymethylcytosine, N4-alkylcytosine, e.g., N4-ethylcytosine, 5-hydroxydeoxycytidine, 5-hydroxymethyldeoxycytidine, N4-alkyldeoxycytidine, e.g., N4-ethyldeoxycytidine, 6-thiodeoxyguanosine, and deoxyribonucleosides of nitropyrrole, C5-propynylpyrimidine, and diaminopurine e.g., 2,6-diaminopurine, inosine, 5-methylcytosine, 2-aminopurine, 2-amino-6-chloropurine, hypoxanthine or other modifications of a natural nucleoside bases. This list is meant to be exemplary and is not to be interpreted to be limiting.

Modified cytosines include but are not limited to 5-substituted cytosines (e.g., 5-methyl-cytosine, 5-fluoro-cytosine, 5-chloro-cytosine, 5-bromo-cytosine, 5-iodo-cytosine, 5-hydroxy-cytosine, 5-hydroxymethyl-cytosine, 5-difluoromethyl-cytosine, and unsubstituted or substituted 5-alkynyl-cytosine), 6-substituted cytosines, N4-substituted cytosines (e.g., N4-ethyl-cytosine), 5-aza-cytosine, 2-mercapto-cytosine, isocytosine, pseudo-isocytosine, cytosine analogs with condensed ring systems (e.g., N,N'-propylene cytosine or phenoxazine), and uracil and its derivatives (e.g., 5-fluoro-uracil, 5-bromo-uracil, 5-bromovinyl-uracil, 4-thio-uracil, 5-hydroxy-uracil, 5-propynyl-uracil). In another embodiment, the cytosine base is substituted by a universal base (e.g., 3-nitropyrrole, P-base), an aromatic ring system (e.g., fluorobenzene or difluorobenzene) or a hydrogen atom (dSpacer).

Modified guanines include but are not limited to 7-deazaguanine, 7-deaza-7-substituted guanine (such as 7-deaza-7-(C<sub>2</sub>-C<sub>6</sub>)alkynylguanine), 7-deaza-8-substituted guanine, hypoxanthine, N2-substituted guanines (e.g., N2-methyl-guanine), 5-amino-3-methyl-3H,6H-thiazolo[4,5-d]pyrimidine-2,7-dione, 2,6-diaminopurine, 2-aminopurine, purine, indole, adenine, substituted adenines (e.g., N6-methyl-adenine, 8-oxo-adenine) 8-substituted guanine (e.g., 8-hydroxyguanine and 8-bromoguanine), and 6-thioguanine. In another embodiment, the guanine base is substituted by a universal base (e.g., 4-methyl-indole, 5-nitro-indole, and K-base), an aromatic ring system (e.g., benzimidazole or dichloro-benzimidazole, 1-methyl-1H-[1,2,4]triazole-3-carboxylic acid amide) or a hydrogen atom (dSpacer).

For use in the instant invention, the oligonucleotide reference compounds and test compounds can be synthesized *de novo* using any of a number of procedures well known in the art, for example, the  $\beta$ -cyanoethyl phosphoramidite method (Beaucage SL et al. (1981) *Tetrahedron Lett* 22:1859), or the nucleoside H-phosphonate method (Garegg et al. (1986) *Tetrahedron Lett* 27:4051-4; Froehler BC et al. (1986) *Nucleic Acids Res* 14:5399-407; Garegg et al (1986) *Tetrahedron Lett* 27:4055-8; Gaffney et al. (1988) *Tetrahedron Lett* 29:2619-22). These chemistries can be performed by a variety of automated nucleic acid synthesizers available in the market. These oligonucleotides are referred to as synthetic oligonucleotides. An isolated oligonucleotide generally refers to an oligonucleotide which is separated from components which it is normally associated with in nature. As an example, an isolated oligonucleotide may be one which is separated from a cell, from a nucleus, from mitochondria or from chromatin.

Modified backbones such as phosphorothioates can be synthesized using automated techniques employing either phosphoramidate or H-phosphonate chemistries. Aryl- and alkyl-phosphonates can be made, e.g., as described in U.S. Pat. No. 4,469,863; and alkylphosphotriesters (in which the charged oxygen moiety is alkylated as described in U.S. Pat. No. 5,023,243 and European Pat. No. 092,574) can be prepared by automated solid phase synthesis using commercially available reagents. Methods for making other DNA backbone modifications and substitutions have been described (e.g., Uhlmann E et al. (1990) *Chem Rev* 90:544; Goodchild J (1990) *Bioconjugate Chem* 1:165).

#### TLR expression

The cell lines can be used in their native state without any modification. For example, in the case of the RPMI 8226 cell line, it can be used to identify compounds that signal through at least TLR9 and/or TLR7. In other instances, however, the cell line can be modified to express a TLR that it does not naturally express. In still other instances, the cell to be used in the screening method may express one or more endogenous TLR and yet still be manipulated to express an additional TLR different from those it endogenously expresses. The cell may also be manipulated in order to increase or decrease the level of TLR that it endogenously expresses. The cells may be stably or transiently transfected.

A cell that does not naturally express a protein or polypeptide, but is genetically manipulated to do so is referred to as ectopically expressing the protein or polypeptide.

The basic screening method remains the same regardless of which TLR is expressed by the cell. However, the reference compound and the readout may vary depending upon the TLR(s) expressed. In the most simple aspect, the screening method is used to identify a compound that signals through a TLR such as for example TLR9. In this case, the positive  
5 reference compound may be an immunostimulatory compound already known to act through TLR9 (e.g., CpG nucleic acid).

The methods of the invention involve, in part, contacting a functional TLR with a test composition. A functional TLR is a full-length TLR protein or a fragment thereof capable of inducing or inhibiting a signal in response to interaction with its ligand. Generally the  
10 functional TLR will include at least a TLR ligand-binding fragment of the extracellular domain of the full-length TLR and at least a fragment of a TIR domain capable of interacting with another Toll homology domain-containing polypeptide, e.g., MyD88. In various embodiments the functional TLR is a full-length TLR selected from TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, and TLR10.

To date, there are eleven TLRs known. Nucleic acid and amino acid sequences for ten  
15 currently known human TLRs are available from public databases such as GenBank. Similarly, nucleic acid and amino acid sequences for various TLRs from numerous non-human species are also available from public databases including GenBank. For example, nucleic acid and amino acid sequences for human TLR9 (hTLR9) can be found as GenBank  
20 accession numbers AF245704 (coding region spanning nucleotides 145-3243) (SEQ ID NO: 60) and AAF78037 (SEQ ID NO: 62), respectively. Nucleic acid and amino acid sequences for murine TLR9 (mTLR9) can be found as GenBank accession numbers AF348140 (coding region spanning nucleotides 40-3138) (SEQ ID NO: 68) and AAK29625 (SEQ ID NO: 72), respectively.

Nucleic acid and amino acid sequences for human TLR8 (hTLR8) can be found as  
25 GenBank accession numbers AF245703 (coding region spanning nucleotides 49-3174) (SEQ ID NO: 46) and AAF78036 (SEQ ID NO: 50), respectively. Nucleic acid and amino acid sequences for murine TLR8 (mTLR8) can be found as GenBank accession numbers AY035890 (coding region spanning nucleotides 59-3157) (SEQ ID NO: 55) and AAK62677  
30 (SEQ ID NO: 57), respectively.

Nucleic acid and amino acid sequences for human TLR7 (hTLR7) can be found as GenBank accession numbers AF240467 (coding region spanning nucleotides 135-3285) (SEQ ID NO: 31) and AAF60188 (SEQ ID NO: 34), respectively. Nucleic acid and amino acid

sequences for murine TLR7 (mTLR7) can be found as GenBank accession numbers AY035889 (coding region spanning nucleotides 49-3201) (SEQ ID NO: 38) and AAK62676 (SEQ ID NO: 41), respectively.

5 Nucleic acid and amino acid sequences for human TLR3 (hTLR3) can be found as GenBank accession numbers NM\_003265 (coding region spanning nucleotides 102-2816) (SEQ ID NO: 7) and NP\_003256 (SEQ ID NO: 8), respectively. Nucleic acid and amino acid sequences for murine TLR3 (hTLR3) can be found as GenBank accession numbers AF355152 (coding region spanning nucleotides 44-2761) (SEQ ID NO: 9) and AAK26117 (SEQ ID NO: 10), respectively.

10 Nucleic acid and amino acid sequences for human TLR1 (hTLR1) can be found as GenBank accession numbers NM\_003263 and NP\_003254, respectively. Nucleic acid and amino acid sequences for murine TLR1 (mTLR1) can be found as GenBank accession numbers NM\_030682 and NP\_109607, respectively.

The functional TLR also is not limited to native TLR polypeptides. As used herein, a  
15 native TLR is one that is naturally occurring. The TLR may be a non-native (or non-naturally occurring TLR). An example is a chimeric TLR having an extracellular domain and the cytoplasmic domain derived from TLRs from different species. Such chimeric TLR polypeptides can include, for example, a human TLR extracellular domain and a murine TLR cytoplasmic domain. In alternative embodiments, such chimeric TLR polypeptides can  
20 include chimerae created with different TLR splice variants or allotypes.

#### TLR Signaling Pathways

The screening methods provided by the invention measure TLR signaling activity. TLR signaling activity is activity that results from interaction of a TLR with a TLR ligand.  
25 TLR signaling can be measured in a number of ways including but not limited to interaction between a TLR and a protein or factor (such as an adaptor protein), interaction between downstream proteins or factors (such as an adaptor protein) with each other, activation of nuclear factors such as transcription factors or transcription complexes, up- or down-regulation of genes, phosphorylation or dephosphorylation of proteins or factors in the  
30 signaling cascade, expression, production and/or secretion of cytokines and/or chemokines, changes in cell cycle status, up- or down-regulation of cell surface marker expression, and the like. Those of ordinary skill in the art are familiar with assays for measuring these latter



events including but not limited to gel shift assays, immunoprecipitations, phosphorylation status analysis of proteins, Northern analysis, RT-PCR analysis, etc.

The following is an exemplary TLR signaling pathway or cascade. It is to be understood that this is meant to be illustrative and that different factors may be involved in the signaling of particular TLR. One TLR signaling pathway is known to use the cytoplasmic Toll/IL-1 receptor (TIR) homology domain, present in all TLRs. This domain interacts (e.g., binds to) and thereby transduces a signal to a similar domain on an adapter protein (e.g., MyD88). This type of interaction is referred to as a like:like interaction of TIR domains. This interaction is followed by an another interaction between the adapter protein and a kinase, through their respective "death domains". In the case of at least TLR4 signaling, the kinase then interacts with tumor necrosis factor (TNF) receptor-associated factor-6 (TRAF6). Medzhitov R et al., *Mol Cell* 2:253 (1998); Kopp EB et al., *Curr Opin Immunol* 11:15 (1999). After TRAF6, two sequential kinase activation steps lead to phosphorylation of the inhibitory protein I kappa B and its dissociation from NF- $\kappa$ B. The first kinase is a mitogen-activated kinase kinase kinase (MAPKKK) known as NIK, for NF- $\kappa$ B-inducing kinase. The target of this kinase is another kinase made up of two chains, called I kappa B kinase  $\alpha$  (IKK  $\alpha$ ) and I kappa B kinase  $\beta$  (IKK  $\beta$ ), that together form a heterodimer of IKK $\alpha$ :IKK $\beta$ , which phosphorylates I kappa B. NF- $\kappa$ B translocates to the nucleus to activate genes with kappa B binding sites in their promoters and enhancers such as the genes encoding IL-6, IL-8, the p40 subunit of IL-12, and the costimulatory molecule CD86. The signaling mechanisms of TLRs are not limited to this pathway; other signaling pathways exist and can be used in the screening readouts of the methods provided herein.

The screening assays employ a number of readouts (or parameters). The readouts can be native readouts. A native readout is one that does not rely on introduction of a reporter construct into the cell of interest. The readouts can be artificial. An artificial readout is one that relies on introduction of a reporter construct into the cell of interest. Examples of both are provided herein. In still other embodiments, a given assay may measure one or more native readouts and one or more artificial readouts. Each readout whether native or artificial is related to signaling pathways that ensue after TLR engagement with a ligand.

Each cell line described herein will be associated with a particular set of native readouts which the invention seeks to determine in the screening assays provided. As an example, the response of the RPMI 8226 cell line to an immunomodulatory molecule can be assessed in terms of native readouts such as CD71 expression, CD86 expression, HLA-DR

expression, IL-8 expression, IL-8 production, IL-8 secretion, IL-10 expression, IL-10 production, IL-10 secretion, IP-10 expression, IP-10 production, IP-10 secretion, TNF- $\alpha$  expression, TNF- $\alpha$  production and TNF- $\alpha$  secretion. RAMOS response can be assessed, inter alia, by CD80 cell surface expression. Raji response can be assessed, inter alia, by IL-6 secretion.

As described in greater detail herein, the cell line can be used in an unmodified form. In one respect, an unmodified cell line will naturally respond to a TLR ligand through a native readout system. For example, an RPMI 8226 cell exposed to an immunostimulatory TLR ligand may increase expression of IP-10 from the native gene locus. Alternatively, the cell line may be modified to contain a reporter construct that acts as a surrogate for the IP-10 gene locus. For example, the reporter construct may contain the TLR responsive promoter elements that are naturally found in the native IP-10 locus operably linked to a reporter coding sequence that encodes a gene product that is detectable and quantifiable. The structure and variability of suitable reporter constructs will be discussed in greater detail herein.

Readouts typically include the induction of a gene under control of a specific promoter such as a NF- $\kappa$ B promoter. The gene under the control of the NF- $\kappa$ B promoter can be a gene which naturally includes an NF- $\kappa$ B promoter or it can be a gene in a construct in which an NF- $\kappa$ B promoter has been inserted. Endogenous genes and transfected constructs which include the NF- $\kappa$ B promoter include but are not limited to IL-8, IL-12 p40, NF- $\kappa$ B-luc, IL-12 p40-luc, and TNF-luc.

Increases in cytokine levels can result from increased production, increased stability, increased secretion, or any combination of the forgoing, of the cytokine in response to the TLR-mediated signaling. Cytokines generally include, without limitation, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-11, IL-12, IL-13, IL-15, IL-18, IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , TNF- $\alpha$ , GM-CSF, G-CSF, M-CSF. Th1 cytokines include but are not limited to IL-2, IFN- $\gamma$ , and IL-12. Th2 cytokines include but are not limited to IL-4, IL-5, and IL-10.

Increases in chemokine levels can result from increased production, increased stability, increased secretion, or any combination of the forgoing, of the chemokine in response to the TLR-mediated signaling. Chemokines of particular significance in the invention include but are not limited to CCL5 (RANTES), CXCL9 (Mig), CXCL10 (IP-10), CXCL11 (I-TAC), IL-8, and MCP-1.

- 53 -

TLR signaling activity can also be measured by phosphorylation, such as total cellular phosphorylation or phosphorylation of specific factors such as but not limited to IRAK, ERK, MyD88, TRAF6, p38, NF- $\kappa$ B subunits, c-Jun and c-Fos.

5 TLR signaling activity can be measured by changes in gene expression. The expression of CD71, CD86, CD80, CD69, CD54, HLA-DR, HLA class I, IL-6, IL-8, IL-10, IP-9, IP-10, IFN- $\alpha$ , TNF- $\alpha$ , and the like can be assessed as a measure of TLR signaling activity. Gene expression analysis may be performed using microarray techniques.

TLR signaling activity can also be measured by cell proliferation status or changes thereto.

10 TLR signaling activity can also be measured by cell surface marker expression such as the cell surface expression of markers such as but not limited to CD71, CD86, HLA-DR, CD80, HLA class I, CD54 and CD69.

TLR signaling activity can also be measured by antibody secretion such as but not limited to IgM secretion.

15

#### Reporter and Expression Constructs

The cells can be manipulated by the introduction of expression and/or reporter constructs. The expression constructs preferably comprise a TLR coding sequence, as described above. The reporter constructs can be used as surrogate measures of native TLR  
20 signaling activity. These reporter constructs are intended to substitute for the "native" readouts capable with the cell line. In order to act as substitutes, the reporter constructs include a promoter element derived from a gene known to be modulated following TLR engagement with a TLR ligand. The reporter construct further includes a coding sequence linked to the promoter. The coding sequence is usually that of a reporter (i.e., a protein that is  
25 detectable or quantifiable).

The reporter construct generally includes a promoter, a coding sequence and a polyadenylation signal. These nucleic acids shall include, as necessary, 5' non-transcribing and 5' non-translating sequences involved with the initiation of transcription and translation, respectively, such as a TATA box, capping sequence, CAAT sequence, in addition to  
30 promoter elements that are responsive to TLR signaling. The nucleic acid constructs may optionally include enhancer sequences or upstream activator sequences as desired.

The promoter in the reporter construct will include a TLR responsive promoter element, and will therefore be regarded as a TLR responsive promoter. As used herein, a

- 54 -

TLR responsive promoter is a promoter having an activity that is modulated (i.e., either activated or inhibited) by signaling through a TLR (e.g., by TLR interaction with its ligand). In order to be modulated by TLR signaling, the promoter contains sites that are bound by transcription factors modulated by TLR signaling. The factors may be activated or inhibited by TLR signaling. Activation of the transcription factor includes increases in the activity of the transcription factor per se, increases in its ability to interact with other factors or with DNA that serve to increase its activity, and increases in its transcription and translation (i.e., increased mRNA and protein levels of the transcription factor). Conversely, inhibition of the transcription factor includes decreases in the activity of the transcription factor per se, decreases in its ability to interact with other factors or with DNA that serve to decrease its activity, and decreases in its transcription and translation (i.e., decreased mRNA and protein levels of the transcription factor). The effect on the transcription factor is usually the downstream result of other interactions in the signaling pathway. The expression of coding sequences linked to such promoters will therefore be modulated by TLR signaling events, and it is the level of expression of these coding sequences that can be used as a readout of TLR signaling in the screening methods provided herein.

The TLR responsive promoter may comprise a transcription factor binding site selected from the group consisting of a NF- $\kappa$ B binding site, an AP-1 binding site, a CRE, a SRE, an interferon-stimulated response element (ISRE), a GAS, an ATF2 binding site, an IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding site, and a TARE, among others. These binding sites and their sequences are known in the art. Below is a exemplary list of these sequences.

W = A or T, R = A or G, Y = C or T

25 NF- $\kappa$ B Binding site:

Consensus p50 subunit  
5' GGGGATYCCC 3' (SEQ ID NO:90)

30 Consensus p65 subunit  
5' GGGRNTTCC 3' (SEQ ID NO:91)

Example of p65 subunit binding site  
5' AGT TGA GGG GAC TTT CCC AGG C 3' (SEQ ID NO:92)

35 CREB Binding site:  
5'AGA GAT TGC CTG ACG TCA GAG AGC TAG 3' (SEQ ID NO:93)

- 55 -

## AP-1 Binding site:

5'- CGC TTG ATG AGT CAG CCG GAA -3' (SEQ ID NO:94)

5'- CGC ATG AGT CAG ACA -3' (SEQ ID NO:95)

## 5 ISRE :

5'- TGCAGAAGTGAAACTGAGG-3' (SEQ ID NO:96)

5'- AGAACGAAACA-3' (SEQ ID NO:97)

5'- GAGAAGTGAAAGTGG-3' (SEQ ID NO:98)

5'- TAAGAACATGAAACTGAA-3' (SEQ ID NO:99)

10 5'- ATGAAACTGAAAGTA-3' (SEQ ID NO:100)

5'- TGAAAACCGAAAGCGC-3' (SEQ ID NO:101)

5'- AGAAATGGAAAGT-3' (SEQ ID NO:102)

## SRE

15 5'- TCACCCAC-3' (SEQ ID NO:103)

5'- CTCACCCAC-3' (SEQ ID NO:104)

5'- GCCACCCTAC-3' (SEQ ID NO:105)

## NFAT:

20 5'- TATGAAACAGTTTTTCC -3' (SEQ ID NO:106)

5'- AGGAAACTC -3' (SEQ ID NO:107)

5'- ARGARATTCC -3' (SEQ ID NO:108)

5'- CCAGTTGAGCCAGAGA -3' (SEQ ID NO:109)

## 25 GAS:

5'- CTTTCAGTTTCATATTACTCTAAATCCATT -3' (SEQ ID NO:110)

## p53 Binding Site :

## 30 p53 Consensus site:

5'- RRRCWWGYYY -3' (SEQ ID NO:111)

## Examples of p53 binding sites:

35 5'- AGGCATGCCT -3' (SEQ ID NO:112)

5'- GGGCTTGCCC -3' (SEQ ID NO:113)

5'- GGGCTTGCTT -3' (SEQ ID NO:114)

5'- GCCTGGACTTGCC -3' (SEQ ID NO:115)

5'- GGACATGCCCCGGGCATGTCC -3' (SEQ ID NO:116)

5'- GTAGCATTAGCCCAGACATGTCC -3' (SEQ ID NO:117)

40

TARE (TNF- $\alpha$  response element):

e.g. from the COL1A1 promoter

5'GAGGTATGCAGACAAGAGTCAGAGTTTCCCCTTGAA 3' (SEQ ID  
NO:118)

45

SRF

5'- CCWWWWWWGG -3' (SEQ ID NO:119)

5'- CCAAATAAGGC -3' (SEQ ID NO:120)

- 56 -

The TLR responsive promoter element can be derived from the promoter of a naturally occurring (i.e., an endogenous) gene that is activated or inhibited by TLR signaling (such as the IL-6 gene, the IL-8 gene, the IL-10 gene, the IL-12 p40 gene, the IP-9 gene, the IP-10 gene, the type 1 IFN gene, the IFN- $\alpha$ 4 gene, the IFN- $\beta$  gene, the TNF- $\alpha$  gene, the TNF- $\beta$  gene, the RANTES gene, the ITAC gene, the IGFBP4 gene, the CD54 gene, the CD69 gene, the CD71 gene, the CD80 gene, the CD86 gene, the HLA-DR gene, the HLA class I gene, and the like). The afore-mentioned genes are genes that are known to be activated in response to TLR interaction with its ligand.

Suitable promoter regions are described in the Examples. Briefly, the upstream (5') – 620 to +50 promoter region of IFN- $\alpha$ 4 or the upstream (5') –140 to +9 promoter region of IFN- $\alpha$ 1 can be used. In one embodiment, the IFN- $\alpha$ 4 sequence is cloned into the *Sma*I site of the pGL3-Basic Vector (Promega) resulting in an expression vector that includes a luciferase gene under the control of the upstream (5') promoter region of IFN- $\alpha$ 4.

The promoter can also be the upstream (5') –280 to +20 promoter region of IFN- $\beta$ .  
The promoter can also be the upstream (5') –397 to +5 promoter region of RANTES. In one embodiment, the RANTES promoter sequence is cloned into the *Nhe*I site (filled in with Klenow) of the pGL3-Basic Vector (Promega) resulting in an expression vector that includes a luciferase gene under the control of the upstream (5') –397 to +5 promoter region of RANTES.

The promoter can also be the upstream truncated (-250 to +30) and full length (-860 to +30) promoter regions derived from human IL-12 p40 genomic DNA. In one embodiment, the truncated IL-12 p40 promoter was cloned as a *Kpn*I-*Xho*I insert into p $\beta$ gal-Basic (Promega) resulting in an expression vector that includes a  $\beta$  gal gene under the control of the upstream (5') –250 to +30 promoter region of human IL-12 p40. In another embodiment, the full length IL-12 p40 promoter was cloned as a *Kpn*I-*Xho*I insert into p $\beta$ gal-Basic (Promega) resulting in an expression vector that includes a  $\beta$  gal gene under the control of the upstream (5') –751 to +30 promoter region of human IL-12 p40. In another embodiment, the truncated –250 to +30 promoter region of human IL-12 p40 was cloned into the pGL3-Basic Vector (Promega) resulting in an expression vector that includes a luciferase gene under the control of the upstream (5') –250 to +30 promoter region of human IL-12 p40. In yet another embodiment, the full length IL-12 p40 promoter of human IL-12 p40 was cloned into the

- 57 -

pGL3-Basic Vector (Promega) resulting in an expression vector that includes a luciferase gene under the control of the upstream (5') -751 to +30 promoter region of human IL-12 p40.

The promoter can also be the upstream (5') -288 to +7 promoter region derived from human IL-6 genomic DNA. The promoter can also be derived from the full-length promoter  
5 region of the IL-6 gene from -1174 to +7 (Accession No M22111, SEQ ID NO:129).

The promoter can also be the upstream (5') -734 to +44 or the upstream (5') -162 to +44 promoter region derived from human IL-8 genomic DNA. Mukaida N et al. (1989) *J Immunol* 143:1366-71.

The promoter can also be derived from the -615 to +30 promoter region of human  
10 TNF- $\alpha$ .

The promoter can also be derived from a promoter region of human TNF- $\beta$ .

The promoter can also be derived from the -875 to +97 promoter region of human IP-  
10.

The promoter can also be derived from the -219 to +114 promoter region of human  
15 CXCL11 (IP9). The promoter can also be derived from the full length (-934 to +114) promoter region of human CXCL11 (IP9).

The promoter can also be derived from the -289 to +217 promoter region of human IGFBP4 (Insulin growth factor binding protein 4). The promoter can also be derived from the full length (-836 to +217) promoter region of human IGFBP4.

20 The promoter response element generally will be present in multiple copies, e.g., as tandem repeats. For example, in one reporter construct, coding sequence for luciferase is under control of an upstream 6X tandem repeat of NF- $\kappa$ B response element. In another example, an ISRE-luciferase reporter construct useful in the invention is available from Stratagene (catalog no. 219092) and includes a 5x ISRE tandem repeat joined to a TATA box  
25 upstream of a luciferase reporter gene.

The reporter construct coding sequence is preferably any nucleotide sequence that codes for a protein capable of detection or quantification. The protein can be an enzyme (e.g., luciferase, alkaline phosphatase,  $\beta$ -galactosidase, chloramphenicol acetyltransferase (CAT), secreted alkaline phosphatase, etc.), a bioluminescence marker (e.g., green fluorescent protein  
30 (GFP, U.S. Pat. No. 5,491,084), etc.), blue fluorescent protein (BFP, e.g., U.S. Pat. No. 6,486,382), etc.), a surface-expressed molecule (e.g., CD25, CD80, CD86), a secreted molecule (e.g., IL-1, IL-6, IL-8, IL-12 p40, TNF- $\alpha$ ), a hapten or antigen, and other detectable protein products known to those of skill in the art. For assays relying on enzyme activity

readout, substrate can be supplied as part of the assay, and detection can involve measurement of chemiluminescence, fluorescence, color development, incorporation of radioactive label, drug resistance, or other marker of enzyme activity. For assays relying on surface expression of a molecule, detection can be accomplished using flow cytometry (FACS) analysis or  
5 functional assays. Secreted molecules can be assayed using enzyme-linked immunosorbent assay (ELISA) or bioassays. Many of these and other suitable readout systems are well known in the art and are commercially available. Preferably, the coding sequence encodes a protein having a level or an activity that is quantifiable, preferably with a wide linear range.

The expression construct coding sequence is preferably a TLR coding sequence  
10 derived from the sequences listed herein. Preferably, the expression construct promoter is a constitutive promoter, although in some embodiments it may be inducible. Those of ordinary skill in the art are familiar with such promoters.

As used herein, a coding sequence and the regulatory sequences (such as promoters) are said to be operably linked when they are covalently linked in such a way as to place the  
15 expression or transcription and/or translation of the coding sequence under the influence or control of the regulatory sequence. Two DNA sequences are said to be operably linked if induction of a promoter in the 5' regulatory sequence results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter  
20 region to direct the transcription of the coding sequence, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a regulatory sequence would be operably linked to a coding sequence if the gene expression sequence were capable of effecting transcription of that coding sequence such that the resulting transcript is translated into the desired protein or polypeptide.

25 Methods for nucleic acid introduction into cells are known in the art.

The nucleic acid may be delivered to the cells alone or in association with a vector. In its broadest sense, a vector is any vehicle capable of facilitating the transfer of the nucleic acid to the cells so that the reporter can be expressed. The vector generally transports the nucleic acid to the cells with reduced degradation relative to the extent of degradation that would  
30 result in the absence of the vector. In general, the vectors useful in the invention include, but are not limited to, plasmids, phagemids, viruses, other vehicles derived from viral or bacterial sources that have been manipulated by the insertion or incorporation of the antigen nucleic acid sequences. Viral vectors are a preferred type of vector and include, but are not limited



- 59 -

to, nucleic acid sequences from the following viruses: retrovirus, such as Moloney murine leukemia virus, Harvey murine sarcoma virus, murine mammary tumor virus, and Rous sarcoma virus; adenovirus, adeno-associated virus; SV40-type viruses; polyoma viruses; Epstein-Barr viruses; papilloma viruses; herpes virus; vaccinia virus; polio virus; and RNA virus such as a retrovirus. One can readily employ other vectors not named but known in the art.

Preferred viral vectors are based on non-cytopathic eukaryotic viruses in which non-essential genes have been replaced with the gene of interest. Non-cytopathic viruses include retroviruses, the life cycle of which involves reverse transcription of genomic viral RNA into DNA with subsequent proviral integration into host cellular DNA. Retroviruses have been approved for human gene therapy trials. Most useful are those retroviruses that are replication-deficient (i.e., capable of directing synthesis of the desired proteins, but incapable of manufacturing an infectious particle). Such genetically altered retroviral expression vectors have general utility for the high-efficiency transduction of genes *in vivo*. Standard protocols for producing replication-deficient retroviruses (including the steps of incorporation of exogenous genetic material into a plasmid, transfection of a packaging cell lined with plasmid, production of recombinant retroviruses by the packaging cell line, collection of viral particles from tissue culture media, and infection of the target cells with viral particles) are provided in Kriegler, M., Gene Transfer and Expression, A Laboratory Manual W.H. Freeman C.O., New York (1990) and Murray, E.J. Methods in Molecular Biology, vol. 7, Humana Press, Inc., Clifton, New Jersey (1991).

A preferred virus for certain applications is the adeno-associated virus, a double-stranded DNA virus. The adeno-associated virus can be engineered to be replication-deficient and is capable of infecting a wide range of cell types and species. It further has advantages such as, heat and lipid solvent stability; high transduction frequencies in cells of diverse lineages, including hemopoietic cells; and lack of superinfection inhibition thus allowing multiple series of transductions. Reportedly, wild-type adeno-associated virus manifest some preference for integration sites into human cellular DNA, thereby minimizing the possibility of insertional mutagenesis and variability of inserted gene expression characteristic of retroviral infection. In addition, wild-type adeno-associated virus infections have been followed in tissue culture for greater than 100 passages in the absence of selective pressure, implying that the adeno-associated virus genomic integration is a relatively stable event. The adeno-associated virus can also function in an extrachromosomal fashion.

Recombinant adeno-associated viruses that lack the replicase protein apparently lack this integration sequence specificity.

Other vectors include plasmid vectors. Plasmid vectors have been extensively described in the art and are well-known to those of skill in the art. See e.g., Sambrook et al.,  
5 Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, 1989. In the last few years, plasmid vectors have been found to be particularly advantageous for delivering genes to cells *in vivo* because of their inability to replicate within and integrate into a host genome. These plasmids, however, having a promoter compatible with the host cell, can express a peptide from a gene operatively encoded within the plasmid.  
10 Some commonly used plasmids include pBR322, pUC18, pUC19, pRc/CMV, SV40, and pBlueScript. Other plasmids are well-known to those of ordinary skill in the art. Additionally, plasmids may be custom designed using restriction enzymes and ligation reactions to remove and add specific fragments of DNA.

In general, the vectors useful in the invention are divided into two classes: biological  
15 vectors and chemical/physical vectors. Biological vectors and chemical/physical vectors are useful in the delivery and/or uptake of reporter constructs of the invention.

Most biological vectors are used for delivery of nucleic acids and thus would be most appropriate in the delivery of nucleic acids.

As used herein, a "chemical/physical vector" refers to a natural or synthetic molecule,  
20 other than those derived from bacteriological or viral sources, capable of delivering the reference and test compound.

A preferred chemical/physical vector of the invention is a colloidal dispersion system. Colloidal dispersion systems include lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. A preferred colloidal system of the invention is a  
25 liposome. Liposomes are artificial membrane vessels which are useful as a delivery vector *in vivo* or *in vitro*. It has been shown that large unilamellar vessels (LUV), which range in size from 0.2 - 4.0  $\mu\text{m}$  can encapsulate large macromolecules. RNA, DNA and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (Fraley, et al., *Trends Biochem. Sci.*, (1981) 6:77).

30 Liposomes may be targeted to a particular tissue by coupling the liposome to a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein. Ligands which may be useful for targeting a liposome to an immune cell include, but are not limited to, intact or fragments of molecules which interact with immune cell specific receptors and molecules,

- 61 -

such as antibodies, which interact with the cell surface markers of immune cells. Such ligands may easily be identified by binding assays well known to those of skill in the art. In still other embodiments, the liposome may be targeted to the cancer by coupling it to a one of the immunotherapeutic antibodies discussed earlier. Additionally, the vector may be coupled  
5 to a nuclear targeting peptide, which will direct the vector to the nucleus of the host cell.

Lipid formulations for transfection are commercially available from QIAGEN, for example, as EFFECTENE™ (a non-liposomal lipid with a special DNA condensing enhancer) and SUPERFECT™ (a novel acting dendrimeric technology).

Liposomes are commercially available from Gibco BRL, for example, as  
10 LIPOFECTIN™ and LIPOFECTACE™, which are formed of cationic lipids such as N-[1-(2, 3 dioleyloxy)-propyl]-N, N, N-trimethylammonium chloride (DOTMA) and dimethyl dioctadecylammonium bromide (DDAB). Methods for making liposomes are well known in the art and have been described in many publications. Liposomes also have been reviewed by Gregoriadis, G. in *Trends in Biotechnology*, (1985) 3:235-241. In some preferred  
15 embodiments, the method of choice for delivering DNA (for transfection) to the cells is electroporation, particularly where a stably transfected cell line is sought.

The present invention is further illustrated by the following Examples, which in no way should be construed as further limiting.

20

### Examples

#### **Example 1. Biological Activity of Production Lot of CpG ODN (SEQ ID NO:1) Assayed Using Cells Stably Transfected with hTLR9 Expression Vector**

CpG ODN (SEQ ID NO:1) is currently in preclinical and clinical trials for a number of  
25 clinical applications. SEQ ID NO:1 has been discovered to induce signaling through TLR9. In order to assess different lots of clinical material, the methods of the invention are employed, using a highly characterized lot of SEQ ID NO:1 as a reference.

In a TLR9 assay, the CpG-non-responsive human embryonal kidney cell line HEK293 (e.g., ATCC CRL-1573) was stably transfected with a hTLR9 expression construct and found  
30 to express full-length human TLR9 constitutively. The cells also contained a genomic copy of a reporter construct with a 6x NF-κB binding site and a luciferase gene reporter cassette. Incubation of the cells with CpG ODN (SEQ ID NO:1) activates NF-κB driven expression of luciferase, while incubation with medium alone (negative control) does not. The cells are

then lysed and activity of the luciferase protein determined by its catalytic activity of luciferin oxidation which is measured in a luminometer. Results are expressed as fold induction above medium control.

Assay set-up includes a reference standard material which is highly pure and well characterized. The reference material is used to create a standard curve within a defined range where the dose-response curve is linear (e.g., in the range of the EC50 value for SEQ ID NO:1, 70-100 nM). The test material is dissolved for testing and assayed at a defined concentration. Activity of the test material is calculated using the standard curve of the reference material. Quality of the tested material is deemed acceptable if activity of the test material compared to activity of the reference material falls within predetermined limits.

**Example 2. Biological Activity of Production Lot of CpG ODN (SEQ ID NO:1) Assayed Using RPMI 8226 Cells**

The assay of Example 1 is performed using RPMI 8226 cells (ATCC CCL-155) in place of the stably transfected HEK cells of Example 1. RPMI 8226 cells naturally express human TLR9. The cells are stably transfected with a 6x NF- $\kappa$ B-luciferase reporter construct. It is to be understood that the assay could also be carried out by measuring a native readout such as IL-10 secretion.

**Example 3. Expression Vectors for Human TLR3 (hTLR3) and Murine TLR3 (mTLR3)**

To create an expression vector for human TLR3, human TLR3 cDNA was amplified by the polymerase chain method (PCR) from a cDNA made from human 293 cells using the primers 5'-GAAACTCGAGCCACCATGAGACAGACTTTGCCTTGTATCTAC-3' (sense, SEQ ID NO:152) and 5'-GAAAGAATTCTTAATGTACAGAGTTTTTGGATCCAAG-3' (antisense, SEQ ID NO:153). The primers introduce *Xho*I and *Eco*RI restriction endonuclease sites at their 5' ends for use in subsequent cloning into the expression vector. The resulting amplification product fragment was cloned into pGEM-T Easy vector (Promega), isolated, cut with *Xho*I and *Eco*RI restriction endonucleases, ligated into an *Xho*I/*Eco*RI-digested pcDNA3.1 expression vector (Invitrogen). The insert was fully sequenced and translated into protein. The cDNA sequence corresponds to the published cDNA sequence for hTLR3, available as GenBank accession no. NM\_003265 (SEQ ID NO:7). The open reading frame codes for a protein 904 amino acids long, having the sequence corresponding to GenBank accession no. NP\_003256 (SEQ ID NO:8).

Corresponding nucleotide and amino acid sequences for murine TLR3 (mTLR3) are known. The nucleotide sequence of mTLR3 cDNA has been reported as GenBank accession no. AF355152 (SEQ ID NO:9), and the amino acid sequence of mTLR3 has been reported as GenBank accession no. AAK26117 (SEQ ID NO:10).

5

#### **Example 4. Reconstitution of TLR3 Signaling in 293 Fibroblasts**

Human TLR3 cDNA and murine TLR3 cDNA in pT-Adv vector (from Clontech) were individually cloned into the expression vector pcDNA3.1(-) from Invitrogen using the *EcoRI* site. The resulting expression vectors mentioned above were transfected into  
10 CpG-DNA non-responsive human 293 fibroblast cells (ATCC, CRL-1573) using the calcium phosphate method. Utilizing a “gain of function” assay it was possible to reconstitute human TLR3 (hTLR3) and murine TLR3 (mTLR3) signaling in 293 fibroblast cells.

Since NF- $\kappa$ B activation is central to the IL-1/TLR signal transduction pathway (Medzhitov R et al. (1998) *Mol Cell* 2:253-8; Muzio M et al. (1998) *J Exp Med*  
15 187:2097-101), in a first set of experiments human 293 fibroblast cells were transfected with hTLR3 alone or co-transfected with hTLR3 and an NF- $\kappa$ B-driven luciferase reporter construct.

Likewise, in a second set of experiments, 293 fibroblast cells were transfected with hTLR3 alone or co-transfected with hTLR3 and an IFN- $\alpha$ 4-driven luciferase reporter  
20 construct (described in Example 8 below).

In a third group of experiments, 293 fibroblast cells were transfected with hTLR3 alone or co-transfected with hTLR3 and a RANTES-driven luciferase reporter construct (described in Example 14 below).

#### **25 Example 5. Reconstitution of TLR7 Signaling**

Methods for cloning murine and human TLR7 have been described in pending U.S. Pat. Application No. 09/954,987 and corresponding published PCT application PCT/US01/29229 (WO 02/22809), both filed September 17, 2001, the contents of which are incorporated herein by reference. Human TLR7 cDNA and murine TLR7 cDNA in pT-Adv  
30 vector (from Clontech) were individually cloned into the expression vector pcDNA3.1(-) from Invitrogen using the *EcoRI* site. Utilizing a “gain of function” assay it was possible to reconstitute human TLR7 (hTLR7) and murine TLR7 (mTLR7) signaling in CpG-DNA non-responsive human 293 fibroblasts (ATCC, CRL-1573). The expression vectors

mentioned above were transfected into 293 fibroblast cells using the calcium phosphate method.

#### **Example 6. Reconstitution of TLR8 Signaling**

5           Methods for cloning murine and human TLR8 have been described in pending U.S. Pat. Application No. 09/954,987 and corresponding published PCT application PCT/US01/29229 (WO 02/22809), both filed September 17, 2001, the contents of which are incorporated by reference. Human TLR8 cDNA and murine TLR8 cDNA in pT-Adv vector (from Clontech) were individually cloned into the expression vector pcDNA3.1(-) from  
10   Invitrogen using the EcoRI site. Utilizing a "gain of function" assay it was possible to reconstitute human TLR8 (hTLR8) and murine TLR8 (mTLR8) signaling in CpG-DNA non-responsive human 293 fibroblasts (ATCC, CRL-1573). The expression vectors mentioned above were transfected into 293 fibroblast cells using the calcium phosphate method.

15

#### **Example 7. Reconstitution of TLR9 Signaling in 293 Fibroblasts**

          Methods for cloning murine and human TLR9 have been described in pending U.S. Pat. Application No. 09/954,987 and corresponding published PCT application PCT/US01/29229 (WO 02/22809), both filed September 17, 2001, the contents of which are  
20   incorporated by reference. Human TLR9 cDNA and murine TLR9 cDNA in pT-Adv vector (from Clontech) were individually cloned into the expression vector pcDNA3.1(-) from Invitrogen using the EcoRI site. Utilizing a "gain of function" assay it was possible to reconstitute human TLR9 (hTLR9) and murine TLR9 (mTLR9) signaling in CpG-DNA non-responsive human 293 fibroblasts (ATCC, CRL-1573). The expression vectors  
25   mentioned above were transfected into 293 fibroblast cells using the calcium phosphate method.

          To generate stable clones expressing human TLR9, murine TLR9, or either TLR9 with the NF- $\kappa$ B-luc reporter plasmid, 293 cells were transfected in 10 cm plates ( $2 \times 10^6$  cells/plate) with 16  $\mu$ g of DNA and selected with 0.7 mg/ml G418 (PAA Laboratories GmbH, Cölbe,  
30   Germany). Clones were tested for TLR9 expression by RT-PCR, for example as shown in Fig. 21. The clones were also screened for IL-8 production or NF- $\kappa$ B-luciferase activity after stimulation with ODN. Four different types of clones were generated.

293-hTLR9-luc: expressing human TLR9 and 6x NF- $\kappa$ B-luciferase reporter  
 293-mTLR9-luc: expressing murine TLR9 and 6x NF- $\kappa$ B-luciferase reporter  
 293-hTLR9: expressing human TLR9  
 293-mTLR9: expressing murine TLR9

5

Human 293 fibroblast cells were transiently transfected with hTLR9 and a 6x NF- $\kappa$ B-luciferase reporter plasmid (NF- $\kappa$ B-luc, kindly provided by Patrick Baeuerle, Munich, Germany) (Fig. 18A) or with hTLR9 alone (Fig. 18B). After stimulus with CpG-ODN (2 $\mu$ M, TCGTCGTTTTGTCGTTTTGTCGTT, SEQ ID NO:1), GpC-ODN (2 $\mu$ M, TGCTGCTTTTTGTGCTTTTTGTGCTT, SEQ ID NO:154), LPS (100 ng/ml) or media, NF- $\kappa$ B activation by luciferase readout (8h, Fig. 18A) or IL-8 production by ELISA (48h, Fig. 18B) was monitored. Results are representative of three independent experiments. Fig. 18 shows that cells expressing hTLR9 responded to CpG-DNA but not to LPS.

Human 293 fibroblast cells were transiently transfected with mTLR9 and the NF- $\kappa$ B-luc construct. Similar data was obtained for IL-8 production (not shown). Thus expression of TLR9 (human or mouse) in 293 cells results in a gain of function for CpG DNA stimulation similar to hTLR4 reconstitution of LPS responses.

Figs. 19 and 20 demonstrate the responsiveness of a stable 293-mTLR9-luc and 293-hTLR9-luc clones after stimulation with CpG-ODN (2 $\mu$ M, SEQ ID NO:1), GpC-ODN (2 $\mu$ M, SEQ ID NO:154), Me-CpG-ODN (2 $\mu$ M; TZGTZGTTTTGTZGTTTTGTZGTT, Z = 5-methylcytidine, SEQ ID NO:147), LPS (100 ng/ml) or media, as measured by monitoring NF- $\kappa$ B activation. Similar results were obtained utilizing IL-8 production with the stable clones. These results demonstrate that CpG-DNA non-responsive cell lines can be stably genetically complemented with TLR9 to become responsive to CpG DNA in a motif-specific manner.

25

#### **Example 8. Method of Making IFN- $\alpha$ 4 Reporter Vector**

A number of reporter vectors may be used in the practice of the invention. Some of the reporter vectors are commercially available, e.g., the luciferase reporter vectors pNF- $\kappa$ B-Luc (Stratagene) and pAP1-Luc (Stratagene). These two reporter vectors place the luciferase gene under control of an upstream (5') promoter region derived from genomic DNA for NF- $\kappa$ B or AP1, respectively. Other reporter vectors can be constructed following standard

30

- 66 -

methods using the desired promoter and a vector containing a suitable reporter, such as luciferase,  $\beta$ -galactosidase ( $\beta$ -gal), chloramphenicol acetyltransferase (CAT), and other reporters known by those skilled in the art. Following are some examples of reporter vectors constructed for use in the present invention.

5 IFN- $\alpha$ 4 is an immediate-early type 1 IFN. Sequence-specific PCR products for the -620 to +50 promoter region of IFN- $\alpha$ 4 were derived from genomic DNA of human 293 cells and cloned into the *Sma*I site of the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') -620 to +50 promoter region of IFN- $\alpha$ 4. The sequence of the -620 to +50 promoter region of IFN- $\alpha$ 4 is provided as  
10 SEQ ID NO:121.

#### Example 9. Method of Making IFN- $\alpha$ 1 Reporter Vector

IFN- $\alpha$ 1 is a late type 1 IFN. Sequence-specific PCR products for the -140 to +9 promoter region of IFN- $\alpha$ 1 were derived from genomic DNA of human 293 cells and cloned  
15 into *Sma*I site of the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') -140 to +9 promoter region of IFN- $\alpha$ 1. A sequence of the -140 to +9 promoter region of IFN- $\alpha$ 1 is provided as SEQ ID NO:122.

#### Example 10. Method of Making IFN- $\beta$ Reporter Vector

20 IFN- $\beta$  is an immediate-early type 1 IFN. The -280 to +20 promoter region of IFN- $\beta$  was derived from the pUC $\beta$ 26 vector (Algarte M et al. (1999) *J Virol* 73:2694-702) by restriction at *Eco*RI and *Taq*I sites. The 300 bp restriction fragment was filled in by Klenow enzyme and cloned into *Nhe*I-digested and filled in pGL3-Basic Vector (Promega). The  
25 resulting expression vector includes a luciferase gene under control of an upstream (5') -280 to +20 promoter region of IFN- $\beta$ . A sequence of the -280 to +20 promoter region of IFN- $\beta$  is provided as SEQ ID NO:123.

#### Example 11. Method of Making Human IL-6 Reporter Vectors

Reporter constructs are made using the -285 to +7 promoter region derived from  
30 human IL-6 genomic DNA. (Takeshita et al. Eur. J. Immunol. 2000. 30: 108-116.) In one reporter construct the IL-6 promoter region is cloned as a *Kpn*I-*Xho*I insert into pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of



- 67 -

an upstream (5') -288 to +7 promoter region derived from human IL-6 genomic DNA. A sequence of the -288 to +7 promoter region of human IL-6 is provided as SEQ ID NO:128.

The promoter can also be derived from the full-length promoter region of the IL-6 gene from -1174 to +7 (GenBank Accession No M22111) as shown below as SEQ ID NO:129.

#### Example 12. Method of Making Human IL-8 Reporter Vectors

Reporter constructs have been made using a -546 to +44 and a truncated -133 to +44 promoter region derived from human IL-8 genomic DNA. Mukaida N et al. (1989) *J Immunol* 143:1366-71. In each reporter construct the IL-8 promoter region was cloned as a *KpnI-XhoI* insert into pGL3-Basic Vector (Promega). One of the resulting expression vectors includes a luciferase gene under control of an upstream (5') -546 to +44 promoter region derived from human IL-8 genomic DNA. Another of the resulting expression vectors includes a luciferase gene under control of an upstream (5') -133 to +44 promoter region derived from human IL-8 genomic DNA.

The promoter can also be the upstream (5') -734 to +44 or the upstream (5') -162 to +44 promoter region derived from human IL-8 genomic DNA. Mukaida N et al. (1989) *J Immunol* 143:1366-71. A sequence of the -734 to +44 promoter region derived from human IL-8 is provided below as SEQ ID NO: 130.

#### Example 13. Method of Making Human IL-12 p40 Reporter Vectors

Reporter constructs have been made using truncated (-250 to +30, SEQ ID NO:127) and full length (-751 to +30, SEQ ID NO:126) promoter regions derived from human IL-12 p40 genomic DNA. (Takeshita et al. *Eur. J. Immunol.* 2000. 30: 108-116.) In one reporter construct the truncated IL-12 p40 promoter was cloned as a *KpnI-XhoI* insert into p $\beta$ gal-Basic (Promega). The resulting expression vector includes a  $\beta$  gal gene under control of an upstream (5') -250 to +30 promoter region of human IL-12 p40. In a second reporter construct the full length IL-12 p40 promoter was cloned as a *KpnI-XhoI* insert into p $\beta$ gal-Basic (Promega). The resulting expression vector includes a  $\beta$  gal gene under control of an upstream (5') -751 to +30 promoter region of human IL-12 p40. In a third reporter construct the truncated -250 to +30 promoter region of human IL-12 p40 was cloned into the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') -250 to +30 promoter region of human IL-12 p40. In a

fourth reporter construct the full length IL-12 p40 promoter of human IL-12 p40 was cloned into the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') -751 to +30 promoter region of human IL-12 p40. A sequence of the -751 to +30 promoter region of human IL-12 p40 is provided as SEQ ID NO:  
5 126.

#### Example 14. Method of Making RANTES Reporter Vector

Transcription of the chemokine RANTES is believed to be regulated at least in part by IRF3 and by NF- $\kappa$ B. Lin R et al. (1999) *J Mol Cell Biol* 19(2):959-66; Genin P et al. (2000) *J Immunol* 164:5352-61. A 483 bp sequence-specific PCR product including the -397 to +5 promoter region of RANTES was derived from genomic DNA of human 293 cells, restricted with *Pst*I and cloned into pCAT-Basic Vector (Promega) using *Hind*III (filled in with Klenow) and *Pst*I sites (filled in). The -397 to +5 promoter region of RANTES was then isolated from the resulting RANTES/chloramphenicol acetyltransferase (CAT) reporter  
15 plasmid by restriction with *Bgl*II and *Sal*I, filled in with Klenow enzyme, and cloned into the *Nhe*I site (filled in with Klenow) of the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') -397 to +5 promoter region of RANTES. Comparison of the insert sequence -397 to +5 of Genin P et al. (2000) *J Immunol* 164:5352-61 and GenBank accession no. AB023652 (SEQ ID NO:125)  
20 revealed two point deletions (at positions 105 and 273 of SEQ ID NO:125) which do not create new restriction sites. A sequence of the -397 to +5 promoter region of RANTES is provided as SEQ ID NO:125.

#### Example 15. RT-PCR Analysis of Cell Lines for TLR Expression

25 TLR expression was determined using total RNA of cells prepared by standard methods (QIAGEN). RNA was transcribed to cDNA using AMV Reverse Transcriptase (Roche). Quantitative PCR was performed with TLR-gene specific primer sets using a LightCycler Instrument (Roche). Controls for genomic DNA impurities were performed by a similar PCR method using RNA (but without reverse transcriptase).

30 A variety of cell lines was screened for their expression of TLR3, 7, 8 and 9. These cell lines are A549 (human lung carcinoma), BeWo (human choriocarcinoma), HeLa (human cervix carcinoma), Hep-2 (human cervix carcinoma), KG-1 (human acute myeloid leukemia), MUTZ-3 (human acute myelomonocytic leukemia), Nalm-6 (human B cell precursor

leukemia), NK-92 (human Natural killer cell line), NK-92 MI (human Natural killer cell line, IL-2 independent), Raji (human Burkitt's lymphoma, B lymphocyte), RAMOS (Burkitt's lymphoma, B lymphocyte), RPMI 8226 (human multiple myeloma, B lymphocyte), THP-1 (human acute monocytic leukemia), U937 (human lymphoma) and Jurkat (human T cell leukemia).

All B cell lines express, as determined by Real Time-PCR (RT-PCR), endogenous TLR9. In addition, all lines except NALM co-express TLR7. Nevertheless, none of the other cell lines appeared to express TLR7, whereas low TLR9 expression on the mRNA level was observed for KG-1 and THP-1. TLR3 appeared to be expressed in most of these cell lines, with the highest mRNA levels for example in the NK cell lines (e.g., NK-92).

Raji cells contain high levels of TLR9 mRNA and low levels of TLR3 and TLR7 mRNA suggesting high expression of TLR9 protein and lower levels of TLR3 and TLR7 protein.

These results indicate that the cell lines expressing TLR9 can be used to screen potential new TLR9 ligands (CpG ODN, etc.), cell lines expressing TLR7 to screen potential new TLR7 ligands (ORN (oligoribonucleotides), small molecules, etc.), and cell lines expressing both receptors may be used to screen for "hybrid" TLR7 and 9 agonists. In addition, cell lines lacking TLR8 expression (i.e., all cell lines tested) can be used to confirm the specificity of a TLR7 versus a TLR8 ligand (i.e., the latter should not be able to stimulate TLR7-expressing cells). In contrast, cell lines expressing TLR3 (e.g., Raji cells) may be used to screen for potential new TLR3 ligands (dsRNA, etc.).

#### **Example 16. Screening of Various Cell Lines for Responses to TLR Ligands**

Except where otherwise indicated, the following general methods were used.

Cells were plated at  $5 \times 10^5$ /ml in 48 well plates in RPMI medium with 10% FBS. Stimulation was performed by addition of the oligonucleotides or other compounds diluted to the test concentrations in TE. Cells were incubated for 24 or 48h and the supernatants were taken to analyse for the presence of cytokines or chemokines.

The TLR ligands used are as follows:

TLR3: Poly I:C

TLR7, TLR8: R-848

TLR9:

T\*C\*C\*A\*G\*G\*A\*C\*T\*T\*C\*T\*C\*T\*C\*A\*G\*G\*T\*T (SEQ ID NO: 2);

- 70 -

T\*C\*G\*T\*C\*G\*T\*T\*T\*T\*G\*T\*C\*G\*T\*T\*T\*T\*G\*T\*C\*G\*T\*T (SEQ ID NO: 1);  
 T\*G\*C\*T\*G\*C\*T\*T\*T\*T\*G\*T\*G\*C\*T\*T\*T\*T\*G\*T\*G\*C\*T\*T (SEQ ID NO: 154);  
 T\*C\*G\*T\*C\*G\*T\*T\*T\*T\*C\*G\*G\*C\*G\*C\*G\*C\*G\*C\*C\*G (SEQ ID NO: 158);  
 G\*G\*G\_G\_A\_C\_G\_A\_C\_G\_T\_C\_G\_T\_G\_G\*G\*G\*G\*G\*G (SEQ ID NO: 159);  
 5 T\*G\*C\*T\*G\*C\*T\*T\*T\*T\*C\*G\*G\*C\*G\*G\*C\*C\*G\*C\*C\*G (SEQ ID NO: 160);  
 G\*G\*G\_G\_A\_G\_C\_A\_G\_C\_T\_G\_C\_T\_G\_G\*G\*G\*G\*G\*G (SEQ ID NO: 161).  
 \* phosphorothioate linkage; \_ phosphodiester linkage.

Increased expression of cell surface markers was determined using cells stimulated as  
 10 described above and then stained with different monoclonal antibody combinations specific  
 for the cell surface markers. Analysis of the cells was performed by flow cytometry.

Changes in reporter gene activity were determined using cells transfected with a  
 NF- $\kappa$ B reporter construct (Stratagene) and a  $\beta$ -galactosidase reporter control plasmid  
 (Invitrogen) using electroporation. For NF- $\kappa$ B analysis, a 5x NF- $\kappa$ B-Luciferase Vector  
 15 (Stratagene) was used. The amount of DNA transfected as well as cell concentration was  
 varied. Stimulation was performed 24h after transfection. Cells were stimulated with the  
 indicated amounts of ODN, R-848, LPS, TNF- $\alpha$ , or IL-1  $\beta$  for the indicated incubation times.  
 Cell extracts were prepared by lysing the cells in 100  $\mu$ l reporter lysis buffer (Promega) using  
 the freeze-thaw method. All data were normalized for  $\beta$ -galactosidase expression.  
 20 Stimulation indices were calculated in reference to luciferase activity of medium without  
 addition of ODN.

Stimulation of the Raji cell line with a TLR9 ligand (CpG ODN), a TLR3 ligand (poly  
 I:C) or a TLR7 ligand (R-848) results in the ligand-specific secretion of cytokines. Figs. 14  
 and 15 show IL-6 production of Raji cells upon stimulation with ODN, poly I:C or R-848.  
 25 Fig. 16 shows IFN- $\alpha$ 2 production of Raji cells upon stimulation with ODN, poly I:C or R-848.  
 In all assays, cells were incubated with Na-Butyrate for 48h before stimulation with TLR  
 ligands. CpG stimulation of the RAMOS cell lines can result in the CpG-specific up-  
 regulation of cell surface markers such as CD80, as shown in Fig. 17.

### 30 **Example 17. Inhibition of a Positive Reference Compound Response with an Inhibitory Test Compound**

Inhibition of CpG mediated chemokine production was determined using RPMI 8226  
 cells incubated with increasing amounts of SEQ ID NO:1 in the presence of an

- 71 -

immunoinhibitory ODN (SEQ ID NO: 151). IP-10 production was measured 24h later by ELISA (Fig. 9).

### Equivalents

5           The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by examples provided, since the examples are intended as a single illustration of one aspect of the invention and other functionally equivalent embodiments are within the scope of the invention. Various modifications of the invention in addition to those shown and described  
10   herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims. The advantages and objects of the invention are not necessarily encompassed by each embodiment of the invention.

          All references, patents and patent publications that are recited in this application are incorporated in their entirety herein by reference.

15

We claim:

- 72 -

Claims

1. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising  
contacting an RPMI 8226 cell that expresses a TLR with a test compound and  
5 measuring a test level of TLR signaling activity,  
wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and  
wherein the TLR signaling activity is selected from the group consisting of CD71 expression, CD86 expression, HLA-DR expression, IL-8 expression, IL-8 production, IL-8  
10 secretion, IL-10 expression, IL-10 production, IL-10 secretion, IP-10 expression, IP-10 production, IP-10 secretion, TNF- $\alpha$  expression, TNF- $\alpha$  production and TNF- $\alpha$  secretion.
2. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising  
15 contacting a cell that expresses a TLR with a test compound and measuring a test level of TLR signaling activity,  
wherein a test level that is positive is indicative of an immunostimulatory compound, and  
wherein the cell is a Raji cell, a RAMOS cell, a Nalm cell, a THP-1 cell, or a KG-  
20 1 cell.
3. The method of claim 1 or 2, wherein the test level is positive relative to a reference level determined by contacting the cell with a reference compound and measuring a reference TLR signaling activity.  
25
4. The method of claim 3, wherein the reference compound is a positive reference compound
5. The method of claim 4, wherein the positive reference compound is  
30 selected from the group consisting of an immunostimulatory nucleic acid and an imidazoquinoline compound.

- 73 -

6. The method of claim 3, wherein the reference compound is a negative reference compound.

7. The method of claim 6, wherein the negative reference compound is  
5 medium alone.

8. The method of claim 5, wherein the immunostimulatory nucleic acid is selected from the group consisting of a CpG nucleic acid, a T-rich nucleic acid, a poly-T nucleic acid and a poly-G nucleic acid.

10

9. The method of claim 5, wherein the imidazoquinoline compound is selected from the group consisting of R-848 and R-847.

10. The method of claim 1 or 2, wherein the test compound is a nucleic  
15 acid.

11. The method of claim 10, wherein the nucleic acid does not comprise a motif selected from the group consisting of a CpG motif, a poly-T motif, a T-rich motif and a poly-G motif.

20

12. The method of claim 10, wherein the nucleic acid comprises a phosphorothioate backbone linkage.

13. The method of claim 10, wherein the nucleic acid is a DNA, an RNA or  
25 a DNA-RNA hybrid.

14. The method of claim 1 or 2, wherein the test compound is a non-nucleic acid small molecule.

15. The method of claim 1 or 2, wherein the test compound comprises an  
30 amino acid, a carbohydrate, a lipid, or a hormone.

16. The method of claim 15, wherein the carbohydrate is a polysaccharide.

17. The method of claim 1 or 2, wherein the test compound is derived from a molecular library.
- 5 18. The method of claim 1, wherein the cell is transfected with a nucleic acid.
19. The method of claim 18, wherein the nucleic acid encodes a TLR or a reporter construct.
- 10 20. The method of claim 2, wherein the cell is transfected with a nucleic acid.
21. The method of claim 20, wherein the nucleic acid encodes a TLR or a reporter construct.
- 15 22. The method of claim 19 or 21, wherein the TLR is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9 and TLR10.
- 20 23. The method of claim 22, wherein the TLR is a human TLR.
24. The method of claim 19 or 21, wherein the reporter construct is selected from the group consisting of a luciferase reporter construct, a  $\beta$ -galactosidase reporter construct, a chloramphenicol acetyltransferase reporter construct, a green fluorescent protein reporter construct, and a secreted alkaline phosphatase construct.
- 25 25. The method of claim 19 or 21, wherein the reporter construct comprises a TLR responsive promoter.
- 30 26. The method of claim 25, wherein the TLR responsive promoter comprises a transcription factor binding site selected from the group consisting of a NF- $\kappa$ B binding site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an



- 75 -

IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding site, and a TARE.

27. The method of claim 25, wherein the TLR responsive promoter is a  
5 promoter region selected from the group consisting of an IL-1 promoter region, an IL-6  
promoter region, an IL-8 promoter region, an IL-10 promoter region, an IL-12 p40 promoter  
region, an IFN- $\alpha$ 1 promoter region, an IFN- $\alpha$ 4 promoter region, an IFN- $\beta$  promoter region, an  
IFN- $\gamma$  promoter region, a TNF- $\alpha$  promoter region, a TNF- $\beta$  promoter region, an IP-9 promoter  
region, an IP-10 promoter region, a RANTES promoter region, an ITAC promoter region, a  
10 MCP-1 promoter region, an IGFBP4 promoter region, a CD54 promoter region, a CD69  
promoter region, a CD71 promoter region, a CD80 promoter region, a CD86 promoter region,  
a HLA-DR promoter region, and a HLA class I promoter region.

28. The method of claim 18 or 20, wherein the cell is stably transfected.  
15

29. The method of claim 1 or 2, wherein the TLR signaling activity is  
measured by cytokine secretion or chemokine secretion.

30. The method of claim 1, wherein the TLR signaling activity is selected  
20 from the group consisting of IL-8 secretion, IL-10 secretion, IP-10 secretion and TNF- $\alpha$   
secretion.

31. The method of claim 2, wherein the TLR signaling activity is selected  
from the group consisting of IL-6 expression, IL-6 production, IL-6 secretion, IL-8  
25 expression, IL-8 production, IL-8 secretion, IL-10 expression, IL-10 production, IL-10  
secretion, IP-10 expression, IP-10 production, IP-10 secretion, IL-12 expression, IL-12  
production, IL-12 secretion, TNF- $\alpha$  expression, TNF- $\alpha$  production and TNF- $\alpha$  secretion.

32. The method of claim 2, wherein the TLR signaling activity is measured  
30 by phosphorylation.

33. The method of claim 32, wherein phosphorylation is total cellular  
phosphorylation.

- 76 -

34. The method of claim 32, wherein phosphorylation is phosphorylation of a factor selected from the group consisting of IRAK, ERK, MyD88, TRAF6, p38, NFkB subunits, c-Jun and c-Fos.

5

35. The method of claim 1 or 2, wherein the TLR signaling activity is measured by gene expression.

36. The method of claim 1, wherein the TLR signaling activity is measured by gene expression selected from the group consisting of CD71 expression, CD86 expression, HLA-DR expression, IL-8 expression, IL-10 expression, IP-10 expression, and TNF- $\alpha$  expression.

37. The method of claim 35, wherein TLR signaling activity is measured by microarray techniques.

38. The method of claim 2, wherein the TLR signaling activity is measured by cell proliferation.

39. The method of claim 1 or 2, wherein TLR signaling activity is measured by cell surface marker expression.

40. The method of claim 1, wherein TLR signaling activity is measured by cell surface expression of CD71, CD86 or HLA-DR.

25

41. The method of claim 2, wherein TLR signaling activity is measured by CD71 cell surface expression, CD86 cell surface expression, HLA-DR cell surface expression, CD80 cell surface expression, HLA class I cell surface expression, CD54 cell surface expression and CD69 cell surface expression.

30

42. The method of claim 2, wherein TLR signaling activity is measured by antibody secretion.

- 77 -

43. The method of claim 42, wherein the antibody secretion is IgM secretion.

44. A composition comprising  
an RPMI 8226 cell stably transfected with a nucleic acid encoding a TLR  
5 polypeptide, or a fragment thereof.

45. The composition of claim 44, further comprising a reporter construct  
comprising a promoter and a reporter sequence wherein the promoter is a TLR responsive  
promoter.

10

46. The composition of claim 45, wherein the TLR responsive promoter  
comprises a nucleic acid sequence selected from the group consisting of an NF- $\kappa$ B binding  
site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an IRF3  
binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding  
15 site, and a TARE.

47. The composition of claim 45, wherein the reporter sequence is selected  
from the group consisting of a luciferase sequence, a  $\beta$ -galactosidase sequence, a green  
fluorescent protein sequence, a secreted alkaline phosphatase sequence and a chloramphenicol  
20 transferase sequence.

48. The composition of claim 44, wherein the TLR polypeptide or fragment  
thereof is a human TLR polypeptide or fragment thereof.

49. The composition of claim 44, wherein the TLR polypeptide or fragment  
thereof is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6,  
TLR7, TLR8, TLR9 and TLR10.

50. The composition of claim 44, wherein the TLR polypeptide or fragment  
30 thereof is a human TLR polypeptide.

51. A screening method for identifying agonists of Toll-like receptor (TLR)  
signaling activity, comprising

- 78 -

contacting an cell that ectopically expresses a TLR with a test compound and measuring a test level of TLR signaling activity,

wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and

5            wherein the cell that ectopically expresses a TLR is selected from the group consisting of RPMI 8226, RAMOS, Raji, Nalm, THP-1, KG-1 and 293 HEK.

52.            The method of claim 51, wherein the test level is positive relative to a reference level determined by contacting the cell with a reference compound and measuring a  
10            reference TLR signaling activity.

53.            The method of claim 52, wherein the reference compound is a positive reference compound.

15            54.            The method of claim 53, wherein the positive reference compound is selected from the group consisting of an immunostimulatory nucleic acid and an imidazoquinoline compound.

20            55.            The method of claim 54, wherein the immunostimulatory nucleic acid is selected from the group consisting of a CpG nucleic acid, a T-rich nucleic acid, a poly-T nucleic acid and a poly-G nucleic acid.

25            56.            The method of claim 54, wherein the imidazoquinoline compound is selected from the group consisting of R-848 and R-847.

57.            The method of claim 52, wherein the reference compound is negative reference compound.

30            58.            The method of claim 57, wherein the negative reference compound is medium alone.

59.            The method of claim 51, wherein the test compound is a nucleic acid.

- 79 -

60. The method of claim 59, wherein the nucleic acid does not comprise a motif selected from the group consisting of a CpG motif, a poly-T motif, a T-rich motif and a poly-G motif.

5 61. The method of claim 59, wherein the nucleic acid comprises a phosphorothioate backbone linkage.

62. The method of claim 59, wherein the nucleic acid is a DNA, an RNA, or a DNA-RNA hybrid.

10

63. The method of claim 51, wherein the test compound is a non-nucleic acid small molecule.

64. The method of claim 51, wherein the test compound comprises an amino acid, a carbohydrate, a lipid, or a hormone.

15

65. The method of claim 64, wherein the carbohydrate is a polysaccharide.

66. The method of claim 51, wherein the test compound is derived from a molecular library.

20

67. The method of claim 51, wherein the TLR signaling activity is selected from the group consisting of CD71 expression, CD86 expression, HLA-DR expression, IL-6 expression, IL-6 production, IL-6 secretion, IL-8 expression, IL-8 production, IL-8 secretion, IL-10 expression, IL-10 production, IL-10 secretion, IL-12 expression, IL-12 production, IL-12 secretion, IP-10 expression, IP-10 production, IP-10 secretion, TNF- $\alpha$  expression, TNF- $\alpha$  production and TNF- $\alpha$  secretion.

25

68. The method of claim 51, wherein the TLR is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9 and TLR10.

30

69. The method of claim 51, wherein the TLR is a human TLR.

70. The method of claim 51, wherein the cell is transfected with a reporter construct.

71. The method of claim 70, wherein the reporter construct is selected from  
5 the group consisting of a luciferase reporter construct, a  $\beta$ -galactosidase reporter construct, a chloramphenicol acetyltransferase reporter construct, a green fluorescent protein reporter construct, and a secreted alkaline phosphatase construct.

72. The method of claim 71, wherein the TLR signaling activity is  
10 measured by luciferase expression,  $\beta$ -galactosidase expression, chloramphenicol expression, acetyltransferase expression, green fluorescent protein expression, alkaline phosphatase expression and alkaline phosphatase secretion.

73. The method of claim 71, wherein the reporter construct comprises a  
15 TLR responsive promoter.

74. The method of claim 25 or 73, wherein the TLR responsive promoter is  
a TLR1 responsive promoter, a TLR2 responsive promoter, a TLR3 responsive promoter, a  
TLR4 responsive promoter, a TLR5 responsive promoter, a TLR6 responsive promoter, a  
20 TLR7 responsive promoter, a TLR8 responsive promoter, a TLR9 responsive promoter and a TLR10 responsive promoter.

75. The method of claim 73, wherein the TLR responsive promoter  
comprises a transcription factor binding site selected from the group consisting of an NF- $\kappa$ B  
25 binding site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding site, and a TARE.

76. The method of claim 73, wherein the TLR responsive promoter is a  
30 promoter region selected from the group consisting of an IL-1 promoter region, an IL-6 promoter region, an IL-8 promoter region, an IL-10 promoter region, an IL-12 p40 promoter region, an IFN- $\alpha$ 1 promoter region, an IFN- $\alpha$ 4 promoter region, an IFN- $\beta$  promoter region, an IFN- $\gamma$  promoter region, a TNF- $\alpha$  promoter region, a TNF- $\beta$  promoter region, an IP-9 promoter

- 81 -

region, an IP-10 promoter region, a RANTES promoter region, an ITAC promoter region, a MCP-1 promoter region, an IGFBP4 promoter region, a CD54 promoter region, a CD69 promoter region, a CD71 promoter region, a CD80 promoter region, a CD86 promoter region, a HLA-DR promoter region, and a HLA class I promoter region.

5

77. The method of claim 51, wherein the cell is stably transfected with a TLR nucleic acid.

78. The method of claim 70, wherein the cell is stably transfected with the  
10 reporter construct.

79. The method of claim 51, wherein the TLR signaling activity is measured by cytokine secretion or chemokine secretion.

80. The method of claim 79, wherein the cytokine secretion or chemokine secretion is selected from the group consisting of IL-8 secretion, TNF- $\alpha$  secretion, IL-10 secretion and IP-10 secretion.

81. The method of claim 79, wherein the cytokine secretion or chemokine  
20 secretion is selected from the group consisting of IL-6 secretion and IL-12 secretion.

82. The method of claim 51, wherein the TLR signaling activity is measured by phosphorylation.

83. The method of claim 82, wherein phosphorylation is total cellular  
25 phosphorylation.

84. The method of claim 82, wherein phosphorylation is phosphorylation of a factor selected from the group consisting of IRAK, ERK, MyD88, TRAF6, p38, NF- $\kappa$ B subunits, c-Jun and c-Fos.  
30

85. The method of claim 51, wherein the TLR signaling activity is measured by gene expression.

86. The method of claim 85, wherein the gene expression is selected from the group consisting of IL-8 expression, IL-10 expression, IP-10 expression, CD71 expression, CD86 expression and HLA-DR expression.

5

87. The method of claim 85, wherein the gene expression is selected from the group consisting of IL-6 expression, IL-12 expression and TNF- $\alpha$  expression.

88. The method of claim 51, wherein the TLR signaling activity is measured by microarray techniques.

89. The method of claim 51, wherein the TLR signaling activity is measured by cell proliferation.

90. The method of claim 51, wherein the TLR signaling activity is measured by cell surface marker expression.

91. The method of claim 90, wherein the cell surface marker expression is selected from the group consisting of CD71 cell surface expression, CD86 cell surface expression and HLA-DR cell surface expression.

20

92. The method of claim 90, wherein the cell surface marker expression is selected from the group consisting of CD80 cell surface expression, HLA class I cell surface expression, CD54 cell surface expression and CD69 cell surface expression.

25

93. The method of claim 51, wherein the TLR signaling activity is measured by antibody secretion.

94. The method of claim 93, wherein the antibody secretion is IgM secretion.

30

95. A screening method for identifying antagonists of Toll-like receptor (TLR) signaling activity, comprising



- 83 -

contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity,

contacting the cell with the positive reference compound and a test compound, and measuring a test level of TLR signaling activity,

5 wherein a test level that is less than a reference level is indicative of test compound that is a TLR antagonist, and

wherein the cell is selected from the group consisting of a RPMI 8226 cell, a RAMOS cell, a Raji cell, a THP-1 cell, a Nalm cell and a KG-1 cell.

10 96. The method of claim 95, wherein the positive reference compound is selected from the group consisting of an immunostimulatory nucleic acid and an immunostimulatory imidazoquinoline compound.

97. The method of claim 96, wherein the immunostimulatory nucleic acid  
15 is selected from the group consisting of a CpG nucleic acid, a T-rich nucleic acid, a poly-T nucleic acid and a poly-G nucleic acid.

98. The method of claim 96, wherein the imidazoquinoline compound is selected from the group consisting of R-848 and R-847.

20 99. The method of claim 95, wherein the test compound is a nucleic acid.

100. The method of claim 99, wherein the nucleic acid does not comprise a motif selected from the group consisting of a CpG motif, a poly-T motif, a T-rich motif and a  
25 poly-G motif.

101. The method of claim 99, wherein the nucleic acid comprises a phosphorothioate backbone linkage.

30 102. The method of claim 99, wherein the nucleic acid is a DNA, an RNA or a DNA-RNA hybrid.

- 84 -

103. The method of claim 95, wherein the test compound is a non-nucleic acid small molecule.

104. The method of claim 95, wherein the test compound comprises an amino acid, a carbohydrate, a lipid, or a hormone.

105. The method of claim 104, wherein the carbohydrate is a polysaccharide.

106. The method of claim 95, wherein the test compound is derived from a molecular library.

107. The method of claim 95, wherein the experimental cell is transfected with a nucleic acid.

108. The method of claim 107, wherein the nucleic acid encodes a TLR or a reporter construct.

109. The method of claim 108, wherein the TLR is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9 and TLR10.

110. The method of claim 108, wherein the TLR is a human TLR.

111. The method of claim 108, wherein the reporter construct is selected from the group consisting of a luciferase reporter construct, a  $\beta$ -galactosidase reporter construct, a chloramphenicol acetyltransferase reporter construct, a green fluorescent protein reporter construct, and a secreted alkaline phosphatase construct.

112. The method of claim 111, wherein the TLR signaling activity is selected from the group consisting of luciferase expression,  $\beta$ -galactosidase expression, chloramphenicol acetyltransferase expression, green fluorescent protein expression, alkaline phosphatase expression and alkaline phosphatase secretion.

113. The method of claim 108, wherein the reporter construct comprises a TLR responsive promoter.

114. The method of claim 113, wherein the TLR responsive promoter  
5 comprises a transcription factor binding site selected from the group consisting of an NF- $\kappa$ B binding site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding site, and a TARE.

115. The method of claim 113, wherein the TLR responsive promoter is a  
10 promoter region selected from the group consisting of an IL-1 promoter region, an IL-6 promoter region, an IL-8 promoter region, an IL-10 promoter region, an IL-12 p40 promoter region, an IFN- $\alpha$ 1 promoter region, an IFN- $\alpha$ 4 promoter region, an IFN- $\beta$  promoter region, an IFN- $\gamma$  promoter region, a TNF- $\alpha$  promoter region, a TNF- $\beta$  promoter region, an IP-9 promoter  
15 region, an IP-10 promoter region, a RANTES promoter region, an ITAC promoter region, a MCP-1 promoter region, an IGFBP4 promoter region, a CD54 promoter region, a CD69 promoter region, a CD71 promoter region, a CD80 promoter region, a CD86 promoter region, a HLA-DR promoter region, and a HLA class I promoter region.

116. The method of claim 113, wherein the TLR responsive promoter is  
20 selected from the group consisting of a TLR1 responsive promoter, TLR2 responsive promoter, a TLR3 responsive promoter, a TLR4 responsive promoter, a TLR5 responsive promoter, a TLR6 responsive promoter, a TLR7 responsive promoter, a TLR8 responsive promoter, a TLR9 responsive promoter and a TLR10 responsive promoter.

25

117. The method of claim 107, wherein the cell is stably transfected with the nucleic acid.

118. The method of claim 95, wherein the TLR signaling activity is  
30 measured by cytokine secretion or chemokine secretion.

119. The method of claim 118, wherein the cytokine secretion or chemokine secretion is selected from the group consisting of IL-6 secretion, IL-12 secretion and TNF- $\alpha$  secretion.

5 120. The method of claim 118, wherein the cytokine secretion or chemokine secretion is selected from the group consisting of IL-8 secretion, IL-10 secretion and IP-10 secretion.

121. The method of claim 95, wherein the TLR signaling activity is  
10 measured by phosphorylation.

122. The method of claim 121, wherein phosphorylation is total cellular phosphorylation.

15 123. The method of claim 122, wherein phosphorylation is phosphorylation of a factor selected from the group consisting of IRAK, ERK, MyD88, TRAF6, p38, NF- $\kappa$ B subunits, c-Jun and c-Fos.

124. The method of claim 95, wherein the TLR signaling activity is  
20 measured by gene expression.

125. The method of claim 124, wherein the gene expression is selected from the group consisting of CD71 expression, CD86 expression, HLA-DR expression, IL-8 expression, IL-10 expression and IP-10 expression.

25 126. The method of claim 124, wherein the gene expression is selected from the group consisting of IL-6 expression, IL-12 expression and TNF- $\alpha$  expression.

127. The method of claim 95, wherein the TLR signaling activity is  
30 measured by microarray techniques.

128. The method of claim 95, wherein the TLR signaling activity is measured by cell proliferation.

129. The method of claim 95, wherein the TLR signaling activity is measured by cell surface marker expression.

5 130. The method of claim 129, wherein the cell surface marker expression is selected from the group consisting of CD71 cell surface expression, CD86 cell surface expression and HLA-DR MHC class II cell surface expression.

10 131. The method of claim 129, wherein the cell surface marker expression is selected from the group consisting of CD80 cell surface expression, HLA class I cell surface expression, CD54 cell surface expression and CD69 cell surface expression.

15 132. The method of claim 95, wherein the TLR signaling activity is measured by antibody secretion.

133. The method of claim 132, wherein the antibody secretion is IgM secretion.

20 134. The method of claim 95, wherein the cell is contacted to the positive reference compound and the test compound simultaneously.

135. The method of claim 95, wherein the cell is contacted to the positive reference compound prior to contact with the test compound.

25 136. The method of claim 95, wherein the cell is contacted to the test compound prior to contact with the positive reference compound.

30 137. A method for quality assessment of a test composition containing a known Toll like receptor (TLR) ligand, comprising:  
measuring a reference activity of a reference composition comprising a known TLR ligand, wherein the known TLR ligand is a nucleic acid molecule;  
measuring a test activity of a test composition comprising the known TLR ligand; and  
comparing the test activity to the reference activity.

138. The method of claim 137, further comprising selecting the test composition if the test activity falls within a predetermined range of variance about the reference activity.

5

139. The method of claim 1, wherein the reference composition is a first production lot of a pharmaceutical composition comprising the known TLR ligand, and wherein the test composition is a second production lot of a pharmaceutical composition comprising the known TLR ligand.

10

140. The method of claim 137, wherein the reference composition is a first in-process lot of a composition comprising the known TLR ligand, and wherein the test composition is a second in-process lot of a composition comprising the known TLR ligand.

15

141. The method of claim 137, wherein the measuring the reference activity comprises contacting the reference composition with an isolated cell expressing a TLR responsive to the known TLR ligand, and wherein the measuring the test activity comprises contacting the test composition with the isolated cell expressing a TLR responsive to the known TLR ligand.

20

142. The method of claim 141, wherein the isolated cell expressing the TLR responsive to the known TLR ligand comprises an expression vector for the TLR responsive to the known TLR ligand.

25

143. The method of claim 141, wherein the isolated cell expressing the TLR responsive to the known TLR ligand naturally expresses the TLR responsive to the known TLR ligand.

30

144. The method of claim 141, wherein the isolated cell expressing the TLR responsive to the known TLR ligand is RPMI 8226.

- 89 -

145. The method of claim 137, wherein the measuring the reference activity and the measuring the test activity each comprise measuring signaling activity mediated by a TLR responsive to the known TLR ligand.

5 146. The method of claim 145, wherein the signaling activity is activity of a reporter construct under control of NF- $\kappa$ B response element.

147. The method of claim 145, wherein the signaling activity is activity of a reporter construct under control of interferon-stimulated response element (ISRE).

10

148. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of an IFN- $\alpha$  promoter.

149. The method of claim 145, wherein the signaling activity is activity of a  
15 reporter gene under control of an IFN- $\beta$  promoter.

150. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of an IL-6 promoter.

20 151. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of an IL-8 promoter.

152. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of an IL-12 p40 promoter.

25

153. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of a RANTES promoter.

154. The method of claim 137, wherein the known TLR ligand is a TLR9  
30 ligand.

155. The method of claim 137, wherein the known TLR ligand is a TLR3 ligand.

- 90 -

156. The method of claim 137, wherein the known TLR ligand is a TLR7 ligand.

5 157. The method of claim 137, wherein the known TLR ligand is a TLR8 ligand.

158. The method of claim 137, wherein the known TLR ligand is an immunostimulatory nucleic acid.

10

159. The method of claim 137, wherein the known TLR ligand is a CpG nucleic acid.

160. The method of claim 137, wherein the known TLR ligand is an immunoinhibitory nucleic acid.

15

161. A method for quality assessment of a test lot of a pharmaceutical product containing a known TLR9 ligand, comprising:

measuring a reference activity of a reference lot of a pharmaceutical product comprising a known TLR9 ligand, wherein the known TLR9 ligand is a nucleic acid molecule;

measuring a test activity of a test lot of a pharmaceutical product comprising the known TLR9 ligand;

comparing the test activity to the reference activity; and

25 rejecting the test lot if the test activity falls outside of a predetermined range of variance about the reference activity.

162. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence TCGTCGTTTTGTCGTTTTGTCGTT (SEQ ID NO:1).

30



- 91 -

163. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTTGACGTTTTGTCGTT-3' (SEQ ID NO:139).
- 5 164. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTTGTCGTTTTTTTCGA-3' (SEQ ID NO:140).
- 10 165. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTCGTCGTTTCGTCGTT-3' (SEQ ID NO:141).
- 15 166. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTCGTCGTTTTGTCGTT-3' (SEQ ID NO:142).
- 20 167. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTTTCGGTCGTTTT-3' (SEQ ID NO:143).
- 25 168. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTTTCGTGCGTTTTT-3' (SEQ ID NO:144).
- 30 169. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTTCGGCGGCCGCCG-3' (SEQ ID NO:145).
170. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTC\_GTTTTAC\_GGCGCC\_GTGCCG-3' (SEQ ID NO:146), wherein every internucleoside linkage is phosphorothioate except for those indicated by “\_”, which are phosphodiester.

- 92 -

171. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising

contacting a cell that expresses a TLR with a test compound and measuring a test level of TLR signaling activity,

5 wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and

wherein the cell is a Raji cell, a RAMOS cell, a Nalm cell, a THP-1 cell, or a KG-1 cell, and the TLR is TLR9.

10 172. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising

contacting a cell that expresses a TLR with a test compound and measuring a test level of TLR signaling activity,

15 wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and

wherein the cell is a Raji cell or a RAMOS cell, and the TLR is TLR7.

173. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising

20 contacting a cell that expresses a TLR with a test compound and measuring a test level of TLR signaling activity,

wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and

25 wherein the cell is a Raji cell, a RAMOS cell, a KG-1 cell, a Nalm-6 cell, a Jurkat cell, a Hela cell, a Hep-2 cell, an A549 cell, a Bewo cell, an NK-92 cell or an NK-92 MI cell, and the TLR is TLR3.

174. A screening method for identifying antagonists of Toll-like receptor (TLR) signaling activity, comprising

30 contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity,

contacting the cell with the positive reference compound and a test compound, and measuring a test level of TLR signaling activity,

- 93 -

wherein a test level that is less than a reference level is indicative of a test compound that is a TLR antagonist, and

wherein the cell is selected from the group consisting of a RPMI 8226 cell, a RAMOS cell, a Raji cell, a THP-1 cell, a Nalm cell and a KG-1 cell, and the TLR is TLR9.

5

175. A screening method for identifying antagonists of Toll-like receptor (TLR) signaling activity, comprising

contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity,

10 contacting the cell with the positive reference compound and a test compound, and measuring a test level of TLR signaling activity,

wherein a test level that is less than a reference level is indicative of a test compound that is a TLR antagonist, and

15 wherein the cell is selected from the group consisting of a RPMI 8226 cell, a RAMOS cell and a Raji cell, and the TLR is TLR7.

175. A screening method for identifying antagonists of Toll-like receptor (TLR) signaling activity, comprising

20 contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity,

contacting the cell with the positive reference compound and a test compound, and measuring a test level of TLR signaling activity,

wherein a test level that is less than a reference level is indicative of a test compound that is a TLR antagonist, and

25 wherein the cell is selected from the group consisting of a Raji cell, a RAMOS cell, a KG-1 cell, a Nalm-6 cell, a Jurkat cell, a Hela cell, a Hep-2 cell, an A549 cell, a Bewo cell, an NK-92 cell and an NK-92 MI cell, and the TLR is TLR3.

176. A screening method for identifying an enhancer of a Toll-like receptor (TLR) agonist, comprising

30 contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity, and

contacting a cell with the positive reference compound and a test compound and measuring a test level of TLR signaling activity,

wherein the positive reference compound is a TLR agonist, and a test level that is greater than the reference level is indicative of a test compound that is an enhancer of a TLR agonist.

177. The method of claim 176, wherein the positive reference compound is an immunostimulatory nucleic acid.

178. The method of claim 176, wherein the positive reference compound is an imidazoquinoline compound.

180. The method of claim 176, wherein the cell is selected from the group consisting of a KG-1 cell, a Nalm-6 cell, a Raji cell, a RAMOS cell, a Jurkat cell, a HeLa cell, a Hep-2 cell, an A549 cell, a Bewo cell, an NK-92 cell and an NK-92 MI cell, and the TLR is TLR3.

181. The method of claim 176, wherein the cell is selected from the group consisting of a KG-1 cell, a Nalm-6 cell, a Raji cell, an RPMI 8226 cell, a RAMOS cell, and a THP-1 cell, and the TLR is TLR9.

182. The method of claim 176, wherein the cell is selected from the group consisting of a Raji cell, an RPMI 8226 cell and a RAMOS cell, and the TLR is TLR7.

183. The method of claim 1, wherein the TLR is TLR7 or TLR9.

184. The method of claim 172-175 or 176, wherein the cell is unmodified.

1/15




Fig. 1

2/15




Fig. 2

3/15




Fig. 3

4/15





Fig. 4



5/15



6/15




Fig. 6

7/15




Fig. 7

8/15




Fig. 8

9/15




Fig. 9

10/15




Fig. 10




Fig. 11

11/15




Fig. 12

12/15




Fig. 13




Fig. 14



13/15




Fig. 15





Fig. 16



ODN [µM]

Fig. 17

14/15




Fig. 18A




Fig. 18B




Fig. 19





Fig. 20



## SEQUENCE LISTING

<110> COLEY PHARMACEUTICAL GmbH  
 COLEY PHARMACEUTICAL GROUP INC.

<120> METHODS AND PRODUCTS FOR IDENTIFICATION AND ASSESSMENT OF TLR  
 LIGANDS

<130> C1041.70024W000

<140> not yet assigned  
 <141> 2004-04-22

<150> US 60/464,586  
 <151> 2003-04-22

<150> US 60/464,588  
 <151> 2003-04-22

<160> 161

<170> PatentIn version 3.2

<210> 1  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 1  
 tcgtcgtttt gtcgttttgt cgtt 24

<210> 2  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 2  
 tccaggactt ctctcaggtt 20

<210> 3  
 <211> 2600  
 <212> DNA  
 <213> Homo sapiens

<400> 3  
 ggatccaaag gagacctata gtgactccca ggagctctta gtgaccaagt gaaggtagct 60  
 gtggggctca ttgtgcccac tgctctttca ctgctttcaa ctggtagtgt tgggttgaag 120  
 cactggacaa tgccacatac tttgtggatg gtgtgggtct tgggggtcat catcagcctc 180  
 tccaaggaag aatcctccaa tcaggcttct ctgtcttctg accgcaatgg tatctgcaag 240

ggcagctcag gatctttaaa ctccattccc tcagggctca cagaagctgt aaaaagcctt 300  
gacctgtcca acaacaggat cacctacatt agcaacagtg acctacagag gtgtgtgaac 360  
ctccaggctc tgggtctgac atccaatgga attaacacaa tagaggaaga ttctttttct 420  
tccttgggca gtcttgaaca tttagactta tcctataatt acttatctaa tttatcgtct 480  
tcctggttca agcccccttc ttctttaaca ttcttaaact tactgggaaa tccttacaaa 540  
accctagggg aaacatctct tttttctcat ctcaaaaat tgcaaatcct gagagtggga 600  
aatatggaca ccttcactaa gattcaaaga aaagattttg ctggacttac cttccttgag 660  
gaacttgaga ttgatgcttc agatctacag agctatgagc caaaaagttt gaagtcaatt 720  
cagaacgtaa gtcactgat ccttcatatg aagcagcata ttttactgct ggagattttt 780  
gtagatgtta caagttccgt ggaatgtttg gaactgagag atactgattt ggacactttc 840  
catttttcag aactatccac tggtgaaaca aattcattga ttaaaaagtt tacatttaga 900  
aatgtgaaaa tcaccgatga aagtttggtt caggttatga aacttttgaa tcagatttct 960  
ggattgttag aattagagtt tgatgactgt acccttaatg gagttggtaa ttttagagca 1020  
tctgataatg acagagttat agatccaggt aaagtggaaa cgtaacaat ccggaggctg 1080  
catattccaa ggttttactt attttatgat ctgagcactt tatattcact tacagaaaga 1140  
gttaaaagaa tcacagtaga aaacagtaaa gtttttctgg ttccttggtt actttcacia 1200  
catttaaaat cattagaata cttggatctc agtgaaaatt tgatgggtga agaatacttg 1260  
aaaaattcag cctgtgagga tgctggccc tctctacaaa ctttaatttt aaggcaaat 1320  
catttgcat cattggaaaa aaccggagag actttgctca ctctgaaaaa cttgactaac 1380  
attgatatca gtaagaatag ttttcattct atgcctgaaa cttgtcagtg gccagaaaag 1440  
atgaaatatt tgaacttatc cagcacacga atacacagtg taacaggctg cattccaag 1500  
acactggaaa ttttagatgt tagcaacaac aatctcaatt tattttcttt gaatttgccg 1560  
caactcaaag aactttatat ttccagaaat aagttgatga ctctaccaga tgccctcctc 1620  
ttaccatgt tactagtatt gaaaatcagt aggaatgcaa taactacgtt ttctaaggag 1680  
caacttgact catttcacac actgaagact ttggaagctg gtggcaataa cttcatttgc 1740  
tcctgtgaat tcctctcctt cactcaggag cagcaagcac tggccaaagt cttgattgat 1800  
tgccagcaa attacctgtg tgactctcca tccatgtgc gtggccagca gggtcaggat 1860  
gtccgcctct cgggtgcgga atgtcacagg acagcactgg tgtctggcat gtgctgtgct 1920  
ctgttcctgc tgatcctgct cacgggggtc ctgtgccacc gtttccatgg cctgtggtat 1980  
atgaaaatga tgtgggcctg gctccaggcc aaaaggaagc ccaggaaagc tcccagcagg 2040  
aacatctgct atgatgcatt tgtttcttac agtgagcggg atgcctactg ggtggagaac 2100

cttatgggtcc aggagctgga gaacttcaat ccccccttca agttgtgtct tcataagcgg 2160  
 gacttcattc ctggcaagtg gatcattgac aatatcattg actccattga aaagagccac 2220  
 aaaactgtct ttgtgctttc tgaaaacttt gtgaagagtg agtgggtgcaa gtatgaactg 2280  
 gacttctccc atttccgtct ttttgaagag aacaatgatg ctgccattct cattcttctg 2340  
 gagcccattg agaaaaaagc cattccccag cgcttctgca agctgcggaa gataatgaac 2400  
 accaagacct acctggagtg gcccatggac gaggctcagc gggaaggatt ttgggtaaatt 2460  
 ctgagagctg cgataaagtc ctaggttccc atatttaaga ccagtctttg tctagttggg 2520  
 atctttatgt cactagttat agttaagttc attcagacat aattatataa aaactacgtg 2580  
 gatgtaccgt catttgagga 2600

<210> 4  
 <211> 784  
 <212> PRT  
 <213> Homo sapiens

<400> 4

Met	Pro	His	Thr	Leu	Trp	Met	Val	Trp	Val	Leu	Gly	Val	Ile	Ile	Ser
1				5					10					15	
Leu	Ser	Lys	Glu	Glu	Ser	Ser	Asn	Gln	Ala	Ser	Leu	Ser	Cys	Asp	Arg
			20					25					30		
Asn	Gly	Ile	Cys	Lys	Gly	Ser	Ser	Gly	Ser	Leu	Asn	Ser	Ile	Pro	Ser
			35					40					45		
Gly	Leu	Thr	Glu	Ala	Val	Lys	Ser	Leu	Asp	Leu	Ser	Asn	Asn	Arg	Ile
			50					55					60		
Thr	Tyr	Ile	Ser	Asn	Ser	Asp	Leu	Gln	Arg	Cys	Val	Asn	Leu	Gln	Ala
65						70				75					80
Leu	Val	Leu	Thr	Ser	Asn	Gly	Ile	Asn	Thr	Ile	Glu	Glu	Asp	Ser	Phe
						85				90					95
Ser	Ser	Leu	Gly	Ser	Leu	Glu	His	Leu	Asp	Leu	Ser	Tyr	Asn	Tyr	Leu
			100					105					110		
Ser	Asn	Leu	Ser	Ser	Ser	Trp	Phe	Lys	Pro	Leu	Ser	Ser	Leu	Thr	Phe
			115					120					125		
Leu	Asn	Leu	Leu	Gly	Asn	Pro	Tyr	Lys	Thr	Leu	Gly	Glu	Thr	Ser	Leu
			130					135					140		
Phe	Ser	His	Leu	Thr	Lys	Leu	Gln	Ile	Leu	Arg	Val	Gly	Asn	Met	Asp
145						150				155					160
Thr	Phe	Thr	Lys	Ile	Gln	Arg	Lys	Asp	Phe	Ala	Gly	Leu	Thr	Phe	Leu
						165				170					175
Glu	Glu	Leu	Glu	Ile	Asp	Ala	Ser	Asp	Leu	Gln	Ser	Tyr	Glu	Pro	Lys
						180			185				190		

Ser Leu Lys Ser Ile Gln Asn Val Ser His Leu Ile Leu His Met Lys  
 195 200 205  
 Gln His Ile Leu Leu Leu Glu Ile Phe Val Asp Val Thr Ser Ser Val  
 210 215 220  
 Glu Cys Leu Glu Leu Arg Asp Thr Asp Leu Asp Thr Phe His Phe Ser  
 225 230 235 240  
 Glu Leu Ser Thr Gly Glu Thr Asn Ser Leu Ile Lys Lys Phe Thr Phe  
 245 250 255  
 Arg Asn Val Lys Ile Thr Asp Glu Ser Leu Phe Gln Val Met Lys Leu  
 260 265 270  
 Leu Asn Gln Ile Ser Gly Leu Leu Glu Leu Glu Phe Asp Asp Cys Thr  
 275 280 285  
 Leu Asn Gly Val Gly Asn Phe Arg Ala Ser Asp Asn Asp Arg Val Ile  
 290 295 300  
 Asp Pro Gly Lys Val Glu Thr Leu Thr Ile Arg Arg Leu His Ile Pro  
 305 310 315 320  
 Arg Phe Tyr Leu Phe Tyr Asp Leu Ser Thr Leu Tyr Ser Leu Thr Glu  
 325 330 335  
 Arg Val Lys Arg Ile Thr Val Glu Asn Ser Lys Val Phe Leu Val Pro  
 340 345 350  
 Cys Leu Leu Ser Gln His Leu Lys Ser Leu Glu Tyr Leu Asp Leu Ser  
 355 360 365  
 Glu Asn Leu Met Val Glu Glu Tyr Leu Lys Asn Ser Ala Cys Glu Asp  
 370 375 380  
 Ala Trp Pro Ser Leu Gln Thr Leu Ile Leu Arg Gln Asn His Leu Ala  
 385 390 395 400  
 Ser Leu Glu Lys Thr Gly Glu Thr Leu Leu Thr Leu Lys Asn Leu Thr  
 405 410 415  
 Asn Ile Asp Ile Ser Lys Asn Ser Phe His Ser Met Pro Glu Thr Cys  
 420 425 430  
 Gln Trp Pro Glu Lys Met Lys Tyr Leu Asn Leu Ser Ser Thr Arg Ile  
 435 440 445  
 His Ser Val Thr Gly Cys Ile Pro Lys Thr Leu Glu Ile Leu Asp Val  
 450 455 460  
 Ser Asn Asn Asn Leu Asn Leu Phe Ser Leu Asn Leu Pro Gln Leu Lys  
 465 470 475 480  
 Glu Leu Tyr Ile Ser Arg Asn Lys Leu Met Thr Leu Pro Asp Ala Ser  
 485 490 495  
 Leu Leu Pro Met Leu Leu Val Leu Lys Ile Ser Arg Asn Ala Ile Thr  
 500 505 510  
 Thr Phe Ser Lys Glu Gln Leu Asp Ser Phe His Thr Leu Lys Thr Leu

```
<210> 5
<211> 2824
<212> DNA
<213> murine

<400> 5
gccccccatg gccatatggg caccggggag cggcggctgg aggactccta ggctcctggg      60
caggcgggtca catggcagaa gatgtgtccg caatcatagt ttctgatggg gaaggttggg      120
cggcagtcctc tgcgacctag aagtggaaaa gatgtcgttc aaggaggtgc ggactgtttc      180
```



cttctgacca	ggatcttgtt	tctgagtgt	ggggcttcac	ttctctgctt	ttcgttcac	240
tctggagcat	ccgaattgca	tcaccgggtca	gaaaacaact	taccgaaacc	tcagacaaag	300
cgtaaactct	cagaggatgc	tacgagctct	ttggctcttc	tggatcttgg	tggccataac	360
agtcctcttc	agcaaacgct	gttctgctca	ggagtctctg	tcagtgtgatg	cttctgggggt	420
gtgtgatggc	cgctccaggt	ctttcacctc	tattccctcc	ggactcacag	cagccatgaa	480
aagccttgac	ctgtctttca	acaagatcac	ctacattggc	catggtgacc	tccgagcgtg	540
tgcaaacctc	caggttctga	ttttgaagtc	cagcagaatc	aatacaatag	agggagacgc	600
cttttattct	ctgggcagtc	ttgaacattt	ggatttgtct	gataatcacc	tatctagttt	660
atcttctctc	tggttcgggc	ccctttcttc	tttgaaatac	ttaaacttaa	tgggaaatcc	720
ttaccagaca	ctgggggtaa	catcgctttt	tcccaatctc	acaaatttac	aaaccctcag	780
gataggaaat	gtagagactt	tcagtgagat	aaggagaata	gattttgctg	ggctgacttc	840
tctcaatgaa	cttgaaatta	aggcataaag	tctccggaat	tatcagtccc	aaagtctaaa	900
gtcgatccgc	gacatccatc	acctgactct	tcacttaagc	gagtctgctt	tcctgctgga	960
gatttttgca	gatattctga	gttctgtgag	atatttagaa	ctaagagata	ctaacttggc	1020
caggttccag	ttttcaccac	tgcccgtaga	tgaagtcagc	tcaccgatga	agaagctggc	1080
attccgaggc	tcggttctca	ctgatgaaag	ctttaacgag	ctcctgaagc	tggtgcggtta	1140
catcttgga	ctgtcggagg	tagagtccga	cgactgtacc	ctcaatgggc	tcggcgattt	1200
caacccctcg	gagtcagacg	tagtgagcga	gctgggtaaa	gtagaaacag	tcactatccg	1260
gaggttgcat	atcccccagt	tctatttgtt	ttatgacctg	agtactgtct	attccctcct	1320
ggagaagggtg	aagcgaatca	cagtagagaa	cagcaaggtc	ttcctgggtc	cctgctcggt	1380
ctcccagcat	ttaaaatcat	tagaattctt	agacctcagc	gaaaatctga	tggttgaaga	1440
atatttgaag	aactcagcct	gtaaggggagc	ctggccttct	ctacaaacct	tagttttgag	1500
ccagaatcat	ttgagatcaa	tgcaaaaaac	aggagagatt	ttgctgactc	tgaaaaacct	1560
gacctccctt	gacatcagca	ggaacacttt	tcatccgatg	cccagacagct	gtcagtggcc	1620
agaaaagatg	cgcttctctga	atgtgtccag	tacagggatc	cgggtggtaa	aaacgtgcat	1680
tcctcagacg	ctggagggtgt	tggatgttag	taacaacaat	cttgactcat	tttctttgtt	1740
cttgccctcg	ctgcaagagc	tctatatattc	cagaaataag	ctgaaaacac	tcccagatgc	1800
ttcgttgttc	cctgtgttgc	tggatcatgaa	aatcagagag	aatgcagtaa	gtactttctc	1860
taaagaccaa	cttggttctt	ttcccaaact	ggagactctg	gaagcaggcg	acaaccactt	1920
tgtttgctcc	tgcaactcc	tatcctttac	tatggagacg	ccagctctgg	ctcaaactct	1980
ggttgactgg	ccagacagct	acctgtgtga	ctctccgcct	cgctgcacg	gccacaggct	2040
tcaggatgcc	cggccctccg	tcttggaatg	tcaccaggct	gcactgggtgt	ctggagtctg	2100

```

ctgtgccctt ctctgttga tcttgcctg aggtgccctg tgccaccatt tccacgggct 2160
gtggtacctg agaatzatgt gggcgtggct ccaggccaag aggaagccca agaaagctcc 2220
ctgcagggac gtttgcctatg atgcctttgt ttcctacagt gagcaggatt cccattgggt 2280
ggagaacctc atggtccagc agctggagaa ctctgacctg ccctttaagc tgtgtctcca 2340
caagcgggac ttcgttccgg gcaaatggat cattgacaac atcatcgatt ccatcgaaaa 2400
gagccacaaa actgtgttcg tgctttctga gaacttcgta cggagcgagt ggtgcaagta 2460
cgaactggac ttctccact tcaggctctt tgacgagaac aacgacggg ccatccttgt 2520
tttgcctggag cccattgaga ggaaagccat tccccagcgc ttctgcaaac tgcgcaagat 2580
aatgaacacc aagacctacc tggagtggcc cttggatgaa ggccagcagg aagtgttttg 2640
ggtaaatctg agaactgcaa taaagtccta ggttctccac ccagttcctg acttccttaa 2700
ctaaggctctt tgtgacacaa actgtaacaa agtttataag taacatagaa ttgtattatt 2760
gaggatatta actatggggt ttgtcttgaa tactgttata taaatatgtg acatcaggct 2820
ttag 2824

```

<210> 6  
 <211> 784  
 <212> PRT  
 <213> murine

<400> 6

```

Met Leu Arg Ala Leu Trp Leu Phe Trp Ile Leu Val Ala Ile Thr Val
1           5           10          15

Leu Phe Ser Lys Arg Cys Ser Ala Gln Glu Ser Leu Ser Cys Asp Ala
20          25          30

Ser Gly Val Cys Asp Gly Arg Ser Arg Ser Phe Thr Ser Ile Pro Ser
35          40          45

Gly Leu Thr Ala Ala Met Lys Ser Leu Asp Leu Ser Phe Asn Lys Ile
50          55          60

Thr Tyr Ile Gly His Gly Asp Leu Arg Ala Cys Ala Asn Leu Gln Val
65          70          75          80

Leu Ile Leu Lys Ser Ser Arg Ile Asn Thr Ile Glu Gly Asp Ala Phe
85          90          95

Tyr Ser Leu Gly Ser Leu Glu His Leu Asp Leu Ser Asp Asn His Leu
100         105         110

Ser Ser Leu Ser Ser Ser Trp Phe Gly Pro Leu Ser Ser Leu Lys Tyr
115         120         125

Leu Asn Leu Met Gly Asn Pro Tyr Gln Thr Leu Gly Val Thr Ser Leu
130         135         140

```

Phe Pro Asn Leu Thr Asn Leu Gln Thr Leu Arg Ile Gly Asn Val Glu  
 145 150 155 160  
 Thr Phe Ser Glu Ile Arg Arg Ile Asp Phe Ala Gly Leu Thr Ser Leu  
 165 170 175  
 Asn Glu Leu Glu Ile Lys Ala Leu Ser Leu Arg Asn Tyr Gln Ser Gln  
 180 185 190  
 Ser Leu Lys Ser Ile Arg Asp Ile His His Leu Thr Leu His Leu Ser  
 195 200 205  
 Glu Ser Ala Phe Leu Leu Glu Ile Phe Ala Asp Ile Leu Ser Ser Val  
 210 215 220  
 Arg Tyr Leu Glu Leu Arg Asp Thr Asn Leu Ala Arg Phe Gln Phe Ser  
 225 230 235 240  
 Pro Leu Pro Val Asp Glu Val Ser Ser Pro Met Lys Lys Leu Ala Phe  
 245 250 255  
 Arg Gly Ser Val Leu Thr Asp Glu Ser Phe Asn Glu Leu Leu Lys Leu  
 260 265 270  
 Leu Arg Tyr Ile Leu Glu Leu Ser Glu Val Glu Phe Asp Asp Cys Thr  
 275 280 285  
 Leu Asn Gly Leu Gly Asp Phe Asn Pro Ser Glu Ser Asp Val Val Ser  
 290 295 300  
 Glu Leu Gly Lys Val Glu Thr Val Thr Ile Arg Arg Leu His Ile Pro  
 305 310 315 320  
 Gln Phe Tyr Leu Phe Tyr Asp Leu Ser Thr Val Tyr Ser Leu Leu Glu  
 325 330 335  
 Lys Val Lys Arg Ile Thr Val Glu Asn Ser Lys Val Phe Leu Val Pro  
 340 345 350  
 Cys Ser Phe Ser Gln His Leu Lys Ser Leu Glu Phe Leu Asp Leu Ser  
 355 360 365  
 Glu Asn Leu Met Val Glu Glu Tyr Leu Lys Asn Ser Ala Cys Lys Gly  
 370 375 380  
 Ala Trp Pro Ser Leu Gln Thr Leu Val Leu Ser Gln Asn His Leu Arg  
 385 390 395 400  
 Ser Met Gln Lys Thr Gly Glu Ile Leu Leu Thr Leu Lys Asn Leu Thr  
 405 410 415  
 Ser Leu Asp Ile Ser Arg Asn Thr Phe His Pro Met Pro Asp Ser Cys  
 420 425 430  
 Gln Trp Pro Glu Lys Met Arg Phe Leu Asn Leu Ser Ser Thr Gly Ile  
 435 440 445  
 Arg Val Val Lys Thr Cys Ile Pro Gln Thr Leu Glu Val Leu Asp Val  
 450 455 460  
 Ser Asn Asn Asn Leu Asp Ser Phe Ser Leu Phe Leu Pro Arg Leu Gln

465                                      470                                      475                                      480  
 Glu Leu Tyr Ile Ser Arg Asn Lys Leu Lys Thr Leu Pro Asp Ala Ser  
    485                                      490                                      495  
  
 Leu Phe Pro Val Leu Leu Val Met Lys Ile Arg Glu Asn Ala Val Ser  
    500                                      505                                      510  
  
 Thr Phe Ser Lys Asp Gln Leu Gly Ser Phe Pro Lys Leu Glu Thr Leu  
    515                                      520                                      525  
  
 Glu Ala Gly Asp Asn His Phe Val Cys Ser Cys Glu Leu Leu Ser Phe  
    530                                      535                                      540  
  
 Thr Met Glu Thr Pro Ala Leu Ala Gln Ile Leu Val Asp Trp Pro Asp  
 545                                      550                                      555                                      560  
  
 Ser Tyr Leu Cys Asp Ser Pro Pro Arg Leu His Gly His Arg Leu Gln  
    565                                      570                                      575  
  
 Asp Ala Arg Pro Ser Val Leu Glu Cys His Gln Ala Ala Leu Val Ser  
    580                                      585                                      590  
  
 Gly Val Cys Cys Ala Leu Leu Leu Leu Ile Leu Leu Val Gly Ala Leu  
    595                                      600                                      605  
  
 Cys His His Phe His Gly Leu Trp Tyr Leu Arg Met Met Trp Ala Trp  
 610                                      615                                      620  
  
 Leu Gln Ala Lys Arg Lys Pro Lys Lys Ala Pro Cys Arg Asp Val Cys  
 625                                      630                                      635                                      640  
  
 Tyr Asp Ala Phe Val Ser Tyr Ser Glu Gln Asp Ser His Trp Val Glu  
    645                                      650                                      655  
  
 Asn Leu Met Val Gln Gln Leu Glu Asn Ser Asp Pro Pro Phe Lys Leu  
    660                                      665                                      670  
  
 Cys Leu His Lys Arg Asp Phe Val Pro Gly Lys Trp Ile Ile Asp Asn  
    675                                      680                                      685  
  
 Ile Ile Asp Ser Ile Glu Lys Ser His Lys Thr Val Phe Val Leu Ser  
 690                                      695                                      700  
  
 Glu Asn Phe Val Arg Ser Glu Trp Cys Lys Tyr Glu Leu Asp Phe Ser  
 705                                      710                                      715                                      720  
  
 His Phe Arg Leu Phe Asp Glu Asn Asn Asp Ala Ala Ile Leu Val Leu  
    725                                      730                                      735  
  
 Leu Glu Pro Ile Glu Arg Lys Ala Ile Pro Gln Arg Phe Cys Lys Leu  
    740                                      745                                      750  
  
 Arg Lys Ile Met Asn Thr Lys Thr Tyr Leu Glu Trp Pro Leu Asp Glu  
    755                                      760                                      765  
  
 Gly Gln Gln Glu Val Phe Trp Val Asn Leu Arg Thr Ala Ile Lys Ser  
 770                                      775                                      780

<210> 7  
 <211> 3029  
 <212> DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 7

gcggccgcgt cgacgaaatg tctggatttg gactaaagaa aaaaggaaag gctagcagtc 60

atccaacaga atcatgagac agactttgcc ttgtatctac ttttgggggg gccttttgcc 120

ctttgggatg ctgtgtgcat cctccaccac caagtgcact gttagccatg aagttgctga 180

ctgcagccac ctgaagttga ctcaggtacc cgatgatcta cccacaaaca taacagtgtt 240

gaaccttacc cataatcaac tcagaagatt accagccgcc aacttcacaa ggtatagcca 300

gctaactagc ttggatgtag gatttaacac catctcaaaa ctggagccag aattgtgcca 360

gaaacttccc atgttaaaag ttttgaacct ccagcacaat gagctatctc aactttctga 420

taaaaccttt gccttctgca cgaatttgac tgaactccat ctcatgtcca actcaatcca 480

gaaaattaaa aataatccct ttgtcaagca gaagaattta atcacattag atctgtctca 540

taatggcttg tcatctacaa aattaggaac tcaggttcag ctggaaaatc tccaagagct 600

tctattatca aacaataaaa ttcaagcgct aaaaagtga gaactggata tctttgccaa 660

ttcatcttta aaaaaattag agttgtcatc gaatcaaatt aaagagtttt ctccagggtg 720

ttttcacgca attggaagat tatttggcct ctttctgaac aatgtccagc tgggtcccag 780

ccttacagag aagctatgtt tggaattagc aaacacaagc attcggaatc tgtctctgag 840

taacagccag ctgtccacca ccagcaatac aactttcttg ggactaaagt ggacaaatct 900

cactatgctc gatctttcct acaacaactt aaatgtgggt ggtaacgatt cctttgcttg 960

gcttccacaa ctagaatatt tcttctctaga gtataataat atacagcatt tgttttctca 1020

ctctttgcac gggcttttca atgtgaggta cctgaatttg aaacggtctt ttactaaaca 1080

aagtatttcc cttgcctcac tccccagat tgatgatttt tcttttcagt ggctaaaatg 1140

tttgagcac cttaacatgg aagataatga tattccaggc ataaaaagca atatgttcac 1200

aggattgata aacctgaaat acttaagtct atccaactcc tttacaagtt tgcgaacttt 1260

gacaaatgaa acatttgtat cacttgctca ttctccctta cacatactca acctaaccaa 1320

gaataaaatc tcaaaaatag agagtgatgc tttctcttgg ttggggccacc tagaagtact 1380

tgacctgggc cttaatgaaa ttgggcaaga actcacaggc caggaaatgga gaggtctaga 1440

aaatattttc gaaatctatc tttcctacaa caagtacctg cagctgacta ggaactcctt 1500

tgcttggtc ccaagccttc aacgactgat gctccgaagg gtggccctta aaaatgtgga 1560

tagctctcct tcaccattcc agcctcttcg taacttgacc attctggatc taagcaacaa 1620

caacatagcc aacataaatg atgacatgtt ggaggggtctt gagaaactag aaattctcga 1680

tttgagcat aacaacttag cacggctctg gaaacacgca aaccctgggtg gtcccattha 1740

tttcttaaag ggtctgtctc acctccacat ccttaacttg gagtccaacg gctttgacga 1800

```

gatcccagtt gaggtcttca aggatttatt tgaactaaag atcatcgatt taggattgaa 1860
taattttaaac acacttccag catctgtctt taataatcag gtgtctctaa agtcattgaa 1920

ccttcagaag aatctcataa catccgttga gaagaagggt ttcgggccag ctttcaggaa 1980

cctgactgag ttagatatgc gctttaatcc ctttgattgc acgtgtgaaa gtattgcctg 2040

gtttgttaat tggattaacg agaccatac caacatccct gagctgtcaa gccactacct 2100

ttgcaacact ccacctcact atcatgggtt cccagtgaga ctttttgata catcatcttg 2160

caaagacagt gcccccttg aactctttt catgatcaat accagtatcc tgttgatttt 2220

tatctttatt gtacttctca tccactttga gggctggagg atatctttt attggaatgt 2280

ttcagtacat cgagttcttg gtttcaaaga aatagacaga cagacagaac agtttgaata 2340

tgcagcatat ataattcatg cctataaaga taaggattgg gtctgggaac atttctcttc 2400

aatggaaaag gaagaccaat ctctcaaatt ttgtctggaa gaaagggact ttgaggcggg 2460

tgtttttgaa ctagaagcaa ttgttaacag catcaaaaga agcagaaaaa ttatttttgt 2520

tataacacac catctattaa aagaccatt atgcaaaaga ttcaaggtag atcatgcagt 2580

tcaacaagct attgaacaaa atctggattc cattatattg gtttctctg aggagattcc 2640

agattataaa ctgaacctg cactctgttt gcgaagagga atgtttaaat ctactgcat 2700

cttgaactgg ccagttcaga aagaacggat aggtgccttt cgtcataaat tgcaagtagc 2760

acttgatcc aaaaactctg tacattaaat ttatttaaatt attcaattag caaaggagaa 2820

actttctcaa tttaaaaagt tctatggcaa atttaagttt tccataaagg tgttataatt 2880

tgtttattca tatttgtaaa tgattatatt ctatcacaat tacatctctt ctaggaaaat 2940

gtgtctcctt atttcaggcc tatttttgac aattgactta attttaccba aaataaaaca 3000

tataagcacg caaaaaaaaa aaaaaaaaaa 3029

```

<210> 8  
 <211> 904  
 <212> PRT  
 <213> Homo sapiens

<400> 8

```

Met Arg Gln Thr Leu Pro Cys Ile Tyr Phe Trp Gly Gly Leu Leu Pro
1           5           10           15

Phe Gly Met Leu Cys Ala Ser Ser Thr Thr Lys Cys Thr Val Ser His
20           25           30

Glu Val Ala Asp Cys Ser His Leu Lys Leu Thr Gln Val Pro Asp Asp
35           40           45

Leu Pro Thr Asn Ile Thr Val Leu Asn Leu Thr His Asn Gln Leu Arg
50           55           60

Arg Leu Pro Ala Ala Asn Phe Thr Arg Tyr Ser Gln Leu Thr Ser Leu

```

65	Asp	Val	Gly	Phe	Asn	Thr	Ile	Ser	Lys	Leu	Glu	Pro	Glu	Leu	Cys	Gln	80
				85						90					95		
Lys	Leu	Pro	Met	Leu	Lys	Val	Leu	Asn	Leu	Gln	His	Asn	Glu	Leu	Ser		
			100					105					110				
Gln	Leu	Ser	Asp	Lys	Thr	Phe	Ala	Phe	Cys	Thr	Asn	Leu	Thr	Glu	Leu		
		115					120					125					
His	Leu	Met	Ser	Asn	Ser	Ile	Gln	Lys	Ile	Lys	Asn	Asn	Pro	Phe	Val		
	130					135					140						
Lys	Gln	Lys	Asn	Leu	Ile	Thr	Leu	Asp	Leu	Ser	His	Asn	Gly	Leu	Ser		
145					150					155					160		
Ser	Thr	Lys	Leu	Gly	Thr	Gln	Val	Gln	Leu	Glu	Asn	Leu	Gln	Glu	Leu		
				165					170					175			
Leu	Leu	Ser	Asn	Asn	Lys	Ile	Gln	Ala	Leu	Lys	Ser	Glu	Glu	Leu	Asp		
			180					185					190				
Ile	Phe	Ala	Asn	Ser	Ser	Leu	Lys	Lys	Leu	Glu	Leu	Ser	Ser	Asn	Gln		
	195						200					205					
Ile	Lys	Glu	Phe	Ser	Pro	Gly	Cys	Phe	His	Ala	Ile	Gly	Arg	Leu	Phe		
210						215				220							
Gly	Leu	Phe	Leu	Asn	Asn	Val	Gln	Leu	Gly	Pro	Ser	Leu	Thr	Glu	Lys		
225					230					235					240		
Leu	Cys	Leu	Glu	Leu	Ala	Asn	Thr	Ser	Ile	Arg	Asn	Leu	Ser	Leu	Ser		
				245					250					255			
Asn	Ser	Gln	Leu	Ser	Thr	Thr	Ser	Asn	Thr	Thr	Phe	Leu	Gly	Leu	Lys		
			260					265					270				
Trp	Thr	Asn	Leu	Thr	Met	Leu	Asp	Leu	Ser	Tyr	Asn	Asn	Leu	Asn	Val		
	275						280					285					
Val	Gly	Asn	Asp	Ser	Phe	Ala	Trp	Leu	Pro	Gln	Leu	Glu	Tyr	Phe	Phe		
	290					295					300						
Leu	Glu	Tyr	Asn	Asn	Ile	Gln	His	Leu	Phe	Ser	His	Ser	Leu	His	Gly		
305					310					315					320		
Leu	Phe	Asn	Val	Arg	Tyr	Leu	Asn	Leu	Lys	Arg	Ser	Phe	Thr	Lys	Gln		
				325					330					335			
Ser	Ile	Ser	Leu	Ala	Ser	Leu	Pro	Lys	Ile	Asp	Asp	Phe	Ser	Phe	Gln		
			340					345					350				
Trp	Leu	Lys	Cys	Leu	Glu	His	Leu	Asn	Met	Glu	Asp	Asn	Asp	Ile	Pro		
	355						360					365					
Gly	Ile	Lys	Ser	Asn	Met	Phe	Thr	Gly	Leu	Ile	Asn	Leu	Lys	Tyr	Leu		
	370					375					380						
Ser	Leu	Ser	Asn	Ser	Phe	Thr	Ser	Leu	Arg	Thr	Leu	Thr	Asn	Glu	Thr		
385					390					395					400		
Phe	Val	Ser	Leu	Ala	His</												

405 410 415  
 Asn Lys Ile Ser Lys Ile Glu Ser Asp Ala Phe Ser Trp Leu Gly His  
 420 425 430  
 Leu Glu Val Leu Asp Leu Gly Leu Asn Glu Ile Gly Gln Glu Leu Thr  
 435 440 445  
 Gly Gln Glu Trp Arg Gly Leu Glu Asn Ile Phe Glu Ile Tyr Leu Ser  
 450 455 460  
 Tyr Asn Lys Tyr Leu Gln Leu Thr Arg Asn Ser Phe Ala Leu Val Pro  
 465 470 475 480  
 Ser Leu Gln Arg Leu Met Leu Arg Arg Val Ala Leu Lys Asn Val Asp  
 485 490 495  
 Ser Ser Pro Ser Pro Phe Gln Pro Leu Arg Asn Leu Thr Ile Leu Asp  
 500 505 510  
 Leu Ser Asn Asn Asn Ile Ala Asn Ile Asn Asp Asp Met Leu Glu Gly  
 515 520 525  
 Leu Glu Lys Leu Glu Ile Leu Asp Leu Gln His Asn Asn Leu Ala Arg  
 530 535 540  
 Leu Trp Lys His Ala Asn Pro Gly Gly Pro Ile Tyr Phe Leu Lys Gly  
 545 550 555 560  
 Leu Ser His Leu His Ile Leu Asn Leu Glu Ser Asn Gly Phe Asp Glu  
 565 570 575  
 Ile Pro Val Glu Val Phe Lys Asp Leu Phe Glu Leu Lys Ile Ile Asp  
 580 585 590  
 Leu Gly Leu Asn Asn Leu Asn Thr Leu Pro Ala Ser Val Phe Asn Asn  
 595 600 605  
 Gln Val Ser Leu Lys Ser Leu Asn Leu Gln Lys Asn Leu Ile Thr Ser  
 610 615 620  
 Val Glu Lys Lys Val Phe Gly Pro Ala Phe Arg Asn Leu Thr Glu Leu  
 625 630 635 640  
 Asp Met Arg Phe Asn Pro Phe Asp Cys Thr Cys Glu Ser Ile Ala Trp  
 645 650 655  
 Phe Val Asn Trp Ile Asn Glu Thr His Thr Asn Ile Pro Glu Leu Ser  
 660 665 670  
 Ser His Tyr Leu Cys Asn Thr Pro Pro His Tyr His Gly Phe Pro Val  
 675 680 685  
 Arg Leu Phe Asp Thr Ser Ser Cys Lys Asp Ser Ala Pro Phe Glu Leu  
 690 695 700  
 Phe Phe Met Ile Asn Thr Ser Ile Leu Leu Ile Phe Ile Phe Ile Val  
 705 710 715 720  
 Leu Leu Ile His Phe Glu Gly Trp Arg Ile Ser Phe Tyr Trp Asn Val  
 725 730 735  
 Ser Val His Arg Val Leu Gly Phe Lys Glu Ile Asp Arg Gln Thr Glu



740 745 750  
 Gln Phe Glu Tyr Ala Ala Tyr Ile Ile His Ala Tyr Lys Asp Lys Asp  
 755 760 765  
 Trp Val Trp Glu His Phe Ser Ser Met Glu Lys Glu Asp Gln Ser Leu  
 770 775 780  
 Lys Phe Cys Leu Glu Glu Arg Asp Phe Glu Ala Gly Val Phe Glu Leu  
 785 790 795 800  
 Glu Ala Ile Val Asn Ser Ile Lys Arg Ser Arg Lys Ile Ile Phe Val  
 805 810 815  
 Ile Thr His His Leu Leu Lys Asp Pro Leu Cys Lys Arg Phe Lys Val  
 820 825 830  
 His His Ala Val Gln Gln Ala Ile Glu Gln Asn Leu Asp Ser Ile Ile  
 835 840 845  
 Leu Val Phe Leu Glu Glu Ile Pro Asp Tyr Lys Leu Asn His Ala Leu  
 850 855 860  
 Cys Leu Arg Arg Gly Met Phe Lys Ser His Cys Ile Leu Asn Trp Pro  
 865 870 875 880  
 Val Gln Lys Glu Arg Ile Gly Ala Phe Arg His Lys Leu Gln Val Ala  
 885 890 895  
 Leu Gly Ser Lys Asn Ser Val His  
 900

<210> 9  
 <211> 3310  
 <212> DNA  
 <213> murine

<400> 9  
 tagaatatga tacagggatt gcaccataa tctgggctga atcatgaaag ggtgttcctc 60  
 ttatctaattg tactcctttg ggggactttt gtccctatgg attcttcttg tgtcttccac 120  
 aaaccaatgc actgtgagat acaacgtagc tgactgcagc catttgaagc taacacacat 180  
 acctgatgat cttccctcta acataacagt gttgaatctt actcacaacc aactcagaag 240  
 attaccacct accaacttta caagatacag ccaacttgct atcttggatg caggatttaa 300  
 ctccatttca aaactggagc cagaactgtg ccaaatactc ctttgttga aagtattgaa 360  
 cctgcaacat aatgagctct ctcagatttc tgatcaaacc tttgtcttct gcacgaacct 420  
 gacagaactc gatctaattg ctaactcaat acacaaaatt aaaagcaacc ctttcaaaaa 480  
 ccagaagaat ctaatcaaat tagatttgct tcataatggt ttatcatcta caaagttggg 540  
 aacggggggtc caactggaga acctccaaga actgctctta gcaaaaaata aaatccttgc 600  
 gttgcgaagt gaagaacttg agtttcttgg caattcttct ttacgaaagt tggacttgtc 660  
 atcaaatcca cttaaagagt tctccccggg gtgtttccag acaattggca agttattgcg 720

cctcctcttg	aacaacgccc	aactgaaccc	ccacctcaca	gagaagcttt	gctgggaact	780
ttcaaacaca	agcatccaga	atctctctct	ggctaacaac	cagctgctgg	ccaccagcga	840
gagcactttc	tctgggctga	agtggacaaa	tctcaccag	ctcgatcttt	cctacaacaa	900
cctccatgat	gtcggcaacg	gttccttctc	ctatctccca	agcctgaggt	atctgtctct	960
ggagtacaac	aatatacagc	gtctgtcccc	tcgctctttt	tatggactct	ccaacctgag	1020
gtacctgagt	ttgaagcgag	catttactaa	gcaaagtgtt	tcacttgctt	cacatcccaa	1080
cattgacgat	ttttcctttc	aatggttaaa	atatttgga	tatctcaaca	tggatgacaa	1140
taatattcca	agtacaaaa	gcaatacctt	cacgggattg	gtgagtctga	agtacctaa	1200
tctttccaaa	actttcacia	gtttgcaaac	tttaacaaat	gaaacatttg	tgctacttgc	1260
tcattctccc	ttgctcactc	tcaacttaac	gaaaaatcac	atctcaaaaa	tagcaaatgg	1320
tactttctct	tggttaggcc	aactcaggat	acttgatctc	ggccttaatg	aaattgaaca	1380
aaaactcagc	ggccaggaat	ggagaggtct	gagaaatata	tttgagatct	acctatccta	1440
taacaaatac	ctccaactgt	ctaccagttc	ctttgcattg	gtccccagcc	ttcaaagact	1500
gatgctcagg	agggtggccc	ttaaaaatgt	ggatatctcc	ccttcacctt	tccgccctct	1560
tcgtaacttg	accattcttg	acttaagcaa	caacaacata	gccaacataa	atgaggactt	1620
gctggagggt	cttgagaatc	tagaaatcct	ggattttcag	cacaataact	tagccaggct	1680
ctggaaacgc	gcaaaccocg	gtggctcccg	taatttcctg	aaggggctgt	ctcacctcca	1740
catcttgaat	ttagagtcca	acggcttaga	tgaaatccca	gtcgggggtt	tcaagaactt	1800
attcgaaata	aagagcatca	atctaggact	gaataactta	aacaaacttg	aaccattcat	1860
ttttgatgac	cagacatctc	taaggctact	gaacctocag	aagaacctca	taacatctgt	1920
tgagaaggat	gttttcgggc	cgccttttca	aaacctgaac	agtttagata	tgcgcttcaa	1980
tccgttcgac	tgcacgtgtg	aaagtatttc	ctggtttggt	aactggatca	accagaccca	2040
cactaatatc	tttgagctgt	ccactcacta	cctctgtaac	actccacatc	attattatgg	2100
cttccccctg	aagcttttctg	atacatcatc	ctgtaaagac	agcgccccct	ttgaactcct	2160
cttcataatc	agcaccagta	tgctcctggg	ttttataact	gtggtagctg	tcattcacat	2220
cgagggtctg	aggatctctt	tttactggaa	tgtttcagtg	catcggtatc	ttggtttcaa	2280
ggaaatagac	acacaggctg	agcagtttga	atatacagcc	tacataattc	atgcccataa	2340
agacagagac	tgggtctggg	aacattttct	cccaatggaa	gaacaagacc	aatctctcaa	2400
atatttgcta	gaagaaagg	actttgaagc	aggcgtcctt	ggacttgaag	caattgttaa	2460
tagcatcaaa	agaagccgaa	aaatcatttt	cgttatcaca	caccatttat	taaaagaccc	2520
tctgtgcaga	agattcaagg	tacatcacgc	agttcagcaa	gctattgagc	aaaatctgga	2580
ttcaattata	ctgatttttc	tccagaatat	tccagattat	aaactaaacc	atgcactctg	2640

```

tttgcgaaga ggaatgttta aatctcattg catcttgaac tggccagttc agaaagaacg 2700
gataaatgcc tttcatcata aattgcaagt agcacttgga tctcggaatt cagcacatta 2760
aactcatttg aagatttgga gtcggtaaag ggatagatcc aatttataaa ggtccatcat 2820
gaatctaagt tttacttgaa agttttgtat atttatttat atgtatagat gatgatatta 2880
catcacaatc caatctcagt tttgaaatat ttcggcttat ttcattgaca tctgggttat 2940
tcaactccaaa taaacacatg ggcagttaaa aacatcctct attaatagat taccattaa 3000
ttcttgaggt gtatcacagc tttaaagggt tttaaatttt tttatataaa taagactgag 3060
agttttataa atgtaatttt ttaaaactcg agtcttactg tgtagctcag aaaggcctgg 3120
aaattaatat attagagagt catgtcttga acttatttat ctctgcctcc ctctgtctcc 3180
agagtgttgc ttttaagggc atgtagcacc acaccagct atgtacgtgt gggattttat 3240
aatgctcatt tttgagacgt ttatagaata aaagataatt gcttttatgg tataaggcta 3300
cttgaggtaa 3310

```

<210> 10  
 <211> 905  
 <212> PRT  
 <213> murine

<400> 10

```

Met Lys Gly Cys Ser Ser Tyr Leu Met Tyr Ser Phe Gly Gly Leu Leu
1          5          10          15

Ser Leu Trp Ile Leu Leu Val Ser Ser Thr Asn Gln Cys Thr Val Arg
20          25          30

Tyr Asn Val Ala Asp Cys Ser His Leu Lys Leu Thr His Ile Pro Asp
35          40          45

Asp Leu Pro Ser Asn Ile Thr Val Leu Asn Leu Thr His Asn Gln Leu
50          55          60

Arg Arg Leu Pro Pro Thr Asn Phe Thr Arg Tyr Ser Gln Leu Ala Ile
65          70          75          80

Leu Asp Ala Gly Phe Asn Ser Ile Ser Lys Leu Glu Pro Glu Leu Cys
85          90          95

Gln Ile Leu Pro Leu Leu Lys Val Leu Asn Leu Gln His Asn Glu Leu
100         105         110

Ser Gln Ile Ser Asp Gln Thr Phe Val Phe Cys Thr Asn Leu Thr Glu
115         120         125

Leu Asp Leu Met Ser Asn Ser Ile His Lys Ile Lys Ser Asn Pro Phe
130         135         140

Lys Asn Gln Lys Asn Leu Ile Lys Leu Asp Leu Ser His Asn Gly Leu
145         150         155         160

```

Ser Ser Thr Lys Leu Gly Thr Gly Val Gln Leu Glu Asn Leu Gln Glu  
 165 170 175  
 Leu Leu Leu Ala Lys Asn Lys Ile Leu Ala Leu Arg Ser Glu Glu Leu  
 180 185 190  
 Glu Phe Leu Gly Asn Ser Ser Leu Arg Lys Leu Asp Leu Ser Ser Asn  
 195 200 205  
 Pro Leu Lys Glu Phe Ser Pro Gly Cys Phe Gln Thr Ile Gly Lys Leu  
 210 215 220  
 Phe Ala Leu Leu Leu Asn Asn Ala Gln Leu Asn Pro His Leu Thr Glu  
 225 230 235 240  
 Lys Leu Cys Trp Glu Leu Ser Asn Thr Ser Ile Gln Asn Leu Ser Leu  
 245 250 255  
 Ala Asn Asn Gln Leu Leu Ala Thr Ser Glu Ser Thr Phe Ser Gly Leu  
 260 265 270  
 Lys Trp Thr Asn Leu Thr Gln Leu Asp Leu Ser Tyr Asn Asn Leu His  
 275 280 285  
 Asp Val Gly Asn Gly Ser Phe Ser Tyr Leu Pro Ser Leu Arg Tyr Leu  
 290 295 300  
 Ser Leu Glu Tyr Asn Asn Ile Gln Arg Leu Ser Pro Arg Ser Phe Tyr  
 305 310 315 320  
 Gly Leu Ser Asn Leu Arg Tyr Leu Ser Leu Lys Arg Ala Phe Thr Lys  
 325 330 335  
 Gln Ser Val Ser Leu Ala Ser His Pro Asn Ile Asp Asp Phe Ser Phe  
 340 345 350  
 Gln Trp Leu Lys Tyr Leu Glu Tyr Leu Asn Met Asp Asp Asn Asn Ile  
 355 360 365  
 Pro Ser Thr Lys Ser Asn Thr Phe Thr Gly Leu Val Ser Leu Lys Tyr  
 370 375 380  
 Leu Ser Leu Ser Lys Thr Phe Thr Ser Leu Gln Thr Leu Thr Asn Glu  
 385 390 395 400  
 Thr Phe Val Ser Leu Ala His Ser Pro Leu Leu Thr Leu Asn Leu Thr  
 405 410 415  
 Lys Asn His Ile Ser Lys Ile Ala Asn Gly Thr Phe Ser Trp Leu Gly  
 420 425 430  
 Gln Leu Arg Ile Leu Asp Leu Gly Leu Asn Glu Ile Glu Gln Lys Leu  
 435 440 445  
 Ser Gly Gln Glu Trp Arg Gly Leu Arg Asn Ile Phe Glu Ile Tyr Leu  
 450 455 460  
 Ser Tyr Asn Lys Tyr Leu Gln Leu Ser Thr Ser Ser Phe Ala Leu Val  
 465 470 475 480  
 Pro Ser Leu Gln Arg Leu Met Leu Arg Arg Val Ala Leu Lys Asn Val

Asp	Ile	Ser	Pro	485	Pro	Phe	Arg	Pro	490	Leu	Arg	Asn	Leu	Thr	495	Ile	Leu
			500					505						510			
Asp	Leu	Ser	Asn	Asn	Asn	Ile	Ala	Asn	Ile	Asn	Glu	Asp	Leu	Leu	Glu		
		515					520					525					
Gly	Leu	Glu	Asn	Leu	Glu	Ile	Leu	Asp	Phe	Gln	His	Asn	Asn	Leu	Ala		
		530				535					540						
Arg	Leu	Trp	Lys	Arg	Ala	Asn	Pro	Gly	Gly	Pro	Val	Asn	Phe	Leu	Lys		
545					550					555					560		
Gly	Leu	Ser	His	Leu	His	Ile	Leu	Asn	Leu	Glu	Ser	Asn	Gly	Leu	Asp		
			565						570					575			
Glu	Ile	Pro	Val	Gly	Val	Phe	Lys	Asn	Leu	Phe	Glu	Leu	Lys	Ser	Ile		
			580					585					590				
Asn	Leu	Gly	Leu	Asn	Asn	Leu	Asn	Lys	Leu	Glu	Pro	Phe	Ile	Phe	Asp		
		595					600					605					
Asp	Gln	Thr	Ser	Leu	Arg	Ser	Leu	Asn	Leu	Gln	Lys	Asn	Leu	Ile	Thr		
	610					615					620						
Ser	Val	Glu	Lys	Asp	Val	Phe	Gly	Pro	Pro	Phe	Gln	Asn	Leu	Asn	Ser		
625					630					635					640		
Leu	Asp	Met	Arg	Phe	Asn	Pro	Phe	Asp	Cys	Thr	Cys	Glu	Ser	Ile	Ser		
				645					650					655			
Trp	Phe	Val	Asn	Trp	Ile	Asn	Gln	Thr	His	Thr	Asn	Ile	Phe	Glu	Leu		
			660					665					670				
Ser	Thr	His	Tyr	Leu	Cys	Asn	Thr	Pro	His	His	Tyr	Tyr	Gly	Phe	Pro		
		675					680					685					
Leu	Lys	Leu	Phe	Asp	Thr	Ser	Ser	Cys	Lys	Asp	Ser	Ala	Pro	Phe	Glu		
	690					695					700						
Leu	Leu	Phe	Ile	Ile	Ser	Thr	Ser	Met	Leu	Leu	Val	Phe	Ile	Leu	Val		
705					710					715					720		
Val	Leu	Leu	Ile	His	Ile	Glu	Gly	Trp	Arg	Ile	Ser	Phe	Tyr	Trp	Asn		
			725						730					735			
Val	Ser	Val	His	Arg	Ile	Leu	Gly	Phe	Lys	Glu	Ile	Asp	Thr	Gln	Ala		
			740					745					750				
Glu	Gln	Phe	Glu	Tyr	Thr	Ala	Tyr	Ile	Ile	His	Ala	His	Lys	Asp	Arg		
		755					760					765					
Asp	Trp	Val	Trp	Glu	His	Phe	Ser	Pro	Met	Glu	Glu	Gln	Asp	Gln	Ser		
		770				775						780					
Leu	Lys	Phe	Cys	Leu	Glu	Glu	Arg	Asp	Phe	Glu	Ala	Gly	Val	Leu	Gly		
785					790					795					800		
Leu	Glu	Ala	Ile	Val	Asn	Ser	Ile	Lys	Arg	Ser	Arg	Lys	Ile	Ile	Phe		
			805						810					815			
Val	Ile	Thr	His	His	Leu	Leu	Lys	Asp	Pro	Leu	Cys	Arg	Arg	Phe	Lys		

820 825 830  
 Val His His Ala Val Gln Gln Ala Ile Glu Gln Asn Leu Asp Ser Ile  
 835 840 845  
 Ile Leu Ile Phe Leu Gln Asn Ile Pro Asp Tyr Lys Leu Asn His Ala  
 850 855 860  
 Leu Cys Leu Arg Arg Gly Met Phe Lys Ser His Cys Ile Leu Asn Trp  
 865 870 875 880  
 Pro Val Gln Lys Glu Arg Ile Asn Ala Phe His His Lys Leu Gln Val  
 885 890 895  
 Ala Leu Gly Ser Arg Asn Ser Ala His  
 900 905

<210> 11  
 <211> 3811  
 <212> DNA  
 <213> Homo sapiens

<400> 11  
 acagggccac tgctgctcac agaagcagtg aggatgatgc caggatgatg tctgcctcgc 60  
 gcctggctgg gactctgac ccagccatgg ccttcctctc ctgcgtgaga ccagaaagct 120  
 gggagccctg cgtggagact tggccctaaa ccacacagaa gagctggcat gaaaccaga 180  
 gctttcagac tccggagcct cagcccttca ccccgattcc attgcttctt gctaaatgct 240  
 gccgttttat cacggaggtg gttcctaata ttacttatca atgcatggag ctgaatttct 300  
 acaaaatccc cgacaacctc cctttctcaa ccaagaacct ggacctgagc ttaaatcccc 360  
 tgaggcattt aggcagctat agcttcttca gtttcccaga actgcagggtg ctggatttat 420  
 ccagggtgtga aatccagaca attgaagatg gggcatatca ggcctaagc cacctctcta 480  
 ccttaatat gacaggaaac cccatccaga gtttagccct gggagccttt tctggactat 540  
 caagtttaca gaagctgggtg gctgtggaga caaatctagc atctctagag aacttcccca 600  
 ttggacatct caaaactttg aaagaactta atgtggctca caatcttatc caatctttca 660  
 aattacctga gtatttttct aatctgacca atctagagca cttggacctt tccagcaaca 720  
 agattcaaag tattttattgc acagaactgc gggttctaca tcaaagccc ctactcaatc 780  
 tctctttaga cctgtccctg aaccctatga actttatcca accagggtgca tttaaagaaa 840  
 ttaggcttca taagctgact ttaagaaata attttgatag tttaaagtga atgaaaactt 900  
 gtattcaagg tctggctggt ttagaagtcc atcgtttgggt tctgggagaa tttagaaatg 960  
 aaggaaactt ggaaaagttt gacaaatctg ctctagaggg cctgtgcaat ttgaccattg 1020  
 aagaattccg attagcatat ttagactact acctcgatga tattattgac ttatttaatt 1080  
 gtttgacaaa tgtttcttca tttccctgg tgagtgtgac tattgaaagg gtaaaagact 1140  
 tttcttataa tttcggatgg caacatttag aattagttaa ctgtaaattt ggacagtttc 1200

ccacattgaa actcaaactct ctcaaaaggc ttactttcac ttccaacaaa ggtgggaatg 1260  
ctttttcaga agttgatcta ccaagccttg agtttctaga tctcagtaga aatggcttga 1320  
gtttcaaagg ttgctgttct caaagtgatt ttgggacaac cagcctaaag tatttagatc 1380  
tgagcttcaa tgggtgttatt accatgagtt caaacttctt gggcttagaa caactagaac 1440  
atctggattt ccagcattcc aatttgaaac aaatgagtga gttttcagta ttcctatcac 1500  
tcagaaacct catttacctt gacatttctc atactcacac cagagttgct ttcaatggca 1560  
tcttcaatgg cttgtccagt ctgaagtct tgaaaatggc tggcaattct ttccaggaaa 1620  
acttccttcc agatatcttc acagagctga gaaacttgac ctctctggac ctctctcagt 1680  
gtcaactgga gcagttgtct ccaacagcat ttaactcact ctccagtctt caggtactaa 1740  
atatgagcca caacaacttc ttttcattgg atacgtttcc ttataagtgt ctgaactccc 1800  
tccaggttct tgattacagt ctcaatcaca taatgacttc caaaaaacag gaactacagc 1860  
attttccaag tagtctagct ttcttaaact ttactcagaa tgactttgct tgtacttgtg 1920  
aacaccagag tttcctgcaa tggatcaagg accagaggca gctcttggtg gaagttgaac 1980  
gaatggaatg tgcaaacct tcagataagc agggcatgcc tgtgtgagt ttgaatatca 2040  
cctgtcagat gaataagacc atcattgggtg tgtcggtcct cagtgtgctt gtagtatctg 2100  
ttgtagcagt tctgggtctat aagttctatt ttcacctgat gcttcttgct ggctgcataa 2160  
agtatggtag aggtgaaaac atctatgatg cctttgttat ctactcaagc caggatgagg 2220  
actgggtaag gaatgagcta gtaaagaatt tagaagaagg ggtgcctcca tttcagctct 2280  
gccttcacta cagagacttt attccgggtg tggccattgc tgccaacatc atccatgaag 2340  
gtttccataa aagccgaaag gtgattgttg tgggtgtcca gcacttcac cagagccgct 2400  
ggtgtatctt tgaatatgag attgctcaga cctggcagtt tctgagcagt cgtgctggta 2460  
tcatcttcat tgtcctgcag aaggtggaga agaccctgct caggcagcag gtggagctgt 2520  
accgccttct cagcaggaac acttacctgg agtgggagga cagtgtcctg gggcggcaca 2580  
tcttctggag acgactcaga aaagccctgc tggatggtaa atcatggaat ccagaaggaa 2640  
cagtgggtac aggatgcaat tggcaggaag caacatctat ctgaagagga aaaataaaaa 2700  
cctcctgagg catttcttgc ccagctgggt ccaacacttg ttcagttaat aagtattaaa 2760  
tgctgccaca tgtcaggcct tatgctaagg gtgagtaatt ccatggtgca ctagatatgc 2820  
agggtgcta atctcaagga gcttccagtg cagagggaaat aaatgctaga ctaaaataca 2880  
gagtcttcca ggtgggcatt tcaaccaact cagtcaagga acccatgaca aagaaagtca 2940  
tttcaactct tacctcatca agttgaataa agacagagaa aacagaaaga gacattgttc 3000  
ttttcctgag tcttttgaat ggaaattgta ttatgttata gccatcataa aaccattttg 3060

gtagttttga ctgaactggg tgttcacttt ttcccttttg attgaataca atttaaattc 3120  
 tacttgatga ctgcagtcgt caaggggctc ctgatgcaag atgccccttc cattttaagt 3180  
 ctgtctcctt acagagggtta aagtctaagt gctaattcct aaggaaacct gattaacaca 3240  
 tgctcacaac catcctgggc attctcgaac atgttctatt ttttaactaa tcaccctga 3300  
 tatattttta tttttatata tccagttttc atttttttac gtcttgcceta taagctaata 3360  
 tcataaataa ggttggttaa gacgtgcttc aaatatccat attaaccact atttttcaag 3420  
 gaagtatgga aaagtacact ctgtcacttt gtcactcgat gtcattccaa agttattgcc 3480  
 tactaagtaa tgactgtcat gaaagcagca ttgaaataat ttgtttaaag ggggcactct 3540  
 tttaaacggg aagaaaattt ccgcttcctg gtcttatcat ggacaatttg ggctataggc 3600  
 atgaaggaag tgggattacc tcaggaagtc accttttctt gattccagaa acatatgggc 3660  
 tgataaaccc ggggtgacct catgaaatga gttgcagcag atgtttattt ttttcagaac 3720  
 aagtgatgtt tgatggacct atgaatctat ttagggagac acagatggct gggatccctc 3780  
 ccctgtacct ttctcactga caggagaact a 3811

<210> 12

<211> 2845

<212> DNA

<213> Homo, sapiens

<400> 12

cctctcacc tttagcccag aactgctttg aatacaccaa ttgctgtggg gcggctcgag 60  
 gaagagaaga caccagtgcc tcagaaactg ctcggtcaga cggatgatagc gagccacgca 120  
 ttcacagggc cactgctgct cacagaagca gtgaggatga tgccaggatg atgtctgect 180  
 cgcgcctggc tgggactctg atcccagcca tggccttcct ctctgcgtg agaccagaaa 240  
 gctgggagcc ctgcgtggag gtgtgaaatc cagacaattg aagatggggc atatcagagc 300  
 ctaagccacc tctctacctt aatattgaca ggaaacccca tccagagttt agccctggga 360  
 gccttttctg gactatcaag tttacagaag ctggtggctg tggagacaaa tctagcatct 420  
 ctagagaact tccccattgg acatctcaaa actttgaaag aacttaatgt ggctcacaat 480  
 cttatccaat ctttcaaatt acctgagtat ttttctaata tgaccaatct agagcacttg 540  
 gacctttcca gcaacaagat tcaaagtatt tattgcacag acttgccggg tctacatcaa 600  
 atgcccctac tcaatctctc tttagacctg tccctgaacc ctatgaactt tatccaacca 660  
 ggtgcattta aagaaattag gcttcataag ctgactttaa gaaataattt tgatagttta 720  
 aatgtaatga aaacttgat tcaaggtctg gctgggttag aagtccatcg tttgggtctg 780  
 ggagaattta gaaatgaagg aaacttgga aagtttgaca aatctgctct agagggcctg 840



tgcaatttga ccattgaaga attccgatta gcatacttag actactacct cgatgatatt	900
attgacttat ttaattgttt gacaaatgtt tcttcatttt ccctgggtgag tgtgactatt	960
gaaagggtaa aagactttttc ttataatttc ggatggcaac atttagaatt agttaactgt	1020
aaatttggac agtttcccac attgaaactc aaatctctca aaaggcttac tttcacttcc	1080
aacaaagggtg ggaatgcttt ttcagaagtt gatctaccaa gccttgagtt tctagatctc	1140
agtagaaatg gcttgagttt caaagggtgc tgttctcaaa gtgattttgg gacaaccagc	1200
ctaaagtatt tagatctgag cttcaatggg gttattacca tgagttcaaa cttcttgggc	1260
ttagaacaac tagaacatct ggatttccag cattccaatt tgaaacaaat gagtgagttt	1320
tcagtattcc tatcactcag aaacctcatt taccttgaca tttctcatac tcacaccaga	1380
gttgctttca atggcatctt caatggcttg tccagtctcg aagtcttgaa aatggctggc	1440
aattctttcc aggaaaactt ccttccagat atcttcacag agctgagaaa cttgaccttc	1500
ctggacctct ctcagtgctc actggagcag ttgtctccaa cagcatttaa ctcactctcc	1560
agtcttcagg tactaaatat gagccacaac aacttctttt cattggatac gtttcttat	1620
aagtgtctga actccctcca ggttcttgat tacagttctc atcacataat gacttccaaa	1680
aaacaggaac tacagcattt tccaagtagt ctagctttct taaatcttac tcagaatgac	1740
tttgcttgta cttgtgaaca ccagagtttc ctgcaatgga tcaaggacca gaggcagctc	1800
ttggtggaag ttgaacgaat ggaatgtgca acaccttcag ataagcaggg catgcctgtg	1860
ctgagtttga atatcacctg tcagatgaat aagaccatca ttggtgtgtc ggtcctcagt	1920
gtgctttag tagtctgttg agcagttctg gtctataagt tctattttca cctgatgctt	1980
cttgctggct gcataaagta tggtagaggt gaaaacatct atgatgcctt tgttatctac	2040
tcaagccagg atgaggactg ggtaaggaat gagctagtaa agaatttaga agaaggggtg	2100
cctccatttc agctctgcct tcaactacaga gactttattc ccggtgtggc cattgctgcc	2160
aacatcatcc atgaagggtt ccataaaagc cgaaagggtga ttgttgtggt gtcccagcac	2220
ttcatccaga gccgctgggt tatctttgaa tatgagattg ctcagacctg gcagtttctg	2280
agcagtcgtg ctggtatcat cttcattgtc ctgcagaagg tggagaagac cctgctcagg	2340
cagcaggtgg agctgtaccg ccttctcagc aggaacactt acctggagtg ggaggacagt	2400
gtcctggggc ggcacatctt ctggagacga ctcagaaaag ccctgctgga tggtaaataca	2460
tggaatccag aaggaacagt gggtagagga tgcaattggc aggaagcaac atctatctga	2520
agaggaaaaa taaaaacctc ctgaggcatt tcttgcccag ctgggtccaa cacttgttca	2580
gttaataagt attaaatgct gccacatgtc aggccttatg ctaagggtga gtaattccat	2640
ggtgcactag atatgcaggg ctgctaactc caaggagctt ccagtgcaga ggaataaat	2700
gctagactaa aatacagagt cttccaggtg ggcatttcaa ccaactcagt caaggaacct	2760

atgacaaaga aagtcatttc aactcttacc tcatcaagtt gaataaagac agagaaaaaca 2820  
 gaaaaaaaaa aaaaaaaaaa aaaaaa 2845

<210> 13  
 <211> 3767  
 <212> DNA  
 <213> Homo sapiens

<400> 13  
 cctctcacc tttagcccag aactgctttg aatacaccaa ttgctgtggg ggggctcgag 60  
 gaagagaaga caccagtgcc tcagaaactg ctcggtcaga cggatgtagc gagccacgca 120  
 ttcacagggc cactgctgct cacagaagca gtgaggatga tgccaggatg atgtctgcct 180  
 cgggcctggc tgggactctg atcccagcca tggccttcct ctctgcgtg agaccagaaa 240  
 gctgggagcc ctgctgggag acttggccct aaaccacaca gaagagctgg catgaaaccc 300  
 agagctttca gactccggag cctcagccct tcaccccgat tccattgctt cttgctaaat 360  
 gctgccgttt tatcacggag gtgtgaaatc cagacaattg aagatggggc atatcagagc 420  
 ctaagccacc tctctacctt aatattgaca ggaaacccca tccagagttt agccctggga 480  
 gccttttctg gactatcaag tttacagaag ctggtggctg tggagacaaa tctagcatct 540  
 ctagagaact tccccattgg acatctcaaa actttgaaag aacttaattg ggctcacaat 600  
 cttatccaat ctttcaaatt acctgagtat ttttctaata tgaccaatct agagcacttg 660  
 gacctttcca gcaacaagat tcaaagtatt tattgcacag acttgccggg tctacatcaa 720  
 atgcccctac tcaatctctc tttagacctg tccctgaacc ctatgaactt tatccaacca 780  
 ggtgcattta aagaaattag gcttcataag ctgactttaa gaaataattt tgatagttta 840  
 aatgtaatga aaacttgtat tcaaggctg gctgggttag aagtccatcg tttggttctg 900  
 ggagaattta gaaatgaagg aaacttgga aagtttgaca aatctgctct agagggcctg 960  
 tgcaatttga ccattgaaga attccgatta gcatacttag actactacct cgatgatatt 1020  
 attgacttat ttaattgttt gacaaatggt tcttcatttt ccctggtgag tgtgactatt 1080  
 gaaagggtaa aagacttttc ttataatttc ggatggcaac atttagaatt agttaactgt 1140  
 aaatttggac agtttccac attgaaactc aaatctctca aaaggcttac tttcacttcc 1200  
 aacaaagggt ggaatgcttt ttcagaagtt gatctaccaa gccttgagtt tctagatctc 1260  
 agtagaaatg gcttgagttt caaagggtgc tgttctcaaa gtgattttgg gacaaccagc 1320  
 ctaaagtatt tagatctgag cttcaatggt gttattacca tgagttcaaa cttcttgggc 1380  
 ttagaacaac tagaacatct ggatttccag cattccaatt tgaaacaaat gagtgagttt 1440  
 tcagtattcc tatcactcag aaacctcatt taccttgaca tttctcatc tcacaccaga 1500

gttgctttca atggcatctt caatggcttg tccagtctcg aagtcttgaa aatggctggc	1560
aattctttcc aggaaaactt ccttccagat atcttcacag agctgagaaa cttgaccttc	1620
ctggacctct ctcaagtgtca actggagcag ttgtctccaa cagcatttaa ctcactctcc	1680
agtcttcagg tactaaatat gagccacaac aacttctttt cattggatac gtttcccttat	1740
aagtgtctga actccctcca ggttcttgat tacagtctca atcacataat gacttccaaa	1800
aaacaggaac tacagcattt tccaagtagt ctagctttct taaatcttac tcagaatgac	1860
tttgcttgta cttgtgaaca ccagagtttc ctgcaatgga tcaaggacca gaggcagctc	1920
ttggtggaag ttgaacgaat ggaatgtgca acaccttcag ataagcaggg catgcctgtg	1980
ctgagtttga atatcacctg tcagatgaat aagaccatca ttggtgtgtc ggtcctcagt	2040
gtgcttgtag tatctgttgt agcagttctg gtctataagt tctattttca cctgatgctt	2100
cttgctggct gcataaagta tggtagaggt gaaaacatct atgatgcctt tgttatctac	2160
tcaagccagg atgaggactg ggtaaggaat gagctagtaa agaatttaga agaaggggtg	2220
cctccatttc agctctgcct tcactacaga gactttattc ccggtgtggc cattgctgcc	2280
aacatcatcc atgaagggtt ccataaaagc cgaaagggtga ttgttgtggt gtcccagcac	2340
ttcatccaga gccgctgggt tatctttgaa tatgagattg ctgagacctg gcagtttctg	2400
agcagtcgtg ctggtatcat cttcattgtc ctgcagaagg tggagaagac cctgctcagg	2460
cagcaggtgg agctgtaccg ccttctcagc aggaacactt acctggagtg ggaggacagt	2520
gtcctggggc ggcacatctt ctggagacga ctgagaaaag ccctgctgga tggtaaatca	2580
tggaaatccag aaggaacagt gggtagagga tgcaattggc aggaagcaac atctatctga	2640
agaggaaaaa taaaaacctc ctgaggcatt tcttgcccag ctgggtccaa cacttgttca	2700
gttaataagt attaaatgct gccacatgtc aggccttatg ctaagggtga gtaattccat	2760
ggtgcactag atatgcaggg ctgctaactc caaggagctt ccagtgcaga gggaataaat	2820
gctagactaa aatacagagt cttccaggtg ggcatttcaa ccaactcagt caaggaaccc	2880
atgacaaaaga aagtcatttc aactcttacc tcatcaagtt gaataaagac agagaaaaca	2940
gaaagagaca ttgttctttt cctgagtctt ttgaatggaa attgtattat gttatagcca	3000
tcataaaaacc attttggtag ttttgactga actgggtggt cactttttcc tttttgattg	3060
aatacaattt aaattctact tgatgactgc agtcgtcaag gggctcctga tgcaagatgc	3120
cccttcattt ttaagtctgt ctcttacag aggttaaagt ctagtggcta attcctaagg	3180
aaacctgatt aacacatgct cacaaccatc ctggtcattc tcgagcatgt tctatttttt	3240
aactaatcac ccctgatata tttttatttt tatatatcca gttttcattt ttttacgtct	3300
tgctataag ctaatatcat aaataagggt gttaagacg tgcttcaa atccatatta	3360
accactattt ttcaaggaag tatggaaaag tacactctgt cactttgtca ctcgatgtca	3420

ttccaaagtt attgcctact aagtaatgac tgtcatgaaa gcagcattga aataatttgt 3480  
 ttaaaggggg cactctttta aacgggaaga aaatttccgc ttcctggtct tatcatggac 3540  
 aatttgggct agaggcagga aggaagtggg atgacctcag gaggtcacct tttcttgatt 3600  
 ccagaaacat atgggctgat aaacccgggg tgacctcatg aaatgagttg cagcagaagt 3660  
 ttatTTTTTTT cagaacaagt gatgtttgat ggacctctga atctcttttag ggagacacag 3720  
 atggctggga tccctccct gtacccttct cactgccagg agaacta 3767

<210> 14

<211> 3814

<212> DNA

<213> Homo sapiens

<400> 14

cctctcaccc tttagcccag aactgctttg aatacaccaa ttgctgtggg gcggtcgag 60  
 gaagagaaga caccagtgcc tcagaaactg ctcggtcaga cggatgtagc gagccacgca 120  
 ttcacagggc cactgctgct cacagaagca gtgaggatga tgccaggatg atgtctgcct 180  
 cgcgcctggc tgggactctg atcccagcca tggccttct ctctgcgtg agaccagaaa 240  
 gctgggagcc ctgcgtggag gtggttccta atattactta tcaatgcatg gagctgaatt 300  
 tctacaaaat ccccgacaac ctccccttct caaccaagaa cctggacctg agctttaatc 360  
 ccctgaggca tttaggcagc tatagcttct tcagtttccc agaactgcag gtgctggatt 420  
 tatccagggtg tgaaatccag acaattgaag atggggcata tcagagccta agccacctct 480  
 ctaccttaat attgacagga aaccccatcc agagttagc cctgggagcc ttttctggac 540  
 tatcaagttt acagaagctg gtggctgtgg agacaaatct agcatctcta gagaacttcc 600  
 ccattggaca tctcaaaact ttgaaagaac ttaatgtggc tcacaatctt atccaatctt 660  
 tcaaattacc tgagtatttt tctaacttga ccaatctaga gcacttgga ctttccagca 720  
 acaagattca aagtatttat tgcacagact tgcgggttct acatcaaatg cccctactca 780  
 atctctcttt agacctgtcc ctgaacccta tgaactttat ccaaccaggc gcatttaaa 840  
 aaattaggct tcataagctg actttaagaa ataattttga tagtttaa at gtaatgaaaa 900  
 cttgtattca aggtctggct ggtttagaag tccatcggtt gggtctggga gaatttagaa 960  
 atgaaggaaa cttggaaaag tttgacaaat ctgctctaga gggcctgtgc aatttgacca 1020  
 ttgaagaatt ccgattagca tacttagact actacctga tgatattatt gacttattta 1080  
 attgtttgac aaatgtttct tcattttccc tgggtgagtgt gactattgaa agggtaaaa 1140  
 acttttctta taatttcgga tggcaacatt tagaattagt taactgtaaa tttggacagt 1200  
 ttcccacatt gaaactcaaa tctctcaaaa ggcttacttt cacttccaac aaagggtggga 1260

atgctttttc	agaagttgat	ctaccaagcc	ttgagtttct	agatctcagt	agaaatggct	1320
tgagtttcaa	aggttgctgt	tctcaaagtg	attttgggac	aaccagccta	aagtatttag	1380
atctgagctt	caatgggtgtt	attaccatga	gttcaaactt	cttgggctta	gaacaactag	1440
aacatctgga	tttccagcat	tccaatttga	aacaaatgag	tgagttttca	gtatttcctat	1500
cactcagaaa	cctcattttac	cttgacattt	ctcatactca	caccagagtt	gctttcaatg	1560
gcactctcaa	tggcttgctc	agtctcgaag	tcttgaaaat	ggctggcaat	tctttccagg	1620
aaaacttcct	tccagatatc	ttcacagagc	tgagaaactt	gaccttcctg	gacctctctc	1680
agtgtcaact	ggagcagttg	tctccaacag	cattttaactc	actctccagt	cttcagggtac	1740
taaatatgag	ccacaacaac	ttcttttcat	tggatacggt	tccttataag	tgtctgaact	1800
ccctccaggt	tcttgattac	agtctcaatc	acataatgac	ttccaaaaaa	caggaaactac	1860
agcattttcc	aagtagtcta	gctttcttaa	atcttactca	gaatgacttt	gcttgtagctt	1920
gtgaacacca	gagtttcctg	caatggatca	aggaccagag	gcagctcttg	gtggaagttg	1980
aacgaatgga	atgtgcaaca	ccttcagata	agcagggcat	gcctgtgctg	agtttgaata	2040
tcacctgtca	gatgaataag	accatcattg	gtgtgtcggt	cctcagtggt	ctttagtagat	2100
ctgtttagtc	agttctggtc	tataagttct	attttcacct	gatgcttctt	gctggctgca	2160
taaagtatgg	tagaggtgaa	aacatctatg	atgcctttgt	tatctactca	agccaggatg	2220
aggactgggt	aaggaatgag	ctagtaaaga	atttagaaga	aggggtgcct	ccatttcagc	2280
tctgccttca	ctacagagac	tttattcccg	gtgtggccat	tgctgccaac	atcatccatg	2340
aaggtttcca	taaaagccga	aagtgattg	ttgtgggtgc	ccagcacttc	atccagagcc	2400
gctgggtgat	ctttgaatat	gagattgtct	agacctggca	gtttctgagc	agtcgtgctg	2460
gtatcatctt	cattgtcctg	cagaagggtg	agaagaccct	gctcaggcag	cagggtggagc	2520
tgtaccgcct	tctcagcagg	aacacttacc	tggagtgagg	ggacagtgtc	ctggggcggc	2580
acatcttctg	gagacgactc	agaaaagccc	tgctggatgg	taaatcatgg	aatccagaag	2640
gaacagtggg	tacaggatgc	aattggcagg	aagcaacatc	tatctgaaga	ggaaaaataa	2700
aaacctctg	aggcatttct	tgcccagctg	ggtccaacac	ttgttcagtt	aataagtatt	2760
aatgctgcc	acatgtcagg	ccttatgcta	agggtgagta	attccatggg	gcactagata	2820
tgcagggctg	ctaactctca	ggagcttcca	gtgcagaggg	aataaatgct	agactaaaat	2880
acagagtctt	ccagggtggc	atttcaacca	actcagtcaa	ggaacccatg	acaaagaaag	2940
tcatttcaac	tcttacctca	tcaagttgaa	taaagacaga	gaaaacagaa	agagacattg	3000
ttcttttctc	gagtcttttg	aatggaaatt	gtattatggt	atagccatca	taaaaccatt	3060
ttggtagttt	tgactgaact	gggtgttcac	tttttccttt	ttgattgaat	acaatttaaa	3120
ttctacttga	tgactgcagt	cgtcaagggg	ctcctgatgc	aagatgcccc	ttccatttta	3180

```

agtctgtctc cttacagagg ttaaagtcta gtggctaatt cctaaggaaa cctgattaac 3240
acatgctcac aaccatcctg gtcattctcg agcatgttct attttttaac taatcacccc 3300
tgatatattt ttatttttat atatccagtt ttcatttttt tacgtcttgc ctataagcta 3360
atatcataaa taaggttggt taagacgtgc ttcaaatac catattaacc actatttttc 3420
aaggaagtat ggaaaagtag actctgtcac tttgtcactc gatgtcattc caaagttatt 3480
gcctactaag taatgactgt catgaaagca gcattgaaat aatttggtta aagggggcac 3540
tcttttaaac gggaagaaaa tttccgcttc ctggctctat catggacaat ttgggctaga 3600
ggcaggaagg aagtgggatg acctcaggag gtcacctttt cttgattcca gaaacatatg 3660
ggctgataaa cccggggtga cctcatgaaa tgagttgcag cagaagttta tttttttcag 3720
aacaagtgat gtttgatgga cctctgaatc tctttagga gacacagatg gctgggatcc 3780
ctcccctgta cccttctcac tgccaggaga acta 3814

```

&lt;210&gt; 15

&lt;211&gt; 3934

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 15

```

cctctcacc ctttagcccag aactgctttg aatacaccaa ttgctgtggg gcggtctgag 60
gaagagaaga caccagtgcc tcagaaactg ctcggtcaga cggtgatagc gagccacgca 120
ttcacagggc cactgctgct cacagaagca gtgaggatga tgccaggatg atgtctgcct 180
cgcgctggc tgggactctg atcccagcca tggccttcct ctctgcgtg agaccagaaa 240
gctgggagcc ctgcgtggag acttggccct aaaccacaca gaagagctgg catgaaacct 300
agagctttca gactccggag cctcagccct tcaccccgat tccattgctt cttgctaaat 360
gctgccgttt tatcacggag gtggttccta atattactta tcaatgcatg gagctgaatt 420
tctacaaaat ccccgacaac ctccccttct caaccaagaa cctggacctg agctttaatc 480
ccctgaggca tttaggcagc tatagcttct tcagtttccc agaactgcag gtgctggatt 540
tatccagggt tgaaatccag acaattgaag atggggcata tcagagccta agccacctct 600
ctaccttaat attgacagga aaccccatcc agagttagc cctgggagcc ttttctggac 660
tatcaagttt acagaagctg gtggctgtgg agacaaatct agcatctcta gagaacttcc 720
ccattggaca tctcaaaaact ttgaaagaac ttaatgtggc tcacaatctt atccaatctt 780
tcaaattacc tgagtatttt tctaactctga ccaatctaga gcacttggac ctttccagca 840
acaagattca aagtatttat tgcacagact tgcgggttct acatcaaagt cccctactca 900
atctctcttt agacctgtcc ctgaacccta tgaactttat ccaaccaggt gcatttaaag 960

```

aaattaggct tcataagctg actttaagaa ataattttga tagtttaaata gtaatgaaaa 1020  
cttgatttca aggtctggct gggttagaag tccatcgttt gggtctggga gaatttagaa 1080  
atgaaggaaa cttggaaaag tttgacaaat ctgctctaga gggcctgtgc aatttgacca 1140  
ttgaagaatt cggattagca tacttagact actacctcga tgatattatt gacttattta 1200  
attgtttgac aaatgtttct tcattttccc tggtagtgt gactattgaa agggtaaaag 1260  
acttttctta taatttcgga tggcaacatt tagaattagt taactgtaaa tttggacagt 1320  
ttcccacatt gaaactcaaa tctctcaaaa ggcttacttt cacttccaac aaagggtggga 1380  
atgctttttc agaagttgat ctaccaagcc ttgagtttct agatctcagt agaaatggct 1440  
tgagtttcaa aggttgctgt tctcaaagtg attttgggac aaccagccta aagtatttag 1500  
atctgagctt caatggtgtt attaccatga gttcaaactt cttgggctta gaacaactag 1560  
aacatctgga tttccagcat tccaatttga aacaaatgag tgagttttca gtattcctat 1620  
cactcagaaa cctcatttac cttgacattt ctcatactca caccagagtt gctttcaatg 1680  
gcatcttcaa tggcttgctc agtctcgaag tcttgaaaat ggctggcaat tctttccagg 1740  
aaaacttcct tccagatata ttcacagagc tgagaaactt gaccttcctg gacctctctc 1800  
agtgtcaact ggagcagttg tctccaacag catttaactc actctccagt cttcaggtag 1860  
taaatatgag ccacaacaac ttcttttcat tggatacgtt tccttataag tgtctgaact 1920  
ccctccaggt tcttgattac agtctcaatc acataatgac ttccaaaaaa caggaactac 1980  
agcattttcc aagtagtcta gctttcttaa atcttactca gaatgacttt gcttgtagtt 2040  
gtgaacacca gagtttctg caatggatca aggaccagag gcagctcttg gtggaagttg 2100  
aacgaatgga atgtgcaaca cttcagata agcagggcat gcctgtgctg agtttgaata 2160  
tcacctgtca gatgaataag accatcattg gtgtgtcggc cctcagtggt cttgtagtat 2220  
ctgttgtagc agttctggtc tataagttct attttcacct gatgcttctt gctggctgca 2280  
taaagtatgg tagaggtgaa aacatctatg atgcctttgt tatctactca agccaggatg 2340  
aggactgggt aaggaatgag ctagtaaaga atttagaaga aggggtgcct ccatttcagc 2400  
tctgccttca ctacagagac tttattcccg gtgtggccat tgctgccaac atcatccatg 2460  
aaggtttcca taaaagccga aaggtagttg ttgtggtgtc ccagcacttc atccagagcc 2520  
gctggtgtat ctttgaatat gagattgtc agacctggca gtttctgagc agtcgtgctg 2580  
gtatcatctt cattgtctg cagaagggtg agaagacct gctcaggcag cagggtggagc 2640  
tgtaccgct tctcagcagg aacacttacc tggagtggga ggacagtgtc ctggggcggc 2700  
acatcttctg gagacgactc agaaaagccc tgctggatgg taaatcatgg aatccagaag 2760  
gaacagtggg tacaggatgc aattggcagg aagcaacatc tatctgaaga ggaaaaataa 2820  
aaacctctg aggcatttct tgcccagctg ggtccaacac ttgttcagtt aataagtatt 2880

```

aatgctgcc acatgtcagg ccttatgcta aggggtgagta attccatggg gcactagata 2940
tgcaggggctg ctaatctcaa ggagcttcca gtgcagaggg aataaatgct agactaaaat 3000
acagagtctt ccagggtgggc atttcaacca actcagtcaa ggaacccatg acaaagaaag 3060
tcatttcaac tcttacctca tcaagttgaa taaagacaga gaaaacagaa agagacattg 3120
ttcttttctt gagtcttttg aatggaaatt gtattatgtt atagccatca taaaaccatt 3180
ttggtagttt tgactgaact ggggtgtcac tttttccttt ttgattgaat acaatttaaa 3240
ttctacttga tgactgcagt cgtcaagggg ctctgatgc aagatgcccc ttccatttta 3300
agtctgtctc cttacagagg ttaaagtcta gtggctaatt cctaaggaaa cctgattaac 3360
acatgctcac aaccatctg gtcattctcg agcatgttct attttttaac taatcacccc 3420
tgatatattt ttatttttat atatccagtt ttcatttttt tacgtcttgc ctataagcta 3480
atatcataaa taaggttggt taagacgtgc ttcaaatatc catattaacc actatttttc 3540
aaggaagtat ggaaaagtac actctgtcac tttgtcactc gatgtcattc caaagttatt 3600
gcctactaag taatgactgt catgaaagca gcattgaaat aatttgttta aagggggcac 3660
tcttttaaac gggaagaaaa tttccgcttc ctggtcttat catggacaat ttgggctaga 3720
ggcaggaagg aagtgggatg acctcaggag gtcacctttt cttgattcca gaaacatatg 3780
ggctgataaa cccgggggtga cctcatgaaa tgagttgcag cagaagttta tttttttcag 3840
aacaagtgat gtttgatgga cctctgaatc tctttagga gacacagatg gctgggatcc 3900
ctccccgtga cccttctcac tgccaggaga acta 3934

```

<210> 16  
 <211> 839  
 <212> PRT  
 <213> Homo sapiens

<400> 16

```

Met Met Ser Ala Ser Arg Leu Ala Gly Thr Leu Ile Pro Ala Met Ala
1           5           10           15

Phe Leu Ser Cys Val Arg Pro Glu Ser Trp Glu Pro Cys Val Glu Val
          20          25          30

Val Pro Asn Ile Thr Tyr Gln Cys Met Glu Leu Asn Phe Tyr Lys Ile
          35          40          45

Pro Asp Asn Leu Pro Phe Ser Thr Lys Asn Leu Asp Leu Ser Phe Asn
50          55          60

Pro Leu Arg His Leu Gly Ser Tyr Ser Phe Phe Ser Phe Pro Glu Leu
65          70          75          80

Gln Val Leu Asp Leu Ser Arg Cys Glu Ile Gln Thr Ile Glu Asp Gly
          85          90          95

```



Ala Tyr Gln Ser Leu Ser His Leu Ser Thr Leu Ile Leu Thr Gly Asn  
 100 105 110  
 Pro Ile Gln Ser Leu Ala Leu Gly Ala Phe Ser Gly Leu Ser Ser Leu  
 115 120 125  
 Gln Lys Leu Val Ala Val Glu Thr Asn Leu Ala Ser Leu Glu Asn Phe  
 130 135 140  
 Pro Ile Gly His Leu Lys Thr Leu Lys Glu Leu Asn Val Ala His Asn  
 145 150 155 160  
 Leu Ile Gln Ser Phe Lys Leu Pro Glu Tyr Phe Ser Asn Leu Thr Asn  
 165 170 175  
 Leu Glu His Leu Asp Leu Ser Ser Asn Lys Ile Gln Ser Ile Tyr Cys  
 180 185 190  
 Thr Asp Leu Arg Val Leu His Gln Met Pro Leu Leu Asn Leu Ser Leu  
 195 200 205  
 Asp Leu Ser Leu Asn Pro Met Asn Phe Ile Gln Pro Gly Ala Phe Lys  
 210 215 220  
 Glu Ile Arg Leu His Lys Leu Thr Leu Arg Asn Asn Phe Asp Ser Leu  
 225 230 235 240  
 Asn Val Met Lys Thr Cys Ile Gln Gly Leu Ala Gly Leu Glu Val His  
 245 250 255  
 Arg Leu Val Leu Gly Glu Phe Arg Asn Glu Gly Asn Leu Glu Lys Phe  
 260 265 270  
 Asp Lys Ser Ala Leu Glu Gly Leu Cys Asn Leu Thr Ile Glu Glu Phe  
 275 280 285  
 Arg Leu Ala Tyr Leu Asp Tyr Tyr Leu Asp Asp Ile Ile Asp Leu Phe  
 290 295 300  
 Asn Cys Leu Thr Asn Val Ser Ser Phe Ser Leu Val Ser Val Thr Ile  
 305 310 315 320  
 Glu Arg Val Lys Asp Phe Ser Tyr Asn Phe Gly Trp Gln His Leu Glu  
 325 330 335  
 Leu Val Asn Cys Lys Phe Gly Gln Phe Pro Thr Leu Lys Leu Lys Ser  
 340 345 350  
 Leu Lys Arg Leu Thr Phe Thr Ser Asn Lys Gly Gly Asn Ala Phe Ser  
 355 360 365  
 Glu Val Asp Leu Pro Ser Leu Glu Phe Leu Asp Leu Ser Arg Asn Gly  
 370 375 380  
 Leu Ser Phe Lys Gly Cys Cys Ser Gln Ser Asp Phe Gly Thr Thr Ser  
 385 390 395 400  
 Leu Lys Tyr Leu Asp Leu Ser Phe Asn Gly Val Ile Thr Met Ser Ser  
 405 410 415  
 Asn Phe Leu Gly Leu Glu Gln Leu Glu His Leu Asp Phe Gln His Ser

420 425 430  
 Asn Leu Lys Gln Met Ser Glu Phe Ser Val Phe Leu Ser Leu Arg Asn  
 435 440 445  
 Leu Ile Tyr Leu Asp Ile Ser His Thr His Thr Arg Val Ala Phe Asn  
 450 455 460  
 Gly Ile Phe Asn Gly Leu Ser Ser Leu Glu Val Leu Lys Met Ala Gly  
 465 470 475 480  
 Asn Ser Phe Gln Glu Asn Phe Leu Pro Asp Ile Phe Thr Glu Leu Arg  
 485 490 495  
 Asn Leu Thr Phe Leu Asp Leu Ser Gln Cys Gln Leu Glu Gln Leu Ser  
 500 505 510  
 Pro Thr Ala Phe Asn Ser Leu Ser Ser Leu Gln Val Leu Asn Met Ser  
 515 520 525  
 His Asn Asn Phe Phe Ser Leu Asp Thr Phe Pro Tyr Lys Cys Leu Asn  
 530 535 540  
 Ser Leu Gln Val Leu Asp Tyr Ser Leu Asn His Ile Met Thr Ser Lys  
 545 550 555 560  
 Lys Gln Glu Leu Gln His Phe Pro Ser Ser Leu Ala Phe Leu Asn Leu  
 565 570 575  
 Thr Gln Asn Asp Phe Ala Cys Thr Cys Glu His Gln Ser Phe Leu Gln  
 580 585 590  
 Trp Ile Lys Asp Gln Arg Gln Leu Leu Val Glu Val Glu Arg Met Glu  
 595 600 605  
 Cys Ala Thr Pro Ser Asp Lys Gln Gly Met Pro Val Leu Ser Leu Asn  
 610 615 620  
 Ile Thr Cys Gln Met Asn Lys Thr Ile Ile Gly Val Ser Val Leu Ser  
 625 630 635 640  
 Val Leu Val Val Ser Val Val Ala Val Leu Val Tyr Lys Phe Tyr Phe  
 645 650 655  
 His Leu Met Leu Leu Ala Gly Cys Ile Lys Tyr Gly Arg Gly Glu Asn  
 660 665 670  
 Ile Tyr Asp Ala Phe Val Ile Tyr Ser Ser Gln Asp Glu Asp Trp Val  
 675 680 685  
 Arg Asn Glu Leu Val Lys Asn Leu Glu Glu Gly Val Pro Pro Phe Gln  
 690 695 700  
 Leu Cys Leu His Tyr Arg Asp Phe Ile Pro Gly Val Ala Ile Ala Ala  
 705 710 715 720  
 Asn Ile Ile His Glu Gly Phe His Lys Ser Arg Lys Val Ile Val Val  
 725 730 735  
 Val Ser Gln His Phe Ile Gln Ser Arg Trp Cys Ile Phe Glu Tyr Glu  
 740 745 750  
 Ile Ala Gln Thr Trp Gln Phe Leu Ser Ser Arg Ala Gly Ile Ile Phe

755 760 765  
 Ile Val Leu Gln Lys Val Glu Lys Thr Leu Leu Arg Gln Gln Val Glu  
 770 775 780  
 Leu Tyr Arg Leu Leu Ser Arg Asn Thr Tyr Leu Glu Trp Glu Asp Ser  
 785 790 795 800  
 Val Leu Gly Arg His Ile Phe Trp Arg Arg Leu Arg Lys Ala Leu Leu  
 805 810 815  
 Asp Gly Lys Ser Trp Asn Pro Glu Gly Thr Val Gly Thr Gly Cys Asn  
 820 825 830  
 Trp Gln Glu Ala Thr Ser Ile  
 835  
 <210> 17  
 <211> 782  
 <212> PRT  
 <213> Homo sapiens  
 <400> 17  
 Met Lys Pro Arg Ala Phe Arg Leu Arg Ser Leu Ser Pro Ser Pro Arg  
 1 5 10 15  
 Phe His Cys Phe Leu Leu Asn Ala Ala Val Leu Ser Arg Arg Cys Glu  
 20 25 30  
 Ile Gln Thr Ile Glu Asp Gly Ala Tyr Gln Ser Leu Ser His Leu Ser  
 35 40 45  
 Thr Leu Ile Leu Thr Gly Asn Pro Ile Gln Ser Leu Ala Leu Gly Ala  
 50 55 60  
 Phe Ser Gly Leu Ser Ser Leu Gln Lys Leu Val Ala Val Glu Thr Asn  
 65 70 75 80  
 Leu Ala Ser Leu Glu Asn Phe Pro Ile Gly His Leu Lys Thr Leu Lys  
 85 90 95  
 Glu Leu Asn Val Ala His Asn Leu Ile Gln Ser Phe Lys Leu Pro Glu  
 100 105 110  
 Tyr Phe Ser Asn Leu Thr Asn Leu Glu His Leu Asp Leu Ser Ser Asn  
 115 120 125  
 Lys Ile Gln Ser Ile Tyr Cys Thr Asp Leu Arg Val Leu His Gln Met  
 130 135 140  
 Pro Leu Leu Asn Leu Ser Leu Asp Leu Ser Leu Asn Pro Met Asn Phe  
 145 150 155 160  
 Ile Gln Pro Gly Ala Phe Lys Glu Ile Arg Leu His Lys Leu Thr Leu  
 165 170 175  
 Arg Asn Asn Phe Asp Ser Leu Asn Val Met Lys Thr Cys Ile Gln Gly  
 180 185 190  
 Leu Ala Gly Leu Glu Val His Arg Leu Val Leu Gly Glu Phe Arg Asn  
 195 200 205

Glu Gly Asn Leu Glu Lys Phe Asp Lys Ser Ala Leu Glu Gly Leu Cys  
 210 215 220  
 Asn Leu Thr Ile Glu Glu Phe Arg Leu Ala Tyr Leu Asp Tyr Tyr Leu  
 225 230 235 240  
 Asp Asp Ile Ile Asp Leu Phe Asn Cys Leu Thr Asn Val Ser Ser Phe  
 245 250 255  
 Ser Leu Val Ser Val Thr Ile Glu Arg Val Lys Asp Phe Ser Tyr Asn  
 260 265 270  
 Phe Gly Trp Gln His Leu Glu Leu Val Asn Cys Lys Phe Gly Gln Phe  
 275 280 285  
 Pro Thr Leu Lys Leu Lys Ser Leu Lys Arg Leu Thr Phe Thr Ser Asn  
 290 295 300  
 Lys Gly Gly Asn Ala Phe Ser Glu Val Asp Leu Pro Ser Leu Glu Phe  
 305 310 315 320  
 Leu Asp Leu Ser Arg Asn Gly Leu Ser Phe Lys Gly Cys Cys Ser Gln  
 325 330 335  
 Ser Asp Phe Gly Thr Thr Ser Leu Lys Tyr Leu Asp Leu Ser Phe Asn  
 340 345 350  
 Gly Val Ile Thr Met Ser Ser Asn Phe Leu Gly Leu Glu Gln Leu Glu  
 355 360 365  
 His Leu Asp Phe Gln His Ser Asn Leu Lys Gln Met Ser Glu Phe Ser  
 370 375 380  
 Val Phe Leu Ser Leu Arg Asn Leu Ile Tyr Leu Asp Ile Ser His Thr  
 385 390 395 400  
 His Thr Arg Val Ala Phe Asn Gly Ile Phe Asn Gly Leu Ser Ser Leu  
 405 410 415  
 Glu Val Leu Lys Met Ala Gly Asn Ser Phe Gln Glu Asn Phe Leu Pro  
 420 425 430  
 Asp Ile Phe Thr Glu Leu Arg Asn Leu Thr Phe Leu Asp Leu Ser Gln  
 435 440 445  
 Cys Gln Leu Glu Gln Leu Ser Pro Thr Ala Phe Asn Ser Leu Ser Ser  
 450 455 460  
 Leu Gln Val Leu Asn Met Ser His Asn Asn Phe Phe Ser Leu Asp Thr  
 465 470 475 480  
 Phe Pro Tyr Lys Cys Leu Asn Ser Leu Gln Val Leu Asp Tyr Ser Leu  
 485 490 495  
 Asn His Ile Met Thr Ser Lys Lys Gln Glu Leu Gln His Phe Pro Ser  
 500 505 510  
 Ser Leu Ala Phe Leu Asn Leu Thr Gln Asn Asp Phe Ala Cys Thr Cys  
 515 520 525  
 Glu His Gln Ser Phe Leu Gln Trp Ile Lys Asp Gln Arg Gln Leu Leu

530                      535                      540  
 Val Glu Val Glu Arg Met Glu Cys Ala Thr Pro Ser Asp Lys Gln Gly  
 545                      550                      555                      560  
 Met Pro Val Leu Ser Leu Asn Ile Thr Cys Gln Met Asn Lys Thr Ile  
                                  565                      570                      575  
 Ile Gly Val Ser Val Leu Ser Val Leu Val Val Ser Val Val Ala Val  
                                  580                      585                      590  
 Leu Val Tyr Lys Phe Tyr Phe His Leu Met Leu Leu Ala Gly Cys Ile  
                                  595                      600                      605  
 Lys Tyr Gly Arg Gly Glu Asn Ile Tyr Asp Ala Phe Val Ile Tyr Ser  
                                  610                      615                      620  
 Ser Gln Asp Glu Asp Trp Val Arg Asn Glu Leu Val Lys Asn Leu Glu  
 625                      630                      635                      640  
 Glu Gly Val Pro Pro Phe Gln Leu Cys Leu His Tyr Arg Asp Phe Ile  
                                  645                      650                      655  
 Pro Gly Val Ala Ile Ala Ala Asn Ile Ile His Glu Gly Phe His Lys  
                                  660                      665                      670  
 Ser Arg Lys Val Ile Val Val Val Ser Gln His Phe Ile Gln Ser Arg  
                                  675                      680                      685  
 Trp Cys Ile Phe Glu Tyr Glu Ile Ala Gln Thr Trp Gln Phe Leu Ser  
                                  690                      695                      700  
 Ser Arg Ala Gly Ile Ile Phe Ile Val Leu Gln Lys Val Glu Lys Thr  
 705                      710                      715                      720  
 Leu Leu Arg Gln Gln Val Glu Leu Tyr Arg Leu Leu Ser Arg Asn Thr  
                                  725                      730                      735  
 Tyr Leu Glu Trp Glu Asp Ser Val Leu Gly Arg His Ile Phe Trp Arg  
                                  740                      745                      750  
 Arg Leu Arg Lys Ala Leu Leu Asp Gly Lys Ser Trp Asn Pro Glu Gly  
                                  755                      760                      765  
 Thr Val Gly Thr Gly Cys Asn Trp Gln Glu Ala Thr Ser Ile  
                                  770                      775                      780

&lt;210&gt; 18

&lt;211&gt; 799

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 18

Met Glu Leu Asn Phe Tyr Lys Ile Pro Asp Asn Leu Pro Phe Ser Thr  
 1                      5                      10                      15  
 Lys Asn Leu Asp Leu Ser Phe Asn Pro Leu Arg His Leu Gly Ser Tyr  
                                  20                      25                      30  
 Ser Phe Phe Ser Phe Pro Glu Leu Gln Val Leu Asp Leu Ser Arg Cys  
                                  35                      40                      45

Glu Ile Gln Thr Ile Glu Asp Gly Ala Tyr Gln Ser Leu Ser His Leu  
 50 55 60  
 Ser Thr Leu Ile Leu Thr Gly Asn Pro Ile Gln Ser Leu Ala Leu Gly  
 65 70 75 80  
 Ala Phe Ser Gly Leu Ser Ser Leu Gln Lys Leu Val Ala Val Glu Thr  
 85 90 95  
 Asn Leu Ala Ser Leu Glu Asn Phe Pro Ile Gly His Leu Lys Thr Leu  
 100 105 110  
 Lys Glu Leu Asn Val Ala His Asn Leu Ile Gln Ser Phe Lys Leu Pro  
 115 120 125  
 Glu Tyr Phe Ser Asn Leu Thr Asn Leu Glu His Leu Asp Leu Ser Ser  
 130 135 140  
 Asn Lys Ile Gln Ser Ile Tyr Cys Thr Asp Leu Arg Val Leu His Gln  
 145 150 155 160  
 Met Pro Leu Leu Asn Leu Ser Leu Asp Leu Ser Leu Asn Pro Met Asn  
 165 170 175  
 Phe Ile Gln Pro Gly Ala Phe Lys Glu Ile Arg Leu His Lys Leu Thr  
 180 185 190  
 Leu Arg Asn Asn Phe Asp Ser Leu Asn Val Met Lys Thr Cys Ile Gln  
 195 200 205  
 Gly Leu Ala Gly Leu Glu Val His Arg Leu Val Leu Gly Glu Phe Arg  
 210 215 220  
 Asn Glu Gly Asn Leu Glu Lys Phe Asp Lys Ser Ala Leu Glu Gly Leu  
 225 230 235 240  
 Cys Asn Leu Thr Ile Glu Glu Phe Arg Leu Ala Tyr Leu Asp Tyr Tyr  
 245 250 255  
 Leu Asp Asp Ile Ile Asp Leu Phe Asn Cys Leu Thr Asn Val Ser Ser  
 260 265 270  
 Phe Ser Leu Val Ser Val Thr Ile Glu Arg Val Lys Asp Phe Ser Tyr  
 275 280 285  
 Asn Phe Gly Trp Gln His Leu Glu Leu Val Asn Cys Lys Phe Gly Gln  
 290 295 300  
 Phe Pro Thr Leu Lys Leu Lys Ser Leu Lys Arg Leu Thr Phe Thr Ser  
 305 310 315 320  
 Asn Lys Gly Gly Asn Ala Phe Ser Glu Val Asp Leu Pro Ser Leu Glu  
 325 330 335  
 Phe Leu Asp Leu Ser Arg Asn Gly Leu Ser Phe Lys Gly Cys Cys Ser  
 340 345 350  
 Gln Ser Asp Phe Gly Thr Thr Ser Leu Lys Tyr Leu Asp Leu Ser Phe  
 355 360 365  
 Asn Gly Val Ile Thr Met Ser Ser Asn Phe Leu Gly Leu Glu Gln Leu

370					375					380					
Glu 385	His	Leu	Asp	Phe	Gln 390	His	Ser	Asn	Leu	Lys 395	Gln	Met	Ser	Glu	Phe 400
Ser	Val	Phe	Leu	Ser 405	Leu	Arg	Asn	Leu	Ile 410	Tyr	Leu	Asp	Ile	Ser	His 415
Thr	His	Thr	Arg 420	Val	Ala	Phe	Asn	Gly 425	Ile	Phe	Asn	Gly	Leu 430	Ser	Ser
Leu	Glu	Val 435	Leu	Lys	Met	Ala	Gly 440	Asn	Ser	Phe	Gln	Glu	Asn	Phe	Leu
Pro	Asp 450	Ile	Phe	Thr	Glu	Leu 455	Arg	Asn	Leu	Thr	Phe 460	Leu	Asp	Leu	Ser
Gln 465	Cys	Gln	Leu	Glu	Gln 470	Leu	Ser	Pro	Thr	Ala 475	Phe	Asn	Ser	Leu	Ser 480
Ser	Leu	Gln	Val 485	Leu	Asn	Met	Ser	His	Asn 490	Asn	Phe	Phe	Ser	Leu 495	Asp
Thr	Phe	Pro	Tyr 500	Lys	Cys	Leu	Asn	Ser 505	Leu	Gln	Val	Leu	Asp 510	Tyr	Ser
Leu	Asn 515	His	Ile	Met	Thr	Ser	Lys 520	Lys	Gln	Glu	Leu	Gln 525	His	Phe	Pro
Ser	Ser 530	Leu	Ala	Phe	Leu	Asn 535	Leu	Thr	Gln	Asn	Asp 540	Phe	Ala	Cys	Thr
Cys 545	Glu	His	Gln	Ser	Phe 550	Leu	Gln	Trp	Ile	Lys 555	Asp	Gln	Arg	Gln	Leu 560
Leu	Val	Glu	Val 565	Glu	Arg	Met	Glu	Cys	Ala 570	Thr	Pro	Ser	Asp	Lys 575	Gln
Gly	Met	Pro	Val 580	Leu	Ser	Leu	Asn	Ile 585	Thr	Cys	Gln	Met	Asn 590	Lys	Thr
Ile	Ile 595	Gly	Val	Ser	Val	Leu	Ser 600	Val	Leu	Val	Val	Ser 605	Val	Val	Ala
Val	Leu 610	Val	Tyr	Lys	Phe	Tyr 615	Phe	His	Leu	Met	Leu 620	Leu	Ala	Gly	Cys
Ile 625	Lys	Tyr	Gly	Arg	Gly 630	Glu	Asn	Ile	Tyr	Asp 635	Ala	Phe	Val	Ile	Tyr 640
Ser	Ser	Gln	Asp 645	Glu	Asp	Trp	Val	Arg	Asn 650	Glu	Leu	Val	Lys	Asn 655	Leu
Glu	Glu	Gly 660	Val	Pro	Pro	Phe	Gln 665	Leu	Cys	Leu	His	Tyr	Arg 670	Asp	Phe
Ile	Pro 675	Gly	Val	Ala	Ile	Ala	Ala 680	Asn	Ile	Ile	His	Glu 685	Gly	Phe	His
Lys	Ser 690	Arg	Lys	Val	Ile	Val	Val 695	Val	Ser	Gln	His	Phe	Ile	Gln	Ser
Arg	Trp	Cys	Ile	Phe	Glu	Tyr	Glu	Ile	Ala	Gln	Thr	Trp	Gln	Phe	Leu

705                      710                      715                      720  
 Ser Ser Arg Ala Gly Ile Ile Phe Ile Val Leu Gln Lys Val Glu Lys  
                              725                      730                      735  
 Thr Leu Leu Arg Gln Gln Val Glu Leu Tyr Arg Leu Leu Ser Arg Asn  
                              740                      745                      750  
 Thr Tyr Leu Glu Trp Glu Asp Ser Val Leu Gly Arg His Ile Phe Trp  
                              755                      760                      765  
 Arg Arg Leu Arg Lys Ala Leu Leu Asp Gly Lys Ser Trp Asn Pro Glu  
                              770                      775                      780  
 Gly Thr Val Gly Thr Gly Cys Asn Trp Gln Glu Ala Thr Ser Ile  
 785                               790                               795

<210> 19  
 <211> 639  
 <212> PRT  
 <213> Homo sapiens

<400> 19

Met Pro Leu Leu Asn Leu Ser Leu Asp Leu Ser Leu Asn Pro Met Asn  
 1                               5                               10                               15  
 Phe Ile Gln Pro Gly Ala Phe Lys Glu Ile Arg Leu His Lys Leu Thr  
                              20                               25                               30  
 Leu Arg Asn Asn Phe Asp Ser Leu Asn Val Met Lys Thr Cys Ile Gln  
                              35                               40                               45  
 Gly Leu Ala Gly Leu Glu Val His Arg Leu Val Leu Gly Glu Phe Arg  
                              50                               55                               60  
 Asn Glu Gly Asn Leu Glu Lys Phe Asp Lys Ser Ala Leu Glu Gly Leu  
 65                               70                               75                               80  
 Cys Asn Leu Thr Ile Glu Glu Phe Arg Leu Ala Tyr Leu Asp Tyr Tyr  
                              85                               90                               95  
 Leu Asp Asp Ile Ile Asp Leu Phe Asn Cys Leu Thr Asn Val Ser Ser  
                              100                               105                               110  
 Phe Ser Leu Val Ser Val Thr Ile Glu Arg Val Lys Asp Phe Ser Tyr  
                              115                               120                               125  
 Asn Phe Gly Trp Gln His Leu Glu Leu Val Asn Cys Lys Phe Gly Gln  
                              130                               135                               140  
 Phe Pro Thr Leu Lys Leu Lys Ser Leu Lys Arg Leu Thr Phe Thr Ser  
 145                               150                               155                               160  
 Asn Lys Gly Gly Asn Ala Phe Ser Glu Val Asp Leu Pro Ser Leu Glu  
                              165                               170                               175  
 Phe Leu Asp Leu Ser Arg Asn Gly Leu Ser Phe Lys Gly Cys Cys Ser  
                              180                               185                               190  
 Gln Ser Asp Phe Gly Thr Thr Ser Leu Lys Tyr Leu Asp Leu Ser Phe  
                              195                               200                               205



Asn Gly Val Ile Thr Met Ser Ser Asn Phe Leu Gly Leu Glu Gln Leu  
 210 215 220  
 Glu His Leu Asp Phe Gln His Ser Asn Leu Lys Gln Met Ser Glu Phe  
 225 230 235 240  
 Ser Val Phe Leu Ser Leu Arg Asn Leu Ile Tyr Leu Asp Ile Ser His  
 245 250 255  
 Thr His Thr Arg Val Ala Phe Asn Gly Ile Phe Asn Gly Leu Ser Ser  
 260 265 270  
 Leu Glu Val Leu Lys Met Ala Gly Asn Ser Phe Gln Glu Asn Phe Leu  
 275 280 285  
 Pro Asp Ile Phe Thr Glu Leu Arg Asn Leu Thr Phe Leu Asp Leu Ser  
 290 295 300  
 Gln Cys Gln Leu Glu Gln Leu Ser Pro Thr Ala Phe Asn Ser Leu Ser  
 305 310 315 320  
 Ser Leu Gln Val Leu Asn Met Ser His Asn Asn Phe Phe Ser Leu Asp  
 325 330 335  
 Thr Phe Pro Tyr Lys Cys Leu Asn Ser Leu Gln Val Leu Asp Tyr Ser  
 340 345 350  
 Leu Asn His Ile Met Thr Ser Lys Lys Gln Glu Leu Gln His Phe Pro  
 355 360 365  
 Ser Ser Leu Ala Phe Leu Asn Leu Thr Gln Asn Asp Phe Ala Cys Thr  
 370 375 380  
 Cys Glu His Gln Ser Phe Leu Gln Trp Ile Lys Asp Gln Arg Gln Leu  
 385 390 395 400  
 Leu Val Glu Val Glu Arg Met Glu Cys Ala Thr Pro Ser Asp Lys Gln  
 405 410 415  
 Gly Met Pro Val Leu Ser Leu Asn Ile Thr Cys Gln Met Asn Lys Thr  
 420 425 430  
 Ile Ile Gly Val Ser Val Leu Ser Val Leu Val Val Ser Val Val Ala  
 435 440 445  
 Val Leu Val Tyr Lys Phe Tyr Phe His Leu Met Leu Leu Ala Gly Cys  
 450 455 460  
 Ile Lys Tyr Gly Arg Gly Glu Asn Ile Tyr Asp Ala Phe Val Ile Tyr  
 465 470 475 480  
 Ser Ser Gln Asp Glu Asp Trp Val Arg Asn Glu Leu Val Lys Asn Leu  
 485 490 495  
 Glu Glu Gly Val Pro Pro Phe Gln Leu Cys Leu His Tyr Arg Asp Phe  
 500 505 510  
 Ile Pro Gly Val Ala Ile Ala Ala Asn Ile Ile His Glu Gly Phe His  
 515 520 525  
 Lys Ser Arg Lys Val Ile Val Val Val Ser Gln His Phe Ile Gln Ser

530                      535                      540  
 Arg Trp Cys Ile Phe Glu Tyr Glu Ile Ala Gln Thr Trp Gln Phe Leu  
 545                      550                      555                      560  
 Ser Ser Arg Ala Gly Ile Ile Phe Ile Val Leu Gln Lys Val Glu Lys  
 565                      570                      575  
 Thr Leu Leu Arg Gln Gln Val Glu Leu Tyr Arg Leu Leu Ser Arg Asn  
 580                      585                      590  
 Thr Tyr Leu Glu Trp Glu Asp Ser Val Leu Gly Arg His Ile Phe Trp  
 595                      600                      605  
 Arg Arg Leu Arg Lys Ala Leu Leu Asp Gly Lys Ser Trp Asn Pro Glu  
 610                      615                      620  
 Gly Thr Val Gly Thr Gly Cys Asn Trp Gln Glu Ala Thr Ser Ile  
 625                      630                      635

<210> 20  
 <211> 3866  
 <212> DNA  
 <213> murine

<400> 20  
 ctgggtgcag aaaatgccag gatgatgcct ccctggctcc tggctaggac tctgatcatg 60  
 gcactgttct tctcctgcct gacaccagga agcttgaatc cctgcataga ggtagttcct 120  
 aatattacct accaatgcat ggatcagaaa ctcagcaaag tccctgatga cattccttct 180  
 tcaaccaaga acatagatct gagcttcaac cccttgaaga tcttaaaaag ctatagcttc 240  
 tccaattttt cagaacttca gtggctggat ttatccaggt gtgaaattga aacaattgaa 300  
 gacaaggcat ggcatggctt acaccacctc tcaaacttga tactgacagg aaaccctatc 360  
 cagagttttt cccaggaag tttctctgga ctaacaagtt tagagaatct ggtggctgtg 420  
 gagacaaaat tggcctctct agaaagcttc cctattggac agcttataac cttaaagaaa 480  
 ctcaatgtgg ctcaaatctt tatacattcc tgtaagttac ctgcatattt ttccaatctg 540  
 acgaacctag tacatgtgga tctttcttat aactatattc aaactattac tgtcaacgac 600  
 ttacagtttc tacgtgaaaa tccacaagtc aatctctctt tagacatgtc tttgaaccca 660  
 attgacttca ttcaagacca agcctttcag ggaattaagc tccatgaact gactctaaga 720  
 ggtaatttta atagctcaaa tataatgaaa acttgccttc aaaacctggc tggtttacac 780  
 gtccatcggg tgatcttggg agaatttaaa gatgaaagga atctggaaat ttttgaaccc 840  
 tctatcatgg aaggactatg tgatgtgacc attgatgagt tcagggttaac atatacaaat 900  
 gatttttcag atgatattgt taagttccat tgcttggcga atgtttctgc aatgtctctg 960  
 gcagggtgat ctataaaata tctagaagat gttcctaaac atttcaaagtg gcaatcctta 1020  
 tcaatcatta gatgtcaact taagcagttt ccaactctgg atctaccctt tcttaaaagt 1080

ttgacttttaa ctatgaacaa agggctctatc agtttttaaaa aagtggccct accaagtctc	1140
agctatcttag atcttagtag aaatgcactg agcttttagtg gttgctgttc ttattctgat	1200
ttgggaacaa acagcctgag acacttagac ctcagcttca atggtgccat cattatgagt	1260
gccaaatttca tgggtctaga agagctgcag cacctggatt ttcagcactc tacttttaaaa	1320
agggtcacag aattctcagc gttcttatcc cttgaaaagc tactttacct tgacatctct	1380
tatactaaca ccaaaattga cttcgatggg atatttcttg gcttgaccag tctcaacaca	1440
ttaaaaatgg ctggcaattc ttccaagac aacacccttt caaatgtctt tgcaaacaca	1500
acaaacttga cattcctgga tctttctaaa tgtcaattgg aacaaatc tttgggggta	1560
tttgacaccc tccatagact tcaattatta aatatgagtc acaacaatct attgtttttg	1620
gattcatccc attataacca gctgtattcc ctcagcactc ttgattgcag tttcaatcgc	1680
atagagacat ctaaaggaat actgcaacat tttccaaaga gtctagcctt cttcaatctt	1740
actaacaatt ctgttgcttg tatatgtgaa catcagaaat tcctgcagtg ggtcaaggaa	1800
cagaagcagt tcttggtgaa tgttgaacaa atgacatgtg caacacctgt agagatgaat	1860
acctccttag tgttggattt taataattct acctgttata tgtacaagac aatcatcagt	1920
gtgtcagtggt tcatgtgat tgtggtatcc actgtagcat ttctgatata ccacttctat	1980
tttcacctga tacttattgc tggctgtaaa aagtacagca gaggagaaag catctatgat	2040
gcatttgtga tctactcgag tcagaatgag gactgggtga gaaatgagct ggtaaagaat	2100
ttagaagaag gagtgcctcg ctttcacctc tgccttcaact acagagactt tattcctggg	2160
gtagccattg ctgccaacat catccaggaa ggcttcaca agagccggaa ggttattgtg	2220
gtagtgtcta gacactttat tcagagccgt tgggtgatct ttgaatatga gattgctcaa	2280
acatggcagt ttctgagcag ccgctctggc atcatcttca ttgtccttga gaagggtgag	2340
aagtccctgc tgaggcagca ggtggaattg tatgccttc ttagcagaaa cacctacctg	2400
gaatgggagg acaatcctct ggggaggcac atcttctgga gaagacttaa aaatgcccta	2460
ttggatggaa aagcctcgaa tcctgagcaa acagcagagg aagaacaaga aacggcaact	2520
tggacctgag gagaacaaaa ctctggggcc taaaccagct ctgtttgcaa ttaataaatg	2580
ctacagctca cctggggctc tgctatggac cgagagccca tggaacacat ggctgctaag	2640
ctatagcatg gaccttaccg ggcagaagga agtagcactg acaccttctt ttccaggggt	2700
atgaattacc taactcggga aaagaaacat aatccagaat ctttaccttt aatctgaagg	2760
agaagaggct aaggcctagt gagaacagaa aggagaacca gtcttcaactg ggccttttga	2820
atacaagcca tgcatgttc tgtgtttcag ttgctttaga agagtattga tagtttcaac	2880
tgaactgaac ggtttcttac tttccctttt ttctactgaa tgcaatatta aatagctctt	2940
tttgagagggt cttcattcca atttcatctt ccattttatg tcattttctt ttcttttttg	3000

```

tttttatctg attctataag aaatatgatt gatacacgct cacagatagc ctggccaatc 3060
ctaagaatgc tatatttatt aaatacaatt cctagtatac ttttactttt ataaattcag 3120
ttatcgtttt tcatgccttg actataaact aatatcataa ataagattgt tacagggtatg 3180
ctaagaaggc ccatatttga ctataatfff ttaagaaagt atataaaata tactttgtca 3240
tattgtcact gaatgtcatt cttaagttat tacctaagtt atggatgtca cagagtcagt 3300
gttaaaaata atttggttga tagaaatatt ttaatcagg agggaaaagt ggagaggggt 3360
gcaggaacag aaatcatgat ttcatcattt attcttgatt tttccggaag ttcacatagc 3420
tgaatgacaa gactacatat gctgcaactg atgttccttc tcatcaagga tactctctga 3480
acttgagaac attttgggga ggaagaaagg tctaacatcc ttttccttca tcattctcat 3540
ttctggacat gccttgtgag atggatcaat gttgggagta cacatttctg ctttcacctt 3600
atctcagtca gcatgaacac tgaatatata atgtcatttc acagtgtgtg tgtgttgtgt 3660
atgtacatat atgaacctgt acatgtgttt aagtttaaag agaaaatagt gtacagagca 3720
gggtgtatatt tgtgataggg ctttaaatag ttgagctaatt tcagaaaagt atggagggtt 3780
cttggtaaac caaaccaaaa gtagaatcat tacaagatct aacaataaaa attttgaaaa 3840
aaaaaaaaa aaaaaaaaaa aaaaaa 3866

```

<210> 21  
<211> 2520  
<212> DNA  
<213> murine

```

<400> 21
atgatgcctc cctggctcct ggctaggact ctgatcatgg cactgttctt ctctgcctg 60
acaccaggaa gcttgaatcc ctgcatagag gtagttccta atattaccta ccaatgcatg 120
gatcagaaac tcagcaaagt ccctgatgac attccttctt caaccaagaa catagatctg 180
agcttcaacc ccttgaagat cttaaaaagc tatagcttct ccaatttttc agaacttcag 240
tggtctggatt tatccagggtg tgaaattgaa acaattgaag acaaggcatg gcatggctta 300
caccacctct caaacttgat actgacagga aaccctatcc agagtttttc cccagggaagt 360
ttctctggac taacaagttt agagaatctg gtggctgtgg agacaaaatt ggcctctcta 420
gaaagcttcc ctattggaca gcttataacc ttaaagaaac tcaatgtggc tcacaatfff 480
atacattcct gtaagttacc tgcataatfff tccaatctga cgaacctagt acatgtggat 540
ctttcttata actatattca aactattact gtcaacgact tacagtttct acgtgaaaat 600
ccacaagtca atctctcttt agacatatct ttgaaccaa ttgacttcat tcaagaccaa 660
gcctttcagg gaattaagct ccatgaactg actctaagag gtaattttta tagctcaaat 720

```

ataatgaaaa	cttgcccttca	aaacctggct	ggtttacaca	tccatcgggt	gatcttggga	780
gaatttaaag	atgaaaggaa	tctggaaatt	tttgaaccct	ctatcatgga	aggactatgt	840
gatgtgacca	ttgatgagtt	caggttaaca	tatacaaatg	atttttcaga	tgatattggt	900
aagttccatt	gcttggcgaa	tgtttctgca	atgtctctgg	cagggtgtatc	tataaaatat	960
ctagaagatg	ttcctaaaca	tttcaaattg	caatccttat	caatcattag	atgtcaactt	1020
aagcagtttc	caactctgga	tctacccttt	cttaaaagtt	tgactttaac	tatgaacaaa	1080
gggtctatca	gttttaaaaa	agtggcccta	ccaagtctca	gctatctaga	tcttagtaga	1140
aatgcactga	gcttttagtg	ttgctgttct	tattctgatt	tggaacaaa	cagcctgaga	1200
cacttagacc	tcagcttcaa	tggtgccatc	attatgagtg	ccaatttcat	gggtctagaa	1260
gagctgcagc	acctggattt	tcagcactct	actttaaaaa	gggtcacaga	attctcagcg	1320
ttcttatccc	ttgaaaagct	actttacctt	gacatctctt	atactaacac	caaaattgac	1380
ttcgatggta	tatttcttgg	cttgaccagt	ctcaacacat	taaaaatggc	tggcaattct	1440
ttcaaagaca	acaccctttc	aaatgtcttt	gcaaacacaa	caaacttgac	attcctggat	1500
ctttctaaat	gtcaattgga	acaaatatct	tgggggggat	ttgacaccct	ccatagactt	1560
caattattaa	atatgagtca	caacaatcta	ttgtttttgg	attcatocca	ttataaccag	1620
ctgtattccc	tcagcactct	tgattgcagt	ttcaatcgca	tagagacatc	taaaggaata	1680
ctgcaacatt	ttccaaagag	tctagccttc	ttcaatctta	ctaacaattc	tggtgcttgt	1740
atatgtgaac	atcagaaatt	cctgcagtgg	gtcaaggacc	agaagcagtt	cttgggtgaat	1800
gttgaacaaa	tgacatgtgc	aacacctgta	gagatgaata	cctccttagt	gttggatttt	1860
aataattcta	cctgttatat	gtacaagaca	atcatcagtg	tgtcagtggt	cagtgtgatt	1920
gtggtatcca	ctgtagcatt	tctgatatac	cacttctatt	ttcacctgat	acttattgct	1980
ggctgtaaaa	agtacagcag	aggagaaagc	atctatgatg	catttgtgat	ctactcgagt	2040
cagaatgagg	actgggtgag	aaatgagctg	gtaaagaatt	tagaagaagg	agtgccccgc	2100
tttcacctct	gccttcacta	cagagacttt	attcctggtg	tagccattgc	tgccaatatc	2160
atccaggaag	gcttcacaaa	gagccggaag	gttattgtgg	tagtgtctag	acactttatt	2220
cagagccgtt	ggtgtatctt	tgaatatgag	attgctcaaa	catggcagtt	tctgagcagc	2280
cactctggca	tcattcttcat	tgctcctgag	aaggttgaga	agtccttgct	gaggcagcag	2340
gtggaattgt	atcgccctct	tagcagaaac	acctacctgg	aatgggagga	caatcctctg	2400
gggaggcaca	tcttctggag	aagacttaaa	aatgccctat	tggtgggaaa	agcctcgaat	2460
cctgagcaaa	cagcagagga	agaacaagaa	acggcaactt	ggacctgagg	agaaccgcgg	2520

&lt;210&gt; 22

&lt;211&gt; 3866

<212> DNA  
<213> murine

<400> 22

ctgggtgcag aaaatgccag gatgatgcct ccctggctcc tggctaggac tctgatcatg	60
gcactgttct tctcctgcct gacaccagga agcttgaatc cctgcataga ggtagttcct	120
aatattacct accaatgcat ggatcagaaa ctacagcaaag tccctgatga cattccttct	180
tcaaccaaga acatagatct gagcttcaac cccttgaaga tcttaaaaag ctatagcttc	240
tccaattttt cagaacttca gtggctggat ttatccaggt gtgaaattga aacaattgaa	300
gacaaggcat ggcattggctt acaccacctc tcaaaactga tactgacagg aaaccctatc	360
cagagttttt cccaggaag tttctctgga ctaacaagtt tagagaatct ggtggctgtg	420
gagacaaaat tggcctctct agaaagcttc cctattggac agcttataac cttaaagaaa	480
ctcaatgtgg ctcaaatctt tatacattcc tgtaagttaac ctgcatatct ttccaatctg	540
acgaacctag tacatgtgga tctttcttat aactatattc aaactattac tgtcaacgac	600
ttacagtctc tacgtgaaaa tccacaagtc aatctctctt tagacatgtc tttgaaccca	660
attgacttca ttcaagacca agcctttcag ggaattaagc tccatgaact gactctaaga	720
ggtaatttta atagctcaaa tataatgaaa acttgccttc aaaacctggc tgggtttacac	780
gtccatcggg tgatcttggg agaatttaaa gatgaaagga atctggaaat ttttgaaccc	840
tctatcatgg aaggactatg tgatgtgacc attgatgagt tcaggttaac atatacaaat	900
gatttttcag atgatattgt taagttccat tgcttggcga atgtttctgc aatgtctctg	960
gcaggtgtat ctataaaata tctagaagat gttcctaaac atttcaaatg gcaatcctta	1020
tcaatcatta gatgtcaact taagcagttt ccaactctgg atctaccctt tcttaaaagt	1080
ttgactttaa ctatgaacaa agggctctatc agttttaaaa aagtggccct accaagtctc	1140
agctatctag atcttagtag aaatgcactg agcttttagtg gttgctgttc ttattctgat	1200
ttgggaacaa acagcctgag acacttagac ctacagcttca atgggtgcat cattatgagt	1260
gccaatctca tgggtctaga agagctgcag cacctggatt ttcagcactc tactttaaaa	1320
agggtcacag aattctcagc gttcttatcc cttgaaaagc tactttacct tgacatctct	1380
tatactaaca ccaaaattga ctctgatggg atatttcttg gcttgaccag tctcaacaca	1440
ttaaaaatgg ctggcaattc tttcaaagac aacacccttt caaatgtctt tgcaaacaca	1500
acaaacttga cattcctgga tctttctaaa tgtcaattgg aacaaatctt ttggggggta	1560
tttgacaccc tccatagact tcaattatta aatatgagtc acaacaatct attgtttttg	1620
gattcatccc attataacca gctgtattcc ctacagcactc ttgattgcag tttcaatcgc	1680
atagagacat ctaaaggaat actgcaacat tttccaaaga gtctagcctt cttcaatctt	1740

actaacaatt ctgttgcttg tataatgtgaa catcagaaat tcctgcagtg ggtaaggaa	1800
cagaagcagt tcttggtgaa tgttgaacaa atgacatgtg caacacctgt agagatgaat	1860
acctccttag tgttggaattt taataattct acctgttata tgtacaagac aatcatcagt	1920
gtgtcagtggt tcagtgatgat tgtggtatcc actgtagcat ttctgatata ccacttctat	1980
tttcacctga tacttattgc tggctgtaaa aagtacagca gaggagaaag catctatgat	2040
gcatttgtga tctactcgag tcagaatgag gactgggtga gaaatgagct ggtaaagaat	2100
ttagaagaag gagtgcctcg ctttcacctc tgccttcact acagagactt tattcctggt	2160
gtagccattg ctgccaacat catccaggaa ggcttcacac agagccggaa ggttattgtg	2220
gtagtgtcta gacactttat tcagagccgt tgggtgtatct ttgaatatga gattgctcaa	2280
acatggcagt ttctgagcag ccgctctggc atcatcttca ttgtccttga gaaggttgag	2340
aagtccttgc tgaggcagca ggtggaattg tatgccttc ttagcagaaa cacctacctg	2400
gaatgggagg acaatcctct ggggaggcac atcttctgga gaagacttaa aaatgccta	2460
ttggatggaa aagcctcgaa tcctgagcaa acagcagagg aagaacaaga aacggcaact	2520
tggacctgag gagaacaaaa ctctggggcc taaaccagc ctgtttgcaa ttaataaatg	2580
ctacagctca cctggggctc tgctatggac cgagagccca tggaacacat ggctgctaag	2640
ctatagcatg gacctaccg ggcagaagga agtagcactg acaccttctt ttccaggggt	2700
atgaattacc taactcggga aaagaaacat aatccagaat ctttaccttt aatctgaagg	2760
agaagaggct aaggcctagt gagaacagaa aggagaacca gtcttctactg ggccttttga	2820
atacaagcca tgtcatgttc tgtgtttcag ttgctttaga agagtattga tagtttcaac	2880
tgaactgaac ggtttcttac tttccctttt ttctactgaa tgcaatatta aatagctctt	2940
tttgagaggc cttcattcca atttcatctt ccattttatg tcattttctt ttcttttttg	3000
tttttatcta attctataag aaatatgatt gatacacgct cacagatagc ctggccaatc	3060
ctaagaatgc tatattttatt aaatacaatt cctagtatac ttttactttt ataaattcag	3120
ttatcggtttt tcatgccttg actataaact aatatcataa ataagattgt tacagggtatg	3180
ctaagaaggc ccataatttga ctataatttt ttaagaaagt atataaaata tactttgtca	3240
tattgtcact gaatgtcatt ctttaagttat tacctaagtt atggatgtca cagagtcagt	3300
gttaaaaata atttggttga tagaaatatt tttaatcagg agggaaaagt ggagaggggt	3360
gcaggaacag aaatcatgat ttcatcattt attcttgatt tttccggaag ttcacatagc	3420
tgaatgacaa gactacatat gctgcaactg atgttccttc tcatcaagga tactctctga	3480
acttgagaac attttgggga ggaagaaagg tctaacatcc ttttccttca tcattctcat	3540
ttctggacat gccttgtgag atggatcaat gttgggagta cacattttctg ctttcacctt	3600
atctcagtcg gcatgaacac tgaatatata atgtcatttc acagtgtgtg tgtgtgtgtg	3660

atgtacatat atgaacctgt acatgtgttt aagtttaaag agaaaatagt gtacagagca 3720  
 ggtgtatatt tgtgataggg ctttaaataag ttgagctaata tcagaaaagt atggaggttt 3780  
 cttggtaaac caaaccaaaa gtagaatcat tacaagatct aacaataaaa attttgaaaa 3840  
 aaaaaaaaaa aaaaaaaaaa aaaaaa 3866

<210> 23  
 <211> 835  
 <212> PRT  
 <213> murine

<400> 23

Met Met Pro Pro Trp Leu Leu Ala Arg Thr Leu Ile Met Ala Leu Phe  
 1 5 10 15  
 Phe Ser Cys Leu Thr Pro Gly Ser Leu Asn Pro Cys Ile Glu Val Val  
 20 25 30  
 Pro Asn Ile Thr Tyr Gln Cys Met Asp Gln Lys Leu Ser Lys Val Pro  
 35 40 45  
 Asp Asp Ile Pro Ser Ser Thr Lys Asn Ile Asp Leu Ser Phe Asn Pro  
 50 55 60  
 Leu Lys Ile Leu Lys Ser Tyr Ser Phe Ser Asn Phe Ser Glu Leu Gln  
 65 70 75 80  
 Trp Leu Asp Leu Ser Arg Cys Glu Ile Glu Thr Ile Glu Asp Lys Ala  
 85 90 95  
 Trp His Gly Leu His His Leu Ser Asn Leu Ile Leu Thr Gly Asn Pro  
 100 105 110  
 Ile Gln Ser Phe Ser Pro Gly Ser Phe Ser Gly Leu Thr Ser Leu Glu  
 115 120 125  
 Asn Leu Val Ala Val Glu Thr Lys Leu Ala Ser Leu Glu Ser Phe Pro  
 130 135 140  
 Ile Gly Gln Leu Ile Thr Leu Lys Lys Leu Asn Val Ala His Asn Phe  
 145 150 155 160  
 Ile His Ser Cys Lys Leu Pro Ala Tyr Phe Ser Asn Leu Thr Asn Leu  
 165 170 175  
 Val His Val Asp Leu Ser Tyr Asn Tyr Ile Gln Thr Ile Thr Val Asn  
 180 185 190  
 Asp Leu Gln Phe Leu Arg Glu Asn Pro Gln Val Asn Leu Ser Leu Asp  
 195 200 205  
 Met Ser Leu Asn Pro Ile Asp Phe Ile Gln Asp Gln Ala Phe Gln Gly  
 210 215 220  
 Ile Lys Leu His Glu Leu Thr Leu Arg Gly Asn Phe Asn Ser Ser Asn  
 225 230 235 240



Ile Met Lys Thr Cys Leu Gln Asn Leu Ala Gly Leu His Val His Arg  
 245 250 255  
 Leu Ile Leu Gly Glu Phe Lys Asp Glu Arg Asn Leu Glu Ile Phe Glu  
 260 265 270  
 Pro Ser Ile Met Glu Gly Leu Cys Asp Val Thr Ile Asp Glu Phe Arg  
 275 280 285  
 Leu Thr Tyr Thr Asn Asp Phe Ser Asp Asp Ile Val Lys Phe His Cys  
 290 295 300  
 Leu Ala Asn Val Ser Ala Met Ser Leu Ala Gly Val Ser Ile Lys Tyr  
 305 310 315 320  
 Leu Glu Asp Val Pro Lys His Phe Lys Trp Gln Ser Leu Ser Ile Ile  
 325 330 335  
 Arg Cys Gln Leu Lys Gln Phe Pro Thr Leu Asp Leu Pro Phe Leu Lys  
 340 345 350  
 Ser Leu Thr Leu Thr Met Asn Lys Gly Ser Ile Ser Phe Lys Lys Val  
 355 360 365  
 Ala Leu Pro Ser Leu Ser Tyr Leu Asp Leu Ser Arg Asn Ala Leu Ser  
 370 375 380  
 Phe Ser Gly Cys Cys Ser Tyr Ser Asp Leu Gly Thr Asn Ser Leu Arg  
 385 390 395 400  
 His Leu Asp Leu Ser Phe Asn Gly Ala Ile Ile Met Ser Ala Asn Phe  
 405 410 415  
 Met Gly Leu Glu Glu Leu Gln His Leu Asp Phe Gln His Ser Thr Leu  
 420 425 430  
 Lys Arg Val Thr Glu Phe Ser Ala Phe Leu Ser Leu Glu Lys Leu Leu  
 435 440 445  
 Tyr Leu Asp Ile Ser Tyr Thr Asn Thr Lys Ile Asp Phe Asp Gly Ile  
 450 455 460  
 Phe Leu Gly Leu Thr Ser Leu Asn Thr Leu Lys Met Ala Gly Asn Ser  
 465 470 475 480  
 Phe Lys Asp Asn Thr Leu Ser Asn Val Phe Ala Asn Thr Thr Asn Leu  
 485 490 495  
 Thr Phe Leu Asp Leu Ser Lys Cys Gln Leu Glu Gln Ile Ser Trp Gly  
 500 505 510  
 Val Phe Asp Thr Leu His Arg Leu Gln Leu Leu Asn Met Ser His Asn  
 515 520 525  
 Asn Leu Leu Phe Leu Asp Ser Ser His Tyr Asn Gln Leu Tyr Ser Leu  
 530 535 540  
 Ser Thr Leu Asp Cys Ser Phe Asn Arg Ile Glu Thr Ser Lys Gly Ile  
 545 550 555 560  
 Leu Gln His Phe Pro Lys Ser Leu Ala Phe Phe Asn Leu Thr Asn Asn

Ser Val Ala Cys Ile Cys Glu His Gln Lys Phe Leu Gln Trp Val Lys  
                   565                  570                  575  
                   580                  585                  590  
 Glu Gln Lys Gln Phe Leu Val Asn Val Glu Gln Met Thr Cys Ala Thr  
                   595                  600                  605  
 Pro Val Glu Met Asn Thr Ser Leu Val Leu Asp Phe Asn Asn Ser Thr  
                   610                  615                  620  
 Cys Tyr Met Tyr Lys Thr Ile Ile Ser Val Ser Val Val Ser Val Ile  
                   625                  630                  635                  640  
 Val Val Ser Thr Val Ala Phe Leu Ile Tyr His Phe Tyr Phe His Leu  
                   645                  650                  655  
 Ile Leu Ile Ala Gly Cys Lys Lys Tyr Ser Arg Gly Glu Ser Ile Tyr  
                   660                  665                  670  
 Asp Ala Phe Val Ile Tyr Ser Ser Gln Asn Glu Asp Trp Val Arg Asn  
                   675                  680                  685  
 Glu Leu Val Lys Asn Leu Glu Glu Gly Val Pro Arg Phe His Leu Cys  
                   690                  695                  700  
 Leu His Tyr Arg Asp Phe Ile Pro Gly Val Ala Ile Ala Ala Asn Ile  
                   705                  710                  715                  720  
 Ile Gln Glu Gly Phe His Lys Ser Arg Lys Val Ile Val Val Val Ser  
                   725                  730                  735  
 Arg His Phe Ile Gln Ser Arg Trp Cys Ile Phe Glu Tyr Glu Ile Ala  
                   740                  745                  750  
 Gln Thr Trp Gln Phe Leu Ser Ser Arg Ser Gly Ile Ile Phe Ile Val  
                   755                  760                  765  
 Leu Glu Lys Val Glu Lys Ser Leu Leu Arg Gln Gln Val Glu Leu Tyr  
                   770                  775                  780  
 Arg Leu Leu Ser Arg Asn Thr Tyr Leu Glu Trp Glu Asp Asn Pro Leu  
                   785                  790                  795                  800  
 Gly Arg His Ile Phe Trp Arg Arg Leu Lys Asn Ala Leu Leu Asp Gly  
                   805                  810                  815  
 Lys Ala Ser Asn Pro Glu Gln Thr Ala Glu Glu Glu Gln Glu Thr Ala  
                   820                  825                  830  
 Thr Trp Thr  
                   835

<210> 24  
 <211> 835  
 <212> PRT  
 <213> murine

<400> 24

Met Met Pro Pro Trp Leu Leu Ala Arg Thr Leu Ile Met Ala Leu Phe  
 1                  5                  10                  15

Phe Ser Cys Leu Thr Pro Gly Ser Leu Asn Pro Cys Ile Glu Val Val  
 20 25 30  
 Pro Asn Ile Thr Tyr Gln Cys Met Asp Gln Lys Leu Ser Lys Val Pro  
 35 40 45  
 Asp Asp Ile Pro Ser Ser Thr Lys Asn Ile Asp Leu Ser Phe Asn Pro  
 50 55 60  
 Leu Lys Ile Leu Lys Ser Tyr Ser Phe Ser Asn Phe Ser Glu Leu Gln  
 65 70 75 80  
 Trp Leu Asp Leu Ser Arg Cys Glu Ile Glu Thr Ile Glu Asp Lys Ala  
 85 90 95  
 Trp His Gly Leu His His Leu Ser Asn Leu Ile Leu Thr Gly Asn Pro  
 100 105 110  
 Ile Gln Ser Phe Ser Pro Gly Ser Phe Ser Gly Leu Thr Ser Leu Glu  
 115 120 125  
 Asn Leu Val Ala Val Glu Thr Lys Leu Ala Ser Leu Glu Ser Phe Pro  
 130 135 140  
 Ile Gly Gln Leu Ile Thr Leu Lys Lys Leu Asn Val Ala His Asn Phe  
 145 150 155 160  
 Ile His Ser Cys Lys Leu Pro Ala Tyr Phe Ser Asn Leu Thr Asn Leu  
 165 170 175  
 Val His Val Asp Leu Ser Tyr Asn Tyr Ile Gln Thr Ile Thr Val Asn  
 180 185 190  
 Asp Leu Gln Phe Leu Arg Glu Asn Pro Gln Val Asn Leu Ser Leu Asp  
 195 200 205  
 Ile Ser Leu Asn Pro Ile Asp Phe Ile Gln Asp Gln Ala Phe Gln Gly  
 210 215 220  
 Ile Lys Leu His Glu Leu Thr Leu Arg Gly Asn Phe Asn Ser Ser Asn  
 225 230 235 240  
 Ile Met Lys Thr Cys Leu Gln Asn Leu Ala Gly Leu His Ile His Arg  
 245 250 255  
 Leu Ile Leu Gly Glu Phe Lys Asp Glu Arg Asn Leu Glu Ile Phe Glu  
 260 265 270  
 Pro Ser Ile Met Glu Gly Leu Cys Asp Val Thr Ile Asp Glu Phe Arg  
 275 280 285  
 Leu Thr Tyr Thr Asn Asp Phe Ser Asp Asp Ile Val Lys Phe His Cys  
 290 295 300  
 Leu Ala Asn Val Ser Ala Met Ser Leu Ala Gly Val Ser Ile Lys Tyr  
 305 310 315 320  
 Leu Glu Asp Val Pro Lys His Phe Lys Trp Gln Ser Leu Ser Ile Ile  
 325 330 335  
 Arg Cys Gln Leu Lys Gln Phe Pro Thr Leu Asp Leu Pro Phe Leu Lys

			340					345					350		
Ser	Leu	Thr	Leu	Thr	Met	Asn	Lys	Gly	Ser	Ile	Ser	Phe	Lys	Lys	Val
		355					360					365			
Ala	Leu	Pro	Ser	Leu	Ser	Tyr	Leu	Asp	Leu	Ser	Arg	Asn	Ala	Leu	Ser
		370				375					380				
Phe	Ser	Gly	Cys	Cys	Ser	Tyr	Ser	Asp	Leu	Gly	Thr	Asn	Ser	Leu	Arg
385					390					395					400
His	Leu	Asp	Leu	Ser	Phe	Asn	Gly	Ala	Ile	Ile	Met	Ser	Ala	Asn	Phe
				405					410					415	
Met	Gly	Leu	Glu	Glu	Leu	Gln	His	Leu	Asp	Phe	Gln	His	Ser	Thr	Leu
			420					425					430		
Lys	Arg	Val	Thr	Glu	Phe	Ser	Ala	Phe	Leu	Ser	Leu	Glu	Lys	Leu	Leu
		435					440					445			
Tyr	Leu	Asp	Ile	Ser	Tyr	Thr	Asn	Thr	Lys	Ile	Asp	Phe	Asp	Gly	Ile
		450				455					460				
Phe	Leu	Gly	Leu	Thr	Ser	Leu	Asn	Thr	Leu	Lys	Met	Ala	Gly	Asn	Ser
465					470					475					480
Phe	Lys	Asp	Asn	Thr	Leu	Ser	Asn	Val	Phe	Ala	Asn	Thr	Thr	Asn	Leu
				485					490					495	
Thr	Phe	Leu	Asp	Leu	Ser	Lys	Cys	Gln	Leu	Glu	Gln	Ile	Ser	Trp	Gly
			500					505					510		
Val	Phe	Asp	Thr	Leu	His	Arg	Leu	Gln	Leu	Leu	Asn	Met	Ser	His	Asn
		515					520					525			
Asn	Leu	Leu	Phe	Leu	Asp	Ser	Ser	His	Tyr	Asn	Gln	Leu	Tyr	Ser	Leu
		530				535					540				
Ser	Thr	Leu	Asp	Cys	Ser	Phe	Asn	Arg	Ile	Glu	Thr	Ser	Lys	Gly	Ile
545					550					555					560
Leu	Gln	His	Phe	Pro	Lys	Ser	Leu	Ala	Phe	Phe	Asn	Leu	Thr	Asn	Asn
				565					570					575	
Ser	Val	Ala	Cys	Ile	Cys	Glu	His	Gln	Lys	Phe	Leu	Gln	Trp	Val	Lys
			580					585					590		
Asp	Gln	Lys	Gln	Phe	Leu	Val	Asn	Val	Glu	Gln	Met	Thr	Cys	Ala	Thr
		595					600					605			
Pro	Val	Glu	Met	Asn	Thr	Ser	Leu	Val	Leu	Asp	Phe	Asn	Asn	Ser	Thr
		610				615					620				
Cys	Tyr	Met	Tyr	Lys	Thr	Ile	Ile	Ser	Val	Ser	Val	Val	Ser	Val	Ile
625					630					635					640
Val	Val	Ser	Thr	Val	Ala	Phe	Leu	Ile	Tyr	His	Phe	Tyr	Phe	His	Leu
				645					650					655	
Ile	Leu	Ile	Ala	Gly	Cys	Lys	Lys	Tyr	Ser	Arg	Gly	Glu	Ser	Ile	Tyr
			660					665				670			
Asp	Ala	Phe	Val	Ile	Tyr	Ser	Ser	Gln	Asn	Glu	Asp	Trp	Val	Arg	Asn

675					680					685						
Glu	Leu	Val	Lys	Asn	Leu	Glu	Glu	Gly	Val	Pro	Arg	Phe	His	Leu	Cys	
690					695					700						
Leu	His	Tyr	Arg	Asp	Phe	Ile	Pro	Gly	Val	Ala	Ile	Ala	Ala	Asn	Ile	
705					710					715					720	
Ile	Gln	Glu	Gly	Phe	His	Lys	Ser	Arg	Lys	Val	Ile	Val	Val	Val	Ser	
725					730					735						
Arg	His	Phe	Ile	Gln	Ser	Arg	Trp	Cys	Ile	Phe	Glu	Tyr	Glu	Ile	Ala	
740					745					750						
Gln	Thr	Trp	Gln	Phe	Leu	Ser	Ser	His	Ser	Gly	Ile	Ile	Phe	Ile	Val	
755					760					765						
Leu	Glu	Lys	Val	Glu	Lys	Ser	Leu	Leu	Arg	Gln	Gln	Val	Glu	Leu	Tyr	
770					775					780						
Arg	Leu	Leu	Ser	Arg	Asn	Thr	Tyr	Leu	Glu	Trp	Glu	Asp	Asn	Pro	Leu	
785					790					795					800	
Gly	Arg	His	Ile	Phe	Trp	Arg	Arg	Leu	Lys	Asn	Ala	Leu	Leu	Asp	Gly	
805					810					815						
Lys	Ala	Ser	Asn	Pro	Glu	Gln	Thr	Ala	Glu	Glu	Glu	Gln	Glu	Thr	Ala	
820					825					830						
Thr	Trp	Thr	835													

```
<210> 25
<211> 3431
<212> DNA
<213> Homo sapiens
```

<400>	25	ggcttatagg	gctcgagcgg	ccgcccgggc	aggtatagaa	ttcagcggcc	gctgaattct	60
		aggggttttca	ggagcccgag	cgagggcgcc	gcttttgctg	ccgggaggag	ccaaccgtgg	120
		cgcaggcggc	gcggggaggc	gtcccagagt	ctcactctgc	cgcccaggct	ggactgcagt	180
		gacacaatct	cggctgactg	caaccactgc	ctccagggtt	caagcgattc	tcttgccctca	240
		gcctcccaag	tagctgggat	tacagattga	tgttcatgtt	cctggcacta	ctacaagatt	300
		catactcctg	atgctactga	caacgtggct	tctccacagt	caccaaacca	gggatgctat	360
		actggacttc	cctactctca	tctgctccag	ccccctgacc	ttatagttgc	ccagctttcc	420
		tggcaattga	ctttgcccat	caatacacag	gatttagcat	ccaggaaga	tgtcggagcc	480
		tcagatgtta	attttcta	tgagaatgtt	ggcgctgtcc	gaacctggag	acagaaaaac	540
		aaaaagtcct	ttctcctgat	tcaccaaaaa	ataaaatact	gactaccatc	actgtgatga	600
		gattcctata	gtctcaggaa	ctgaagtctt	taaacaacca	gggaccctct	gccctagaa	660
		taagaacata	ctagaagtcc	cttctgctag	gacaacgaqg	atcatgggag	accacctgga	720

ccttctccta	ggagtgggtgc	tcatggccgg	tctgtgtttt	ggaattcctt	cctgctcctt	780
tgatggccga	atagcctttt	atcgttttctg	caacctcacc	caggtccccc	aggtcctcaa	840
caccactgag	aggctcctgc	tgagcttcaa	ctatatcagg	acagtcaactg	cttcacacctt	900
cccctttctg	gaacagctgc	agctgctgga	gctcgggagc	cagtataccc	ccttgactat	960
tgacaaggag	gccttcagaa	acctgcccga	ccttagaatc	ttggacctgg	gaagtagtaa	1020
gatatacttc	ttgcatccag	atgcttttca	gggactgttc	catctgtttg	aacttagact	1080
gtatttctgt	ggtctctctg	atgctgtatt	gaaagatgg	tatttcagaa	atttaaaggc	1140
tttaactcgc	ttggatctat	ccaaaaatca	gattcgtagc	ctttaccttc	atccttcatt	1200
tggaagtgtg	aattccttaa	agtccataga	tttttcctcc	aaccaaatat	tccttgatg	1260
tgaacatgag	ctcgagcccc	tacaaggga	aacgctctcc	tttttttagcc	tcgcagctaa	1320
tagcttgtat	agcagagtct	cagtggactg	gggaaaatgt	atgaacccat	tcagaaacat	1380
ggtgctggag	atactagatg	tttctggaaa	tggctggaca	gtggacatca	caggaaactt	1440
tagcaatgcc	atcagcaaaa	gccaggcctt	ctctttgatt	cttgcccacc	acatcatggg	1500
tgccggggtt	ggcttcata	acatcaaaga	tcctgaccag	aacacatttg	ctggcctggc	1560
cagaagttca	gtgagacacc	tggatctttc	acatgggttt	gtcttctccc	tgaactcacg	1620
agtctttgag	acactcaagg	atttgaaggt	tctgaacctt	gcctacaaca	agataaataa	1680
gattgcagat	gaagcatttt	acggacttga	caacctccaa	gttctcaatt	tgtcatataa	1740
ccttctgggg	gaactttaca	gttcgaattt	ctatggacta	cctaaggtag	cctacattga	1800
tttgcaaaag	aatcacattg	caataattca	agaccaaaaca	ttcaaattcc	tggaaaaatt	1860
acagaccttg	gatctccgag	acaatgctct	tacaaccatt	cattttattc	caagcatacc	1920
cgatatcttc	ttgagtggca	ataaactagt	gactttgcc	aagatcaacc	ttacagcgaa	1980
cctcatccac	ttatcagaaa	acaggctaga	aaatctagat	attctctact	ttcttctacg	2040
ggtacctcat	ctccagattc	tcattttaaa	tcaaaatcgc	ttctcctcct	gtagtggaga	2100
tcaaaccctt	tcagagaatc	ccagcttaga	acagcttttc	cttgagagaa	atatgttgca	2160
acttgcttgg	gaaactgagc	tctgttggga	tgtttttgag	ggactttctc	atcttcaagt	2220
tctgtatttg	aatcataact	atcttaattc	ccttccacca	ggagtattta	gccatctgac	2280
tgcattaagg	ggactaagcc	tcaactccaa	caggctgaca	gttctttctc	acaatgatth	2340
acctgcta	ttagagatcc	tggacatatc	caggaaccag	ctcctagctc	ctaactctga	2400
tgtatttgta	tcacttagtg	tcttggatat	aactcataac	aagttcattt	gtgaatgtga	2460
acttagcact	tttatcaatt	ggcttaatca	caccaatgtc	actatagctg	ggcctcctgc	2520
agacatat	tgtgtgtacc	ctgactcggt	ctctgggggt	tcctctctct	ctctttccac	2580
ggaagggtgt	gatgaagagg	aagtcttaaa	gtccctaaag	ttctcccttt	tcattgtatg	2640

cactgtcact ctgactctgt tcctcatgac catcctcaca gtcacaaagt tccggggcctt 2700  
 ctgttttatc tgttataaga cagcccagag actggtgttc aaggaccatc cccagggcac 2760  
 agaacctgat atgtacaaat atgatgccta tttgtgcttc agcagcaaag acttcacatg 2820  
 ggtgcagaat gctttgctca aacacctgga cactcaatac agtgaccaa acagattcaa 2880  
 cctgtgcttt gaagaaagag actttgtccc aggagaaaac cgcattgccca atatccagga 2940  
 tgccatctgg aacagtagaa agatcgtttg tcttgtgagc agacacttcc ttagagatgg 3000  
 ctggtgcctt gaagccttca gttatgccca gggcaggtgc ttatctgacc ttaacagtgc 3060  
 tctcatcatg gtggtggttg ggtccttgtc ccagtaccag ttgatgaaac atcaatccat 3120  
 cagaggcttt gtacagaaac agcagtatct gaggtggcct gaggatctcc aggatggttg 3180  
 ctggtttctt cataaactct ctcaacagat actaaagaaa gaaaaagaaa agaagaaaga 3240  
 caataacatt ccgttgcaaa ctgtagcaac catctcctaa tcaaaggagc aatttccaac 3300  
 ttatctcaag ccacaaataa ctcttcactt tgtatttgca ccaagttatc attttgggggt 3360  
 cctctctgga ggtttttttt ttctttttgc tactatgaaa acaacataaa tctctcaatt 3420  
 ttcgtatcaa a 3431

<210> 26  
 <211> 858  
 <212> PRT  
 <213> Homo sapiens

<400> 26

Met Gly Asp His Leu Asp Leu Leu Leu Gly Val Val Leu Met Ala Gly  
 1 5 10 15  
 Pro Val Phe Gly Ile Pro Ser Cys Ser Phe Asp Gly Arg Ile Ala Phe  
 20 25 30  
 Tyr Arg Phe Cys Asn Leu Thr Gln Val Pro Gln Val Leu Asn Thr Thr  
 35 40 45  
 Glu Arg Leu Leu Leu Ser Phe Asn Tyr Ile Arg Thr Val Thr Ala Ser  
 50 55 60  
 Ser Phe Pro Phe Leu Glu Gln Leu Gln Leu Leu Glu Leu Gly Ser Gln  
 65 70 75 80  
 Tyr Thr Pro Leu Thr Ile Asp Lys Glu Ala Phe Arg Asn Leu Pro Asn  
 85 90 95  
 Leu Arg Ile Leu Asp Leu Gly Ser Ser Lys Ile Tyr Phe Leu His Pro  
 100 105 110  
 Asp Ala Phe Gln Gly Leu Phe His Leu Phe Glu Leu Arg Leu Tyr Phe  
 115 120 125  
 Cys Gly Leu Ser Asp Ala Val Leu Lys Asp Gly Tyr Phe Arg Asn Leu

130 135 140  
 Lys Ala Leu Thr Arg Leu Asp Leu Ser Lys Asn Gln Ile Arg Ser Leu  
 145 150 155 160  
 Tyr Leu His Pro Ser Phe Gly Lys Leu Asn Ser Leu Lys Ser Ile Asp  
 165 170 175  
 Phe Ser Ser Asn Gln Ile Phe Leu Val Cys Glu His Glu Leu Glu Pro  
 180 185 190  
 Leu Gln Gly Lys Thr Leu Ser Phe Phe Ser Leu Ala Ala Asn Ser Leu  
 195 200 205  
 Tyr Ser Arg Val Ser Val Asp Trp Gly Lys Cys Met Asn Pro Phe Arg  
 210 215 220  
 Asn Met Val Leu Glu Ile Leu Asp Val Ser Gly Asn Gly Trp Thr Val  
 225 230 235 240  
 Asp Ile Thr Gly Asn Phe Ser Asn Ala Ile Ser Lys Ser Gln Ala Phe  
 245 250 255  
 Ser Leu Ile Leu Ala His His Ile Met Gly Ala Gly Phe Gly Phe His  
 260 265 270  
 Asn Ile Lys Asp Pro Asp Gln Asn Thr Phe Ala Gly Leu Ala Arg Ser  
 275 280 285  
 Ser Val Arg His Leu Asp Leu Ser His Gly Phe Val Phe Ser Leu Asn  
 290 295 300  
 Ser Arg Val Phe Glu Thr Leu Lys Asp Leu Lys Val Leu Asn Leu Ala  
 305 310 315 320  
 Tyr Asn Lys Ile Asn Lys Ile Ala Asp Glu Ala Phe Tyr Gly Leu Asp  
 325 330 335  
 Asn Leu Gln Val Leu Asn Leu Ser Tyr Asn Leu Leu Gly Glu Leu Tyr  
 340 345 350  
 Ser Ser Asn Phe Tyr Gly Leu Pro Lys Val Ala Tyr Ile Asp Leu Gln  
 355 360 365  
 Lys Asn His Ile Ala Ile Ile Gln Asp Gln Thr Phe Lys Phe Leu Glu  
 370 375 380  
 Lys Leu Gln Thr Leu Asp Leu Arg Asp Asn Ala Leu Thr Thr Ile His  
 385 390 395 400  
 Phe Ile Pro Ser Ile Pro Asp Ile Phe Leu Ser Gly Asn Lys Leu Val  
 405 410 415  
 Thr Leu Pro Lys Ile Asn Leu Thr Ala Asn Leu Ile His Leu Ser Glu  
 420 425 430  
 Asn Arg Leu Glu Asn Leu Asp Ile Leu Tyr Phe Leu Leu Arg Val Pro  
 435 440 445  
 His Leu Gln Ile Leu Ile Leu Asn Gln Asn Arg Phe Ser Ser Cys Ser  
 450 455 460  
 Gly Asp Gln Thr Pro Ser Glu Asn Pro Ser Leu Glu Gln Leu Phe Leu



465                      470                      475                      480  
 Gly Glu Asn Met Leu Gln Leu Ala Trp Glu Thr Glu Leu Cys Trp Asp  
                                  485                      490                      495  
  
 Val Phe Glu Gly Leu Ser His Leu Gln Val Leu Tyr Leu Asn His Asn  
                                  500                      505                      510  
  
 Tyr Leu Asn Ser Leu Pro Pro Gly Val Phe Ser His Leu Thr Ala Leu  
                                  515                      520                      525  
  
 Arg Gly Leu Ser Leu Asn Ser Asn Arg Leu Thr Val Leu Ser His Asn  
                                  530                      535                      540  
  
 Asp Leu Pro Ala Asn Leu Glu Ile Leu Asp Ile Ser Arg Asn Gln Leu  
 545                                   550                      555                      560  
  
 Leu Ala Pro Asn Pro Asp Val Phe Val Ser Leu Ser Val Leu Asp Ile  
                                  565                      570                      575  
  
 Thr His Asn Lys Phe Ile Cys Glu Cys Glu Leu Ser Thr Phe Ile Asn  
                                  580                      585                      590  
  
 Trp Leu Asn His Thr Asn Val Thr Ile Ala Gly Pro Pro Ala Asp Ile  
                                  595                      600                      605  
  
 Tyr Cys Val Tyr Pro Asp Ser Phe Ser Gly Val Ser Leu Phe Ser Leu  
                                  610                      615                      620  
  
 Ser Thr Glu Gly Cys Asp Glu Glu Glu Val Leu Lys Ser Leu Lys Phe  
 625                                   630                      635                      640  
  
 Ser Leu Phe Ile Val Cys Thr Val Thr Leu Thr Leu Phe Leu Met Thr  
                                  645                      650                      655  
  
 Ile Leu Thr Val Thr Lys Phe Arg Gly Phe Cys Phe Ile Cys Tyr Lys  
                                  660                      665                      670  
  
 Thr Ala Gln Arg Leu Val Phe Lys Asp His Pro Gln Gly Thr Glu Pro  
                                  675                      680                      685  
  
 Asp Met Tyr Lys Tyr Asp Ala Tyr Leu Cys Phe Ser Ser Lys Asp Phe  
                                  690                      695                      700  
  
 Thr Trp Val Gln Asn Ala Leu Leu Lys His Leu Asp Thr Gln Tyr Ser  
 705                                   710                      715                      720  
  
 Asp Gln Asn Arg Phe Asn Leu Cys Phe Glu Glu Arg Asp Phe Val Pro  
                                  725                      730                      735  
  
 Gly Glu Asn Arg Ile Ala Asn Ile Gln Asp Ala Ile Trp Asn Ser Arg  
                                  740                      745                      750  
  
 Lys Ile Val Cys Leu Val Ser Arg His Phe Leu Arg Asp Gly Trp Cys  
                                  755                      760                      765  
  
 Leu Glu Ala Phe Ser Tyr Ala Gln Gly Arg Cys Leu Ser Asp Leu Asn  
                                  770                      775                      780  
  
 Ser Ala Leu Ile Met Val Val Val Gly Ser Leu Ser Gln Tyr Gln Leu  
 785                                   790                      795                      800  
  
 Met Lys His Gln Ser Ile Arg Gly Phe Val Gln Lys Gln Gln Tyr Leu

805 810 815  
 Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu His Lys Leu  
 820 825 830  
 Ser Gln Gln Ile Leu Lys Lys Glu Lys Glu Lys Lys Lys Asp Asn Asn  
 835 840 845  
 Ile Pro Leu Gln Thr Val Ala Thr Ile Ser  
 850 855

<210> 27  
 <211> 858  
 <212> PRT  
 <213> Homo sapiens

<400> 27

Met Gly Asp His Leu Asp Leu Leu Leu Gly Val Val Leu Met Ala Gly  
 1 5 10 15  
 Pro Val Phe Gly Ile Pro Ser Cys Ser Phe Asp Gly Arg Ile Ala Phe  
 20 25 30  
 Tyr Arg Phe Cys Asn Leu Thr Gln Val Pro Gln Val Leu Asn Thr Thr  
 35 40 45  
 Glu Arg Leu Leu Leu Ser Phe Asn Tyr Ile Arg Thr Val Thr Ala Ser  
 50 55 60  
 Ser Phe Pro Phe Leu Glu Gln Leu Gln Leu Leu Glu Leu Gly Ser Gln  
 65 70 75 80  
 Tyr Thr Pro Leu Thr Ile Asp Lys Glu Ala Phe Arg Asn Leu Pro Asn  
 85 90 95  
 Leu Arg Ile Leu Asp Leu Gly Ser Ser Lys Ile Tyr Phe Leu His Pro  
 100 105 110  
 Asp Ala Phe Gln Gly Leu Phe His Leu Phe Glu Leu Arg Leu Tyr Phe  
 115 120 125  
 Cys Gly Leu Ser Asp Ala Val Leu Lys Asp Gly Tyr Phe Arg Asn Leu  
 130 135 140  
 Lys Ala Leu Thr Arg Leu Asp Leu Ser Lys Asn Gln Ile Arg Ser Leu  
 145 150 155 160  
 Tyr Leu His Pro Ser Phe Gly Lys Leu Asn Ser Leu Lys Ser Ile Asp  
 165 170 175  
 Phe Ser Ser Asn Gln Ile Phe Leu Val Cys Glu His Glu Leu Glu Pro  
 180 185 190  
 Leu Gln Gly Lys Thr Leu Ser Phe Phe Ser Leu Ala Ala Asn Ser Leu  
 195 200 205  
 Tyr Ser Arg Val Ser Val Asp Trp Gly Lys Cys Met Asn Pro Phe Arg  
 210 215 220  
 Asn Met Val Leu Glu Ile Val Asp Val Ser Gly Asn Gly Trp Thr Val  
 225 230 235 240

Asp Ile Thr Gly Asn Phe Ser Asn Ala Ile Ser Lys Ser Gln Ala Phe  
 245 250 255  
 Ser Leu Ile Leu Ala His His Ile Met Gly Ala Gly Phe Gly Phe His  
 260 265 270  
 Asn Ile Lys Asp Pro Asp Gln Asn Thr Phe Ala Gly Leu Ala Arg Ser  
 275 280 285  
 Ser Val Arg His Leu Asp Leu Ser His Gly Phe Val Phe Ser Leu Asn  
 290 295 300  
 Ser Arg Val Phe Glu Thr Leu Lys Asp Leu Lys Val Leu Asn Leu Ala  
 305 310 315 320  
 Tyr Asn Lys Ile Asn Lys Ile Ala Asp Glu Ala Phe Tyr Gly Leu Asp  
 325 330 335  
 Asn Leu Gln Val Leu Asn Leu Ser Tyr Asn Leu Leu Gly Glu Leu Cys  
 340 345 350  
 Ser Ser Asn Phe Tyr Gly Leu Pro Lys Val Ala Tyr Ile Asp Leu Gln  
 355 360 365  
 Lys Asn His Ile Ala Ile Ile Gln Asp Gln Thr Phe Lys Phe Leu Glu  
 370 375 380  
 Lys Leu Gln Thr Leu Asp Leu Arg Asp Asn Ala Leu Thr Thr Ile His  
 385 390 395 400  
 Phe Ile Pro Ser Ile Pro Asp Ile Phe Leu Ser Gly Asn Lys Leu Val  
 405 410 415  
 Thr Leu Pro Lys Ile Asn Leu Thr Ala Asn Leu Ile His Leu Ser Glu  
 420 425 430  
 Asn Arg Leu Glu Asn Leu Asp Ile Leu Tyr Phe Leu Leu Arg Val Pro  
 435 440 445  
 His Leu Gln Ile Leu Ile Leu Asn Gln Asn Arg Phe Ser Ser Cys Ser  
 450 455 460  
 Gly Asp Gln Thr Pro Ser Glu Asn Pro Ser Leu Glu Gln Leu Phe Leu  
 465 470 475 480  
 Gly Glu Asn Met Leu Gln Leu Ala Trp Glu Thr Glu Leu Cys Trp Asp  
 485 490 495  
 Val Phe Glu Gly Leu Ser His Leu Gln Val Leu Tyr Leu Asn His Asn  
 500 505 510  
 Tyr Leu Asn Ser Leu Pro Pro Gly Val Phe Ser His Leu Thr Ala Leu  
 515 520 525  
 Arg Gly Leu Ser Leu Asn Ser Asn Arg Leu Thr Val Leu Ser His Asn  
 530 535 540  
 Asp Leu Pro Ala Asn Leu Glu Ile Leu Asp Ile Ser Arg Asn Gln Leu  
 545 550 555 560  
 Leu Ala Pro Asn Pro Asp Val Phe Val Ser Leu Ser Val Leu Asp Ile

```

      565      570      575
Thr His Asn Lys Phe Ile Cys Glu Cys Glu Leu Ser Thr Phe Ile Asn
      580      585      590

Trp Leu Asn His Thr Asn Val Thr Ile Ala Gly Pro Pro Ala Asp Ile
      595      600      605

Tyr Cys Val Tyr Pro Asp Ser Phe Ser Gly Val Ser Leu Phe Ser Leu
      610      615      620

Ser Thr Glu Gly Cys Asp Glu Glu Glu Val Leu Lys Ser Leu Lys Phe
      625      630      635      640

Ser Leu Phe Ile Val Cys Thr Val Thr Leu Thr Leu Phe Leu Met Thr
      645      650      655

Ile Leu Thr Val Thr Lys Phe Arg Gly Phe Cys Phe Ile Cys Tyr Lys
      660      665      670

Thr Ala Gln Arg Leu Val Phe Lys Asp His Pro Gln Gly Thr Glu Pro
      675      680      685

Asp Met Tyr Lys Tyr Asp Ala Tyr Leu Cys Phe Ser Ser Lys Asp Phe
      690      695      700

Thr Trp Val Gln Asn Ala Leu Leu Lys His Leu Asp Thr Gln Tyr Ser
      705      710      715      720

Asp Gln Asn Arg Phe Asn Leu Cys Phe Glu Glu Arg Asp Phe Val Pro
      725      730      735

Gly Glu Asn Arg Ile Ala Asn Ile Gln Asp Ala Ile Trp Asn Ser Arg
      740      745      750

Lys Ile Val Cys Leu Val Ser Arg His Phe Leu Arg Asp Gly Trp Cys
      755      760      765

Leu Glu Ala Phe Ser Tyr Ala Gln Gly Arg Cys Leu Ser Asp Leu Asn
      770      775      780

Ser Ala Leu Ile Met Val Val Val Gly Ser Leu Ser Gln Tyr Gln Leu
      785      790      795      800

Met Lys His Gln Ser Ile Arg Gly Phe Val Gln Lys Gln Gln Tyr Leu
      805      810      815

Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu His Lys Leu
      820      825      830

Ser Gln Gln Ile Leu Lys Lys Glu Lys Glu Lys Lys Lys Asp Asn Asn
      835      840      845

Ile Pro Leu Gln Thr Val Ala Thr Ile Ser
      850      855

```

&lt;210&gt; 28

&lt;211&gt; 365

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 28

Cys Trp Asp Val Phe Glu Gly Leu Ser His Leu Gln Val Leu Tyr Leu  
 1 5 10 15  
 Asn His Asn Tyr Leu Asn Ser Leu Pro Pro Gly Val Phe Ser His Leu  
 20 25 30  
 Thr Ala Leu Arg Gly Leu Ser Leu Asn Ser Asn Arg Leu Thr Val Leu  
 35 40 45  
 Ser His Asn Asp Leu Pro Ala Asn Leu Glu Ile Leu Asp Ile Ser Arg  
 50 55 60  
 Asn Gln Leu Leu Ala Pro Asn Pro Asp Val Phe Val Ser Leu Ser Val  
 65 70 75 80  
 Leu Asp Ile Thr His Asn Lys Phe Ile Cys Glu Cys Glu Leu Ser Thr  
 85 90 95  
 Phe Ile Asn Trp Leu Asn His Thr Asn Val Thr Ile Ala Gly Pro Pro  
 100 105 110  
 Ala Asp Ile Tyr Cys Val Tyr Pro Asp Ser Phe Ser Gly Val Ser Leu  
 115 120 125  
 Phe Ser Leu Ser Thr Glu Gly Cys Asp Glu Glu Glu Val Leu Lys Ser  
 130 135 140  
 Leu Lys Phe Ser Leu Phe Ile Val Cys Thr Val Thr Leu Thr Leu Phe  
 145 150 155 160  
 Leu Met Thr Ile Leu Thr Val Thr Lys Phe Arg Gly Phe Cys Phe Ile  
 165 170 175  
 Cys Tyr Lys Thr Ala Gln Arg Leu Val Phe Lys Asp His Pro Gln Gly  
 180 185 190  
 Thr Glu Pro Asp Met Tyr Lys Tyr Asp Ala Tyr Leu Cys Phe Ser Ser  
 195 200 205  
 Lys Asp Phe Thr Trp Val Gln Asn Ala Leu Leu Lys His Leu Asp Thr  
 210 215 220  
 Gln Tyr Ser Asp Gln Asn Arg Phe Asn Leu Cys Phe Glu Glu Arg Asp  
 225 230 235 240  
 Phe Val Pro Gly Glu Asn Arg Ile Ala Asn Ile Gln Asp Ala Ile Trp  
 245 250 255  
 Asn Ser Arg Lys Ile Val Cys Leu Val Ser Arg His Phe Leu Arg Asp  
 260 265 270  
 Gly Trp Cys Leu Glu Ala Phe Ser Tyr Ala Gln Gly Arg Cys Leu Ser  
 275 280 285  
 Asp Leu Asn Ser Ala Leu Ile Met Val Val Val Gly Ser Leu Ser Gln  
 290 295 300  
 Tyr Gln Leu Met Lys His Gln Ser Ile Arg Gly Phe Val Gln Lys Gln  
 305 310 315 320  
 Gln Tyr Leu Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu

				325					330					335		
His	Lys	Leu	Ser	Gln	Gln	Ile	Leu	Lys	Lys	Glu	Lys	Glu	Lys	Lys	Lys	
			340					345					350			
Asp	Asn	Asn	Ile	Pro	Leu	Gln	Thr	Val	Ala	Thr	Ile	Ser				
		355					360					365				

<210>	29
<211>	4286
<212>	DNA
<213>	murine

<400>	29
ttgaaatctc acagcccgggt tggttgcagt gaccacttc gttgaacata ttcttcctaa	60
tcctagtact ttcaatttg ctcattccct ggtgtctatg catttaaatc gactatgggg	120
ccattotttc ttgaaccacc acagaagaca ttagctctct gggatccttg ttaatttttt	180
ctctctttac atagcaccta cgcttggaac atatgccaga cacatctgtg agacacctt	240
tgccgctgca gctcatggat ggatgctgag ttccccacg caccacactt cagcaggagg	300
gtgtatttct gcttcacatt atactccac acggccatgc atgtcaggca tggagcaggc	360
tcataacca cttaattaag gtgatcata cagatccttt atcaagatgc atagagtgt	420
cagtgcctgt actatgatct cggatccttg ggagatgggc tagatagagt ctgggacaga	480
atacagcaga gaaaccgata tgttttattgt ccgatcatca gctaagcttc tgggagctag	540
gaatggggct ccttg gatga acagaagtaa aaatgcctcg tctttatgac tttcaacttc	600
cctcagcagg tctggaatgg gtgaacaaac actgcctgcg tgggtgataa atagcctctt	660
tttgtctgtt gtttgtgtgt tttatggttc tgggagggaa cctagaacct agcacatgt	720
agacaagtcc tctagcactg agctatctcc ccagcttgga tgaaatatct gttaaagtact	780
ggtgcccgty tgtaaaaatat gcaccattaa gtgttcaaga agaaaagact gggcatttct	840
gttccaccaa gacaagaaga atctgccagc agaattgttg cgcagtcatt tgagcaaagg	900
ggtccaaggy acagtacct ccagtgttg ggacccatgt gccgagctc aggctgtgat	960
gtggtgttgt, ttttaattct ctcttttccc ataggatcat ggcagtcaa cttgacttgc	1020
tcatagggtgt gatcttcatt gccagccccg tgttggtaat atctccctgt tcttcagacg	1080
gcaggatagc ctttttccga ggctgtaacc tcaccagat tccctggatc ctcaatacta	1140
ccactgagag gtcctgtct agcttcaact atatcagtat ggtgggtgcc acatcatttc	1200
cactcctgga ggggtccag ttgctggagc tggggacca gtatgctaac ttgaccattg	1260
gtccaggggc tttcagaaac ctgccaatc ttaggatctt ggacttgggc caaagccaga	1320
togaagtctt gaatcgagat, gcctttcaag gtctgcccc tctcttgga cttcggctgt	1380
tttctgttg actctccagt gctgtgttaa gtgacggtta cttcagaaat ctatattcat	1440

tagctcgctt agacctatct ggcaaccaga ttcacagcct ccgcctccat tcttcattcc	1500
gggaactgaa ttccttaagc gacgtaaatt ttgctttcaa ccaaattattc actatatgtg	1560
aagatgaact cgagcctctg cagggcaaaa cactgtcttt ctttggcctc aaattaacta	1620
agctgttcag cagagtctct gtgggctggg agacatgcag gaaccccttc agaggcgtga	1680
ggctagaaac tctagatctt tctgaaaatg gctggacggt ggacatcaca aggaacttca	1740
gcaacatcat ccaggggaagc cagatttcct ctttgattct taaacaccac atcatgggtc	1800
ctggctttgg cttccagaac atcagagatc ctgaccagag cacatttgcc agcctggcca	1860
gaagttcggg gctgcaactg gacctttcgc acggctttat cttctccttg aatcctcgac	1920
tgtttgggac actgaaggat ttgaagatgc tgaaccttgc cttcaacaag ataaacaaga	1980
ttggagagaa tgccttttat gggcttgaca gcctccaggt tctcaatcta tcctataatc	2040
ttttggggga actctataat tccaacttct atgggcttcc tagagtagcc tacgttgacc	2100
ttcaaaggaa ccacattggg atcattcaag accaaacatt cagattatta aaaacgttac	2160
aaaccttaga tctccgtgac aatgctotta aggccattgg ttttattcca agcatacaga	2220
tggtcctcct gggaggcaat aagctgggtc atttgccaca catccacttt actgccaaact	2280
tcctagagtt atctgaaaac aggctagaaa acctgtccga cctctacttc ctctgcgag	2340
tccccagct ccagtttctc atcttgaatc agaatcgctt ttcgtcatgc aaggcagccc	2400
acactccctc ggagaacca agcttagaac agcttttctt tacagagaat atgctgcagc	2460
tggcctggga gaccggcctc tgttgggatg tttttcaagg cctttccgc ctccagattc	2520
tttacctgag taataactac cttaatttcc ttccacctgg gataattaac gacctggtg	2580
cattacggat gcttagtctt agtgctaaca agctgaccgt gctctctccg ggcagtttac	2640
ctgctaattt agagattctc gacatatcta gaaatcagct tttgtgtcct gaccctgctt	2700
tgttttcttc gcttcgtgtt ttggacataa ctcataacga gttcgtctgc aactgtgaac	2760
ttagcacttt tatctcctgg ctcaaccaa ccaacgtcac cctgttcggc tctcctgcag	2820
acgtgtattg catgtaccct aactcactgc tagggggctc cctctacaac atatccaccg	2880
aagactgcga tgaagaggaa gccatgcggt ccctaaagtt ttcccttttc atcctgtgca	2940
cggtcacttt gactctattc ctcgatcatc ccctttagt cataaagttc cggggaatct	3000
gtttcctgtg ctataagacc atccagaagc tgggtgtcaa ggacaaggtc tggagtttgg	3060
aacctggtgc atatagatat gatgcctact tctgcttcag cagcaaagac tttgaatggg	3120
cacagaatgc tttgctcaaa cacctggatg ctactacag ttcccgaac aggctcaggc	3180
tatgctttga agaaagagac ttcatcccg gggaaaacca tatctccaac atccaggcgg	3240
ctgtctgggg cagcaggaag acggtgtgtc tagtgagcag acacttcctg aaggatggtt	3300
ggtgcctgga ggccttcagg tatgccaga gccggagtct gtctgacctc aagagcatte	3360

```

tcatcgtggt ggtggtggga tcgctgtccc agtatcagct gatgagacat gagaccatca 3420
gaggggtttct gcaaaagcaa cagtacttga ggtggcctga agacctccag gatgttggct 3480
ggtttctcga taaactctcc ggatgcattc taaaggaaga aaaaggaaag aaaagaagca 3540
gttccatcca gttgcgaacc atagcaacca tttcctagca ggagcgcctc ctagcagaag 3600
tgcaagcatc gtagataact ctccacgctt tatccgcaca gccgctgggg gtccttccct 3660
ggagtcattt ttctgacaat gaaaacaaca ccaatctctt gatttttcat gtcaacaggg 3720
agctttgtct tctactgtttt ccaaatggaa agtaagaggt ccagaaagct gcctctaagg 3780
gctctcacct gccattgatg tcctttcagg cccaatgaca tggtttccct ccacctatt 3840
gcgtactgtc tgctaccag gtggcaagag caccttggga gaagttacag gcagcttcat 3900
gctttctgtg ctgttcagtt caaaagcagg tgcttgaga atcctgaatt caagcactct 3960
gtagaacatg gacagacaag atgggtcctt ctctggccat aggcagagg gccagttgct 4020
gaggactgct ctactacac ctaagtgcac aagtataag aagttggaca gatagacaga 4080
tagcagcagt cccattgctg tagccagaat gcacttattt cctgttctga ccctgcaggc 4140
ccagcttttg gggaccacag ccatgttctg cacgggacct ctcaacctgg cattcatgcc 4200
ctttcacgac ttagcacagg cctgcccttc tttcttcccc acaactatac aagagctgtt 4260
gcaaccactg aaaaaaaaaa aaaaaa 4286

```

<210> 30  
 <211> 859  
 <212> PRT  
 <213> murine

<400> 30

```

Met Ala Cys Gln Leu Asp Leu Leu Ile Gly Val Ile Phe Met Ala Ser
1           5           10           15

Pro Val Leu Val Ile Ser Pro Cys Ser Ser Asp Gly Arg Ile Ala Phe
20          25          30

Phe Arg Gly Cys Asn Leu Thr Gln Ile Pro Trp Ile Leu Asn Thr Thr
35          40          45

Thr Glu Arg Leu Leu Leu Ser Phe Asn Tyr Ile Ser Met Val Val Ala
50          55          60

Thr Ser Phe Pro Leu Leu Glu Arg Leu Gln Leu Leu Glu Leu Gly Thr
65          70          75          80

Gln Tyr Ala Asn Leu Thr Ile Gly Pro Gly Ala Phe Arg Asn Leu Pro
85          90          95

Asn Leu Arg Ile Leu Asp Leu Gly Gln Ser Gln Ile Glu Val Leu Asn
100         105         110

```



Arg Asp Ala Phe Gln Gly Leu Pro His Leu Leu Glu Leu Arg Leu Phe  
 115 120 125  
 Ser Cys Gly Leu Ser Ser Ala Val Leu Ser Asp Gly Tyr Phe Arg Asn  
 130 135 140  
 Leu Tyr Ser Leu Ala Arg Leu Asp Leu Ser Gly Asn Gln Ile His Ser  
 145 150 155 160  
 Leu Arg Leu His Ser Ser Phe Arg Glu Leu Asn Ser Leu Ser Asp Val  
 165 170 175  
 Asn Phe Ala Phe Asn Gln Ile Phe Thr Ile Cys Glu Asp Glu Leu Glu  
 180 185 190  
 Pro Leu Gln Gly Lys Thr Leu Ser Phe Phe Gly Leu Lys Leu Thr Lys  
 195 200 205  
 Leu Phe Ser Arg Val Ser Val Gly Trp Glu Thr Cys Arg Asn Pro Phe  
 210 215 220  
 Arg Gly Val Arg Leu Glu Thr Leu Asp Leu Ser Glu Asn Gly Trp Thr  
 225 230 235 240  
 Val Asp Ile Thr Arg Asn Phe Ser Asn Ile Ile Gln Gly Ser Gln Ile  
 245 250 255  
 Ser Ser Leu Ile Leu Lys His His Ile Met Gly Pro Gly Phe Gly Phe  
 260 265 270  
 Gln Asn Ile Arg Asp Pro Asp Gln Ser Thr Phe Ala Ser Leu Ala Arg  
 275 280 285  
 Ser Ser Val Leu Gln Leu Asp Leu Ser His Gly Phe Ile Phe Ser Leu  
 290 295 300  
 Asn Pro Arg Leu Phe Gly Thr Leu Lys Asp Leu Lys Met Leu Asn Leu  
 305 310 315 320  
 Ala Phe Asn Lys Ile Asn Lys Ile Gly Glu Asn Ala Phe Tyr Gly Leu  
 325 330 335  
 Asp Ser Leu Gln Val Leu Asn Leu Ser Tyr Asn Leu Leu Gly Glu Leu  
 340 345 350  
 Tyr Asn Ser Asn Phe Tyr Gly Leu Pro Arg Val Ala Tyr Val Asp Leu  
 355 360 365  
 Gln Arg Asn His Ile Gly Ile Ile Gln Asp Gln Thr Phe Arg Leu Leu  
 370 375 380  
 Lys Thr Leu Gln Thr Leu Asp Leu Arg Asp Asn Ala Leu Lys Ala Ile  
 385 390 395 400  
 Gly Phe Ile Pro Ser Ile Gln Met Val Leu Leu Gly Gly Asn Lys Leu  
 405 410 415  
 Val His Leu Pro His Ile His Phe Thr Ala Asn Phe Leu Glu Leu Ser  
 420 425 430  
 Glu Asn Arg Leu Glu Asn Leu Ser Asp Leu Tyr Phe Leu Leu Arg Val

435	440	445
Pro Gln Leu Gln Phe Leu Ile Leu Asn Gln Asn Arg Leu Ser Ser Cys		
450	455	460
Lys Ala Ala His Thr Pro Ser Glu Asn Pro Ser Leu Glu Gln Leu Phe		
465	470	475
480		
Leu Thr Glu Asn Met Leu Gln Leu Ala Trp Glu Thr Gly Leu Cys Trp		
485	490	495
Asp Val Phe Gln Gly Leu Ser Arg Leu Gln Ile Leu Tyr Leu Ser Asn		
500	505	510
Asn Tyr Leu Asn Phe Leu Pro Pro Gly Ile Phe Asn Asp Leu Val Ala		
515	520	525
Leu Arg Met Leu Ser Leu Ser Ala Asn Lys Leu Thr Val Leu Ser Pro		
530	535	540
Gly Ser Leu Pro Ala Asn Leu Glu Ile Leu Asp Ile Ser Arg Asn Gln		
545	550	555
560		
Leu Leu Cys Pro Asp Pro Ala Leu Phe Ser Ser Leu Arg Val Leu Asp		
565	570	575
Ile Thr His Asn Glu Phe Val Cys Asn Cys Glu Leu Ser Thr Phe Ile		
580	585	590
Ser Trp Leu Asn Gln Thr Asn Val Thr Leu Phe Gly Ser Pro Ala Asp		
595	600	605
Val Tyr Cys Met Tyr Pro Asn Ser Leu Leu Gly Gly Ser Leu Tyr Asn		
610	615	620
Ile Ser Thr Glu Asp Cys Asp Glu Glu Glu Ala Met Arg Ser Leu Lys		
625	630	635
640		
Phe Ser Leu Phe Ile Leu Cys Thr Val Thr Leu Thr Leu Phe Leu Val		
645	650	655
Ile Thr Leu Val Val Ile Lys Phe Arg Gly Ile Cys Phe Leu Cys Tyr		
660	665	670
Lys Thr Ile Gln Lys Leu Val Phe Lys Asp Lys Val Trp Ser Leu Glu		
675	680	685
Pro Gly Ala Tyr Arg Tyr Asp Ala Tyr Phe Cys Phe Ser Ser Lys Asp		
690	695	700
Phe Glu Trp Ala Gln Asn Ala Leu Leu Lys His Leu Asp Ala His Tyr		
705	710	715
720		
Ser Ser Arg Asn Arg Leu Arg Leu Cys Phe Glu Glu Arg Asp Phe Ile		
725	730	735
Pro Gly Glu Asn His Ile Ser Asn Ile Gln Ala Ala Val Trp Gly Ser		
740	745	750
Arg Lys Thr Val Cys Leu Val Ser Arg His Phe Leu Lys Asp Gly Trp		
755	760	765
Cys Leu Glu Ala Phe Arg Tyr Ala Gln Ser Arg Ser Leu Ser Asp Leu		

770	775	780
Lys Ser Ile Leu Ile Val Val Val Val Gly Ser Leu Ser Gln Tyr Gln		
785	790	795 800
Leu Met Arg His Glu Thr Ile Arg Gly Phe Leu Gln Lys Gln Gln Tyr		
	805	810 815
Leu Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu Asp Lys		
	820	825 830
Leu Ser Gly Cys Ile Leu Lys Glu Glu Lys Gly Lys Lys Arg Ser Ser		
	835	840 845
Ser Ile Gln Leu Arg Thr Ile Ala Thr Ile Ser		
	850	855

<210> 31  
 <211> 3373  
 <212> DNA  
 <213> Homo sapiens

<400> 31  
 agctggcctag cgttttaaacg ggccctctag actcgagcgg ccgcgaattc actagtgtatt 60  
 cacctctcat gctctgctct cttcaaccag acctctacat tccatttttg aagaagacta 120  
 aaaatgggtgt ttccaatgtg gacactgaag agacaaattc ttatcctttt taacataatc 180  
 ctaattttcca aactccttgg ggctagatgg tttcctaaaa ctctgccctg tgatgtcact 240  
 ctggatgttc caaagaacca tgtgatcgtg gactgcacag acaagcattt gacagaaatt 300  
 cctggaggta ttcccacgaa caccacgaac ctaccctca ccattaacca cataccagac 360  
 atctccccag cgtcctttca cagactggac catctggtag agatcgattt cagatgcaac 420  
 tgtgtacctt ttccactggg gtcaaaaaac aacatgtgca tcaagaggct gcagattaaa 480  
 cccagaagct ttagtggact cacttattta aaatcccttt acctggatgg aaaccagcta 540  
 ctagagatac cgcagggcct ccgcctagc ttacagcttc tcagccttga ggccaacaac 600  
 atctttttcca tcagaaaaga gaatctaaca gaactggcca acatagaaat actctacctg 660  
 ggccaaaact gttattatcg aaatccttgt tatgtttcat attcaataga gaaagatgcc 720  
 ttcttaaaact tgacaaagtt aaaagtgtc tcctgaaag ataacaatgt cacagccgtc 780  
 cctactgttt tgccatctac tttaacagaa ctatatctct acaacaacat gattgcaaaa 840  
 atccaagaag atgattttta taacctcaac caattacaaa ttcttgacct aagtggaaat 900  
 tgccctcggt gttataatgc ccatttctt tgtgcgccgt gtaaaaataa ttctccccta 960  
 cagatccctg taaatgcttt tgatgcgtg acagaattaa aagttttacg tctacacagt 1020  
 aactctcttc agcatgtgcc cccaagatgg tttaagaaca tcaacaaact ccaggaactg 1080  
 gatctgtccc aaaacttctt ggccaaagaa attggggatg cttaaattct gcattttctc 1140  
 cccagcctca tccaattgga tctgtctttc aattttgaac ttcaggtcta tcgtgcatct 1200

atgaatctat cacaagcatt ttcttcactg aaaagcctga aaattctgcg gatcagagga 1260  
tatgtcttta aagagttgaa aagctttaac ctctcgccat tacataatct tcaaaatctt 1320  
gaagttcttg atcttggcac taactttata aaaattgcta acctcagcat gtttaaacia 1380  
tttaaaagac tgaaagtcac agatctttca gtgaataaaa taccaccttc aggagattca 1440  
agtgaagttg gcttctgctc aaatgccaga acttctgtag aaagttatga accccaggctc 1500  
ctggaacaat tacattatct cagatatgat aagtatgcaa ggagttgcag attcaaaaac 1560  
aaagaggctt ctttcatgtc tgttaatgaa agctgctaca agtatgggca gaccttggat 1620  
ctaagtaaaa atagtatatt ttttgtcaag tcctctgatt ttcagcatct ttctttcttc 1680  
aaatgcctga atctgtcagg aaatctcatt agccaaactc ttaatggcag tgaattccaa 1740  
ccttttagcag agctgagata tttggacttc tccaacaacc ggcttgattt actccattca 1800  
acagcatttg aagagcttca caaactggaa gttctggata taagcagtaa tagccattat 1860  
tttcaatcag aaggaattac tcatatgcta aactttacca agaacctaaa ggttctgcag 1920  
aaactgatga tgaacgacaa tgacatctct tcctccacca gcaggacctt ggagagtgcg 1980  
tctcttagaa ctctggaatt cagaggaaat cacttagatg ttttatggag agaagggtgat 2040  
aacagatact tacaattatt caagaatctg ctaaaattag aggaattaga catctctaaa 2100  
aattccctaa gtttcttgcc ttctggagtt tttgatggta tgctccaaa tctaaagaat 2160  
ctctcttttg ccaaaaatgg gctcaaactt ttcatgttga agaaactcca gtgtctaaag 2220  
aacctggaaa ctttggacct cagccacaac caactgacca ctgtccctga gagattatcc 2280  
aactgttcca gaagcctcaa gaatctgatt cttaagaata atcaaatcag gagtctgcg 2340  
aagtattttc tacaagatgc cttccagttg cgatatctgg atctcagctc aaataaaatc 2400  
cagatgatcc aaaagaccag cttccagaaa aatgtcctca acaatctgaa gatgttgcct 2460  
ttgcatcata atcggtttct gtgcacctgt gatgctgtgt ggtttgtctg gtgggttaac 2520  
catacggagg tgactattcc ttacctggcc acagatgtga cttgtgtggg gccaggagca 2580  
cacaagggcc aaagtgtgat ctccctggat ctgtacacct gtgagttaga tctgactaac 2640  
ctgattctgt tctcactttc catatctgta tctctcttcc tcatgggtgat gatgacagca 2700  
agtcacctct atttctggga tgtgtggtat atttaccatt tctgtaaggc caagataaag 2760  
gggtatcagc gtctaataatc accagactgt tgctatgatg cttttattgt gtatgacact 2820  
aaagaccag ctgtgaccga gtgggttttg gctgagctgg tggccaaact ggaagacca 2880  
agagagaaac attttaattt atgtctcgag gaaagggact gggtaccagg gcagccagtt 2940  
ctggaaaacc tttccagag catcacgctt agcaaaaaga cagtgtttgt gatgacagac 3000  
aagtatgcaa agactgaaaa ttttaagata gcattttact tgtcccatca gaggctcatg 3060

gatgaaaaag ttgatgtgat tatcttgata tttcttgaga agccttttca gaagtccaag 3120  
 ttctccagc tccggaaaag gctctgtggg agttctgtcc ttgagtggcc aacaaacccg 3180  
 caagctcacc catacttctg gcagtgtcta aagaacgccc tggccacaga caatcatgtg 3240  
 gcctatagtc aggtgttcaa ggaaacggtc tagaatcgaa tttccgcggc cgccactgtg 3300  
 ctggatatct gcagaattcc accacactgg actagtggat ccgagctcgg taccaagctt 3360  
 aagtttaaac cgc 3373

<210> 32

<211> 3416

<212> DNA

<213> Homo sapiens

<400> 32

tccagatata ggatcactcc atgccatcaa gaaagttgat gctattgggc ccatctcaag 60  
 ctgatcttgg cacctctcat gctctgtctt cttcaaccag acctctacat tccatthtgg 120  
 aagaagacta aaaatgggtgt ttccaatgtg gacactgaag agacaaattc ttatcctttt 180  
 taacataatc ctaattttcca aactccttgg ggctagatgg tttcctaaaa ctctgccctg 240  
 tgatgtcact ctggatgttc caaagaacca tgtgatcgtg gactgcacag acaagcattt 300  
 gacagaaatt cctggaggta tttccacgaa caccacgaac ctacccctca ccattaacca 360  
 cataccagac atctccccag cgtcctttca cagactggac catctggtag agatcgattt 420  
 cagatgcaac tgtgtaccta ttccactggg gtcaaaaaac aacatgtgca tcaagaggct 480  
 gcagattaaa cccagaagct ttagtggact cacttattta aaatcccttt acctggatgg 540  
 aaaccagcta ctagagatac cgcagggcct cccgcctagc ttacagcttc tcagccttga 600  
 ggccaacaac atctttttcca tcagaaaaga gaatctaaca gaactggcca acatagaaat 660  
 actctacctg ggccaaaact gttattatcg aaatccttgt tatgtttcat attcaataga 720  
 gaaagatgcc ttcctaaact tgacaaagtt aaaagtgtc tccctgaaag ataacaatgt 780  
 cacagcogtc cctactgttt tgccatctac tttaacagaa ctatatctct acaacaacat 840  
 gattgcaaaa atccaagaag atgattttta taacctcaac caattacaaa ttcttgacct 900  
 aagtggaaat tgccctcggt gttataatgc ccatttcct tgtgcgcogt gtaaaaataa 960  
 ttctccccta cagatccctg taaatgcttt tgatgcgctg acagaattaa aagttttacg 1020  
 tctacacagt aactctcttc agcatgtgcc cccaagatgg ttttaagaaca tcaacaaact 1080  
 ccagggaactg gatctgtccc aaaacttctt ggccaaagaa attggggatg ctaaaattct 1140  
 gcattttctc cccagcctca tccaattgga tctgtctttc aattttgaac ttcaggtcta 1200  
 tcgtgcatct atgaatctat cacaagcatt ttcttcactg aaaagcctga aaattctgcg 1260

gatcagagga	tatgtcttta	aagagttgaa	aagctttaac	ctctcgccat	tacataatct	1320
tcaaaatctt	gaagttcttg	atcttggcac	taactttata	aaaattgcta	acctcagcat	1380
gtttaaacia	tttaaaagac	tgaaagtcac	agatctttca	gtgaataaaa	tatcaccttc	1440
aggagattca	agtgaagttg	gcttctgctc	aaatgccaga	acttctgtag	aaagttatga	1500
accccaggtc	ctggaacaat	tacattatct	cagatatgat	aagtatgcaa	ggagttgcag	1560
attcaaaaac	aaagaggctt	ctttcatgtc	tgtaaatgaa	agctgctaca	agtatgggca	1620
gaccttggat	ctaagtaaaa	atagtatatt	ttttgtcaag	tcctctgatt	ttcagcatct	1680
ttctttcttc	aaatgcctga	atctgtcagg	aaatctcatt	agccaaactc	ttaatggcag	1740
tgaattccaa	ccttttagcag	agttgagata	tttggacttc	tccaacaacc	ggcttgattt	1800
actccattca	acagcatttg	aagagcttca	caaactggaa	gttctggata	taagcagtaa	1860
tagccattat	tttcaatcag	aaggaattac	tcatatgcta	aactttacca	agaacctaaa	1920
ggttctgcag	aaactgatga	tgaacgacaa	tgacatctct	tcctccacca	gcaggaccat	1980
ggagagttag	tctcttagaa	ctctggaatt	cagaggaaat	cacttagatg	ttttatggag	2040
agaagggtgat	aacagatact	tacaattatt	caagaatctg	ctaaaattag	aggaattaga	2100
catctctaaa	aattccctaa	gtttcttgcc	ttctggagtt	tttgatggta	tgctcccaaa	2160
tctaaagaat	ctctcttttg	ccaaaaatgg	gctcaaactc	ttcagttgga	agaaactcca	2220
gtgtctaaag	aacctggaaa	ctttggacct	cagccacaac	caactgacca	ctgtccctga	2280
gagattatcc	aactgttcca	gaagccacaa	gaatctgatt	cttaagaata	atcaaatcag	2340
gagtccgacg	aagtattttc	tacaagatgc	cttccagttg	cgatatctgg	atctcagctc	2400
aaataaaaatc	cagatgatcc	aaaagaccag	cttcccagaa	aatgtcctca	acaatctgaa	2460
gatgttgctt	ttgcatcata	atcggtttct	gtgcacctgt	gatgctgtgt	ggtttgtctg	2520
gtgggttaac	catacggagg	tgactattcc	ttacctggcc	acagatgtga	cttgtgtggg	2580
gccaggagca	cacaagggcc	aaagtgtgat	ctccctggat	ctgtacacct	gtgagttaga	2640
tctgactaac	ctgattctgt	tctcactttc	catatctgta	tctctctttc	tcatgggtgat	2700
gatgacagca	agtcacctct	atctctggga	tgtgtgggtat	atttaccatt	tctgtaaggc	2760
caagataaag	gggtatcagc	gtctaatatc	accagactgt	tgctatgatg	cttttattgt	2820
gtatgacact	aaagaccag	ctgtgaccga	gtgggttttg	gctgagctgg	tggccaaact	2880
ggaagaccca	agagagaaac	attttaattt	atgtctcgag	gaaagggact	ggttaccagg	2940
gcagccagtt	ctggaaaacc	tttcccagag	catacagctt	agcaaaaaga	cagtgtttgt	3000
gatgacagac	aagtatgcaa	agactgaaaa	ttttaagata	gcattttact	tgccccatca	3060
gaggctcatg	gatgaaaaag	ttgatgtgat	tatcttgata	tttcttgaga	agccctttca	3120
gaagtccaag	ttctccagc	tccggaaaag	gctctgtggg	agttctgtcc	ttgagtggcc	3180

aacaaacccg caagctcacc catacttctg gcagtgtcta aagaacgccc tggccacaga 3240  
caatcatgtg gcctatagtc aggtgttcaa ggaaacggtc tagcccttct ttgcaaaaca 3300  
caactgccta gtttaccaag gagaggcctg gctgtttaaa ttgttttcat atatatcaca 3360  
ccaaaagcgt gttttgaaat tcttcaagaa atgagattgc ccatatttca ggggag 3416

<210> 33

<211> 3418

<212> DNA

<213> Homo sapiens

<400> 33

actccagata taggatcact ccatgccatc aagaaagttg atgctattgg gcccatctca 60  
agctgatctt ggcacctctc atgctctgct ctcttcaacc agacctctac attccatttt 120  
ggaagaagac taaaaatggg gtttccaatg tggacactga agagacaaat tcttatcctt 180  
tttaacataa tcctaatttc caaactcctt ggggctagat ggtttcctaa aactctgccc 240  
tgtgatgtca ctctggatgt tccaaagaac catgtgatcg tggactgcac agacaagcat 300  
ttgacagaaa ttcttgaggg tattcccacg aacaccacga acctcaccct caccattaac 360  
cacataccag acatctcccc agcgtccttt cacagactgg accatctggg agagatcgat 420  
ttcagatgca actgtgtacc tattccactg ggggtcaaaaa acaacatgtg catcaagagg 480  
ctgcagatta aaccagaag ctttagtgga ctcaattatt taaaatccct ttacctggat 540  
ggaaaccagc tactagagat accgcagggc ctcccgcta gcttacagct tctcagcctt 600  
gaggccaaca acatcttttc catcagaaaa gagaatctaa cagaactggc caacatagaa 660  
atactctacc tgggccaaaa ctgttattat cgaaatcctt gttatgtttc atattcaata 720  
gagaaagatg ccttcctaaa cttgacaaag ttaaaagtgc tctccctgaa agataacaat 780  
gtcacagccg tccctactgt ttgcatctt actttaacag aactatatct ctacaacaac 840  
atgattgcaa aaatccaaga agatgatttt aataacctca accaattaca aattcttgac 900  
ctaagtggaa attgcctctg ttgttataat gccccatttc cttgtgcgcc gtgtaaaaat 960  
aattctcccc tacagatccc tgtaaatgct tttgatgcgc tgacagaatt aaaagtttta 1020  
cgtctacaca gtaactctct tcagcatgtg cccccaagat ggtttaagaa catcaacaaa 1080  
ctccaggaac tggatctgtc ccaaaacttc ttggccaaag aaattgggga tgctaaattt 1140  
ctgcattttc tccccagcct catccaattg gatctgtctt tcaattttga acttcaggtc 1200  
tatcgtgcat ctatgaatct atcacaagca ttttcttcac tgaaaagcct gaaaattctg 1260  
cggatcagag gatatgtctt taaagagttg aaaagcttta acctctcgcc attacataat 1320  
cttcaaaatc ttgaagttct tgatcttggc actaacttta taaaaattgc taacctcagc 1380

atgtttaaac aatttaaaag actgaaagtc atagatcttt cagtgaataa aatatcacct	1440
tcaggagatt caagtgaagt tggcttctgc tcaaattgcc gaacttctgt agaaagtat	1500
gaacccagg tcctggaaca attacattat ttcagatatg ataagtatgc aaggagttgc	1560
agattcaaaa acaaagaggc ttctttcatg tctgttaatg aaagctgcta caagtatggg	1620
cagaccttgg atctaagtaa aaatagtata ttttttgtca agtcctctga ttttcagcat	1680
ctttctttcc tcaaattgcct gaatctgtca ggaaatctca ttagccaaac tcttaatggc	1740
agtgaattcc aacctttagc agagctgaga tatttggact tctccaacaa ccggcttgat	1800
ttactccatt caacagcatt tgaagagctt cacaaactgg aagttctgga tataagcagt	1860
aatagccatt attttcaatc agaaggaatt actcatatgc taaactttac caagaacct	1920
aaggttctgc agaaactgat gatgaacgac aatgacatct cttcctccac cagcaggacc	1980
atggagagtg agtctcttag aactctggaa ttcagaggaa atcacttaga tgttttatgg	2040
agagaagtg ataacagata cttacaatta ttcaagaatc tgctaaaatt agaggaatta	2100
gacatctcta aaaattccct aagtttcttg ccttctggag tttttgatgg tatgcctcca	2160
aatctaaaga atctctcttt ggccaaaaat gggctcaaat ctttcagttg gaagaaactc	2220
cagtgtctaa agaacctgga aactttggac ctcagccaca accaactgac cactgtccct	2280
gagagattat ccaactgttc cagaagctc agaactctga ttcttaagaa taatcaaatc	2340
aggagtctga cgaagtattt tctacaagat gccttccagt tgcgatatct ggatctcagc	2400
tcaataaaaa tccagatgat ccaaaagacc agcttcccag aaaatgtcct caacaatctg	2460
aagatgttgc ttttgcata taatcggttt ctgtgcacct gtgatgctgt gtggtttgtc	2520
tggtgggtta accatacggg ggtgactatt ccttacctgg ccacagatgt gacttgtgtg	2580
gggccaggag cacacaaggg ccaaagtgtg atctccctgg atctgtacac ctgtgagtta	2640
gatctgacta acctgattct gttctcactt tccatatctg tatctctctt tctcatggtg	2700
atgatgacag caagtcacct ctatttctgg gatgtgtggt atatttacca tttctgtaag	2760
gccaagataa aggggtatca gcgtctaata tcaccagact gttgctatga tgcttttatt	2820
gtgtatgaca ctaaagacct agctgtgacc gagtgggttt tggctgagct ggtggccaaa	2880
ctggaagacc caagagagaa acattttaat ttatgtctcg aggaaaggga ctggttacca	2940
gggcagccag ttctggaaaa cctttcccag agcatacagc ttagcaaaaa gacagtgttt	3000
gtgatgacag acaagtatgc aaagactgaa aattttaaga tagcatttta cttgtcccat	3060
cagaggctca tggatgaaaa agttgatgtg attatcttga tatttcttga gaagcccttt	3120
cagaagtcca agttcctcca gctccggaaa aggetctgtg ggagttctgt ccttgagtgg	3180
ccaacaaacc cgcaagctca cccatacttc tggcagtgtc taaagaacgc cctggccaca	3240
gacaatcatg tggcctatag tcaggtgttc aaggaaacgg tctagccctt ctttgcaaaa	3300



cacaactgcc tagtttacca aggagaggcc tggtgttta aattgttttc atatatatca 3360

cacaaaaagc gtgttttgaa attcttcaag aaatgagatt gcccatattt caggggag 3418

<210> 34

<211> 1049

<212> PRT

<213> Homo sapiens

<400> 34

Met Val Phe Pro Met Trp Thr Leu Lys Arg Gln Ile Leu Ile Leu Phe  
1 5 10 15

Asn Ile Ile Leu Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro Lys  
20 25 30

Thr Leu Pro Cys Asp Val Thr Leu Asp Val Pro Lys Asn His Val Ile  
35 40 45

Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Gly Gly Ile Pro  
50 55 60

Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Asp Ile  
65 70 75 80

Ser Pro Ala Ser Phe His Arg Leu Asp His Leu Val Glu Ile Asp Phe  
85 90 95

Arg Cys Asn Cys Val Pro Ile Pro Leu Gly Ser Lys Asn Asn Met Cys  
100 105 110

Ile Lys Arg Leu Gln Ile Lys Pro Arg Ser Phe Ser Gly Leu Thr Tyr  
115 120 125

Leu Lys Ser Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
130 135 140

Gly Leu Pro Pro Ser Leu Gln Leu Leu Ser Leu Glu Ala Asn Asn Ile  
145 150 155 160

Phe Ser Ile Arg Lys Glu Asn Leu Thr Glu Leu Ala Asn Ile Glu Ile  
165 170 175

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Tyr Val Ser  
180 185 190

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Asn Leu Thr Lys Leu Lys Val  
195 200 205

Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Val Leu Pro  
210 215 220

Ser Thr Leu Thr Glu Leu Tyr Leu Tyr Asn Asn Met Ile Ala Lys Ile  
225 230 235 240

Gln Glu Asp Asp Phe Asn Asn Leu Asn Gln Leu Gln Ile Leu Asp Leu  
245 250 255

Ser Gly Asn Cys Pro Arg Cys Tyr Asn Ala Pro Phe Pro Cys Ala Pro

			260						265					270				
Cys	Lys	Asn	Asn	Ser	Pro	Leu	Gln	Ile	Pro	Val	Asn	Ala	Phe	Asp	Ala			
		275					280					285						
Leu	Thr	Glu	Leu	Lys	Val	Leu	Arg	Leu	His	Ser	Asn	Ser	Leu	Gln	His			
	290					295					300							
Val	Pro	Pro	Arg	Trp	Phe	Lys	Asn	Ile	Asn	Lys	Leu	Gln	Glu	Leu	Asp			
305					310					315					320			
Leu	Ser	Gln	Asn	Phe	Leu	Ala	Lys	Glu	Ile	Gly	Asp	Ala	Lys	Phe	Leu			
				325					330					335				
His	Phe	Leu	Pro	Ser	Leu	Ile	Gln	Leu	Asp	Leu	Ser	Phe	Asn	Phe	Glu			
			340					345					350					
Leu	Gln	Val	Tyr	Arg	Ala	Ser	Met	Asn	Leu	Ser	Gln	Ala	Phe	Ser	Ser			
		355					360					365						
Leu	Lys	Ser	Leu	Lys	Ile	Leu	Arg	Ile	Arg	Gly	Tyr	Val	Phe	Lys	Glu			
	370					375					380							
Leu	Lys	Ser	Phe	Asn	Leu	Ser	Pro	Leu	His	Asn	Leu	Gln	Asn	Leu	Glu			
385					390					395					400			
Val	Leu	Asp	Leu	Gly	Thr	Asn	Phe	Ile	Lys	Ile	Ala	Asn	Leu	Ser	Met			
				405					410					415				
Phe	Lys	Gln	Phe	Lys	Arg	Leu	Lys	Val	Ile	Asp	Leu	Ser	Val	Asn	Lys			
			420					425					430					
Ile	Ser	Pro	Ser	Gly	Asp	Ser	Ser	Glu	Val	Gly	Phe	Cys	Ser	Asn	Ala			
		435					440					445						
Arg	Thr	Ser	Val	Glu	Ser	Tyr	Glu	Pro	Gln	Val	Leu	Glu	Gln	Leu	His			
	450					455					460							
Tyr	Phe	Arg	Tyr	Asp	Lys	Tyr	Ala	Arg	Ser	Cys	Arg	Phe	Lys	Asn	Lys			
465					470					475					480			
Glu	Ala	Ser	Phe	Met	Ser	Val	Asn	Glu	Ser	Cys	Tyr	Lys	Tyr	Gly	Gln			
				485					490					495				
Thr	Leu	Asp	Leu	Ser	Lys	Asn	Ser	Ile	Phe	Phe	Val	Lys	Ser	Ser	Asp			
			500					505					510					
Phe	Gln	His	Leu	Ser	Phe	Leu	Lys	Cys	Leu	Asn	Leu	Ser	Gly	Asn	Leu			
		515					520					525						
Ile	Ser	Gln	Thr	Leu	Asn	Gly	Ser	Glu	Phe	Gln	Pro	Leu	Ala	Glu	Leu			
		530				535					540							
Arg	Tyr	Leu	Asp	Phe	Ser	Asn	Asn	Arg	Leu	Asp	Leu	Leu	His	Ser	Thr			
545					550					555					560			
Ala	Phe	Glu	Glu	Leu	His	Lys	Leu	Glu	Val	Leu	Asp	Ile	Ser	Ser	Asn			
				565					570					575				
Ser	His	Tyr	Phe	Gln	Ser	Glu	Gly	Ile	Thr	His	Met	Leu	Asn	Phe	Thr			
			580					585					590					
Lys	Asn	Leu	Lys	Val	Leu	Gln	Lys	Leu	Met	Met	Asn	Asp	Asn	Asp	Ile			

595					600					605				
Ser	Ser	Thr	Ser	Arg	Thr	Met	Glu	Ser	Glu	Ser	Leu	Arg	Thr	Leu
610					615					620				
Glu	Phe	Arg	Gly	Asn	His	Leu	Asp	Val	Leu	Trp	Arg	Glu	Gly	Asp
625					630					635				640
Arg	Tyr	Leu	Gln	Leu	Phe	Lys	Asn	Leu	Leu	Lys	Leu	Glu	Glu	Leu
				645					650					655
Ile	Ser	Lys	Asn	Ser	Leu	Ser	Phe	Leu	Pro	Ser	Gly	Val	Phe	Asp
			660					665						670
Met	Pro	Pro	Asn	Leu	Lys	Asn	Leu	Ser	Leu	Ala	Lys	Asn	Gly	Leu
			675				680						685	Lys
Ser	Phe	Ser	Trp	Lys	Lys	Leu	Gln	Cys	Leu	Lys	Asn	Leu	Glu	Thr
							695					700		Leu
Asp	Leu	Ser	His	Asn	Gln	Leu	Thr	Thr	Val	Pro	Glu	Arg	Leu	Ser
705						710					715			720
Cys	Ser	Arg	Ser	Leu	Lys	Asn	Leu	Ile	Leu	Lys	Asn	Asn	Gln	Ile
				725					730					735
Ser	Leu	Thr	Lys	Tyr	Phe	Leu	Gln	Asp	Ala	Phe	Gln	Leu	Arg	Tyr
				740				745						750
Asp	Leu	Ser	Ser	Asn	Lys	Ile	Gln	Met	Ile	Gln	Lys	Thr	Ser	Phe
				755				760						765
Glu	Asn	Val	Leu	Asn	Asn	Leu	Lys	Met	Leu	Leu	Leu	Leu	His	His
							775							Asn
														Arg
Phe	Leu	Cys	Thr	Cys	Asp	Ala	Val	Trp	Phe	Val	Trp	Trp	Val	Asn
785						790					795			800
Thr	Glu	Val	Thr	Ile	Pro	Tyr	Leu	Ala	Thr	Asp	Val	Thr	Cys	Val
				805					810					815
Pro	Gly	Ala	His	Lys	Gly	Gln	Ser	Val	Ile	Ser	Leu	Asp	Leu	Tyr
				820				825						830
Cys	Glu	Leu	Asp	Leu	Thr	Asn	Leu	Ile	Leu	Phe	Ser	Leu	Ser	Ile
				835				840						845
Val	Ser	Leu	Phe	Leu	Met	Val	Met	Met	Thr	Ala	Ser	His	Leu	Tyr
														Phe
Trp	Asp	Val	Trp	Tyr	Ile	Tyr	His	Phe	Cys	Lys	Ala	Lys	Ile	Lys
865						870					875			880
Tyr	Gln	Arg	Leu	Ile	Ser	Pro	Asp	Cys	Cys	Tyr	Asp	Ala	Phe	Ile
				885					890					895
Tyr	Asp	Thr	Lys	Asp	Pro	Ala	Val	Thr	Glu	Trp	Val	Leu	Ala	Glu
				900					905					910
Val	Ala	Lys	Leu	Glu	Asp	Pro	Arg	Glu	Lys	His	Phe	Asn	Leu	Cys
				915				920						925
Glu	Glu	Arg	Asp	Trp	Leu	Pro	Gly	Gln	Pro	Val	Leu	Glu	Asn	Leu
														Ser

930                      935                      940  
 Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Asp Lys  
 945                      950                      955                      960  
 Tyr Ala Lys Thr Glu Asn Phe Lys Ile Ala Phe Tyr Leu Ser His Gln  
                          965                      970                      975  
 Arg Leu Met Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu Glu  
                          980                      985                      990  
 Lys Pro Phe Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu Cys  
                          995                      1000                      1005  
 Gly Ser Ser Val Leu Glu Trp Pro Thr Asn Pro Gln Ala His Pro  
                          1010                      1015                      1020  
 Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Ala Thr Asp Asn His  
                          1025                      1030                      1035  
 Val Ala Tyr Ser Gln Val Phe Lys Glu Thr Val  
                          1040                      1045

<210> 35  
 <211> 1049  
 <212> PRT  
 <213> Homo sapiens

<400> 35

Met Val Phe Pro Met Trp Thr Leu Lys Arg Gln Ile Leu Ile Leu Phe  
 1                      5                      10                      15  
 Asn Ile Ile Leu Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro Lys  
                          20                      25                      30  
 Thr Leu Pro Cys Asp Val Thr Leu Asp Val Pro Lys Asn His Val Ile  
                          35                      40                      45  
 Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Gly Gly Ile Pro  
                          50                      55                      60  
 Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Asp Ile  
 65                      70                      75                      80  
 Ser Pro Ala Ser Phe His Arg Leu Asp His Leu Val Glu Ile Asp Phe  
                          85                      90                      95  
 Arg Cys Asn Cys Val Pro Ile Pro Leu Gly Ser Lys Asn Asn Met Cys  
                          100                      105                      110  
 Ile Lys Arg Leu Gln Ile Lys Pro Arg Ser Phe Ser Gly Leu Thr Tyr  
                          115                      120                      125  
 Leu Lys Ser Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
                          130                      135                      140  
 Gly Leu Pro Pro Ser Leu Gln Leu Leu Ser Leu Glu Ala Asn Asn Ile  
 145                      150                      155                      160  
 Phe Ser Ile Arg Lys Glu Asn Leu Thr Glu Leu Ala Asn Ile Glu Ile  
                          165                      170                      175

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Tyr Val Ser  
 180 185 190  
 Tyr Ser Ile Glu Lys Asp Ala Phe Leu Asn Leu Thr Lys Leu Lys Val  
 195 200 205  
 Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Val Leu Pro  
 210 215 220  
 Ser Thr Leu Thr Glu Leu Tyr Leu Tyr Asn Asn Met Ile Ala Lys Ile  
 225 230 235 240  
 Gln Glu Asp Asp Phe Asn Asn Leu Asn Gln Leu Gln Ile Leu Asp Leu  
 245 250 255  
 Ser Gly Asn Cys Pro Arg Cys Tyr Asn Ala Pro Phe Pro Cys Ala Pro  
 260 265 270  
 Cys Lys Asn Asn Ser Pro Leu Gln Ile Pro Val Asn Ala Phe Asp Ala  
 275 280 285  
 Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
 290 295 300  
 Val Pro Pro Arg Trp Phe Lys Asn Ile Asn Lys Leu Gln Glu Leu Asp  
 305 310 315 320  
 Leu Ser Gln Asn Phe Leu Ala Lys Glu Ile Gly Asp Ala Lys Phe Leu  
 325 330 335  
 His Phe Leu Pro Ser Leu Ile Gln Leu Asp Leu Ser Phe Asn Phe Glu  
 340 345 350  
 Leu Gln Val Tyr Arg Ala Ser Met Asn Leu Ser Gln Ala Phe Ser Ser  
 355 360 365  
 Leu Lys Ser Leu Lys Ile Leu Arg Ile Arg Gly Tyr Val Phe Lys Glu  
 370 375 380  
 Leu Lys Ser Phe Asn Leu Ser Pro Leu His Asn Leu Gln Asn Leu Glu  
 385 390 395 400  
 Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asn Leu Ser Met  
 405 410 415  
 Phe Lys Gln Phe Lys Arg Leu Lys Val Ile Asp Leu Ser Val Asn Lys  
 420 425 430  
 Ile Ser Pro Ser Gly Asp Ser Ser Glu Val Gly Phe Cys Ser Asn Ala  
 435 440 445  
 Arg Thr Ser Val Glu Ser Tyr Glu Pro Gln Val Leu Glu Gln Leu His  
 450 455 460  
 Tyr Phe Arg Tyr Asp Lys Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
 465 470 475 480  
 Glu Ala Ser Phe Met Ser Val Asn Glu Ser Cys Tyr Lys Tyr Gly Gln  
 485 490 495  
 Thr Leu Asp Leu Ser Lys Asn Ser Ile Phe Phe Val Lys Ser Ser Asp

500					505					510						
Phe	Gln	His	Leu	Ser	Phe	Leu	Lys	Cys	Leu	Asn	Leu	Ser	Gly	Asn	Leu	
515					520					525						
Ile	Ser	Gln	Thr	Leu	Asn	Gly	Ser	Glu	Phe	Gln	Pro	Leu	Ala	Glu	Leu	
530					535					540						
Arg	Tyr	Leu	Asp	Phe	Ser	Asn	Asn	Arg	Leu	Asp	Leu	Leu	His	Ser	Thr	
545					550					555					560	
Ala	Phe	Glu	Glu	Leu	His	Lys	Leu	Glu	Val	Leu	Asp	Ile	Ser	Ser	Asn	
565					570					575						
Ser	His	Tyr	Phe	Gln	Ser	Glu	Gly	Ile	Thr	His	Met	Leu	Asn	Phe	Thr	
580					585					590						
Lys	Asn	Leu	Lys	Val	Leu	Gln	Lys	Leu	Met	Met	Asn	Asp	Asn	Asp	Ile	
595					600					605						
Ser	Ser	Ser	Thr	Ser	Arg	Thr	Met	Glu	Ser	Glu	Ser	Leu	Arg	Thr	Leu	
610					615					620						
Glu	Phe	Arg	Gly	Asn	His	Leu	Asp	Val	Leu	Trp	Arg	Glu	Gly	Asp	Asn	
625					630					635					640	
Arg	Tyr	Leu	Gln	Leu	Phe	Lys	Asn	Leu	Leu	Lys	Leu	Glu	Glu	Leu	Asp	
645					650					655						
Ile	Ser	Lys	Asn	Ser	Leu	Ser	Phe	Leu	Pro	Ser	Gly	Val	Phe	Asp	Gly	
660					665					670						
Met	Pro	Pro	Asn	Leu	Lys	Asn	Leu	Ser	Leu	Ala	Lys	Asn	Gly	Leu	Lys	
675					680					685						
Ser	Phe	Ser	Trp	Lys	Lys	Leu	Gln	Cys	Leu	Lys	Asn	Leu	Glu	Thr	Leu	
690					695					700						
Asp	Leu	Ser	His	Asn	Gln	Leu	Thr	Thr	Val	Pro	Glu	Arg	Leu	Ser	Asn	
705					710					715					720	
Cys	Ser	Arg	Ser	His	Lys	Asn	Leu	Ile	Leu	Lys	Asn	Asn	Gln	Ile	Arg	
725					730					735						
Ser	Pro	Thr	Lys	Tyr	Phe	Leu	Gln	Asp	Ala	Phe	Gln	Leu	Arg	Tyr	Leu	
740					745					750						
Asp	Leu	Ser	Ser	Asn	Lys	Ile	Gln	Met	Ile	Gln	Lys	Thr	Ser	Phe	Pro	
755					760					765						
Glu	Asn	Val	Leu	Asn	Asn	Leu	Lys	Met	Leu	Leu	Leu	His	His	Asn	Arg	
770					775					780						
Phe	Leu	Cys	Thr	Cys	Asp	Ala	Val	Trp	Phe	Val	Trp	Trp	Val	Asn	His	
785					790					795					800	
Thr	Glu	Val	Thr	Ile	Pro	Tyr	Leu	Ala	Thr	Asp	Val	Thr	Cys	Val	Gly	
805					810					815						
Pro	Gly	Ala	His	Lys	Gly	Gln	Ser	Val	Ile	Ser	Leu	Asp	Leu	Tyr	Thr	
820					825					830						
Cys	Glu	Leu	Asp	Leu	Thr	Asn	Leu	Ile	Leu	Phe	Ser	Leu	Ser	Ile	Ser	

835	840	845
Val Ser Leu Phe Leu Met	Val Met Met Thr Ala Ser	His Leu Tyr Phe
850	855	860
Trp Asp Val Trp Tyr Ile Tyr His Phe Cys Lys Ala Lys Ile Lys Gly		
865	870	875 880
Tyr Gln Arg Leu Ile Ser Pro Asp Cys Cys Tyr Asp Ala Phe Ile Val		
885	890	895
Tyr Asp Thr Lys Asp Pro Ala Val Thr Glu Trp Val Leu Ala Glu Leu		
900	905	910
Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys Leu		
915	920	925
Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu Ser		
930	935	940
Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Asp Lys		
945	950	955 960
Tyr Ala Lys Thr Glu Asn Phe Lys Ile Ala Phe Tyr Leu Ser His Gln		
965	970	975
Arg Leu Met Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu Glu		
980	985	990
Lys Pro Phe Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu Cys		
995	1000	1005
Gly Ser Ser Val Leu Glu Trp Pro Thr Asn Pro Gln Ala His Pro		
1010	1015	1020
Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Ala Thr Asp Asn His		
1025	1030	1035
Val Ala Tyr Ser Gln Val Phe Lys Glu Thr Val		
1040	1045	

<210> 36  
 <211> 1049  
 <212> PRT  
 <213> Homo sapiens

<400> 36

Met Val Phe Pro Met Trp Thr Leu Lys Arg Gln Ile Leu Ile Leu Phe	
1	15
Asn Ile Ile Leu Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro Lys	
20	30
Thr Leu Pro Cys Asp Val Thr Leu Asp Val Pro Lys Asn His Val Ile	
35	45
Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Gly Gly Ile Pro	
50	60
Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Asp Ile	
65	80

Ser Pro Ala Ser Phe His Arg Leu Asp His Leu Val Glu Ile Asp Phe  
                                   85                                  90                                  95  
 Arg Cys Asn Cys Val Pro Ile Pro Leu Gly Ser Lys Asn Asn Met Cys  
                                   100                                  105                                  110  
 Ile Lys Arg Leu Gln Ile Lys Pro Arg Ser Phe Ser Gly Leu Thr Tyr  
                                   115                                  120                                  125  
 Leu Lys Ser Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
                                   130                                  135                                  140  
 Gly Leu Pro Pro Ser Leu Gln Leu Leu Ser Leu Glu Ala Asn Asn Ile  
                                   145                                  150                                  155                                  160  
 Phe Ser Ile Arg Lys Glu Asn Leu Thr Glu Leu Ala Asn Ile Glu Ile  
                                   165                                  170                                  175  
 Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Tyr Val Ser  
                                   180                                  185                                  190  
 Tyr Ser Ile Glu Lys Asp Ala Phe Leu Asn Leu Thr Lys Leu Lys Val  
                                   195                                  200                                  205  
 Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Val Leu Pro  
                                   210                                  215                                  220  
 Ser Thr Leu Thr Glu Leu Tyr Leu Tyr Asn Asn Met Ile Ala Lys Ile  
                                   225                                  230                                  235                                  240  
 Gln Glu Asp Asp Phe Asn Asn Leu Asn Gln Leu Gln Ile Leu Asp Leu  
                                   245                                  250                                  255  
 Ser Gly Asn Cys Pro Arg Cys Tyr Asn Ala Pro Phe Pro Cys Ala Pro  
                                   260                                  265                                  270  
 Cys Lys Asn Asn Ser Pro Leu Gln Ile Pro Val Asn Ala Phe Asp Ala  
                                   275                                  280                                  285  
 Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
                                   290                                  295                                  300  
 Val Pro Pro Arg Trp Phe Lys Asn Ile Asn Lys Leu Gln Glu Leu Asp  
                                   305                                  310                                  315                                  320  
 Leu Ser Gln Asn Phe Leu Ala Lys Glu Ile Gly Asp Ala Lys Phe Leu  
                                   325                                  330                                  335  
 His Phe Leu Pro Ser Leu Ile Gln Leu Asp Leu Ser Phe Asn Phe Glu  
                                   340                                  345                                  350  
 Leu Gln Val Tyr Arg Ala Ser Met Asn Leu Ser Gln Ala Phe Ser Ser  
                                   355                                  360                                  365  
 Leu Lys Ser Leu Lys Ile Leu Arg Ile Arg Gly Tyr Val Phe Lys Glu  
                                   370                                  375                                  380  
 Leu Lys Ser Phe Asn Leu Ser Pro Leu His Asn Leu Gln Asn Leu Glu  
                                   385                                  390                                  395                                  400  
 Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asn Leu Ser Met



405 410 415  
 Phe Lys Gln Phe Lys Arg Leu Lys Val Ile Asp Leu Ser Val Asn Lys  
 420 425 430  
 Ile Ser Pro Ser Gly Asp Ser Ser Glu Val Gly Phe Cys Ser Asn Ala  
 435 440 445  
 Arg Thr Ser Val Glu Ser Tyr Glu Pro Gln Val Leu Glu Gln Leu His  
 450 455 460  
 Tyr Phe Arg Tyr Asp Lys Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
 465 470 475 480  
 Glu Ala Ser Phe Met Ser Val Asn Glu Ser Cys Tyr Lys Tyr Gly Gln  
 485 490 495  
 Thr Leu Asp Leu Ser Lys Asn Ser Ile Phe Phe Val Lys Ser Ser Asp  
 500 505 510  
 Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn Leu  
 515 520 525  
 Ile Ser Gln Thr Leu Asn Gly Ser Glu Phe Gln Pro Leu Ala Glu Leu  
 530 535 540  
 Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu His Ser Thr  
 545 550 555 560  
 Ala Phe Glu Glu Leu His Lys Leu Glu Val Leu Asp Ile Ser Ser Asn  
 565 570 575  
 Ser His Tyr Phe Gln Ser Glu Gly Ile Thr His Met Leu Asn Phe Thr  
 580 585 590  
 Lys Asn Leu Lys Val Leu Gln Lys Leu Met Met Asn Asp Asn Asp Ile  
 595 600 605  
 Ser Ser Ser Thr Ser Arg Thr Met Glu Ser Glu Ser Leu Arg Thr Leu  
 610 615 620  
 Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Glu Gly Asp Asn  
 625 630 635 640  
 Arg Tyr Leu Gln Leu Phe Lys Asn Leu Leu Lys Leu Glu Glu Leu Asp  
 645 650 655  
 Ile Ser Lys Asn Ser Leu Ser Phe Leu Pro Ser Gly Val Phe Asp Gly  
 660 665 670  
 Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu Lys  
 675 680 685  
 Ser Phe Ser Trp Lys Lys Leu Gln Cys Leu Lys Asn Leu Glu Thr Leu  
 690 695 700  
 Asp Leu Ser His Asn Gln Leu Thr Thr Val Pro Glu Arg Leu Ser Asn  
 705 710 715 720  
 Cys Ser Arg Ser Leu Lys Asn Leu Ile Leu Lys Asn Asn Gln Ile Arg  
 725 730 735  
 Ser Leu Thr Lys Tyr Phe Leu Gln Asp Ala Phe Gln Leu Arg Tyr Leu

```

      740      745      750
Asp Leu Ser Ser Asn Lys Ile Gln Met Ile Gln Lys Thr Ser Phe Pro
      755      760      765

Glu Asn Val Leu Asn Asn Leu Lys Met Leu Leu Leu His His Asn Arg
      770      775      780

Phe Leu Cys Thr Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn His
      785      790      795      800

Thr Glu Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val Gly
      805      810      815

Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr Thr
      820      825      830

Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Leu Ser Ile Ser
      835      840      845

Val Ser Leu Phe Leu Met Val Met Met Thr Ala Ser His Leu Tyr Phe
      850      855      860

Trp Asp Val Trp Tyr Ile Tyr His Phe Cys Lys Ala Lys Ile Lys Gly
      865      870      875      880

Tyr Gln Arg Leu Ile Ser Pro Asp Cys Cys Tyr Asp Ala Phe Ile Val
      885      890      895

Tyr Asp Thr Lys Asp Pro Ala Val Thr Glu Trp Val Leu Ala Glu Leu
      900      905      910

Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys Leu
      915      920      925

Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu Ser
      930      935      940

Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Asp Lys
      945      950      955      960

Tyr Ala Lys Thr Glu Asn Phe Lys Ile Ala Phe Tyr Leu Ser His Gln
      965      970      975

Arg Leu Met Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu Glu
      980      985      990

Lys Pro Phe Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu Cys
      995      1000      1005

Gly Ser Ser Val Leu Glu Trp Pro Thr Asn Pro Gln Ala His Pro
      1010      1015      1020

Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Ala Thr Asp Asn His
      1025      1030      1035

Val Ala Tyr Ser Gln Val Phe Lys Glu Thr Val
      1040      1045

```

<210> 37  
 <211> 1049  
 <212> PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 37

```

Met Val Phe Pro Met Trp Thr Leu Lys Arg Gln Ile Leu Ile Leu Phe
1           5           10           15

Asn Ile Ile Leu Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro Lys
20           25           30

Thr Leu Pro Cys Asp Val Thr Leu Asp Val Pro Lys Asn His Val Ile
35           40           45

Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Gly Gly Ile Pro
50           55           60

Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Asp Ile
65           70           75           80

Ser Pro Ala Ser Phe His Arg Leu Asp His Leu Val Glu Ile Asp Phe
85           90           95

Arg Cys Asn Cys Val Pro Ile Pro Leu Gly Ser Lys Asn Asn Met Cys
100          105          110

Ile Lys Arg Leu Gln Ile Lys Pro Arg Ser Phe Ser Gly Leu Thr Tyr
115          120          125

Leu Lys Ser Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln
130          135          140

Gly Leu Pro Pro Ser Leu Gln Leu Leu Ser Leu Glu Ala Asn Asn Ile
145          150          155          160

Phe Ser Ile Arg Lys Glu Asn Leu Thr Glu Leu Ala Asn Ile Glu Ile
165          170          175

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Tyr Val Ser
180          185          190

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Asn Leu Thr Lys Leu Lys Val
195          200          205

Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Val Leu Pro
210          215          220

Ser Thr Leu Thr Glu Leu Tyr Leu Tyr Asn Asn Met Ile Ala Lys Ile
225          230          235          240

Gln Glu Asp Asp Phe Asn Asn Leu Asn Gln Leu Gln Ile Leu Asp Leu
245          250          255

Ser Gly Asn Cys Pro Arg Cys Tyr Asn Ala Pro Phe Pro Cys Ala Pro
260          265          270

Cys Lys Asn Asn Ser Pro Leu Gln Ile Pro Val Asn Ala Phe Asp Ala
275          280          285

Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His
290          295          300

Val Pro Pro Arg Trp Phe Lys Asn Ile Asn Lys Leu Gln Glu Leu Asp
305          310          315          320

```

Leu Ser Gln Asn Phe Leu Ala Lys Glu Ile Gly Asp Ala Lys Phe Leu  
 325 330 335  
 His Phe Leu Pro Ser Leu Ile Gln Leu Asp Leu Ser Phe Asn Phe Glu  
 340 345 350  
 Leu Gln Val Tyr Arg Ala Ser Met Asn Leu Ser Gln Ala Phe Ser Ser  
 355 360 365  
 Leu Lys Ser Leu Lys Ile Leu Arg Ile Arg Gly Tyr Val Phe Lys Glu  
 370 375 380  
 Leu Lys Ser Phe Asn Leu Ser Pro Leu His Asn Leu Gln Asn Leu Glu  
 385 390 395 400  
 Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asn Leu Ser Met  
 405 410 415  
 Phe Lys Gln Phe Lys Arg Leu Lys Val Ile Asp Leu Ser Val Asn Lys  
 420 425 430  
 Ile Ser Pro Ser Gly Asp Ser Ser Glu Val Gly Phe Cys Ser Asn Ala  
 435 440 445  
 Arg Thr Ser Val Glu Ser Tyr Glu Pro Gln Val Leu Glu Gln Leu His  
 450 455 460  
 Tyr Phe Arg Tyr Asp Lys Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
 465 470 475 480  
 Glu Ala Ser Phe Met Ser Val Asn Glu Ser Cys Tyr Lys Tyr Gly Gln  
 485 490 495  
 Thr Leu Asp Leu Ser Lys Asn Ser Ile Phe Phe Val Lys Ser Ser Asp  
 500 505 510  
 Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn Leu  
 515 520 525  
 Ile Ser Gln Thr Leu Asn Gly Ser Glu Phe Gln Pro Leu Ala Glu Leu  
 530 535 540  
 Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu His Ser Thr  
 545 550 555 560  
 Ala Phe Glu Glu Leu His Lys Leu Glu Val Leu Asp Ile Ser Ser Asn  
 565 570 575  
 Ser His Tyr Phe Gln Ser Glu Gly Ile Thr His Met Leu Asn Phe Thr  
 580 585 590  
 Lys Asn Leu Lys Val Leu Gln Lys Leu Met Met Asn Asp Asn Asp Ile  
 595 600 605  
 Ser Ser Ser Thr Ser Arg Thr Met Glu Ser Glu Ser Leu Arg Thr Leu  
 610 615 620  
 Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Glu Gly Asp Asn  
 625 630 635 640  
 Arg Tyr Leu Gln Leu Phe Lys Asn Leu Leu Lys Leu Glu Glu Leu Asp

Ile	Ser	Lys	Asn	Ser	Leu	Ser	Phe	Leu	Pro	Ser	Gly	Val	Phe	Asp	Gly
			645					650					655		
			660					665					670		
Met	Pro	Pro	Asn	Leu	Lys	Asn	Leu	Ser	Leu	Ala	Lys	Asn	Gly	Leu	Lys
			675				680					685			
Ser	Phe	Ser	Trp	Lys	Lys	Leu	Gln	Cys	Leu	Lys	Asn	Leu	Glu	Thr	Leu
			690			695					700				
Asp	Leu	Ser	His	Asn	Gln	Leu	Thr	Thr	Val	Pro	Glu	Arg	Leu	Ser	Asn
705					710					715					720
Cys	Ser	Arg	Ser	Leu	Lys	Asn	Leu	Ile	Leu	Lys	Asn	Asn	Gln	Ile	Arg
				725					730					735	
Ser	Leu	Thr	Lys	Tyr	Phe	Leu	Gln	Asp	Ala	Phe	Gln	Leu	Arg	Tyr	Leu
			740					745					750		
Asp	Leu	Ser	Ser	Asn	Lys	Ile	Gln	Met	Ile	Gln	Lys	Thr	Ser	Phe	Pro
			755				760					765			
Glu	Asn	Val	Leu	Asn	Asn	Leu	Lys	Met	Leu	Leu	Leu	His	His	Asn	Arg
			770			775					780				
Phe	Leu	Cys	Thr	Cys	Asp	Ala	Val	Trp	Phe	Val	Trp	Trp	Val	Asn	His
785					790					795					800
Thr	Glu	Val	Thr	Ile	Pro	Tyr	Leu	Ala	Thr	Asp	Val	Thr	Cys	Val	Gly
				805					810					815	
Pro	Gly	Ala	His	Lys	Gly	Gln	Ser	Val	Ile	Ser	Leu	Asp	Leu	Tyr	Thr
			820					825					830		
Cys	Glu	Leu	Asp	Leu	Thr	Asn	Leu	Ile	Leu	Phe	Ser	Leu	Ser	Ile	Ser
			835				840					845			
Val	Ser	Leu	Phe	Leu	Met	Val	Met	Met	Thr	Ala	Ser	His	Leu	Tyr	Phe
						855					860				
Trp	Asp	Val	Trp	Tyr	Ile	Tyr	His	Phe	Cys	Lys	Ala	Lys	Ile	Lys	Gly
865					870					875					880
Tyr	Gln	Arg	Leu	Ile	Ser	Pro	Asp	Cys	Cys	Tyr	Asp	Ala	Phe	Ile	Val
				885					890					895	
Tyr	Asp	Thr	Lys	Asp	Pro	Ala	Val	Thr	Glu	Trp	Val	Leu	Ala	Glu	Leu
			900					905					910		
Val	Ala	Lys	Leu	Glu	Asp	Pro	Arg	Glu	Lys	His	Phe	Asn	Leu	Cys	Leu
			915				920					925			
Glu	Glu	Arg	Asp	Trp	Leu	Pro	Gly	Gln	Pro	Val	Leu	Glu	Asn	Leu	Ser
			930			935					940				
Gln	Ser	Ile	Gln	Leu	Ser	Lys	Lys	Thr	Val	Phe	Val	Met	Thr	Asp	Lys
945					950					955					960
Tyr	Ala	Lys	Thr	Glu	Asn	Phe	Lys	Ile	Ala	Phe	Tyr	Leu	Ser	His	Gln
				965				970						975	
Arg	Leu	Met	Asp	Glu	Lys	Val	Asp	Val	Ile	Ile	Leu	Ile	Phe	Leu	Glu

[illegible]

<210>	38
<211>	3243
<212>	DNA
<213>	murine

<400>	38						
atttctcctcc	accgacctc	ttgattccat	tttgaaagaa	aactgaaaat	ggtgttttcg		60
atgtggacac	ggaagagaca	aattttgatc	tttttaaata	tgctcttagt	ttctagagtc		120
tttgggtttc	gatggtttcc	taaaactcta	ccttgtgaag	ttaaagtaaa	tatcccagag		180
gcccattgtga	tcgtggactg	cacagacaag	catttgacag	aaatccctga	gggcattccc		240
actaacacca	ccaatcttac	ccttaccatc	aaccacatac	caagcatctc	tccagattcc		300
ttccgtaggc	tgaaccatct	ggaagaaatc	gatttaagat	gcaattgtgt	acctgttcta		360
ctgggggtcca	aagccaatgt	gtgtaccaag	aggctgcaga	ttagacctgg	aagcttttagt		420
ggactctctg	acttaaaagc	cctttacctg	gatggaaacc	aacttctgga	gataccacag		480
gatctgccat	ccagcttaca	tcttctgagc	cttgaggcta	acaacatctt	ctccatcacg		540
aaggagaatc	taacagaact	ggtcaacatt	gaaacactct	acctgggtca	aaactgttat		600
tatcgaaatc	cttgcaatgt	ttctatttct	attgaaaaag	atgctttcct	agttatgaga		660
aatttgaagg	ttctctcact	aaaagataac	aatgtcacag	ctgtccccac	cactttgcca		720
cctaatttac	tagagctcta	tctttataac	aatatcatta	agaaaatcca	agaaaatgat		780
tttaataaacc	tcaatgagtt	gcaagttctt	gacctaagtg	gaaattgccc	tcgatgttat		840
aatgtcccat	atccgtgtac	accgtgtgaa	aataattccc	ccttacagat	ccatgacaat		900
gctttcaatt	cattgacaga	attaaaagtt	ttacgtttac	acagtaattc	tcttcagcat		960
gtgcccccaa	catggtttaa	aaacatgaga	aacctccagg	aactagacct	ctcccaaaac		1020
tacttgGCCA	gagaaattga	ggaggccaaa	tttttgcat	ttcttcccaa	ccttggtgag		1080
ttggatTTTT	ctttcaatta	tgagctgcag	gtctaccatg	catctataac	tttaccacat		1140
tcactctctt	cattgaaaa	cttgaaaatt	ctgcgtgtca	aggggtatgt	ctttaagag		1200
ctgaaaaaact	ccagtccttc	tgtattgcac	aagcttccca	ggctggaagt	tcttgacctt		1260

ggcactaact	tcataaaaat	tgctgacctc	aacatattca	aacattttga	aaacctcaaa	1320
ctcatagacc	tttcagtgaa	taagatatct	ccttcagaag	agtcaagaga	agttggcttt	1380
tgctctaattg	ctcaaaacttc	tgtagaccgt	catggggccc	aggtccttga	ggccttacac	1440
tattttccgat	acgatgaata	tgacacggagc	tgacaggttca	aaaacaaaga	gccaccttct	1500
ttcttgccctt	tgaatgcaga	ctgccacata	tatgggcaga	ccttagactt	aagtagaaat	1560
aacatattttt	ttattaaacc	ttctgattttt	cagcatctttt	cattcctcaa	atgcctcaac	1620
ttatcaggaa	acaccattgg	ccaaactctt	aatggcagtg	aactctggcc	gttgagagag	1680
ttgcggtact	tagacttctc	caacaaccgg	cttgattttac	tctactcaac	agcctttgaa	1740
gagctccaga	gtcttgaagt	tctggatcta	agtagtaaca	gccactattt	tcaagcagaa	1800
ggaattactc	acatgctaaa	ctttaccaag	aaattacggc	ttctggacaa	actcatgatg	1860
aatgataatg	acatctctac	ttcggccagc	aggaccatgg	aaagtgactc	tcttcgaatt	1920
ctggagttca	gaggcaacca	tttagatggt	ctatggagag	cgggtgataa	cagatacttg	1980
gactttcttca	agaatttggt	caatttagag	gtattagata	tctccagaaa	ttccctgaat	2040
tccttgccctc	ctgagggtttt	tgagggtatg	ccgccaaatc	taaagaatct	ctccttggcc	2100
aaaaatgggc	tcaaactctt	cttttgggac	agactccagt	tactgaagca	tttggaatt	2160
ttggacctca	gccataacca	gctgacaaaa	gtacctgaga	gattggccaa	ctgttccaaa	2220
agtctcacia	cactgattct	taagcataat	caaatcaggc	aattgacaaa	atattttcta	2280
gaagatgctt	tgcaattgag	ctatctagac	atcagttcaa	ataaaatcca	ggtcattcag	2340
aagactagct	ttccagaaaa	tgctcctcaac	aatctggaga	tgttggtttt	acatcacaa	2400
cgctttcttt	gcaactgtga	tgctgtgtgg	tttgtctggt	gggttaacca	tacagatggt	2460
actattccat	acctggccac	tgatgtgact	tgtgtaggtc	caggagcaca	caaaggctca	2520
agtgatcatat	cccttgatct	gtatacgtgt	gagttagatc	tcacaaacct	gattctgttc	2580
tcagtttcca	tatcatcagt	cctctttctt	atggtagtta	tgacaacaag	tcacctcttt	2640
ttctgggata	tgtggtacat	ttattatttt	tggaaagcaa	agataaagg	gtatcagcat	2700
ctgcaatcca	tggagtcttg	ttatgatgct	tttattgtgt	atgacactaa	aaactcagct	2760
gtgacagaat	gggttttgca	ggagctgggtg	gcaaaattgg	aagatccaag	agaaaaacac	2820
ttcaatttgt	gtctagaaga	aagagactgg	ctaccaggac	agccagttct	agaaaacctt	2880
ttccagagca	tacagctcag	caaaaagaca	gtgtttgtga	tgacacagaa	atatgctaag	2940
actgagagtt	ttaagatggc	attttatattg	tctcatcaga	ggctcctgga	tgaaaaagtg	3000
gatgtgatta	tcttgatatt	cttggaaaag	cctcttcaga	agtctaagtt	tcttcagctc	3060
aggaagagac	tctgcaggag	ctctgtcctt	gagtggcctg	caaatccaca	ggctcaccca	3120
tacttctggc	agtgctgaa	aaatgccctg	accacagaca	atcatgtggc	ttatagtcaa	3180

atgttcaagg aaacagtcta gctctctgaa gaatgtcacc acctaggaca tgccttgaat 3240  
cga 3243

<210> 39  
<211> 3747  
<212> DNA  
<213> murine

<400> 39  
gagctcaaag gctctgag gctcggtttt ctgttgccct ctctctgtct cagaggactc 60  
catctataga accactctat gccttcaaga aagatgtcct tggctccctt ctcaggatga 120  
tcctggccta tctctgactc tcttctctc caccagacct cttgattcca ttttgaaaga 180  
aaactgaaaa tgggtgttttc gatgtggaca cggaagagac aaattttgat ctttttaaata 240  
atgctcttag tttctagagt ctttgggttt cgatgggttc ctaaaactct accttgtgaa 300  
gttaaagtaa atatcccaga ggcccatgtg atcgtggact gcacagacaa gcatttgaca 360  
gaaatccctg agggcattcc cactaacacc accaatctta cccttaccat caaccacata 420  
ccaagcatct ctccagattc cttccgtagg ctgaaccatc tggaagaaat cgatttaaga 480  
tgcaattgtg tacctgttct actgggggtcc aaagccaatg tgtgtaccaa gaggctgcag 540  
attagacctg gaagcttttag tggactctct gacttaaaag ccctttacct ggatggaaac 600  
caacttctgg agataccaca ggatctgcca tccagcttac atcttctgag ccttgaggct 660  
aacaacatct tctccatcac gaaggagaat ctaacagaac tgggtcaacat tgaaacactc 720  
tacctgggtc aaaactgtta ttatcgaaat ccttgcaatg tttcctattc tattgaaaaa 780  
gatgctttcc tagttatgag aaatttgaag gttctctcac taaaagataa caatgtcaca 840  
gctgtcccca ccactttgcc acctaattta ctagagctct atctttataa caatatcatt 900  
aagaaaatcc aagaaaatga ttttaataac ctcaatgagt tgcaagttct tgacctagt 960  
ggaaattgcc ctcgatgtta taatgtccca tatccgtgta caccgtgtga aaataattcc 1020  
cccttacaga tccatgacaa tgctttcaat tcattgacag aattaaaagt tttacgttta 1080  
cacagtaatt ctcttcagca tgtgccccca acatgggttta aaaacatgag aaacctccag 1140  
gaactagacc tctcccaaaa ctacttggtc agagaaattg aggaggccaa atttttgcat 1200  
tttcttccca accttggtga gttggatttt tctttcaatt atgagctgca ggtctaccat 1260  
gcatctataa ctttaccaca ttcactctct tcattggaaa acttgaaaat tctgcgtgtc 1320  
aaggggtatg tctttaaaga gctgaaaaac tccagtcttt ctgtattgca caagcttccc 1380  
aggctggaag ttcttgacct tggcactaac ttcataaaaa ttgctgacct caacatattc 1440  
aaacattttg aaaacctcaa actcatagac ctttcagtga ataagatatc tccttcagaa 1500



gagtcaagag aagttggctt ttgtcctaata gctcaaactt ctgtagaccg tcatgggccc 1560  
caggtccttg aggccttaca ctatttccga tacgatgaat atgcacggag ctgcaggttc 1620  
  
aaaaacaaag agccaccttc tttcttgccct ttgaatgcag actgccacat atatgggcag 1680  
accttagact taagtagaaa taacatattt ttatttaaac cttctgattt tcagcatctt 1740  
tcattcctca aatgcctcaa cttatcagga aacaccattg gccaaactct taatggcagt 1800  
gaactctggc cgttgagaga gttgcgggtac ttagactttct ccaacaaccg gcttgattta 1860  
ctctactcaa cagcctttga agagctccag agtcttgaag ttctggatct aagtagtaac 1920  
agccactatt ttcaagcaga aggaattact cacatgctaa actttacca gaaattacgg 1980  
cttctggaca aactcatgat gaatgataat gacatctcta cttcggccag caggaccatg 2040  
gaaagtgact ctcttcgaat tctggagttc agaggcaacc atttagatgt tctatggaga 2100  
gccggtgata acagatactt ggacttcttc aagaatttgt tcaattttaga ggtattagat 2160  
atctccagaa attccctgaa ttccttgccct cctgaggttt ttgaggggtat gccgccaat 2220  
ctaaagaatc tctccttggc caaaaatggg ctcaaactct tcttttggga cagactccag 2280  
ttactgaagc atttggaat tttggacctc agccataacc agctgacaaa agtacctgag 2340  
agattggcca actgttccaa aagtctcaca aactgattc ttaagcataa tcaaactcag 2400  
caattgacaa aatattttct agaagatgct ttgcaattgc gctatctaga catcagttca 2460  
aataaaatcc aggtcattca gaagactagc ttcccagaaa atgtcctcaa caatctggag 2520  
atgttggttt tacatcacia tcgctttctt tgcaactgtg atgctgtgtg gtttgtctgg 2580  
tgggttaacc atacagatgt tactattcca tacctggcca ctgatgtgac ttgtgtaggt 2640  
ccaggagcac acaaaggcca aagtgtcata tcccttgatc tgtatacgtg tgagttagat 2700  
ctcaciaacc tgattctgtt ctcagtttcc atatcatcag tcctctttct tatggtagtt 2760  
atgacaacaa gtcacctctt tttctgggat atgtggtaca tttattattt ttggaaagca 2820  
aagataaagg ggtatcagca tctgcaatcc atggagtctt gttatgatgc ttttattgtg 2880  
tatgacacta aaaactcagc tgtgacagaa tgggttttgc aggagctggg ggcaaaattg 2940  
gaagatccaa gagaaaaaca cttcaatttg tgtctagaag aaagagactg gctaccagga 3000  
cagccagttc tagaaaacct ttcccagagc atacagctca gcaaaaagac agtgtttgtg 3060  
atgacacaga aatatgctaa gactgagagt tttaagatgg cattttattt gtctcatcag 3120  
aggctcctgg atgaaaaagt ggatgtgatt atcttgatat tcttggaata gcctcttcag 3180  
aagtctaagt ttcttcagct caggaagaga ctctgcagga gctctgtcct tgagtggcct 3240  
gcaaatccac aggtccaccc atacttctgg cagtgcctga aaaatgcctt gaccacagac 3300  
aatcatgtgg cttatagtca aatgttcaag gaaacagtct agctctctga agaattgcac 3360  
cacctaggac atgccttggg acctgaagtt ttcataaagg tttccataaa tgaaggctcg 3420

aatttttcct aacagttgtc atggctcaga ttggtgggaa atcatcaata tatggctaag	3480
aaattaagaa ggggagactg atagaagata atttctttct tcatgtgcca tgctcagtta	3540
aatatttccc ctagctcaaa tctgaaaaac tgtgcctagg agacaacaca aggctttgat	3600
ttatctgcat acaattgata agagccacac atctgccctg aagaagtact agtagtttta	3660
gtagtagggg aaaaattaca caagctttct ctctctctga tactgaactg taccagagtt	3720
caatgaaata aaagcccaga gaacttc	3747

<210> 40  
 <211> 3449  
 <212> DNA  
 <213> murine

<400> 40	
gcgagtctcg gttttctgtt gccttctctc tgtctcagag gactccatct atagaaccac	60
tctatgcctt caagaaagat gtccttggtt cccttctcag gatgatcctg gcctatctct	120
gactctcttc tctccacca gacctcttga ttccattttg aaagaaaact gaaaatgggtg	180
ttttcgatgt ggacacggaa gagacaaatt ttgatctttt taaatatgct cttagtttct	240
agagtctttg ggtttcgatg gtttctctaa actctacctt gtgaagttaa agtaaatatc	300
ccagaggccc atgtgatcgt ggactgcaca gacaagcatt tgacagaaat ccctgagggc	360
attcccacta acaccaccaa tcttaccctt accatcaacc acataccaag catctctcca	420
gattccttcc gtaggctgaa ccatctggaa gaaatcgatt taagatgcaa ttgtgtacct	480
gttctactgg ggtccaaagc caatgtgtgt accaagaggc tgcagattag acctggaagc	540
tttagtggac tctctgactt aaaagccctt tacctggatg gaaaccaact tctggagata	600
ccacaggatc tgccatccag cttacatctt ctgagccttg aggctaacaa catcttctcc	660
atcacgaagg agaactctaac agaactggtc aacattgaaa cactctacct gggtcaaaac	720
tggtattatc gaaatccttg caatgtttcc tattctattg aaaaagatgc tttcctagtt	780
atgagaaatt tgaaggttct ctactaaaa gataacaatg tcacagctgt cccaccact	840
ttgccaccta atttactaga gctctatctt tataacaata tcattaagaa aatccaagaa	900
aatgatttta ataacctcaa tgagttgcaa gttcttgacc taagtggaaa ttgccctcga	960
tggtataatg tcccatatcc gtgtacaccg tgtgaaaata attccccctt acagatccat	1020
gacaatgctt tcaattcatt gacagaatta aaagttttac gtttacacag taattctctt	1080
cagcatgtgc cccaacatg gtttaaaaac atgagaaacc tccaggaact agacctctcc	1140
caaaactact tggccagaga aattgaggag gccaaathtt tgcattttct tcccaacctt	1200
gttgagttgg atttttcttt caattatgag ctgcaggtct accatgcac tataacttta	1260

ccacattcac	tctcttcatt	ggaaaacttg	aaaattctgc	gtgtcaaggg	gtatgtcttt	1320
aaagagctga	aaaactccag	tctttctgta	ttgcacaagc	ttcccaggct	ggaagttctt	1380
gaccttgcca	ctaacttcat	aaaaattgct	gacctcaaca	tattcaaaca	ttttgaaaac	1440
ctcaaactca	tagacctttc	agtgaataag	atatctcctt	cagaagagtc	aagagaagtt	1500
ggcttttgtc	ctaattgctca	aacttctgta	gaccgtcatg	ggccccaggt	ccttgaggcc	1560
ttacactatt	tccgatacga	tgaatatgca	cggagctgca	ggttcaaaaa	caaagagcca	1620
ccttctttct	tgcttttgaa	tgcagactgc	cacatatatg	ggcagacctt	agacttaagt	1680
agaaataaca	tattttttat	taaaccttct	gattttcagc	atcttttcatt	cctcaaatgc	1740
ctcaacttat	caggaaacac	cattggccaa	actcttaatg	gcagtgaact	ctggccgttg	1800
agagagttgc	ggtacttaga	cttctccaac	aaccggcttg	atttactcta	ctcaacagcc	1860
tttgaagagc	tccagagtct	tgaagttctg	gatctaagta	gtaacagcca	ctattttcaa	1920
gcagaaggaa	ttactcacat	gctaaacttt	accaagaaat	tacgggttct	ggacaaaactc	1980
atgatgaatg	ataatgacat	ctctacttcg	gccagcagga	ccatggaaag	tgactctctt	2040
cgaattcttg	agttcagagg	caaccattta	gatgttctat	ggagagccgg	tgataacaga	2100
tacttggact	tcttcaagaa	tttgttcaat	ttagaggtat	tagatatctc	cagaaattcc	2160
ctgaattcct	tgctctctga	ggtttttgag	ggtatgccgc	caaactctaa	gaatctctcc	2220
ttggccaaaa	atgggctcaa	atctttcttt	tgggacagac	tccagttact	gaagcatttg	2280
gaaatttttg	acctcagcca	taaccagctg	acaaaagtac	ctgagagatt	ggccaactgt	2340
tccaaaagtc	tcacaacact	gattcttaag	cataatcaaa	tcaggcaatt	gacaaaatat	2400
tttctagaag	atgctttgca	attgcgtat	ctagacatca	gttcaaataa	aatccaggtc	2460
attcagaaga	ctagcttccc	agaaaatgtc	ctcaacaatc	tgagagtggt	ggttttacat	2520
cacaatcgct	ttctttgcaa	ctgtgatgct	gtgtggtttg	tctggtggtg	taaccatata	2580
gatgttacta	ttccatacct	ggccactgat	gtgacttggt	taggtccagg	agcacacaaa	2640
ggtcaaagtg	tcatatccct	tgatctgtat	acgtgtgagt	tagatctcac	aaacctgatt	2700
ctgttctcag	tttccatata	atcagtcctc	tttcttatgg	tagttatgac	aacaagtcac	2760
ctctttttct	gggatatgtg	gtacatttat	tatttttgga	aagcaaagat	aaaggggtat	2820
cagcatctgc	aatccatgga	gtcttggtat	gatgctttta	ttgtgtatga	cactaaaaac	2880
tcagctgtga	cagaatgggt	tttgcaggag	ctggtggcaa	aattggaaga	tccaagagaa	2940
aaacacttca	atttgtgtct	agaagaaaga	gactggctac	caggacagcc	agttctagaa	3000
aacctttccc	agagcatata	gctcagcaaa	aagacagtgt	ttgtgatgac	acagaaatat	3060
gctaagactg	agagttttta	gatggcattt	tatttgtctc	atcagaggct	cctggatgaa	3120
aaagtggatg	tgattatctt	gatattcttg	gaaaagcctc	ttcagaagtc	taagtttctt	3180

cagctcagga agagactctg caggagctct gtccttgagt ggctgcaaa tccacaggct 3240  
 caccatact tctggcagtg cctgaaaaat gccctgacca cagacaatca tgtggcttat 3300  
 agtcaaatgt tcaaggaaac agtctagctc tctgaagaat gtcaccacct aggacatgcc 3360  
 ttggtacctg aagttttcat aaaggtttcc ataaatgaag gtctgaattt ttcctaacag 3420  
 ttgtcatggc tcagattggt gggaaatca 3449

<210> 41  
 <211> 1050  
 <212> PRT  
 <213> murine

<400> 41

Met Val Phe Ser Met Trp Thr Arg Lys Arg Gln Ile Leu Ile Phe Leu  
 1 5 10 15

Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys  
 20 25 30

Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile  
 35 40 45

Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro  
 50 55 60

Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Ser Ile  
 65 70 75 80

Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu  
 85 90 95

Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys  
 100 105 110

Thr Lys Arg Leu Gln Ile Arg Pro Gly Ser Phe Ser Gly Leu Ser Asp  
 115 120 125

Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
 130 135 140

Asp Leu Pro Ser Ser Leu His Leu Leu Ser Leu Glu Ala Asn Asn Ile  
 145 150 155 160

Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr  
 165 170 175

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Asn Val Ser  
 180 185 190

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val  
 195 200 205

Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro  
 210 215 220

Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile

225	230																240
Gln	Glu	Asn	Asp	Phe	Asn	Asn	Leu	Asn	Glu	Leu	Gln	Val	Leu	Asp	Leu		
				245					250					255			
Ser	Gly	Asn	Cys	Pro	Arg	Cys	Tyr	Asn	Val	Pro	Tyr	Pro	Cys	Thr	Pro		
			260					265					270				
Cys	Glu	Asn	Asn	Ser	Pro	Leu	Gln	Ile	His	Asp	Asn	Ala	Phe	Asn	Ser		
		275					280					285					
Leu	Thr	Glu	Leu	Lys	Val	Leu	Arg	Leu	His	Ser	Asn	Ser	Leu	Gln	His		
	290					295					300						
Val	Pro	Pro	Thr	Trp	Phe	Lys	Asn	Met	Arg	Asn	Leu	Gln	Glu	Leu	Asp		
305					310					315					320		
Leu	Ser	Gln	Asn	Tyr	Leu	Ala	Arg	Glu	Ile	Glu	Glu	Ala	Lys	Phe	Leu		
				325					330					335			
His	Phe	Leu	Pro	Asn	Leu	Val	Glu	Leu	Asp	Phe	Ser	Phe	Asn	Tyr	Glu		
			340					345					350				
Leu	Gln	Val	Tyr	His	Ala	Ser	Ile	Thr	Leu	Pro	His	Ser	Leu	Ser	Ser		
		355					360					365					
Leu	Glu	Asn	Leu	Lys	Ile	Leu	Arg	Val	Lys	Gly	Tyr	Val	Phe	Lys	Glu		
	370					375					380						
Leu	Lys	Asn	Ser	Ser	Leu	Ser	Val	Leu	His	Lys	Leu	Pro	Arg	Leu	Glu		
385					390					395					400		
Val	Leu	Asp	Leu	Gly	Thr	Asn	Phe	Ile	Lys	Ile	Ala	Asp	Leu	Asn	Ile		
				405					410					415			
Phe	Lys	His	Phe	Glu	Asn	Leu	Lys	Leu	Ile	Asp	Leu	Ser	Val	Asn	Lys		
			420					425					430				
Ile	Ser	Pro	Ser	Glu	Glu	Ser	Arg	Glu	Val	Gly	Phe	Cys	Pro	Asn	Ala		
		435					440					445					
Gln	Thr	Ser	Val	Asp	Arg	His	Gly	Pro	Gln	Val	Leu	Glu	Ala	Leu	His		
	450					455					460						
Tyr	Phe	Arg	Tyr	Asp	Glu	Tyr	Ala	Arg	Ser	Cys	Arg	Phe	Lys	Asn	Lys		
465				470						475					480		
Glu	Pro	Pro	Ser	Phe	Leu	Pro	Leu	Asn	Ala	Asp	Cys	His	Ile	Tyr	Gly		
				485					490					495			
Gln	Thr	Leu	Asp	Leu	Ser	Arg	Asn	Asn	Ile	Phe	Phe	Ile	Lys	Pro	Ser		
		500						505					510				
Asp	Phe	Gln	His	Leu	Ser	Phe	Leu	Lys	Cys	Leu	Asn	Leu	Ser	Gly	Asn		
		515					520					525					
Thr	Ile	Gly	Gln	Thr	Leu	Asn	Gly	Ser	Glu	Leu	Trp	Pro	Leu	Arg	Glu		
	530					535					540						
Leu	Arg	Tyr	Leu	Asp	Phe	Ser	Asn	Asn	Arg	Leu	Asp	Leu	Leu	Tyr	Ser		
545					550					555					560		
Thr	Ala	Phe	Glu	Glu	Leu	Gln	Ser	Leu	Glu	Val	Leu	Asp	Leu	Ser	Ser		

				565					570					575		
Asn	Ser	His	Tyr	Phe	Gln	Ala	Glu	Gly	Ile	Thr	His	Met	Leu	Asn	Phe	
			580					585					590			
Thr	Lys	Lys	Leu	Arg	Leu	Leu	Asp	Lys	Leu	Met	Met	Asn	Asp	Asn	Asp	
		595					600					605				
Ile	Ser	Thr	Ser	Ala	Ser	Arg	Thr	Met	Glu	Ser	Asp	Ser	Leu	Arg	Ile	
	610					615					620					
Leu	Glu	Phe	Arg	Gly	Asn	His	Leu	Asp	Val	Leu	Trp	Arg	Ala	Gly	Asp	
625					630					635					640	
Asn	Arg	Tyr	Leu	Asp	Phe	Phe	Lys	Asn	Leu	Phe	Asn	Leu	Glu	Val	Leu	
				645					650					655		
Asp	Ile	Ser	Arg	Asn	Ser	Leu	Asn	Ser	Leu	Pro	Pro	Glu	Val	Phe	Glu	
			660					665					670			
Gly	Met	Pro	Pro	Asn	Leu	Lys	Asn	Leu	Ser	Leu	Ala	Lys	Asn	Gly	Leu	
		675					680					685				
Lys	Ser	Phe	Phe	Trp	Asp	Arg	Leu	Gln	Leu	Leu	Lys	His	Leu	Glu	Ile	
	690					695					700					
Leu	Asp	Leu	Ser	His	Asn	Gln	Leu	Thr	Lys	Val	Pro	Glu	Arg	Leu	Ala	
705					710					715					720	
Asn	Cys	Ser	Lys	Ser	Leu	Thr	Thr	Leu	Ile	Leu	Lys	His	Asn	Gln	Ile	
				725					730					735		
Arg	Gln	Leu	Thr	Lys	Tyr	Phe	Leu	Glu	Asp	Ala	Leu	Gln	Leu	Arg	Tyr	
			740					745					750			
Leu	Asp	Ile	Ser	Ser	Asn	Lys	Ile	Gln	Val	Ile	Gln	Lys	Thr	Ser	Phe	
		755					760					765				
Pro	Glu	Asn	Val	Leu	Asn	Asn	Leu	Glu	Met	Leu	Val	Leu	His	His	Asn	
	770					775					780					
Arg	Phe	Leu	Cys	Asn	Cys	Asp	Ala	Val	Trp	Phe	Val	Trp	Trp	Val	Asn	
785					790					795					800	
His	Thr	Asp	Val	Thr	Ile	Pro	Tyr	Leu	Ala	Thr	Asp	Val	Thr	Cys	Val	
				805					810					815		
Gly	Pro	Gly	Ala	His	Lys	Gly	Gln	Ser	Val	Ile	Ser	Leu	Asp	Leu	Tyr	
			820					825					830			
Thr	Cys	Glu	Leu	Asp	Leu	Thr	Asn	Leu	Ile	Leu	Phe	Ser	Val	Ser	Ile	
		835					840					845				
Ser	Ser	Val	Leu	Phe	Leu	Met	Val	Val	Met	Thr	Thr	Ser	His	Leu	Phe	
	850					855					860					
Phe	Trp	Asp	Met	Trp	Tyr	Ile	Tyr	Tyr	Phe	Trp	Lys	Ala	Lys	Ile	Lys	
865					870					875					880	
Gly	Tyr	Gln	His	Leu	Gln	Ser	Met	Glu	Ser	Cys	Tyr	Asp	Ala	Phe	Ile	
				885					890					895		
Val	Tyr	Asp	Thr	Lys	Asn	Ser	Ala	Val	Thr	Glu	Trp	Val	Leu	Gln	Glu	

900 905 910  
 Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys  
 915 920 925  
 Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu  
 930 935 940  
 Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln  
 945 950 955 960  
 Lys Tyr Ala Lys Thr Glu Ser Phe Lys Met Ala Phe Tyr Leu Ser His  
 965 970 975  
 Gln Arg Leu Leu Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu  
 980 985 990  
 Glu Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu  
 995 1000 1005  
 Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His  
 1010 1015 1020  
 Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn  
 1025 1030 1035  
 His Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val  
 1040 1045 1050

<210> 42  
 <211> 1050  
 <212> PRT  
 <213> murine

<400> 42

Met Val Phe Ser Met Trp Thr Arg Lys Arg Gln Ile Leu Ile Phe Leu  
 1 5 10 15  
 Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys  
 20 25 30  
 Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile  
 35 40 45  
 Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro  
 50 55 60  
 Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Ser Ile  
 65 70 75 80  
 Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu  
 85 90 95  
 Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys  
 100 105 110  
 Thr Lys Arg Leu Gln Ile Arg Pro Gly Ser Phe Ser Gly Leu Ser Asp  
 115 120 125  
 Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
 130 135 140

Asp Leu Pro Ser Ser Leu His Leu Leu Ser Leu Glu Ala Asn Asn Ile  
 145 150 155 160  
 Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr  
 165 170 175  
 Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Asn Val Ser  
 180 185 190  
 Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val  
 195 200 205  
 Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro  
 210 215 220  
 Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile  
 225 230 235 240  
 Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp Leu  
 245 250 255  
 Ser Gly Asn Cys Pro Arg Cys Tyr Asn Val Pro Tyr Pro Cys Thr Pro  
 260 265 270  
 Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn Ser  
 275 280 285  
 Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
 290 295 300  
 Val Pro Pro Thr Trp Phe Lys Asn Met Arg Asn Leu Gln Glu Leu Asp  
 305 310 315 320  
 Leu Ser Gln Asn Tyr Leu Ala Arg Glu Ile Glu Glu Ala Lys Phe Leu  
 325 330 335  
 His Phe Leu Pro Asn Leu Val Glu Leu Asp Phe Ser Phe Asn Tyr Glu  
 340 345 350  
 Leu Gln Val Tyr His Ala Ser Ile Thr Leu Pro His Ser Leu Ser Ser  
 355 360 365  
 Leu Glu Asn Leu Lys Ile Leu Arg Val Lys Gly Tyr Val Phe Lys Glu  
 370 375 380  
 Leu Lys Asn Ser Ser Leu Ser Val Leu His Lys Leu Pro Arg Leu Glu  
 385 390 395 400  
 Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asp Leu Asn Ile  
 405 410 415  
 Phe Lys His Phe Glu Asn Leu Lys Leu Ile Asp Leu Ser Val Asn Lys  
 420 425 430  
 Ile Ser Pro Ser Glu Glu Ser Arg Glu Val Gly Phe Cys Pro Asn Ala  
 435 440 445  
 Gln Thr Ser Val Asp Arg His Gly Pro Gln Val Leu Glu Ala Leu His  
 450 455 460  
 Tyr Phe Arg Tyr Asp Glu Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys



465                      470                      475                      480  
 Glu Pro Pro Ser Phe Leu Pro Leu Asn Ala Asp Cys His Ile Tyr Gly  
                                  485                      490                      495  
  
 Gln Thr Leu Asp Leu Ser Arg Asn Asn Ile Phe Phe Ile Lys Pro Ser  
                                  500                      505                      510  
  
 Asp Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn  
                                  515                      520                      525  
  
 Thr Ile Gly Gln Thr Leu Asn Gly Ser Glu Leu Trp Pro Leu Arg Glu  
                                  530                      535                      540  
  
 Leu Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu Tyr Ser  
 545                                   550                      555                      560  
  
 Thr Ala Phe Glu Glu Leu Gln Ser Leu Glu Val Leu Asp Leu Ser Ser  
                                  565                      570                      575  
  
 Asn Ser His Tyr Phe Gln Ala Glu Gly Ile Thr His Met Leu Asn Phe  
                                  580                      585                      590  
  
 Thr Lys Lys Leu Arg Leu Leu Asp Lys Leu Met Met Asn Asp Asn Asp  
                                  595                      600                      605  
  
 Ile Ser Thr Ser Ala Ser Arg Thr Met Glu Ser Asp Ser Leu Arg Ile  
                                  610                      615                      620  
  
 Leu Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Ala Gly Asp  
 625                                   630                      635                      640  
  
 Asn Arg Tyr Leu Asp Phe Phe Lys Asn Leu Phe Asn Leu Glu Val Leu  
                                  645                      650                      655  
  
 Asp Ile Ser Arg Asn Ser Leu Asn Ser Leu Pro Pro Glu Val Phe Glu  
                                  660                      665                      670  
  
 Gly Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu  
                                  675                      680                      685  
  
 Lys Ser Phe Phe Trp Asp Arg Leu Gln Leu Leu Lys His Leu Glu Ile  
                                  690                      695                      700  
  
 Leu Asp Leu Ser His Asn Gln Leu Thr Lys Val Pro Glu Arg Leu Ala  
 705                                   710                      715                      720  
  
 Asn Cys Ser Lys Ser Leu Thr Thr Leu Ile Leu Lys His Asn Gln Ile  
                                  725                      730                      735  
  
 Arg Gln Leu Thr Lys Tyr Phe Leu Glu Asp Ala Leu Gln Leu Arg Tyr  
                                  740                      745                      750  
  
 Leu Asp Ile Ser Ser Asn Lys Ile Gln Val Ile Gln Lys Thr Ser Phe  
                                  755                      760                      765  
  
 Pro Glu Asn Val Leu Asn Asn Leu Glu Met Leu Val Leu His His Asn  
                                  770                      775                      780  
  
 Arg Phe Leu Cys Asn Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn  
 785                                   790                      795                      800  
  
 His Thr Asp Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val

805 810 815  
 Gly Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr  
 820 825 830  
 Thr Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Val Ser Ile  
 835 840 845  
 Ser Ser Val Leu Phe Leu Met Val Val Met Thr Thr Ser His Leu Phe  
 850 855 860  
 Phe Trp Asp Met Trp Tyr Ile Tyr Tyr Phe Trp Lys Ala Lys Ile Lys  
 865 870 875 880  
 Gly Tyr Gln His Leu Gln Ser Met Glu Ser Cys Tyr Asp Ala Phe Ile  
 885 890 895  
 Val Tyr Asp Thr Lys Asn Ser Ala Val Thr Glu Trp Val Leu Gln Glu  
 900 905 910  
 Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys  
 915 920 925  
 Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu  
 930 935 940  
 Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln  
 945 950 955 960  
 Lys Tyr Ala Lys Thr Glu Ser Phe Lys Met Ala Phe Tyr Leu Ser His  
 965 970 975  
 Gln Arg Leu Leu Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu  
 980 985 990  
 Glu Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu  
 995 1000 1005  
 Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His  
 1010 1015 1020  
 Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn  
 1025 1030 1035  
 His Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val  
 1040 1045 1050

<210> 43  
 <211> 1050  
 <212> PRT  
 <213> murine

<400> 43

Met Val Phe Ser Met Trp Thr Arg Lys Arg Gln Ile Leu Ile Phe Leu  
 1 5 10 15  
 Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys  
 20 25 30  
 Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile  
 35 40 45

Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro  
 50 55 60  
 Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Ser Ile  
 65 70 75 80  
 Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu  
 85 90 95  
 Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys  
 100 105 110  
 Thr Lys Arg Leu Gln Ile Arg Pro Gly Ser Phe Ser Gly Leu Ser Asp  
 115 120 125  
 Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
 130 135 140  
 Asp Leu Pro Ser Ser Leu His Leu Leu Ser Leu Glu Ala Asn Asn Ile  
 145 150 155 160  
 Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr  
 165 170 175  
 Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Asn Val Ser  
 180 185 190  
 Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val  
 195 200 205  
 Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro  
 210 215 220  
 Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile  
 225 230 235 240  
 Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp Leu  
 245 250 255  
 Ser Gly Asn Cys Pro Arg Cys Tyr Asn Val Pro Tyr Pro Cys Thr Pro  
 260 265 270  
 Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn Ser  
 275 280 285  
 Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
 290 295 300  
 Val Pro Pro Thr Trp Phe Lys Asn Met Arg Asn Leu Gln Glu Leu Asp  
 305 310 315 320  
 Leu Ser Gln Asn Tyr Leu Ala Arg Glu Ile Glu Glu Ala Lys Phe Leu  
 325 330 335  
 His Phe Leu Pro Asn Leu Val Glu Leu Asp Phe Ser Phe Asn Tyr Glu  
 340 345 350  
 Leu Gln Val Tyr His Ala Ser Ile Thr Leu Pro His Ser Leu Ser Ser  
 355 360 365  
 Leu Glu Asn Leu Lys Ile Leu Arg Val Lys Gly Tyr Val Phe Lys Glu

370	375	380
Leu Lys Asn Ser Ser	Leu Ser Val Leu His Lys	Leu Pro Arg Leu Glu
385	390	395 400
Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asp Leu Asn Ile		
	405 410	415
Phe Lys His Phe Glu Asn Leu Lys Leu Ile Asp Leu Ser Val Asn Lys		
	420 425	430
Ile Ser Pro Ser Glu Glu Ser Arg Glu Val Gly Phe Cys Pro Asn Ala		
	435 440	445
Gln Thr Ser Val Asp Arg His Gly Pro Gln Val Leu Glu Ala Leu His		
	450 455	460
Tyr Phe Arg Tyr Asp Glu Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys		
	465 470	475 480
Glu Pro Pro Ser Phe Leu Pro Leu Asn Ala Asp Cys His Ile Tyr Gly		
	485 490	495
Gln Thr Leu Asp Leu Ser Arg Asn Asn Ile Phe Phe Ile Lys Pro Ser		
	500 505	510
Asp Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn		
	515 520	525
Thr Ile Gly Gln Thr Leu Asn Gly Ser Glu Leu Trp Pro Leu Arg Glu		
	530 535	540
Leu Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu Tyr Ser		
	545 550	555 560
Thr Ala Phe Glu Glu Leu Gln Ser Leu Glu Val Leu Asp Leu Ser Ser		
	565 570	575
Asn Ser His Tyr Phe Gln Ala Glu Gly Ile Thr His Met Leu Asn Phe		
	580 585	590
Thr Lys Lys Leu Arg Leu Leu Asp Lys Leu Met Met Asn Asp Asn Asp		
	595 600	605
Ile Ser Thr Ser Ala Ser Arg Thr Met Glu Ser Asp Ser Leu Arg Ile		
	610 615	620
Leu Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Ala Gly Asp		
	625 630	635 640
Asn Arg Tyr Leu Asp Phe Phe Lys Asn Leu Phe Asn Leu Glu Val Leu		
	645 650	655
Asp Ile Ser Arg Asn Ser Leu Asn Ser Leu Pro Pro Glu Val Phe Glu		
	660 665	670
Gly Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu		
	675 680	685
Lys Ser Phe Phe Trp Asp Arg Leu Gln Leu Leu Lys His Leu Glu Ile		
	690 695	700
Leu Asp Leu Ser His Asn Gln Leu Thr Lys Val Pro Glu Arg Leu Ala		

705                      710                      715                      720  
 Asn Cys Ser Lys Ser Leu Thr Thr Leu Ile Leu Lys His Asn Gln Ile  
                                  725                      730                      735  
  
 Arg Gln Leu Thr Lys Tyr Phe Leu Glu Asp Ala Leu Gln Leu Arg Tyr  
                                  740                      745                      750  
  
 Leu Asp Ile Ser Ser Asn Lys Ile Gln Val Ile Gln Lys Thr Ser Phe  
                                  755                      760                      765  
  
 Pro Glu Asn Val Leu Asn Asn Leu Glu Met Leu Val Leu His His Asn  
                                  770                      775                      780  
  
 Arg Phe Leu Cys Asn Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn  
 785                                   790                      795                      800  
  
 His Thr Asp Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val  
                                  805                      810                      815  
  
 Gly Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr  
                                  820                      825                      830  
  
 Thr Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Val Ser Ile  
                                  835                      840                      845  
  
 Ser Ser Val Leu Phe Leu Met Val Val Met Thr Thr Ser His Leu Phe  
                                  850                      855                      860  
  
 Phe Trp Asp Met Trp Tyr Ile Tyr Tyr Phe Trp Lys Ala Lys Ile Lys  
 865                                   870                      875                      880  
  
 Gly Tyr Gln His Leu Gln Ser Met Glu Ser Cys Tyr Asp Ala Phe Ile  
                                  885                      890                      895  
  
 Val Tyr Asp Thr Lys Asn Ser Ala Val Thr Glu Trp Val Leu Gln Glu  
                                  900                      905                      910  
  
 Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys  
                                  915                      920                      925  
  
 Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu  
                                  930                      935                      940  
  
 Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln  
 945                                   950                      955                      960  
  
 Lys Tyr Ala Lys Thr Glu Ser Phe Lys Met Ala Phe Tyr Leu Ser His  
                                  965                      970                      975  
  
 Gln Arg Leu Leu Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu  
                                  980                      985                      990  
  
 Glu Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu  
                                  995                      1000                      1005  
  
 Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His  
 1010                                   1015                      1020  
  
 Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn  
 1025                                   1030                      1035  
  
 His Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val

1040  
 <210> 44  
 <211> 1050  
 <212> PRT  
 <213> murine  
  
 <400> 44  
  
 Met Val Phe Ser Met Trp Thr Arg Lys Arg Gln Ile Leu Ile Phe Leu  
 1 5 10 15  
 Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys  
 20 25 30  
 Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile  
 35 40 45  
 Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro  
 50 55 60  
 Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Ser Ile  
 65 70 75 80  
 Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu  
 85 90 95  
 Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys  
 100 105 110  
 Thr Lys Arg Leu Gln Ile Arg Pro Gly Ser Phe Ser Gly Leu Ser Asp  
 115 120 125  
 Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
 130 135 140  
 Asp Leu Pro Ser Ser Leu His Leu Leu Ser Leu Glu Ala Asn Asn Ile  
 145 150 155 160  
 Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr  
 165 170 175  
 Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Asn Val Ser  
 180 185 190  
 Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val  
 195 200 205  
 Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro  
 210 215 220  
 Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile  
 225 230 235 240  
 Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp Leu  
 245 250 255  
 Ser Gly Asn Cys Pro Arg Cys Tyr Asn Val Pro Tyr Pro Cys Thr Pro  
 260 265 270  
 Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn Ser  
 275 280 285

Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
 290 295 300  
 Val Pro Pro Thr Trp Phe Lys Asn Met Arg Asn Leu Gln Glu Leu Asp  
 305 310 315 320  
 Leu Ser Gln Asn Tyr Leu Ala Arg Glu Ile Glu Glu Ala Lys Phe Leu  
 325 330 335  
 His Phe Leu Pro Asn Leu Val Glu Leu Asp Phe Ser Phe Asn Tyr Glu  
 340 345 350  
 Leu Gln Val Tyr His Ala Ser Ile Thr Leu Pro His Ser Leu Ser Ser  
 355 360 365  
 Leu Glu Asn Leu Lys Ile Leu Arg Val Lys Gly Tyr Val Phe Lys Glu  
 370 375 380  
 Leu Lys Asn Ser Ser Leu Ser Val Leu His Lys Leu Pro Arg Leu Glu  
 385 390 395 400  
 Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asp Leu Asn Ile  
 405 410 415  
 Phe Lys His Phe Glu Asn Leu Lys Leu Ile Asp Leu Ser Val Asn Lys  
 420 425 430  
 Ile Ser Pro Ser Glu Glu Ser Arg Glu Val Gly Phe Cys Pro Asn Ala  
 435 440 445  
 Gln Thr Ser Val Asp Arg His Gly Pro Gln Val Leu Glu Ala Leu His  
 450 455 460  
 Tyr Phe Arg Tyr Asp Glu Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
 465 470 475 480  
 Glu Pro Pro Ser Phe Leu Pro Leu Asn Ala Asp Cys His Ile Tyr Gly  
 485 490 495  
 Gln Thr Leu Asp Leu Ser Arg Asn Asn Ile Phe Phe Ile Lys Pro Ser  
 500 505 510  
 Asp Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn  
 515 520 525  
 Thr Ile Gly Gln Thr Leu Asn Gly Ser Glu Leu Trp Pro Leu Arg Glu  
 530 535 540  
 Leu Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu Tyr Ser  
 545 550 555 560  
 Thr Ala Phe Glu Glu Leu Gln Ser Leu Glu Val Leu Asp Leu Ser Ser  
 565 570 575  
 Asn Ser His Tyr Phe Gln Ala Glu Gly Ile Thr His Met Leu Asn Phe  
 580 585 590  
 Thr Lys Lys Leu Arg Leu Leu Asp Lys Leu Met Met Asn Asp Asn Asp  
 595 600 605  
 Ile Ser Thr Ser Ala Ser Arg Thr Met Glu Ser Asp Ser Leu Arg Ile

610 615 620  
 Leu Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Ala Gly Asp  
 625 630 635 640  
 Asn Arg Tyr Leu Asp Phe Phe Lys Asn Leu Phe Asn Leu Glu Val Leu  
 645 650 655  
 Asp Ile Ser Arg Asn Ser Leu Asn Ser Leu Pro Pro Glu Val Phe Glu  
 660 665 670  
 Gly Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu  
 675 680 685  
 Lys Ser Phe Phe Trp Asp Arg Leu Gln Leu Leu Lys His Leu Glu Ile  
 690 695 700  
 Leu Asp Leu Ser His Asn Gln Leu Thr Lys Val Pro Glu Arg Leu Ala  
 705 710 715 720  
 Asn Cys Ser Lys Ser Leu Thr Thr Leu Ile Leu Lys His Asn Gln Ile  
 725 730 735  
 Arg Gln Leu Thr Lys Tyr Phe Leu Glu Asp Ala Leu Gln Leu Arg Tyr  
 740 745 750  
 Leu Asp Ile Ser Ser Asn Lys Ile Gln Val Ile Gln Lys Thr Ser Phe  
 755 760 765  
 Pro Glu Asn Val Leu Asn Asn Leu Glu Met Leu Val Leu His His Asn  
 770 775 780  
 Arg Phe Leu Cys Asn Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn  
 785 790 795 800  
 His Thr Asp Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val  
 805 810 815  
 Gly Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr  
 820 825 830  
 Thr Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Val Ser Ile  
 835 840 845  
 Ser Ser Val Leu Phe Leu Met Val Val Met Thr Thr Ser His Leu Phe  
 850 855 860  
 Phe Trp Asp Met Trp Tyr Ile Tyr Tyr Phe Trp Lys Ala Lys Ile Lys  
 865 870 875 880  
 Gly Tyr Gln His Leu Gln Ser Met Glu Ser Cys Tyr Asp Ala Phe Ile  
 885 890 895  
 Val Tyr Asp Thr Lys Asn Ser Ala Val Thr Glu Trp Val Leu Gln Glu  
 900 905 910  
 Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys  
 915 920 925  
 Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu  
 930 935 940  
 Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln



945                      950                      955                      960  
 Lys Tyr Ala Lys Thr Glu Ser Phe Lys Met Ala Phe Tyr Leu Ser His  
                                  965                      970                      975  
  
 Gln Arg Leu Leu Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu  
                                  980                      985                      990  
  
 Glu Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu  
                                  995                      1000                      1005  
  
 Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His  
                                  1010                      1015                      1020  
  
 Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn  
                                  1025                      1030                      1035  
  
 His Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val  
                                  1040                      1045                      1050

<210> 45  
 <211> 1050  
 <212> PRT  
 <213> murine

<400> 45

Met Val Phe Ser Met Trp Thr Arg Lys Arg Gln Ile Leu Ile Phe Leu  
 1                      5                      10                      15  
  
 Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys  
                                  20                      25                      30  
  
 Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile  
                                  35                      40                      45  
  
 Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro  
                                  50                      55                      60  
  
 Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Ser Ile  
 65                      70                      75                      80  
  
 Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu  
                                  85                      90                      95  
  
 Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys  
                                  100                      105                      110  
  
 Thr Lys Arg Leu Gln Ile Arg Pro Gly Ser Phe Ser Gly Leu Ser Asp  
                                  115                      120                      125  
  
 Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
                                  130                      135                      140  
  
 Asp Leu Pro Ser Ser Leu His Leu Leu Ser Leu Glu Ala Asn Asn Ile  
 145                      150                      155                      160  
  
 Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr  
                                  165                      170                      175  
  
 Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Asn Val Ser  
                                  180                      185                      190

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val  
 195 200 205  
 Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro  
 210 215 220  
 Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile  
 225 230 235 240  
 Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp Leu  
 245 250 255  
 Ser Gly Asn Cys Pro Arg Cys Tyr Asn Val Pro Tyr Pro Cys Thr Pro  
 260 265 270  
 Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn Ser  
 275 280 285  
 Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
 290 295 300  
 Val Pro Pro Thr Trp Phe Lys Asn Met Arg Asn Leu Gln Glu Leu Asp  
 305 310 315 320  
 Leu Ser Gln Asn Tyr Leu Ala Arg Glu Ile Glu Glu Ala Lys Phe Leu  
 325 330 335  
 His Phe Leu Pro Asn Leu Val Glu Leu Asp Phe Ser Phe Asn Tyr Glu  
 340 345 350  
 Leu Gln Val Tyr His Ala Ser Ile Thr Leu Pro His Ser Leu Ser Ser  
 355 360 365  
 Leu Glu Asn Leu Lys Ile Leu Arg Val Lys Gly Tyr Val Phe Lys Glu  
 370 375 380  
 Leu Lys Asn Ser Ser Leu Ser Val Leu His Lys Leu Pro Arg Leu Glu  
 385 390 395 400  
 Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asp Leu Asn Ile  
 405 410 415  
 Phe Lys His Phe Glu Asn Leu Lys Leu Ile Asp Leu Ser Val Asn Lys  
 420 425 430  
 Ile Ser Pro Ser Glu Glu Ser Arg Glu Val Gly Phe Cys Pro Asn Ala  
 435 440 445  
 Gln Thr Ser Val Asp Arg His Gly Pro Gln Val Leu Glu Ala Leu His  
 450 455 460  
 Tyr Phe Arg Tyr Asp Glu Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
 465 470 475 480  
 Glu Pro Pro Ser Phe Leu Pro Leu Asn Ala Asp Cys His Ile Tyr Gly  
 485 490 495  
 Gln Thr Leu Asp Leu Ser Arg Asn Asn Ile Phe Phe Ile Lys Pro Ser  
 500 505 510  
 Asp Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn

515                      520                      525  
 Thr Ile Gly Gln Thr Leu Asn Gly Ser Glu Leu Trp Pro Leu Arg Glu  
 530                      535                      540  
 Leu Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu Tyr Ser  
 545                      550                      555                      560  
 Thr Ala Phe Glu Glu Leu Gln Ser Leu Glu Val Leu Asp Leu Ser Ser  
 565                      570                      575  
 Asn Ser His Tyr Phe Gln Ala Glu Gly Ile Thr His Met Leu Asn Phe  
 580                      585                      590  
 Thr Lys Lys Leu Arg Leu Leu Asp Lys Leu Met Met Asn Asp Asn Asp  
 595                      600                      605  
 Ile Ser Thr Ser Ala Ser Arg Thr Met Glu Ser Asp Ser Leu Arg Ile  
 610                      615                      620  
 Leu Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Ala Gly Asp  
 625                      630                      635                      640  
 Asn Arg Tyr Leu Asp Phe Phe Lys Asn Leu Phe Asn Leu Glu Val Leu  
 645                      650                      655  
 Asp Ile Ser Arg Asn Ser Leu Asn Ser Leu Pro Pro Glu Val Phe Glu  
 660                      665                      670  
 Gly Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu  
 675                      680                      685  
 Lys Ser Phe Phe Trp Asp Arg Leu Gln Leu Leu Lys His Leu Glu Ile  
 690                      695                      700  
 Leu Asp Leu Ser His Asn Gln Leu Thr Lys Val Pro Glu Arg Leu Ala  
 705                      710                      715                      720  
 Asn Cys Ser Lys Ser Leu Thr Thr Leu Ile Leu Lys His Asn Gln Ile  
 725                      730                      735  
 Arg Gln Leu Thr Lys Tyr Phe Leu Glu Asp Ala Leu Gln Leu Arg Tyr  
 740                      745                      750  
 Leu Asp Ile Ser Ser Asn Lys Ile Gln Val Ile Gln Lys Thr Ser Phe  
 755                      760                      765  
 Pro Glu Asn Val Leu Asn Asn Leu Glu Met Leu Val Leu His His Asn  
 770                      775                      780  
 Arg Phe Leu Cys Asn Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn  
 785                      790                      795                      800  
 His Thr Asp Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val  
 805                      810                      815  
 Gly Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr  
 820                      825                      830  
 Thr Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Val Ser Ile  
 835                      840                      845  
 Ser Ser Val Leu Phe Leu Met Val Val Met Thr Thr Ser His Leu Phe

850                      855                      860  
 Phe Trp Asp Met Trp Tyr Ile Tyr Tyr Phe Trp Lys Ala Lys Ile Lys  
 865                      870                      875                      880  
 Gly Tyr Gln His Leu Gln Ser Met Glu Ser Cys Tyr Asp Ala Phe Ile  
                                  885                      890                      895  
 Val Tyr Asp Thr Lys Asn Ser Ala Val Thr Glu Trp Val Leu Gln Glu  
                                  900                      905                      910  
 Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys  
                                  915                      920                      925  
 Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu  
                                  930                      935                      940  
 Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln  
 945                      950                      955                      960  
 Lys Tyr Ala Lys Thr Glu Ser Phe Lys Met Ala Phe Tyr Leu Ser His  
                                  965                      970                      975  
 Gln Arg Leu Leu Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu  
                                  980                      985                      990  
 Glu Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu  
                                  995                      1000                      1005  
 Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His  
                                  1010                      1015                      1020  
 Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn  
                                  1025                      1030                      1035  
 His Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val  
                                  1040                      1045                      1050

&lt;210&gt; 46

&lt;211&gt; 3311

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 46

ttctgcgctg ctgcaagtta cggaatgaaa aattagaaca acagaaacat ggaaaacatg 60  
 ttccttcagt cgtcaatgct gacctgcatt ttctgctaa tatctggttc ctgtgagtta 120  
 tgcgccgaag aaaatttttc tagaagctat ccttgatgat agaaaaagca aaatgactca 180  
 gttattgcag agtgcagcaa tcgtcgacta caggaagttc cccaaacggt gggcaaatat 240  
 gtgacagaac tagacctgtc tgataatttc atcacacaca taacgaatga atcatttcaa 300  
 gggctgcaaa atctcactaa aataaatcta aaccacaacc ccaatgtaca gcaccagaac 360  
 ggaaatcccg gtatacaatc aaatggcttg aatatcacag acggggcatt cctcaaccta 420  
 aaaaacctaa gggagttact gcttgaagac aaccagttac cccaaatacc ctctggtttg 480  
 ccagagtctt tgacagaact tagtctaatt caaaacaata tataacaacat aactaaagag 540

ggcatttcaa gacttataaa cttgaaaaat ctctatttgg cctggaactg ctattttaac	600
aaagtttgcg agaaaactaa catagaagat ggagtatattg aaacgctgac aaatttggag	660
ttgctatcac tatctttcaa ttctctttca cacgtgccac ccaaactgcc aagctcccta	720
cgcaaacttt ttctgagcaa caccagatc aaatacatta gtgaagaaga tttcaaggga	780
ttgataaatt taacattact agatttaagc gggaaactgtc cgagggtgctt caatgccccca	840
tttccatgcg tgccttgtga tgggtggtgct tcaattaata tagatcgttt tgcttttcaa	900
aacttgacct aacttcgata cctaaacctc tctagcactt ccctcaggaa gattaatgct	960
gcctgggttta aaaatatgcc tcatctgaag gtgctggatc ttgaattcaa ctatttagtg	1020
ggagaaatag cctctggggc atttttaacg atgctgcccc gcttagaaat acttgacttg	1080
tcttttaact atataaaggg gagttatcca cagcatatta atatttccag aaacttctct	1140
aaacttttgt ctctacgggc attgcattta agagggtatg tgttccagga actcagagaa	1200
gatgatttcc agccctgat gcagcttcca aacttatcga ctatcaactt gggatattaat	1260
tttattaagc aaatogattt caaacttttc caaaatttct ccaatctgga aattatttac	1320
ttgtcagaaa acagaatata accgttggtgta aaagataccc ggcagagtta tgcaaatagt	1380
tcctcttttc aacgtcatat ccggaaacga cgctcaacag attttgagtt tgacccacat	1440
tcgaactttt atcatttcac ccgtccttta ataaagccac aatgtgctgc ttatggaaaa	1500
gccttagatt taagcctcaa cagtattttc ttcattgggc caaaccaatt tgaaaatctt	1560
cctgacattg cctgtttaaa tctgtctgca aatagcaatg ctcaagtgtt aagtggaact	1620
gaattttcag ccattcctca tgtcaaatat ttggatttga caaacaatag actagacttt	1680
gataatgcta gtgctcttac tgaattgtcc gacttgggaag ttctagatct cagctataat	1740
tcacactatt tcagaatagc aggcgtaaca catcatctag aatttattca aaatttcaca	1800
aatctaaaag ttttaaactt gagccacaac aacatttata ctttaacaga taagtataac	1860
ctggaaagca agtccctggg agaattagtt ttcagtggca atcgccctga cattttgtgg	1920
aatgatgatg acaacaggta tatctccatt ttcaaaggtc tcaagaatct gacacgtctg	1980
gatttatccc ttaatagggt gaagcacatc ccaaataag cattccttaa tttgccagcg	2040
agtctcactg aactacatat aaatgataat atgttaaagt tttttaactg gacattactc	2100
cagcagttcc ctgctctcga gttgcttgac ttacgtggaa acaaactact ctttttaact	2160
gatagcctat ctgactttac atcttccctt cggacactgc tgctgagtca taacaggatt	2220
tcccacctac cctctggctt tctttctgaa gtcagtagtc tgaagcacct cgatttaagt	2280
tccaatctgc taaaaacaat caacaaatcc gcacttgaaa ctaagaccac caccaaatta	2340
tctatgttgg aactacacgg aaaccctttt gaatgcacct gtgacattgg agatttccga	2400
agatggatgg atgaacatct gaatgtcaaa attcccagac tggtagatgt catttgtgcc	2460

```

agtcctgggg atcaaagagg gaagagtatt gtgagtctgg agctgacaac ttgtgtttca 2520
gatgtcactg cagtgatatt atttttcttc acgttcttta tcaccaccat ggttatgttg 2580
gctgccctgg ctcaccattht gttttactgg gatgttttgt ttatatataa tgtgtgttta 2640
gctaaggtaa aaggctacag gtctctttcc acatcccaaa ctttctatga tgcttacatt 2700
tcttatgaca ccaaagatgc ctctgttact gactgggtga taaatgagct gcgctaccac 2760
cttgaagaga gccgagacaa aaacgttctc ctttgtctag aggagagggg ttgggacccg 2820
ggattggcca tcatcgacaa cctcatgcag agcatcaacc aaagcaagaa aacagtattht 2880
gttttaacca aaaaatatgc aaaaagctgg aactttaaaa cagcttttta cttggctttg 2940
cagaggctaa tggatgagaa catggatgtg attatattha tcctgctgga gccagtgtta 3000
cagcattctc agtatthtgg gctacggcag cggatctgta agagctccat cctccagtgg 3060
cctgacaacc cgaaggcaga aggtctgttt tggcaaacctc tgagaaatgt ggtcttgact 3120
gaaaatgatt cacggtataa caatatgtat gtcgattcca ttaagcaata ctaactgacg 3180
ttaagtcatg atthtcgccc ataataaaga tgcaaaggaa tgacatthct gtattagtta 3240
tctattgcta tgtaacaaat tatcccaaaa cttagtgggt taaaacaaca catttgctgg 3300
cccacagtht t 3311

```

&lt;210&gt; 47

&lt;211&gt; 3367

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 47

```

ctctgcata gaggtacca ttctgcgtg ctgcaagtta cggaatgaaa aattagaaca 60
acagaaacgt ggttctcttg acacttcagt gttagggaac atcagcaaga .cccatcccag 120
gagaccttga aggaagcctt tgaaagggag aatgaaggag tcatctttgc aaaatagctc 180
ctgcagcctg ggaaaggaga ctaaaaagga aaacatgttc cttcagtcgt caatgctgac 240
ctgcatttht ctgctaatat ctggttctctg tgagttatgc gccgaagaaa atthttctag 300
aagctatcct tgtgatgaga aaaagcaaaa tgactcagtt attgcagagt gcagcaatcg 360
tcgactacag gaagttcccc aaacggtggg caaatatgtg acagaactag acctgtctga 420
taatthcatc acacacataa cgaatgaatc atthcaaggg ctgcaaaatc tactaaaaat 480
aaatctaaac cacaacccca atgtacagca ccagaacgga aatcccggta tacaatcaaa 540
tggttgaat atcacagacg gggcattcct caacctaaaa aacctagggt agttactgct 600
tgaagacaac cagthacccc aaataccctc tggthtgcca gagtctthga cagaacttag 660
tctaattcaa aacaatatat acaacataac taaagagggt atthcaagac ttataaactt 720

```

gaaaaatctc tatttggcct ggaactgcta ttttaacaaa gtttgcgaga aaactaacat	780
agaagatgga gtatttgaaa cgctgacaaa tttggagttg ctatcactat ctttcaattc	840
tctttcacac gtgtcaccca aactgccaaag ctccctacgc aaactttttc tgagcaacac	900
ccagatcaaa tacattagtg aagaagattt caagggattg ataaatttaa cattactaga	960
tttaagcggg aactgtccga ggtgcttcaa tgccccattt ccatgcgtgc cttgtgatgg	1020
tggtgcttca attaatatag atcgttttgc ttttcaaaac ttgacccaac ttcgatacct	1080
aaacctctct agcacttccc tcaggaagat taatgctgcc tggtttaaaa atatgcctca	1140
tctgaaggtg ctggatcttg aattcaacta tttagtggga gaaatagcct ctggggcatt	1200
tttaacgatg ctgccccgct tagaaatact tgacttgtct ttttaactata taaaggggag	1260
ttatccacag catattaata tttccagaaa cttctctaaa cctttgtctc tacgggcatt	1320
gcatttaaga ggttatgtgt tccaggaact cagagaagat gatttccagc ccctgatgca	1380
gcttccaaac ttatcgacta tcaacttggg tattaatttt attaagcaaa tcgatttcaa	1440
acttttccaa aatttctcca atctggaaat tatttacttg tcagaaaaca gaatatcacc	1500
gttggtaaaa gatacccggc agagttagtc aaatagttcc tcttttcaac gtcatatccg	1560
gaaacgacgc tcaacagatt ttgagtttga cccacattcg aacttttacc atttcacccg	1620
tcctttaata aagccacaat gtgctgctta tggaaaagcc ttagatttaa gcctcaacag	1680
tattttcttc attgggccaa accaatttga aaatcttccg gacattgcct gtttaaactc	1740
gtctgcaaat agcaatgctc aagtgttaag tggaaactgaa ttttcagcca ttcctcatgt	1800
caaatatttg gatgtgacaa acaatagact agactttgat aatgctagtg ctcttactga	1860
attgtccgac ttggaagttc tagatctcag ctataattca cactatttca gaatagcagg	1920
cgtaacacat catctagaat ttattcaaaa tttcacaat ctaaaagttt taaacttgag	1980
ccacaacaac atttatactt taacagataa gtataacctg gaaagcaagt ccctggtaga	2040
attagttttc agtggaacac gccttgacat tttgtggaat gatgatgaca acaggtatat	2100
ctccattttc aaagggtctc agaattctgac acgtctggat ttatccctta ataggctgaa	2160
gcacatccca aatgaagcat tccttaattt gccagcgagt ctactgaac tacatataaa	2220
tgataaatatg ttaaagtttt ttaactggac attactccag cagtttctc gtctcgagtt	2280
gcttgactta cgtggaaaca aactactctt ttttaactgat agcctatctg actttacatc	2340
ttcccttcgg aactgctgc tgagtcataa caggatttcc cacctacct ctggctttct	2400
ttctgaagtc agtagtctga agcacctcga ttttaagttcc aatctgctaa aaacaatcaa	2460
caaatccgca cttgaaacta agaccaccac caaattatct atgttggaac tacacggaaa	2520
cccctttgaa tgcacctgtg acattggaga tttccgaaga tggatggatg aacatctgaa	2580
tgtcaaaatt cccagactgg tagatgtcat ttgtgccagt cctggggatc aaagagggaa	2640

gagtattgtg agtctggagc taacaacttg tgtttcagat gtcactgcag tgatattatt 2700  
 tttcttcacg ttctttatca ccaccatggc tatgttggct gccctggctc accatttggt 2760  
 ttactgggat gtttggttta tatataatgt gtgttttagct aagataaaag gctacaggctc 2820  
 tctttccaca toccaaactt tctatgatgc ttacatttct tatgacacca aagatgcctc 2880  
 tgttactgac tgggtgataa atgagctgcg ctaccacctt gaagagagcc gagacaaaaa 2940  
 cgttctcctt tgtctagagg agagggattg ggaccggga ttggccatca tcgacaacct 3000  
 catgcagagc atcaaccaa gcaagaaaac agtatttggt ttaacaaaaa aatatgcaaa 3060  
 aagctggaac tttaaaacag ctttttactt ggctttgcag aggctaattg atgagaacat 3120  
 ggatgtgatt atatttatcc tgctggagcc agtggtacag cattctcagt atttgaggct 3180  
 acggcagcgg atctgtaaga gctccatcct ccagtggcct gacaaccoga aggcagaagg 3240  
 cttgttttgg caaactctga gaaatgtggt cttgactgaa aatgattcac ggtataacaa 3300  
 tatgtatgtc gattccatta agcaatacta actgacgtta agtcatgatt tcgcgccata 3360  
 ataaaga 3367

<210> 48

<211> 4211

<212> DNA

<213> Homo sapiens

<400> 48

ctctgcata gagggtagca ttctgcgctg ctgcaagtta cggaatgaaa aattagaaca 60  
 acagaaacat ggaaaacatg ttccttcagt cgtcaatgct gacctgcatt ttcttgctaa 120  
 tatctggttc ctgtgagtta tgcgccgaag aaaattttct tagaagctat ccttgtgatg 180  
 agaaaaagca aaatgactca gttattgcag agtgcagcaa tcgtcgacta caggaagttc 240  
 cccaaacggt gggcaaatat gtgacagaac tagacctgtc tgataatttc atcacacaca 300  
 taacgaatga atcatttcaa gggctgcaaa atctcactaa aataaatcta aaccacaacc 360  
 ccaatgtaca gcaccagaac ggaaatcccg gtatacaatc aaatggcttg aatatcacag 420  
 acggggcatt cctcaacctc aaaaacctaa gggagtact gcttgaagac aaccagttac 480  
 cccaaatacc ctctggtttg ccagagtctt tgacagaact tagtctaatt caaaacaata 540  
 tataacaacat aactaaagag ggcatttcaa gacttataaa cttgaaaaat ctctatttgg 600  
 cctggaactg ctattttaac aaagtttgcg agaaaactaa catagaagat ggagtatttg 660  
 aaacgctgac aaatttggag ttgctatcac tatctttcaa ttctctttca cacgtgccac 720  
 ccaaactgcc aagctcccta cgcaaaacttt ttctgagcaa caccagatc aaatacatta 780  
 gtgaagaaga tttcaaggga ttgataaatt taacattact agatttaagc gggaactgtc 840



cgagggtgctt	caatgcccc	tttccatgcg	tgccttgtga	tggtgggtgct	tcaattaata	900
tagatcgttt	tgcttttcaa	aacttgaccc	aacttcgata	cctaaacctc	tctagcactt	960
ccctcaggaa	gattaatgct	gcctgggtta	aaaatatgcc	tcatctgaag	gtgctggatc	1020
ttgaattcaa	ctatttagtg	ggagaaatag	cctctggggc	atttttaacg	atgctgcccc	1080
gcttagaaat	acttgacttg	tcttttaact	atataaagg	gagttatcca	cagcatatta	1140
atatttccag	aaacttctct	aaacttttgt	ctctacgggc	attgcattta	agaggttatg	1200
tgttccagga	actcagagaa	gatgatttcc	agcccctgat	gcagcttcca	aacttatcga	1260
ctatcaactt	gggtattaat	tttattaagc	aaatcgattt	caaacttttc	caaaatttct	1320
ccaatctgga	aattatttac	ttgtcagaaa	acagaatata	accgttggtg	aaagataccc	1380
ggcagagtta	tgcaaatagt	tcctcttttc	aacgtcatat	ccggaacga	cgctcaacag	1440
attttgagtt	tgaccacacat	tcgaactttt	atcatttcac	ccgtccttta	ataaagccac	1500
aatgtgctgc	ttatggaaaa	gccttagatt	taagcctcaa	cagtattttc	ttcattgggc	1560
caaaccaatt	tgaaaatctt	cctgacattg	cctgtttaaa	tctgtctgca	aatagcaatg	1620
ctcaagtgtt	aagtggaaact	gaattttcag	ccattcctca	tgtcaaata	ttggatttga	1680
caaacaatag	actagacttt	gataatgcta	gtgctcttac	tgaattgtcc	gacttggaag	1740
ttctagatct	cagctataat	tcacactatt	tcagaatagc	aggcgtaaca	catcatctag	1800
aatttattca	aaatttcaca	aatctaaaag	ttttaaactt	gagccacaac	aacatttata	1860
ctttaacaga	taagtataac	ctggaaagca	agtccctggg	agaattagtt	ttcagtggca	1920
atcgccctga	cattttgtgg	aatgatgatg	acaacaggta	tatctccatt	ttcaaaggtc	1980
tcaagaatct	gacacgtctg	gatttatccc	ttaataggct	gaagcacatc	ccaaatgaag	2040
cattccttaa	tttgccagcg	agtctcactg	aactacatat	aatgataat	atgttaaagt	2100
tttttaactg	gacattactc	cagcagtttc	ctcgtctcga	gttgcttgac	ttacgtggaa	2160
acaaactact	ctttttaact	gatagcctat	ctgactttac	atcttccctt	cggacactgc	2220
tgctgagtca	taacaggatt	tcccacctac	cctctggctt	tctttctgaa	gtcagtagtc	2280
tgaagcacct	cgatttaagt	tccaatctgc	taaaaacaat	caacaaatcc	gcacttgaaa	2340
ctaagaccac	caccaaatta	tctatgttgg	aactacacgg	aaaccctttt	gaatgcacct	2400
gtgacattgg	agatttccga	agatggatgg	atgaacatct	gaatgtcaaa	attcccagac	2460
tggtagatgt	catttgtgcc	agtcctgggg	atcaaagagg	gaagagtatt	gtgagtctgg	2520
agctaacaac	ttgtgtttca	gatgtcactg	cagtgatatt	atttttcttc	acgttcttta	2580
tcaccaccat	ggttatgttg	gctgccctgg	ctcaccattt	gttttactgg	gatgtttggg	2640
ttatatataa	tgtgtgttta	gctaaggtaa	aaggctacag	gtctctttcc	acatcccaaa	2700
ctttctatga	tgcttacatt	tcttatgaca	ccaaagatgc	ctctgttact	gactgggtga	2760

```

taaatgagct gcgctaccac cttgaagaga gccgagacaa aaacgttctc ctttgtctag 2820
aggagagggga ttgggatccg ggattggcca tcatcgacaa cctcatgcag agcatcaacc 2880
aaagcaagaa aacagtattt gttttaacca aaaaatatgc aaaaagctgg aactttaaaa 2940
cagcttttta cttggctttg cagaggctaa tggatgagaa catggatgtg attatattta 3000
tcctgctgga gccagtgtta cagcattctc agtatttgag gctacggcag cggatctgta 3060
agagctccat cctccagtgg cctgacaacc cgaaggcaga aggcttgttt tggcaaaactc 3120
tgagaaatgt ggtcttgact gaaaatgatt cacggтатаa caatatgtat gtcgattcca 3180
ttaagcaata ctaactgacg ttaagtcatg atttcgcgcc ataataaaga tgcaaaggaa 3240
tgacatttct gtattagtta tctattgcta tgtaacaaat tatcccaaaa cttagtgggtt 3300
taaaacaaca catttgctgg ccacagttt ttgagggta ggagtccagg cccagcataa 3360
ctgggtctc tgctcagggt gtctcagagg ctgcaatgta ggtgttcacc agagacatag 3420
gcatcactgg ggtcacactc atgtggttgt tttctggatt caattcctoc tgggctattg 3480
gccaaaggct atactcatgt aagccatgcg agcctctccc acaaggcagc ttgcttcac 3540
agagctagca aaaaagagag gttgctagca agatgaagtc acaatctttt gtaatcgaat 3600
caaaaaagtg atatctcatc actttggcca tattctattt gttagaagta aaccacaggt 3660
cccaccagct ccatgggagt gaccacctca gtccaggga aacagctgaa gaccaagatg 3720
gtgagctctg attgcttcag ttggatca actatcttcc cttgactgct gtctgggat 3780
ggcctgctat cttgatgata gattgtgaat atcaggaggc agggatcact gtggaccatc 3840
ttagcagttg acctaacaca tcttcttttc aatatctaag aacttttgcc actgtgacta 3900
atggctcctaa tattaagctg ttgtttatat ttatcatata tctatggcta catggttata 3960
ttatgctgtg gttgcgttcg gttttattta cagttgcttt taaaaatatt tgctgtaaca 4020
tttgacttct aaggtttaga tgcatttaa gaactgagat ggatagcttt taaagcatct 4080
tttacttctt accatttttt aaaagtatgc agctaaatc gaagcttttg gtctatattg 4140
ttaattgcca ttgctgtaaa tcttaaaatg aatgaataaa aatgtttcat ttacaaaaa 4200
aaaaaaaaa a 4211

```

&lt;210&gt; 49

&lt;211&gt; 3468

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 49

```

ctcctgcata gaggtacca ttctgcgtg ctgcaagtta cggaatgaaa aattagaaca 60
acagaaacat ggttctcttg acatttcagt gttagggaac atcagcaaga cccatcccag 120

```

```

gagaccttga aggaagcctt tgaaaggag aatgaaggag tcatctttgc aaaatagctc 180
ctgcagcctg ggaaaggaga ctaaaaagga aaacatgttc cttcagtcgt caatgctgac 240

ctgcattttc ctgctaatat ctggttcctg tgagttatgc gccgaagaaa atttttctag 300
aagctatcct tgtgatgaga aaaagcaaaa tgactcagtt attgcagagt gcagcaatcg 360
tcgactacag gaagttcccc aaacggtggg caaatatgtg acagaactag acctgtctga 420
taatttcata acacacataa cgaatgaatc atttcaaggg ctgcaaaatc tcactaaaat 480
aatctaaac cacaacccca atgtacagca ccagaacgga aatcccggta tacaatcaaa 540
tggtttgaat atcacagacg gggcattcct caacctaaaa aacctagggt agttactgct 600
tgaagacaac cagttacccc aaataccctc tggtttgcca gagtctttga cagaacttag 660
tctaattcaa aacaatatat acaacataac taaagagggtc atttcaagac ttataaactt 720
gaaaaatctc tatttggcct ggaactgcta ttttaacaaa gtttgcgaga aaactaacat 780
agaagatgga gtatttgaaa cgtgacaaa tttggagttg ctatcactat ctttcaattc 840
tctttcacac gtgccacca aactgccag ctccctacgc aaactttttc tgagcaacac 900
ccagatcaaa tacattagtg aagaagattt caagggttg ataaatttaa cattactaga 960
tttaagcggg aactgtccga ggtgcttcaa tgccccattt ccatgcgtgc cttgtgatgg 1020
tggtgcttca attaatatag atcgttttgc ttttcaaaac ttgacccaac ttogatacct 1080
aaacctctct agcacttccc tcaggaagat taatgctgcc tggtttaaaa atatgcctca 1140
tctgaagggtg ctggatcttg aattcaacta tttagtggga gaaatagcct ctggggcatt 1200
tttaacgatg ctgccccgt tagaaatact tgacttgtct ttttaactata taaaggggag 1260
ttatccacag catattaata tttccagaaa cttctctaaa cttttgtctc tacgggcatt 1320
gcatttaaga ggttatgtgt tccaggaact cagagaagat gatttccagc ccctgatgca 1380
gcttccaaac ttatogacta tcaacttggg tattaatttt attaagcaaa tcgatttcaa 1440
acttttccaa aatttctcca atctggaaat tatttacttg tcagaaaaca gaatatcacc 1500
gttggtaaaa gatacccggt agagttatgc aaatagttcc tcttttcaac gtcatatccg 1560
gaaacgacgc tcaacagatt ttgagtttga cccacattcg aacttttatc atttcacccg 1620
tcctttaata aagccacaat gtgctgttta tggaaaagcc ttagatttaa gcctcaacag 1680
tattttcttc attgggccaa accaatttga aaatcttcct gacattgcct gtttaaactc 1740
gtctgcaaat agcaatgctc aagtgttaag tggaactgaa ttttcagcca ttcctcatgt 1800
caaatatttg gatttgacaa acaatagact agactttgat aatgctagtg ctcttactga 1860
attgtccgac ttggaagttc tagatctcag ctataattca cactatttca gaatagcagg 1920
cgtaacacat catctagaat ttattcaaaa tttcaciaat ctaaaagttt taaacttgag 1980
ccacaacaac atttatactt taacagataa gtataacctg gaaagcaagt ccctggtaga 2040

```

```

attagttttc agtggcaatc gccttgacat tttgtggaat gatgatgaca acaggtatat 2100
ctccattttc aaaggtctca agaactctgac acgtctggat ttatccctta ataggctgaa 2160
gcacatccca aatgaagcat tccttaattt gccagcgagt ctactgaac tacatataaa 2220
tgataatatg ttaaagtttt ttaactggac attactccag cagtttcctc gtctcgagtt 2280
gcttgactta cgtggaaaca aactactctt tttaactgat agcctatctg actttacatc 2340
ttcccttcgg aactgctgc tgagtcataa caggatttcc cacctaccct ctggctttct 2400
ttctgaagtc agtagtctga agcacctcga tttaagttcc aatctgctaa aaacaatcaa 2460
caaatccgca cttgaaacta agaccaccac caaattatct atgttggaac tacacggaaa 2520
cccctttgaa tgcacctgtg acattggaga tttccgaaga tggatggatg aacatctgaa 2580
tgtcaaaatt ccagactgg tagatgtcat ttgtgccagt cctggggatc aaagagggaa 2640
gagtattgtg agtctggagc taacaacttg tgtttcagat gtcactgcag tgatattatt 2700
ttctttcacg ttctttatca ccaccatggt tatgttggct gccctggctc accatttggt 2760
ttactgggat gtttggttta tatataatgt gtgttttagct aaggtaaaag gctacaggtc 2820
tctttccaca tcccaaactt tctatgatgc ttacatttct tatgacacca aagatgcctc 2880
tgttactgac tgggtgataa atgagctgcg ctaccacctt gaagagagcc gagacaaaaa 2940
cgttctcctt tgtctagagg agagggattg ggatccggga ttggccatca tcgacaacct 3000
catgcagagc atcaacaaaa gcaagaaaac agtattttgtt ttaacaaaaa aatatgcaaa 3060
aagctggaac tttaaaacag ctttttactt ggctttgcag aggctaattg atgagaacat 3120
ggatgtgatt atatttatcc tgctggagcc agtgttacag cattctcagt atttgaggct 3180
acggcagcgg atctgtaaga gctccatcct ccagtggcct gacaaccgga aggcagaagg 3240
cttgtttttg caaactctga gaaatgtggt cttgactgaa aatgattcac ggtataacaa 3300
tatgtatgtc gattccatta agcaatacta actgacgtta agtcatgatt tcgcgccata 3360
ataaagatgc aaaggaatga cttttctgta ttagttatct attgctatgt aacaaattat 3420
cccaaaactt agtgggttaa aacaacacat ttgctggccc acagtttt 3468

```

&lt;210&gt; 50

&lt;211&gt; 1041

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 50

```

Met Glu Asn Met Phe Leu Gln Ser Ser Met Leu Thr Cys Ile Phe Leu
1           5           10           15

```

```

Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe Ser Arg
          20           25           30

```

Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile Ala Glu  
 35 40 45  
 Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly Lys Tyr  
 50 55 60  
 Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile Thr Asn  
 65 70 75 80  
 Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu Asn His  
 85 90 95  
 Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln Ser Asn  
 100 105 110  
 Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn Leu Arg  
 115 120 125  
 Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser Gly Leu  
 130 135 140  
 Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile Tyr Asn  
 145 150 155 160  
 Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn Leu Tyr  
 165 170 175  
 Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr Asn Ile  
 180 185 190  
 Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu Ser Leu  
 195 200 205  
 Ser Phe Asn Ser Leu Ser His Val Pro Pro Lys Leu Pro Ser Ser Leu  
 210 215 220  
 Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser Glu Glu  
 225 230 235 240  
 Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn  
 245 250 255  
 Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys Asp Gly  
 260 265 270  
 Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu Thr Gln  
 275 280 285  
 Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile Asn Ala  
 290 295 300  
 Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu Glu Phe  
 305 310 315 320  
 Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr Met Leu  
 325 330 335  
 Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys Gly Ser  
 340 345 350  
 Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Leu Leu Ser

355	360	365
Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu Arg Glu		
370	375	380
Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr Ile Asn		
385	390	395
400		
Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe Gln Asn		
405	410	415
Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile Ser Pro		
420	425	430
Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Ser Phe Gln		
435	440	445
Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp Pro His		
450	455	460
Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln Cys Ala		
465	470	475
480		
Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe Phe Ile		
485	490	495
Gly Pro Asn Gln Phe Glu Asn Leu Pro Asp Ile Ala Cys Leu Asn Leu		
500	505	510
Ser Ala Asn Ser Asn Ala Gln Val Leu Ser Gly Thr Glu Phe Ser Ala		
515	520	525
Ile Pro His Val Lys Tyr Leu Asp Leu Thr Asn Asn Arg Leu Asp Phe		
530	535	540
Asp Asn Ala Ser Ala Leu Thr Glu Leu Ser Asp Leu Glu Val Leu Asp		
545	550	555
560		
Leu Ser Tyr Asn Ser His Tyr Phe Arg Ile Ala Gly Val Thr His His		
565	570	575
Leu Glu Phe Ile Gln Asn Phe Thr Asn Leu Lys Val Leu Asn Leu Ser		
580	585	590
His Asn Asn Ile Tyr Thr Leu Thr Asp Lys Tyr Asn Leu Glu Ser Lys		
595	600	605
Ser Leu Val Glu Leu Val Phe Ser Gly Asn Arg Leu Asp Ile Leu Trp		
610	615	620
Asn Asp Asp Asp Asn Arg Tyr Ile Ser Ile Phe Lys Gly Leu Lys Asn		
625	630	635
640		
Leu Thr Arg Leu Asp Leu Ser Leu Asn Arg Leu Lys His Ile Pro Asn		
645	650	655
Glu Ala Phe Leu Asn Leu Pro Ala Ser Leu Thr Glu Leu His Ile Asn		
660	665	670
Asp Asn Met Leu Lys Phe Phe Asn Trp Thr Leu Leu Gln Gln Phe Pro		
675	680	685
Arg Leu Glu Leu Leu Asp Leu Arg Gly Asn Lys Leu Leu Phe Leu Thr		

690	695	700
Asp Ser Leu Ser Asp Phe Thr Ser Ser Leu Arg Thr Leu Leu Leu Ser		
705	710	715 720
His Asn Arg Ile Ser His Leu Pro Ser Gly Phe Leu Ser Glu Val Ser		
	725	730 735
Ser Leu Lys His Leu Asp Leu Ser Ser Asn Leu Leu Lys Thr Ile Asn		
	740	745 750
Lys Ser Ala Leu Glu Thr Lys Thr Thr Thr Lys Leu Ser Met Leu Glu		
	755	760 765
Leu His Gly Asn Pro Phe Glu Cys Thr Cys Asp Ile Gly Asp Phe Arg		
	770	775 780
Arg Trp Met Asp Glu His Leu Asn Val Lys Ile Pro Arg Leu Val Asp		
	785	790 795 800
Val Ile Cys Ala Ser Pro Gly Asp Gln Arg Gly Lys Ser Ile Val Ser		
	805	810 815
Leu Glu Leu Thr Thr Cys Val Ser Asp Val Thr Ala Val Ile Leu Phe		
	820	825 830
Phe Phe Thr Phe Phe Ile Thr Thr Met Val Met Leu Ala Ala Leu Ala		
	835	840 845
His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val Cys Leu		
	850	855 860
Ala Lys Val Lys Gly Tyr Arg Ser Leu Ser Thr Ser Gln Thr Phe Tyr		
	865	870 875 880
Asp Ala Tyr Ile Ser Tyr Asp Thr Lys Asp Ala Ser Val Thr Asp Trp		
	885	890 895
Val Ile Asn Glu Leu Arg Tyr His Leu Glu Glu Ser Arg Asp Lys Asn		
	900	905 910
Val Leu Leu Cys Leu Glu Glu Arg Asp Trp Asp Pro Gly Leu Ala Ile		
	915	920 925
Ile Asp Asn Leu Met Gln Ser Ile Asn Gln Ser Lys Lys Thr Val Phe		
	930	935 940
Val Leu Thr Lys Lys Tyr Ala Lys Ser Trp Asn Phe Lys Thr Ala Phe		
	945	950 955 960
Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val Ile Ile		
	965	970 975
Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr Leu Arg Leu		
	980	985 990
Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln Trp Pro Asp Asn Pro		
	995	1000 1005
Lys Ala Glu Gly Leu Phe Trp Gln Thr Leu Arg Asn Val Val Leu		
	1010	1015 1020
Thr Glu Asn Asp Ser Arg Tyr Asn Asn Met Tyr Val Asp Ser Ile		

1025  
Lys Gln Tyr  
1040

1030

1035

<210> 51  
<211> 1059  
<212> PRT  
<213> Homo sapiens

<400> 51

Met	Lys	Glu	Ser	Ser	Leu	Gln	Asn	Ser	Ser	Cys	Ser	Leu	Gly	Lys	Glu	1	5	10	15
Thr	Lys	Lys	Glu	Asn	Met	Phe	Leu	Gln	Ser	Ser	Met	Leu	Thr	Cys	Ile	20	25	30	
Phe	Leu	Leu	Ile	Ser	Gly	Ser	Cys	Glu	Leu	Cys	Ala	Glu	Glu	Asn	Phe	35	40	45	
Ser	Arg	Ser	Tyr	Pro	Cys	Asp	Glu	Lys	Lys	Gln	Asn	Asp	Ser	Val	Ile	50	55	60	
Ala	Glu	Cys	Ser	Asn	Arg	Arg	Leu	Gln	Glu	Val	Pro	Gln	Thr	Val	Gly	65	70	75	80
Lys	Tyr	Val	Thr	Glu	Leu	Asp	Leu	Ser	Asp	Asn	Phe	Ile	Thr	His	Ile	85	90	95	
Thr	Asn	Glu	Ser	Phe	Gln	Gly	Leu	Gln	Asn	Leu	Thr	Lys	Ile	Asn	Leu	100	105	110	
Asn	His	Asn	Pro	Asn	Val	Gln	His	Gln	Asn	Gly	Asn	Pro	Gly	Ile	Gln	115	120	125	
Ser	Asn	Gly	Leu	Asn	Ile	Thr	Asp	Gly	Ala	Phe	Leu	Asn	Leu	Lys	Asn	130	135	140	
Leu	Arg	Glu	Leu	Leu	Leu	Glu	Asp	Asn	Gln	Leu	Pro	Gln	Ile	Pro	Ser	145	150	155	160
Gly	Leu	Pro	Glu	Ser	Leu	Thr	Glu	Leu	Ser	Leu	Ile	Gln	Asn	Asn	Ile	165	170	175	
Tyr	Asn	Ile	Thr	Lys	Glu	Gly	Ile	Ser	Arg	Leu	Ile	Asn	Leu	Lys	Asn	180	185	190	
Leu	Tyr	Leu	Ala	Trp	Asn	Cys	Tyr	Phe	Asn	Lys	Val	Cys	Glu	Lys	Thr	195	200	205	
Asn	Ile	Glu	Asp	Gly	Val	Phe	Glu	Thr	Leu	Thr	Asn	Leu	Glu	Leu	Leu	210	215	220	
Ser	Leu	Ser	Phe	Asn	Ser	Leu	Ser	His	Val	Ser	Pro	Lys	Leu	Pro	Ser	225	230	235	240
Ser	Leu	Arg	Lys	Leu	Phe	Leu	Ser	Asn	Thr	Gln	Ile	Lys	Tyr	Ile	Ser	245	250	255	
Glu	Glu	Asp	Phe	Lys	Gly	Leu	Ile	Asn	Leu	Thr	Leu	Leu	Asp	Leu	Ser	260	265	270	



Gly Asn Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys  
 275 280 285  
 Asp Gly Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu  
 290 295 300  
 Thr Gln Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile  
 305 310 315 320  
 Asn Ala Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu  
 325 330 335  
 Glu Phe Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr  
 340 345 350  
 Met Leu Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys  
 355 360 365  
 Gly Ser Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Pro  
 370 375 380  
 Leu Ser Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu  
 385 390 395 400  
 Arg Glu Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr  
 405 410 415  
 Ile Asn Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe  
 420 425 430  
 Gln Asn Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile  
 435 440 445  
 Ser Pro Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Ser  
 450 455 460  
 Phe Gln Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp  
 465 470 475 480  
 Pro His Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln  
 485 490 495  
 Cys Ala Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe  
 500 505 510  
 Phe Ile Gly Pro Asn Gln Phe Glu Asn Leu Pro Asp Ile Ala Cys Leu  
 515 520 525  
 Asn Leu Ser Ala Asn Ser Asn Ala Gln Val Leu Ser Gly Thr Glu Phe  
 530 535 540  
 Ser Ala Ile Pro His Val Lys Tyr Leu Asp Leu Thr Asn Asn Arg Leu  
 545 550 555 560  
 Asp Phe Asp Asn Ala Ser Ala Leu Thr Glu Leu Ser Asp Leu Glu Val  
 565 570 575  
 Leu Asp Leu Ser Tyr Asn Ser His Tyr Phe Arg Ile Ala Gly Val Thr  
 580 585 590  
 His His Leu Glu Phe Ile Gln Asn Phe Thr Asn Leu Lys Val Leu Asn

595 600 605  
 Leu Ser His Asn Asn Ile Tyr Thr Leu Thr Asp Lys Tyr Asn Leu Glu  
 610 615 620  
 Ser Lys Ser Leu Val Glu Leu Val Phe Ser Gly Asn Arg Leu Asp Ile  
 625 630 635 640  
 Leu Trp Asn Asp Asp Asp Asn Arg Tyr Ile Ser Ile Phe Lys Gly Leu  
 645 650 655  
 Lys Asn Leu Thr Arg Leu Asp Leu Ser Leu Asn Arg Leu Lys His Ile  
 660 665 670  
 Pro Asn Glu Ala Phe Leu Asn Leu Pro Ala Ser Leu Thr Glu Leu His  
 675 680 685  
 Ile Asn Asp Asn Met Leu Lys Phe Phe Asn Trp Thr Leu Leu Gln Gln  
 690 695 700  
 Phe Pro Arg Leu Glu Leu Leu Asp Leu Arg Gly Asn Lys Leu Leu Phe  
 705 710 715 720  
 Leu Thr Asp Ser Leu Ser Asp Phe Thr Ser Ser Leu Arg Thr Leu Leu  
 725 730 735  
 Leu Ser His Asn Arg Ile Ser His Leu Pro Ser Gly Phe Leu Ser Glu  
 740 745 750  
 Val Ser Ser Leu Lys His Leu Asp Leu Ser Ser Asn Leu Leu Lys Thr  
 755 760 765  
 Ile Asn Lys Ser Ala Leu Glu Thr Lys Thr Thr Thr Lys Leu Ser Met  
 770 775 780  
 Leu Glu Leu His Gly Asn Pro Phe Glu Cys Thr Cys Asp Ile Gly Asp  
 785 790 795 800  
 Phe Arg Arg Trp Met Asp Glu His Leu Asn Val Lys Ile Pro Arg Leu  
 805 810 815  
 Val Asp Val Ile Cys Ala Ser Pro Gly Asp Gln Arg Gly Lys Ser Ile  
 820 825 830  
 Val Ser Leu Glu Leu Thr Thr Cys Val Ser Asp Val Thr Ala Val Ile  
 835 840 845  
 Leu Phe Phe Phe Thr Phe Phe Ile Thr Thr Met Val Met Leu Ala Ala  
 850 855 860  
 Leu Ala His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val  
 865 870 875 880  
 Cys Leu Ala Lys Ile Lys Gly Tyr Arg Ser Leu Ser Thr Ser Gln Thr  
 885 890 895  
 Phe Tyr Asp Ala Tyr Ile Ser Tyr Asp Thr Lys Asp Ala Ser Val Thr  
 900 905 910  
 Asp Trp Val Ile Asn Glu Leu Arg Tyr His Leu Glu Glu Ser Arg Asp  
 915 920 925  
 Lys Asn Val Leu Leu Cys Leu Glu Glu Arg Asp Trp Asp Pro Gly Leu

930 935 940  
 Ala Ile Ile Asp Asn Leu Met Gln Ser Ile Asn Gln Ser Lys Lys Thr  
 945 950 955 960  
 Val Phe Val Leu Thr Lys Lys Tyr Ala Lys Ser Trp Asn Phe Lys Thr  
 965 970 975  
 Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val  
 980 985 990  
 Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr Leu  
 995 1000 1005  
 Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln Trp Pro  
 1010 1015 1020  
 Asp Asn Pro Lys Ala Glu Gly Leu Phe Trp Gln Thr Leu Arg Asn  
 1025 1030 1035  
 Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asn Asn Met Tyr Val  
 1040 1045 1050  
 Asp Ser Ile Lys Gln Tyr  
 1055

<210> 52  
 <211> 1041  
 <212> PRT  
 <213> Homo sapiens

<400> 52

Met Glu Asn Met Phe Leu Gln Ser Ser Met Leu Thr Cys Ile Phe Leu  
 1 5 10 15  
 Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe Ser Arg  
 20 25 30  
 Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile Ala Glu  
 35 40 45  
 Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly Lys Tyr  
 50 55 60  
 Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile Thr Asn  
 65 70 75 80  
 Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu Asn His  
 85 90 95  
 Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln Ser Asn  
 100 105 110  
 Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn Leu Arg  
 115 120 125  
 Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser Gly Leu  
 130 135 140  
 Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile Tyr Asn  
 145 150 155 160

Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn Leu Tyr  
 165 170 175  
 Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr Asn Ile  
 180 185 190  
 Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu Ser Leu  
 195 200 205  
 Ser Phe Asn Ser Leu Ser His Val Pro Pro Lys Leu Pro Ser Ser Leu  
 210 215 220  
 Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser Glu Glu  
 225 230 235 240  
 Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn  
 245 250 255  
 Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys Asp Gly  
 260 265 270  
 Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu Thr Gln  
 275 280 285  
 Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile Asn Ala  
 290 295 300  
 Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu Glu Phe  
 305 310 315 320  
 Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr Met Leu  
 325 330 335  
 Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys Gly Ser  
 340 345 350  
 Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Leu Leu Ser  
 355 360 365  
 Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu Arg Glu  
 370 375 380  
 Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr Ile Asn  
 385 390 395 400  
 Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe Gln Asn  
 405 410 415  
 Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile Ser Pro  
 420 425 430  
 Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Ser Phe Gln  
 435 440 445  
 Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp Pro His  
 450 455 460  
 Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln Cys Ala  
 465 470 475 480  
 Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe Phe Ile

				485					490					495			
Gly	Pro	Asn	Gln	Phe	Glu	Asn	Leu	Pro	Asp	Ile	Ala	Cys	Leu	Asn	Leu		
			500					505					510				
Ser	Ala	Asn	Ser	Asn	Ala	Gln	Val	Leu	Ser	Gly	Thr	Glu	Phe	Ser	Ala		
		515					520					525					
Ile	Pro	His	Val	Lys	Tyr	Leu	Asp	Leu	Thr	Asn	Asn	Arg	Leu	Asp	Phe		
	530					535					540						
Asp	Asn	Ala	Ser	Ala	Leu	Thr	Glu	Leu	Ser	Asp	Leu	Glu	Val	Leu	Asp		
545					550					555					560		
Leu	Ser	Tyr	Asn	Ser	His	Tyr	Phe	Arg	Ile	Ala	Gly	Val	Thr	His	His		
				565					570					575			
Leu	Glu	Phe	Ile	Gln	Asn	Phe	Thr	Asn	Leu	Lys	Val	Leu	Asn	Leu	Ser		
			580					585					590				
His	Asn	Asn	Ile	Tyr	Thr	Leu	Thr	Asp	Lys	Tyr	Asn	Leu	Glu	Ser	Lys		
		595					600					605					
Ser	Leu	Val	Glu	Leu	Val	Phe	Ser	Gly	Asn	Arg	Leu	Asp	Ile	Leu	Trp		
	610					615					620						
Asn	Asp	Asp	Asp	Asn	Arg	Tyr	Ile	Ser	Ile	Phe	Lys	Gly	Leu	Lys	Asn		
625					630					635					640		
Leu	Thr	Arg	Leu	Asp	Leu	Ser	Leu	Asn	Arg	Leu	Lys	His	Ile	Pro	Asn		
				645					650					655			
Glu	Ala	Phe	Leu	Asn	Leu	Pro	Ala	Ser	Leu	Thr	Glu	Leu	His	Ile	Asn		
			660					665					670				
Asp	Asn	Met	Leu	Lys	Phe	Phe	Asn	Trp	Thr	Leu	Leu	Gln	Gln	Phe	Pro		
		675					680					685					
Arg	Leu	Glu	Leu	Leu	Asp	Leu	Arg	Gly	Asn	Lys	Leu	Leu	Phe	Leu	Thr		
	690					695					700						
Asp	Ser	Leu	Ser	Asp	Phe	Thr	Ser	Ser	Leu	Arg	Thr	Leu	Leu	Leu	Ser		
705					710					715					720		
His	Asn	Arg	Ile	Ser	His	Leu	Pro	Ser	Gly	Phe	Leu	Ser	Glu	Val	Ser		
				725					730					735			
Ser	Leu	Lys	His	Leu	Asp	Leu	Ser	Ser	Asn	Leu	Leu	Lys	Thr	Ile	Asn		
			740					745					750				
Lys	Ser	Ala	Leu	Glu	Thr	Lys	Thr	Thr	Thr	Lys	Leu	Ser	Met	Leu	Glu		
		755					760					765					
Leu	His	Gly	Asn	Pro	Phe	Glu	Cys	Thr	Cys	Asp	Ile	Gly	Asp	Phe	Arg		
	770					775					780						
Arg	Trp	Met	Asp	Glu	His	Leu	Asn	Val	Lys	Ile	Pro	Arg	Leu	Val	Asp		
785					790					795					800		
Val	Ile	Cys	Ala	Ser	Pro	Gly	Asp	Gln	Arg	Gly	Lys	Ser	Ile	Val	Ser		
				805					810					815			
Leu	Glu	Leu	Thr	Thr	Cys	Val	Ser	Asp	Val	Thr	Ala	Val	Ile	Leu	Phe		

820 825 830  
 Phe Phe Thr Phe Phe Ile Thr Thr Met Val Met Leu Ala Ala Leu Ala  
 835 840 845  
 His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val Cys Leu  
 850 855 860  
 Ala Lys Val Lys Gly Tyr Arg Ser Leu Ser Thr Ser Gln Thr Phe Tyr  
 865 870 875 880  
 Asp Ala Tyr Ile Ser Tyr Asp Thr Lys Asp Ala Ser Val Thr Asp Trp  
 885 890 895  
 Val Ile Asn Glu Leu Arg Tyr His Leu Glu Glu Ser Arg Asp Lys Asn  
 900 905 910  
 Val Leu Leu Cys Leu Glu Glu Arg Asp Trp Asp Pro Gly Leu Ala Ile  
 915 920 925  
 Ile Asp Asn Leu Met Gln Ser Ile Asn Gln Ser Lys Lys Thr Val Phe  
 930 935 940  
 Val Leu Thr Lys Lys Tyr Ala Lys Ser Trp Asn Phe Lys Thr Ala Phe  
 945 950 955 960  
 Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val Ile Ile  
 965 970 975  
 Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr Leu Arg Leu  
 980 985 990  
 Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln Trp Pro Asp Asn Pro  
 995 1000 1005  
 Lys Ala Glu Gly Leu Phe Trp Gln Thr Leu Arg Asn Val Val Leu  
 1010 1015 1020  
 Thr Glu Asn Asp Ser Arg Tyr Asn Asn Met Tyr Val Asp Ser Ile  
 1025 1030 1035  
 Lys Gln Tyr  
 1040  
  
 <210> 53  
 <211> 1041  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 53  
  
 Met Glu Asn Met Phe Leu Gln Ser Ser Met Leu Thr Cys Ile Phe Leu  
 1 5 10 15  
 Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe Ser Arg  
 20 25 30  
 Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile Ala Glu  
 35 40 45  
 Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly Lys Tyr  
 50 55 60

Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile Thr Asn  
 65 70 75 80  
 Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu Asn His  
 85 90 95  
 Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln Ser Asn  
 100 105 110  
 Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn Leu Arg  
 115 120 125  
 Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser Gly Leu  
 130 135 140  
 Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile Tyr Asn  
 145 150 155 160  
 Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn Leu Tyr  
 165 170 175  
 Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr Asn Ile  
 180 185 190  
 Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu Ser Leu  
 195 200 205  
 Ser Phe Asn Ser Leu Ser His Val Pro Pro Lys Leu Pro Ser Ser Leu  
 210 215 220  
 Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser Glu Glu  
 225 230 235 240  
 Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn  
 245 250 255  
 Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys Asp Gly  
 260 265 270  
 Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu Thr Gln  
 275 280 285  
 Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile Asn Ala  
 290 295 300  
 Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu Glu Phe  
 305 310 315 320  
 Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr Met Leu  
 325 330 335  
 Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys Gly Ser  
 340 345 350  
 Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Leu Leu Ser  
 355 360 365  
 Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu Arg Glu  
 370 375 380  
 Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr Ile Asn

385	390										395					400			
Leu	Gly	Ile	Asn	Phe	Ile	Lys	Gln	Ile	Asp	Phe	Lys	Leu	Phe	Gln	Asn				
				405						410		415							
Phe	Ser	Asn	Leu	Glu	Ile	Ile	Tyr	Leu	Ser	Glu	Asn	Arg	Ile	Ser	Pro				
				420						425		430							
Leu	Val	Lys	Asp	Thr	Arg	Gln	Ser	Tyr	Ala	Asn	Ser	Ser	Ser	Phe	Gln				
				435								445							
Arg	His	Ile	Arg	Lys	Arg	Arg	Ser	Thr	Asp	Phe	Glu	Phe	Asp	Pro	His				
				450		455				460									
Ser	Asn	Phe	Tyr	His	Phe	Thr	Arg	Pro	Leu	Ile	Lys	Pro	Gln	Cys	Ala				
465				470				475								480			
Ala	Tyr	Gly	Lys	Ala	Leu	Asp	Leu	Ser	Leu	Asn	Ser	Ile	Phe	Phe	Ile				
				485						490		495							
Gly	Pro	Asn	Gln	Phe	Glu	Asn	Leu	Pro	Asp	Ile	Ala	Cys	Leu	Asn	Leu				
				500		505				510									
Ser	Ala	Asn	Ser	Asn	Ala	Gln	Val	Leu	Ser	Gly	Thr	Glu	Phe	Ser	Ala				
				515		520				525									
Ile	Pro	His	Val	Lys	Tyr	Leu	Asp	Leu	Thr	Asn	Asn	Arg	Leu	Asp	Phe				
530				535				540											
Asp	Asn	Ala	Ser	Ala	Leu	Thr	Glu	Leu	Ser	Asp	Leu	Glu	Val	Leu	Asp				
545				550				555								560			
Leu	Ser	Tyr	Asn	Ser	His	Tyr	Phe	Arg	Ile	Ala	Gly	Val	Thr	His	His				
				565						570		575							
Leu	Glu	Phe	Ile	Gln	Asn	Phe	Thr	Asn	Leu	Lys	Val	Leu	Asn	Leu	Ser				
				580		585				590									
His	Asn	Asn	Ile	Tyr	Thr	Leu	Thr	Asp	Lys	Tyr	Asn	Leu	Glu	Ser	Lys				
				595		600				605									
Ser	Leu	Val	Glu	Leu	Val	Phe	Ser	Gly	Asn	Arg	Leu	Asp	Ile	Leu	Trp				
610				615				620											
Asn	Asp	Asp	Asp	Asn	Arg	Tyr	Ile	Ser	Ile	Phe	Lys	Gly	Leu	Lys	Asn				
625				630				635								640			
Leu	Thr	Arg	Leu	Asp	Leu	Ser	Leu	Asn	Arg	Leu	Lys	His	Ile	Pro	Asn				
				645		650				655									
Glu	Ala	Phe	Leu	Asn	Leu	Pro	Ala	Ser	Leu	Thr	Glu	Leu	His	Ile	Asn				
				660		665				670									
Asp	Asn	Met	Leu	Lys	Phe	Phe	Asn	Trp	Thr	Leu	Leu	Gln	Gln	Phe	Pro				
675				680				685											
Arg	Leu	Glu	Leu	Leu	Asp	Leu	Arg	Gly	Asn	Lys	Leu	Leu	Phe	Leu	Thr				
690				695				700											
Asp	Ser	Leu	Ser	Asp	Phe	Thr	Ser	Ser	Leu	Arg	Thr	Leu	Leu	Leu	Ser				
705				710				715								720			
His	Asn	Arg	Ile	Ser	His	Leu	Pro	Ser	Gly	Phe	Leu	Ser	Glu	Val	Ser				



[illegible]

<210> 54  
 <211> 1059  
 <212> PRT  
 <213> Homo sapiens

<400> 54

```

Met Lys Glu Ser Ser Leu Gln Asn Ser Ser Cys Ser Leu Gly Lys Glu
1          5          10          15

Thr Lys Lys Glu Asn Met Phe Leu Gln Ser Ser Met Leu Thr Cys Ile
          20          25          30

Phe Leu Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe
          35          40          45

Ser Arg Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile
          50          55          60

Ala Glu Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly
65          70          75          80

Lys Tyr Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile
          85          90          95

Thr Asn Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu
          100          105          110

Asn His Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln
          115          120          125

Ser Asn Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn
          130          135          140

Leu Arg Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser
          145          150          155          160

Gly Leu Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile
          165          170          175

Tyr Asn Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn
          180          185          190

Leu Tyr Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr
          195          200          205

Asn Ile Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu
          210          215          220

Ser Leu Ser Phe Asn Ser Leu Ser His Val Pro Pro Lys Leu Pro Ser
          225          230          235          240

Ser Leu Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser
          245          250          255

Glu Glu Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser
          260          265          270

Gly Asn Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys
          275          280          285

```

Asp Gly Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu  
 290 295 300  
 Thr Gln Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile  
 305 310 315 320  
 Asn Ala Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu  
 325 330 335  
 Glu Phe Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr  
 340 345 350  
 Met Leu Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys  
 355 360 365  
 Gly Ser Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Leu  
 370 375 380  
 Leu Ser Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu  
 385 390 395 400  
 Arg Glu Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr  
 405 410 415  
 Ile Asn Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe  
 420 425 430  
 Gln Asn Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile  
 435 440 445  
 Ser Pro Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Ser  
 450 455 460  
 Phe Gln Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp  
 465 470 475 480  
 Pro His Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln  
 485 490 495  
 Cys Ala Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe  
 500 505 510  
 Phe Ile Gly Pro Asn Gln Phe Glu Asn Leu Pro Asp Ile Ala Cys Leu  
 515 520 525  
 Asn Leu Ser Ala Asn Ser Asn Ala Gln Val Leu Ser Gly Thr Glu Phe  
 530 535 540  
 Ser Ala Ile Pro His Val Lys Tyr Leu Asp Leu Thr Asn Asn Arg Leu  
 545 550 555 560  
 Asp Phe Asp Asn Ala Ser Ala Leu Thr Glu Leu Ser Asp Leu Glu Val  
 565 570 575  
 Leu Asp Leu Ser Tyr Asn Ser His Tyr Phe Arg Ile Ala Gly Val Thr  
 580 585 590  
 His His Leu Glu Phe Ile Gln Asn Phe Thr Asn Leu Lys Val Leu Asn  
 595 600 605  
 Leu Ser His Asn Asn Ile Tyr Thr Leu Thr Asp Lys Tyr Asn Leu Glu

610	615	620
Ser Lys Ser Leu Val	Glu Leu Val Phe Ser	Gly Asn Arg Leu Asp Ile
625	630	635 640
Leu Trp Asn Asp Asp	Asp Asn Arg Tyr Ile	Ser Ile Phe Lys Gly Leu
	645	650 655
Lys Asn Leu Thr Arg	Leu Asp Leu Ser Leu	Asn Arg Leu Lys His Ile
	660	665 670
Pro Asn Glu Ala Phe	Leu Asn Leu Pro Ala	Ser Leu Thr Glu Leu His
	675	680 685
Ile Asn Asp Asn Met	Leu Lys Phe Phe Asn	Trp Thr Leu Leu Gln Gln
	690	695 700
Phe Pro Arg Leu Glu	Leu Leu Asp Leu Arg	Gly Asn Lys Leu Leu Phe
	705	710 715 720
Leu Thr Asp Ser Leu	Ser Asp Phe Thr Ser	Ser Leu Arg Thr Leu Leu
	725	730 735
Leu Ser His Asn Arg	Ile Ser His Leu Pro	Ser Gly Phe Leu Ser Glu
	740	745 750
Val Ser Ser Leu Lys	His Leu Asp Leu Ser	Ser Asn Leu Leu Lys Thr
	755	760 765
Ile Asn Lys Ser Ala	Leu Glu Thr Lys Thr	Thr Thr Lys Leu Ser Met
	770	775 780
Leu Glu Leu His Gly	Asn Pro Phe Glu Cys	Thr Cys Asp Ile Gly Asp
	785	790 795 800
Phe Arg Arg Trp Met	Asp Glu His Leu Asn	Val Lys Ile Pro Arg Leu
	805	810 815
Val Asp Val Ile Cys	Ala Ser Pro Gly Asp	Gln Arg Gly Lys Ser Ile
	820	825 830
Val Ser Leu Glu Leu	Thr Thr Cys Val Ser	Asp Val Thr Ala Val Ile
	835	840 845
Leu Phe Phe Phe Thr	Phe Phe Ile Thr Thr	Met Val Met Leu Ala Ala
	850	855 860
Leu Ala His His Leu	Phe Tyr Trp Asp Val	Trp Phe Ile Tyr Asn Val
	865	870 875 880
Cys Leu Ala Lys Val	Lys Gly Tyr Arg Ser	Leu Ser Thr Ser Gln Thr
	885	890 895
Phe Tyr Asp Ala Tyr	Ile Ser Tyr Asp Thr	Lys Asp Ala Ser Val Thr
	900	905 910
Asp Trp Val Ile Asn	Glu Leu Arg Tyr His	Leu Glu Glu Ser Arg Asp
	915	920 925
Lys Asn Val Leu Leu	Cys Leu Glu Glu Arg	Asp Trp Asp Pro Gly Leu
	930	935 940
Ala Ile Ile Asp Asn	Leu Met Gln Ser Ile	Asn Gln Ser Lys Lys Thr

945                                      950                                      955                                      960  
 Val Phe Val Leu Thr Lys Lys Tyr Ala Lys Ser Trp Asn Phe Lys Thr  
    965                                      970                                      975  
  
 Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val  
    980                                      985                                      990  
  
 Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr Leu  
    995                                      1000                                      1005  
  
 Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln Trp Pro  
    1010                                      1015                                      1020  
  
 Asp Asn Pro Lys Ala Glu Gly Leu Phe Trp Gln Thr Leu Arg Asn  
    1025                                      1030                                      1035  
  
 Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asn Asn Met Tyr Val  
    1040                                      1045                                      1050  
  
 Asp Ser Ile Lys Gln Tyr  
    1055

<210> 55  
 <211> 3220  
 <212> DNA  
 <213> murine

<400> 55  
 attcagagtt ggatgttaag agagaaacaa acgtttttacc ttcctttgtc tatagaacat 60  
  
 ggaaaaacatg cccctcagc catggattct gacgtgcttt tgtctgctgt cctctggaac 120  
  
 cagtgccatc ttccataaag cgaactattc cagaagctat ccttgtgacg agataaggca 180  
  
 caactccctt gtgattgcag aatgcaacca tcgtcaactg catgaagtgc cccaaactat 240  
  
 aggcaagtat gtgacaaaca tagacttgct agacaatgcc attacacata taacgaaaga 300  
  
 gtcctttcaa aagctgcaaa acctcactaa aatcgatctg aaccacaatg ccaaacaaca 360  
  
 gcaccccaat gaaaataaaa atgggtatgaa tattacagaa ggggcacttc tcagcctaag 420  
  
 aaatctaaca gttttactgc tggaagacaa ccagttatat actatacctg ctgggttgcc 480  
  
 tgagtctttg aaagaactta gcctaattca aaacaatata tttcaggtaa ctaaaaacaa 540  
  
 cacttttggg cttaggaact tggaagact ctatttgggc tggaactgct attttaaatg 600  
  
 taatcaaacc tttaaggtag aagatggggc atttaaaaat cttatacact tgaaggtag 660  
  
 ctcatatctt ttcaataacc ttttctatgt gcccccaaa ctaccaagtt ctctaaggaa 720  
  
 actttttctg agtaatgcca aaatcatgaa catcactcag gaagacttca aaggactgga 780  
  
 aaatttaaca ttactagatc tgagtggaaa ctgtccaagg tgttacaatg ctccatttcc 840  
  
 ttgcacacct tgcaaggaaa actcatccat ccacatacat cctctggcct ttcaaagtct 900  
  
 caccacaact ctctatctaa acctttccag cacttcctc aggacgattc cttctacctg 960  
  
 gtttgaaaat ctgtcaaact tgaagggaact ccactctgaa ttcaactatt tagttcaaga 1020

aattgcctcg ggggcatttt taacaaaact acccagttta caaatccttg atttgcctt 1080  
caactttcaa tataaggaat atttacaatt tattaatatt tcctcaaatt tctctaagct 1140  
tcgttctctc aagaagttgc acttaagagg ctatgtgttc cgagaactta aaaagaagca 1200  
tttcgagcat ctccagagtc ttccaaactt ggcaaccatc aacttgggca ttaactttat 1260  
tgagaaaatt gatttcaaag ctttccagaa tttttccaaa ctcgacgtta tctattttatc 1320  
aggaaaatcg atagcatctg tattagatgg tacagattat tcctcttggc gaaatcgtct 1380  
tcggaaacct ctctcaacag acgatgatga gtttgatcca cacgtgaatt tttaccatag 1440  
caccaaacct ttaataaagc cacagtgtac tgcttatggc aaggccttgg atttaagttt 1500  
gaacaatatt ttcattattg ggaaaagcca atttgaaggt tttcaggata tcgcctgctt 1560  
aaatctgtcc ttcaatgcc aactcaagt gtttaatggc acagaattct cctccatgcc 1620  
ccacattaaa ttttggatt taaccaacaa cagactagac tttgatgata acaatgcttt 1680  
cagtgatctt cacgatctag aagtgtctga cctgagccac aatgcacact atttcagtat 1740  
agcaggggta acgcacogtc taggatttat ccagaactta ataaacctca ggggtgttaa 1800  
cctgagccac aatggcattt acaccctcac agaggaaagt gagctgaaaa gcatctcact 1860  
gaaagaattg gttttcagt gaaatcgtct tgaccatttg tggaatgcaa atgatggcaa 1920  
atactgggtcc atttttaaaa gtctccagaa tttgatacgc ctggacttat catacaataa 1980  
ccttcaacaa atcccaaatg gagcattcct caatttgcct cagagcctcc aagagtact 2040  
tatcagtggg aacaaattac gtttctttaa ttggacatta ctccagtatt ttcctcacct 2100  
tcacttgctg gatttatoga gaaatgagct gtattttcta cccaattgcc tatctaagtt 2160  
tgcacattcc ctggagacac tgctactgag ccataatcat ttctctcacc taccctctgg 2220  
cttcctctcc gaagccagga atctgggtgca cctggatcta agtttcaaca caataaagat 2280  
gatcaataaa tcctccctgc aaaccaagat gaaaacgaac ttgtctattc tggagctaca 2340  
tgggaactat tttgactgca cgtgtgacat aagtgatttt cgaagctggc tagatgaaaa 2400  
tctgaatata acaattccta aattggtaaa tgttatatgt tccaatcctg gggatcaaaa 2460  
atcaaagagt atcatgagcc tagatctcac gacttgtgta tcggatacca ctgcagctgt 2520  
cctgtttttc ctacattcc ttaccacctc catggttatg ttggctgctc tggttcacca 2580  
cctgtttttac tgggatgttt ggtttatcta tcacatgtgc tctgctaagt taaaaggcta 2640  
caggacttca tccacatccc aaactttcta tgatgcttat atttcttatg acaccaaga 2700  
tgcactgttt actgactggg taatcaatga actgcgctac caccttgaag agagtgaaga 2760  
caaaagtgtc ctctttgtt tagaggagag ggattgggat ccaggattac ccatcattga 2820  
taacctcatg cagagcataa accagagcaa gaaaacaatc tttgttttaa ccaagaaata 2880

tgccaagagc tggaacttta aaacagcttt ctacttggcc ttgcagaggc taatggatga 2940  
gaacatggat gtgattatTT tcatcctcct ggaaccagtg ttacagtact cacagtacct 3000  
gaggcttcgg cagaggatct gtaagagctc catcctccag tggcccaaca atcccaaagc 3060  
agaaaacttg ttttggcaaa gtctgaaaaa tgtgggtcttg actgaaaatg attcacggta 3120  
tgacgatttg tacattgatt ccattaggca atactagtga tgggaagtca cgactctgcc 3180  
atcataaaaa cacacagctt ctccttacia tgaaccgaat 3220

<210> 56

<211> 3220

<212> DNA

<213> murine

<400> 56

attcagagtt ggatgttaag agagaaacaa acgttttacc ttcctttgtc tatagaacat 60  
ggaaaacatg cccctcagt catggattct gacgtgcttt tgtctgctgt cctctggaac 120  
cagtgccatc ttccataaag cgaactattc cagaagctat ccttgtgacg agataaggca 180  
caactccctt gtgattgcag aatgcaacca tcgtcaactg catgaagtcc cccaaactat 240  
aggcaagtat gtgacaaaca tagacttgct agacaatgcc attacacata taacgaaaga 300  
gtcctttcaa aagctgcaaa acctcactaa aatcgatctg aaccacaatg ccaaacaaca 360  
gcacccaaat gaaaataaaa atggtatgaa tattacagaa ggggcacttc tcagcctaag 420  
aaatctaaca gttttactgc tggaaagaaa ccagttatat actatacttg ctgggttgcc 480  
tgagtctttg aaagaactta gcctaattca aaacaatata tttcaggtaa ctaaaaacaa 540  
cacttttggg cttaggaact tggaaagact ctatttgggc tggaaactgct attttaaagt 600  
taatcaaacc ttttaaggtag aagatggggc atttaaaaat cttatacact tgaagggtact 660  
ctcattatct ttcaataacc ttttctatgt gcccccaaa ctaccaagtt ctctaaggaa 720  
actttttctg agtaatgcca aaatcatgaa catcactcag gaagacttca aaggactgga 780  
aaatttaaca ttactagatc tgagtggaaa ctgtccaagg tgttacaatg ctccatttcc 840  
ttgcacacct tgcaaggaaa actcatccat ccacatacat cctctggctt ttcaaagtct 900  
cacccaactt ctctatctaa acctttccag cacttccctc aggacgattc cttctacctg 960  
gtttgaaaat ctgtcaaatc tgaaggaaact ccatcttgaa ttcaactatt tagttcaaga 1020  
aattgcctcg ggggcatttt taacaaaact acccagttta caaatccttg atttgtcctt 1080  
caactttcaa tataaggaat atttacaatt tattaatatt tcctcaaatt tctctaagct 1140  
tcgttctctc aagaagttgc acttaagagg ctatgtgttc cgagaactta aaaagaagca 1200  
tttcgagcat ctccagagtc ttccaaactt ggcaaccatc aacttgggca ttaactttat 1260

tgagaaaatt gatttcaaag ctttccagaa tttttccaaa ctcgacgtta tctatattatc	1320
aggaaatcgc atagcatctg tattagatgg tacagattat tcctcttggc gaaatcgtct	1380
tcggaaacct ctctcaacag acgatgatga gtttgatcca cacgtgaatt tttaccatag	1440
caccaaacct ttaataaagc cacagtgtac tgcttatggc aaggccttgg atttaagttt	1500
gaacaatatt ttcatatttg ggaaaagcca atttgaaggc tttcaggata tcgcctgctt	1560
aaatctgtcc ttcaatgcc aactcaagt gttaaatggc acagaattct cctccatgcc	1620
ccacattaaa tatgttgatt taaccaacaa cagactagac tttgatgata acaatgcttt	1680
cagtgatctt cacgatctag aagtgttgga cctgagccac aatgcacact atttcagtat	1740
agcaggggta acgcaccgtc taggatttat ccagaactta ataaacctca ggggtgttaa	1800
cctgagccac aatggcattt acaccctcac agaggaaagt gagctgaaaa gcatctcact	1860
gaaagaattg gttttcagtg gaaatcgtct tgaccatttg tggaatgcaa atgatggcaa	1920
atactgggtcc atttttaaaa gtctccagaa tttgatacgc ctggacttat catacaataa	1980
ccttcaacaa atcccaaatg gagcattcct caatttgcct cagagcctcc aagagttact	2040
tatcagtggg aacaaattac gtttctttaa ttggacatta ctccagtatt ttcctcacct	2100
tcacttgctg gatttatcga gaaatgagct gtattttcta cccaattgcc tatctaagtt	2160
tgcacattcc ctggagacac tgctactgag ccataatcat ttctctcacc taccctctgg	2220
cttcctctcc gaagccagga atctggtgca cctggatcta agtttcaaca caataaagat	2280
gatcaataaa tcctccctgc aaaccaagat gaaaacgaac ttgtctattc tggagctaca	2340
tgggaactat tttgactgca cgtgtgacat aagtgatttt cgaagctggc tagatgaaaa	2400
tctgaatatc acaattccta aattggtaaa tgttatatgt tccaatcctg gggatcaaaa	2460
atcaaagagt atcatgagcc tagatctcac gacttgtgta tcggatacca ctgcagctgt	2520
cctgtttttc ctcacattcc ttaccacctc catgggttatg ttggctgctc tggttcacca	2580
cctgtttttac tgggatgttt ggtttatcta tcacatgtgc tctgctaagt taaaaggcta	2640
caggacttca tccacatccc aaactttcta tgatgcttat atttcttatg acaccaaaga	2700
tgcatctggt actgactggg taatcaatga actgcgctac caccttgaag agagtgaaga	2760
caaaagtgtc ctctttgtt tagaggagag ggattgggat ccaggattac ccatcattga	2820
taacctcatg cagagcataa accagagcaa gaaaacaatc tttgttttaa ccaagaaata	2880
tgccaagagc tggaacttta aaacagcttt ctacttggcc ttgcagaggc taatggatga	2940
gaacatggat gtgattatth tcatcctcct ggaaccagtg ttacagtact cacagtacct	3000
gaggtctcgg cagaggatct gtaagagctc catcctccag tggcccaaca atcccaaagc	3060
agaaaacttg ttttggcaaa gtctgaaaaa tgtggtcttg actgaaaatg attcacggta	3120
tgacgatttg tacattgatt ccattaggca atactagtga tgggaagtca cgactctgcc	3180



atcataaaaa cacacagctt ctccttataa tgaaccgaat

3220

&lt;210&gt; 57

&lt;211&gt; 1032

&lt;212&gt; PRT

&lt;213&gt; murine

&lt;400&gt; 57

Met Glu Asn Met Pro Pro Gln Ser Trp Ile Leu Thr Cys Phe Cys Leu  
 1 5 10 15

Leu Ser Ser Gly Thr Ser Ala Ile Phe His Lys Ala Asn Tyr Ser Arg  
 20 25 30

Ser Tyr Pro Cys Asp Glu Ile Arg His Asn Ser Leu Val Ile Ala Glu  
 35 40 45

Cys Asn His Arg Gln Leu His Glu Val Pro Gln Thr Ile Gly Lys Tyr  
 50 55 60

Val Thr Asn Ile Asp Leu Ser Asp Asn Ala Ile Thr His Ile Thr Lys  
 65 70 75 80

Glu Ser Phe Gln Lys Leu Gln Asn Leu Thr Lys Ile Asp Leu Asn His  
 85 90 95

Asn Ala Lys Gln Gln His Pro Asn Glu Asn Lys Asn Gly Met Asn Ile  
 100 105 110

Thr Glu Gly Ala Leu Leu Ser Leu Arg Asn Leu Thr Val Leu Leu Leu  
 115 120 125

Glu Asp Asn Gln Leu Tyr Thr Ile Pro Ala Gly Leu Pro Glu Ser Leu  
 130 135 140

Lys Glu Leu Ser Leu Ile Gln Asn Asn Ile Phe Gln Val Thr Lys Asn  
 145 150 155 160

Asn Thr Phe Gly Leu Arg Asn Leu Glu Arg Leu Tyr Leu Gly Trp Asn  
 165 170 175

Cys Tyr Phe Lys Cys Asn Gln Thr Phe Lys Val Glu Asp Gly Ala Phe  
 180 185 190

Lys Asn Leu Ile His Leu Lys Val Leu Ser Leu Ser Phe Asn Asn Leu  
 195 200 205

Phe Tyr Val Pro Pro Lys Leu Pro Ser Ser Leu Arg Lys Leu Phe Leu  
 210 215 220

Ser Asn Ala Lys Ile Met Asn Ile Thr Gln Glu Asp Phe Lys Gly Leu  
 225 230 235 240

Glu Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn Cys Pro Arg Cys Tyr  
 245 250 255

Asn Ala Pro Phe Pro Cys Thr Pro Cys Lys Glu Asn Ser Ser Ile His  
 260 265 270

Ile His Pro Leu Ala Phe Gln Ser Leu Thr Gln Leu Leu Tyr Leu Asn  
 275 280 285  
 Leu Ser Ser Thr Ser Leu Arg Thr Ile Pro Ser Thr Trp Phe Glu Asn  
 290 295 300  
 Leu Ser Asn Leu Lys Glu Leu His Leu Glu Phe Asn Tyr Leu Val Gln  
 305 310 315 320  
 Glu Ile Ala Ser Gly Ala Phe Leu Thr Lys Leu Pro Ser Leu Gln Ile  
 325 330 335  
 Leu Asp Leu Ser Phe Asn Phe Gln Tyr Lys Glu Tyr Leu Gln Phe Ile  
 340 345 350  
 Asn Ile Ser Ser Asn Phe Ser Lys Leu Arg Ser Leu Lys Lys Leu His  
 355 360 365  
 Leu Arg Gly Tyr Val Phe Arg Glu Leu Lys Lys Lys His Phe Glu His  
 370 375 380  
 Leu Gln Ser Leu Pro Asn Leu Ala Thr Ile Asn Leu Gly Ile Asn Phe  
 385 390 395 400  
 Ile Glu Lys Ile Asp Phe Lys Ala Phe Gln Asn Phe Ser Lys Leu Asp  
 405 410 415  
 Val Ile Tyr Leu Ser Gly Asn Arg Ile Ala Ser Val Leu Asp Gly Thr  
 420 425 430  
 Asp Tyr Ser Ser Trp Arg Asn Arg Leu Arg Lys Pro Leu Ser Thr Asp  
 435 440 445  
 Asp Asp Glu Phe Asp Pro His Val Asn Phe Tyr His Ser Thr Lys Pro  
 450 455 460  
 Leu Ile Lys Pro Gln Cys Thr Ala Tyr Gly Lys Ala Leu Asp Leu Ser  
 465 470 475 480  
 Leu Asn Asn Ile Phe Ile Ile Gly Lys Ser Gln Phe Glu Gly Phe Gln  
 485 490 495  
 Asp Ile Ala Cys Leu Asn Leu Ser Phe Asn Ala Asn Thr Gln Val Phe  
 500 505 510  
 Asn Gly Thr Glu Phe Ser Ser Met Pro His Ile Lys Tyr Leu Asp Leu  
 515 520 525  
 Thr Asn Asn Arg Leu Asp Phe Asp Asp Asn Asn Ala Phe Ser Asp Leu  
 530 535 540  
 His Asp Leu Glu Val Leu Asp Leu Ser His Asn Ala His Tyr Phe Ser  
 545 550 555 560  
 Ile Ala Gly Val Thr His Arg Leu Gly Phe Ile Gln Asn Leu Ile Asn  
 565 570 575  
 Leu Arg Val Leu Asn Leu Ser His Asn Gly Ile Tyr Thr Leu Thr Glu  
 580 585 590  
 Glu Ser Glu Leu Lys Ser Ile Ser Leu Lys Glu Leu Val Phe Ser Gly

595	600	605
Asn Arg Leu Asp His Leu Trp	Asn Ala Asn Asp Gly Lys Tyr Trp Ser	
610	615	620
Ile Phe Lys Ser Leu Gln Asn Leu Ile Arg Leu Asp Leu Ser Tyr Asn		
625	630	635
Asn Leu Gln Gln Ile Pro Asn Gly Ala Phe Leu Asn Leu Pro Gln Ser		
645	650	655
Leu Gln Glu Leu Leu Ile Ser Gly Asn Lys Leu Arg Phe Phe Asn Trp		
660	665	670
Thr Leu Leu Gln Tyr Phe Pro His Leu His Leu Leu Asp Leu Ser Arg		
675	680	685
Asn Glu Leu Tyr Phe Leu Pro Asn Cys Leu Ser Lys Phe Ala His Ser		
690	695	700
Leu Glu Thr Leu Leu Leu Ser His Asn His Phe Ser His Leu Pro Ser		
705	710	715
Gly Phe Leu Ser Glu Ala Arg Asn Leu Val His Leu Asp Leu Ser Phe		
725	730	735
Asn Thr Ile Lys Met Ile Asn Lys Ser Ser Leu Gln Thr Lys Met Lys		
740	745	750
Thr Asn Leu Ser Ile Leu Glu Leu His Gly Asn Tyr Phe Asp Cys Thr		
755	760	765
Cys Asp Ile Ser Asp Phe Arg Ser Trp Leu Asp Glu Asn Leu Asn Ile		
770	775	780
Thr Ile Pro Lys Leu Val Asn Val Ile Cys Ser Asn Pro Gly Asp Gln		
785	790	795
Lys Ser Lys Ser Ile Met Ser Leu Asp Leu Thr Thr Cys Val Ser Asp		
805	810	815
Thr Thr Ala Ala Val Leu Phe Phe Leu Thr Phe Leu Thr Thr Ser Met		
820	825	830
Val Met Leu Ala Ala Leu Val His His Leu Phe Tyr Trp Asp Val Trp		
835	840	845
Phe Ile Tyr His Met Cys Ser Ala Lys Leu Lys Gly Tyr Arg Thr Ser		
850	855	860
Ser Thr Ser Gln Thr Phe Tyr Asp Ala Tyr Ile Ser Tyr Asp Thr Lys		
865	870	875
Asp Ala Ser Val Thr Asp Trp Val Ile Asn Glu Leu Arg Tyr His Leu		
885	890	895
Glu Glu Ser Glu Asp Lys Ser Val Leu Leu Cys Leu Glu Glu Arg Asp		
900	905	910
Trp Asp Pro Gly Leu Pro Ile Ile Asp Asn Leu Met Gln Ser Ile Asn		
915	920	925
Gln Ser Lys Lys Thr Ile Phe Val Leu Thr Lys Lys Tyr Ala Lys Ser		

930                      935                      940  
 Trp Asn Phe Lys Thr Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp  
 945                      950                      955                      960  
  
 Glu Asn Met Asp Val Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln  
                          965                                      970                                      975  
  
 Tyr Ser Gln Tyr Leu Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile  
                          980                                      985                                      990  
  
 Leu Gln Trp Pro Asn Asn Pro Lys Ala Glu Asn Leu Phe Trp Gln Ser  
                          995                                      1000                                      1005  
  
 Leu Lys Asn Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asp Asp  
                          1010                                      1015                                      1020  
  
 Leu Tyr Ile Asp Ser Ile Arg Gln Tyr  
                          1025                                      1030

<210> 58  
 <211> 1032  
 <212> PRT  
 <213> murine

<400> 58

Met Glu Asn Met Pro Pro Gln Ser Trp Ile Leu Thr Cys Phe Cys Leu  
 1                      5                      10                      15  
  
 Leu Ser Ser Gly Thr Ser Ala Ile Phe His Lys Ala Asn Tyr Ser Arg  
                          20                                      25                                      30  
  
 Ser Tyr Pro Cys Asp Glu Ile Arg His Asn Ser Leu Val Ile Ala Glu  
                          35                                      40                                      45  
  
 Cys Asn His Arg Gln Leu His Glu Val Pro Gln Thr Ile Gly Lys Tyr  
                          50                                      55                                      60  
  
 Val Thr Asn Ile Asp Leu Ser Asp Asn Ala Ile Thr His Ile Thr Lys  
 65                                      70                                      75                                      80  
  
 Glu Ser Phe Gln Lys Leu Gln Asn Leu Thr Lys Ile Asp Leu Asn His  
                          85                                      90                                      95  
  
 Asn Ala Lys Gln Gln His Pro Asn Glu Asn Lys Asn Gly Met Asn Ile  
                          100                                      105                                      110  
  
 Thr Glu Gly Ala Leu Leu Ser Leu Arg Asn Leu Thr Val Leu Leu Leu  
                          115                                      120                                      125  
  
 Glu Asp Asn Gln Leu Tyr Thr Ile Pro Ala Gly Leu Pro Glu Ser Leu  
                          130                                      135                                      140  
  
 Lys Glu Leu Ser Leu Ile Gln Asn Asn Ile Phe Gln Val Thr Lys Asn  
 145                                      150                                      155                                      160  
  
 Asn Thr Phe Gly Leu Arg Asn Leu Glu Arg Leu Tyr Leu Gly Trp Asn  
                          165                                      170                                      175  
  
 Cys Tyr Phe Lys Cys Asn Gln Thr Phe Lys Val Glu Asp Gly Ala Phe  
                          180                                      185                                      190

Lys Asn Leu Ile His Leu Lys Val Leu Ser Leu Ser Phe Asn Asn Leu  
 195 200 205  
 Phe Tyr Val Pro Pro Lys Leu Pro Ser Ser Leu Arg Lys Leu Phe Leu  
 210 215 220  
 Ser Asn Ala Lys Ile Met Asn Ile Thr Gln Glu Asp Phe Lys Gly Leu  
 225 230 235 240  
 Glu Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn Cys Pro Arg Cys Tyr  
 245 250 255  
 Asn Ala Pro Phe Pro Cys Thr Pro Cys Lys Glu Asn Ser Ser Ile His  
 260 265 270  
 Ile His Pro Leu Ala Phe Gln Ser Leu Thr Gln Leu Leu Tyr Leu Asn  
 275 280 285  
 Leu Ser Ser Thr Ser Leu Arg Thr Ile Pro Ser Thr Trp Phe Glu Asn  
 290 295 300  
 Leu Ser Asn Leu Lys Glu Leu His Leu Glu Phe Asn Tyr Leu Val Gln  
 305 310 315 320  
 Glu Ile Ala Ser Gly Ala Phe Leu Thr Lys Leu Pro Ser Leu Gln Ile  
 325 330 335  
 Leu Asp Leu Ser Phe Asn Phe Gln Tyr Lys Glu Tyr Leu Gln Phe Ile  
 340 345 350  
 Asn Ile Ser Ser Asn Phe Ser Lys Leu Arg Ser Leu Lys Lys Leu His  
 355 360 365  
 Leu Arg Gly Tyr Val Phe Arg Glu Leu Lys Lys Lys His Phe Glu His  
 370 375 380  
 Leu Gln Ser Leu Pro Asn Leu Ala Thr Ile Asn Leu Gly Ile Asn Phe  
 385 390 395 400  
 Ile Glu Lys Ile Asp Phe Lys Ala Phe Gln Asn Phe Ser Lys Leu Asp  
 405 410 415  
 Val Ile Tyr Leu Ser Gly Asn Arg Ile Ala Ser Val Leu Asp Gly Thr  
 420 425 430  
 Asp Tyr Ser Ser Trp Arg Asn Arg Leu Arg Lys Pro Leu Ser Thr Asp  
 435 440 445  
 Asp Asp Glu Phe Asp Pro His Val Asn Phe Tyr His Ser Thr Lys Pro  
 450 455 460  
 Leu Ile Lys Pro Gln Cys Thr Ala Tyr Gly Lys Ala Leu Asp Leu Ser  
 465 470 475 480  
 Leu Asn Asn Ile Phe Ile Ile Gly Lys Ser Gln Phe Glu Gly Phe Gln  
 485 490 495  
 Asp Ile Ala Cys Leu Asn Leu Ser Phe Asn Ala Asn Thr Gln Val Phe  
 500 505 510  
 Asn Gly Thr Glu Phe Ser Ser Met Pro His Ile Lys Tyr Leu Asp Leu

515	520	525
Thr Asn Asn Arg Leu Asp Phe Asp Asp Asn Asn Ala Phe Ser Asp Leu		
530	535	540
His Asp Leu Glu Val Leu Asp Leu Ser His Asn Ala His Tyr Phe Ser		
545	550	555
Ile Ala Gly Val Thr His Arg Leu Gly Phe Ile Gln Asn Leu Ile Asn		
565	570	575
Leu Arg Val Leu Asn Leu Ser His Asn Gly Ile Tyr Thr Leu Thr Glu		
580	585	590
Glu Ser Glu Leu Lys Ser Ile Ser Leu Lys Glu Leu Val Phe Ser Gly		
595	600	605
Asn Arg Leu Asp His Leu Trp Asn Ala Asn Asp Gly Lys Tyr Trp Ser		
610	615	620
Ile Phe Lys Ser Leu Gln Asn Leu Ile Arg Leu Asp Leu Ser Tyr Asn		
625	630	635
Asn Leu Gln Gln Ile Pro Asn Gly Ala Phe Leu Asn Leu Pro Gln Ser		
645	650	655
Leu Gln Glu Leu Leu Ile Ser Gly Asn Lys Leu Arg Phe Phe Asn Trp		
660	665	670
Thr Leu Leu Gln Tyr Phe Pro His Leu His Leu Leu Asp Leu Ser Arg		
675	680	685
Asn Glu Leu Tyr Phe Leu Pro Asn Cys Leu Ser Lys Phe Ala His Ser		
690	695	700
Leu Glu Thr Leu Leu Leu Ser His Asn His Phe Ser His Leu Pro Ser		
705	710	715
Gly Phe Leu Ser Glu Ala Arg Asn Leu Val His Leu Asp Leu Ser Phe		
725	730	735
Asn Thr Ile Lys Met Ile Asn Lys Ser Ser Leu Gln Thr Lys Met Lys		
740	745	750
Thr Asn Leu Ser Ile Leu Glu Leu His Gly Asn Tyr Phe Asp Cys Thr		
755	760	765
Cys Asp Ile Ser Asp Phe Arg Ser Trp Leu Asp Glu Asn Leu Asn Ile		
770	775	780
Thr Ile Pro Lys Leu Val Asn Val Ile Cys Ser Asn Pro Gly Asp Gln		
785	790	795
Lys Ser Lys Ser Ile Met Ser Leu Asp Leu Thr Thr Cys Val Ser Asp		
805	810	815
Thr Thr Ala Ala Val Leu Phe Phe Leu Thr Phe Leu Thr Thr Ser Met		
820	825	830
Val Met Leu Ala Ala Leu Val His His Leu Phe Tyr Trp Asp Val Trp		
835	840	845
Phe Ile Tyr His Met Cys Ser Ala Lys Leu Lys Gly Tyr Arg Thr Ser		

850                      855                      860  
 Ser Thr Ser Gln Thr Phe Tyr Asp Ala Tyr Ile Ser Tyr Asp Thr Lys  
 865                      870                      875                      880  
 Asp Ala Ser Val Thr Asp Trp Val Ile Asn Glu Leu Arg Tyr His Leu  
                          885                      890                      895  
 Glu Glu Ser Glu Asp Lys Ser Val Leu Leu Cys Leu Glu Glu Arg Asp  
                          900                      905                      910  
 Trp Asp Pro Gly Leu Pro Ile Ile Asp Asn Leu Met Gln Ser Ile Asn  
                          915                      920                      925  
 Gln Ser Lys Lys Thr Ile Phe Val Leu Thr Lys Lys Tyr Ala Lys Ser  
                          930                      935                      940  
 Trp Asn Phe Lys Thr Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp  
 945                      950                      955                      960  
 Glu Asn Met Asp Val Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln  
                          965                      970                      975  
 Tyr Ser Gln Tyr Leu Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile  
                          980                      985                      990  
 Leu Gln Trp Pro Asn Asn Pro Lys Ala Glu Asn Leu Phe Trp Gln Ser  
                          995                      1000                      1005  
 Leu Lys Asn Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asp Asp  
                          1010                      1015                      1020  
 Leu Tyr Ile Asp Ser Ile Arg Gln Tyr  
                          1025                      1030

<210> 59  
 <211> 1032  
 <212> PRT  
 <213> murine

<400> 59

Met Glu Asn Met Pro Pro Gln Ser Trp Ile Leu Thr Cys Phe Cys Leu  
 1                      5                      10                      15  
 Leu Ser Ser Gly Thr Ser Ala Ile Phe His Lys Ala Asn Tyr Ser Arg  
                          20                      25                      30  
 Ser Tyr Pro Cys Asp Glu Ile Arg His Asn Ser Leu Val Ile Ala Glu  
                          35                      40                      45  
 Cys Asn His Arg Gln Leu His Glu Val Pro Gln Thr Ile Gly Lys Tyr  
                          50                      55                      60  
 Val Thr Asn Ile Asp Leu Ser Asp Asn Ala Ile Thr His Ile Thr Lys  
 65                      70                      75                      80  
 Glu Ser Phe Gln Lys Leu Gln Asn Leu Thr Lys Ile Asp Leu Asn His  
                          85                      90                      95  
 Asn Ala Lys Gln Gln His Pro Asn Glu Asn Lys Asn Gly Met Asn Ile  
                          100                      105                      110

Thr Glu Gly Ala Leu Leu Ser Leu Arg Asn Leu Thr Val Leu Leu Leu  
 115 120 125  
 Glu Asp Asn Gln Leu Tyr Thr Ile Pro Ala Gly Leu Pro Glu Ser Leu  
 130 135 140  
 Lys Glu Leu Ser Leu Ile Gln Asn Asn Ile Phe Gln Val Thr Lys Asn  
 145 150 155 160  
 Asn Thr Phe Gly Leu Arg Asn Leu Glu Arg Leu Tyr Leu Gly Trp Asn  
 165 170 175  
 Cys Tyr Phe Lys Cys Asn Gln Thr Phe Lys Val Glu Asp Gly Ala Phe  
 180 185 190  
 Lys Asn Leu Ile His Leu Lys Val Leu Ser Leu Ser Phe Asn Asn Leu  
 195 200 205  
 Phe Tyr Val Pro Pro Lys Leu Pro Ser Ser Leu Arg Lys Leu Phe Leu  
 210 215 220  
 Ser Asn Ala Lys Ile Met Asn Ile Thr Gln Glu Asp Phe Lys Gly Leu  
 225 230 235 240  
 Glu Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn Cys Pro Arg Cys Tyr  
 245 250 255  
 Asn Ala Pro Phe Pro Cys Thr Pro Cys Lys Glu Asn Ser Ser Ile His  
 260 265 270  
 Ile His Pro Leu Ala Phe Gln Ser Leu Thr Gln Leu Leu Tyr Leu Asn  
 275 280 285  
 Leu Ser Ser Thr Ser Leu Arg Thr Ile Pro Ser Thr Trp Phe Glu Asn  
 290 295 300  
 Leu Ser Asn Leu Lys Glu Leu His Leu Glu Phe Asn Tyr Leu Val Gln  
 305 310 315 320  
 Glu Ile Ala Ser Gly Ala Phe Leu Thr Lys Leu Pro Ser Leu Gln Ile  
 325 330 335  
 Leu Asp Leu Ser Phe Asn Phe Gln Tyr Lys Glu Tyr Leu Gln Phe Ile  
 340 345 350  
 Asn Ile Ser Ser Asn Phe Ser Lys Leu Arg Ser Leu Lys Lys Leu His  
 355 360 365  
 Leu Arg Gly Tyr Val Phe Arg Glu Leu Lys Lys Lys His Phe Glu His  
 370 375 380  
 Leu Gln Ser Leu Pro Asn Leu Ala Thr Ile Asn Leu Gly Ile Asn Phe  
 385 390 395 400  
 Ile Glu Lys Ile Asp Phe Lys Ala Phe Gln Asn Phe Ser Lys Leu Asp  
 405 410 415  
 Val Ile Tyr Leu Ser Gly Asn Arg Ile Ala Ser Val Leu Asp Gly Thr  
 420 425 430  
 Asp Tyr Ser Ser Trp Arg Asn Arg Leu Arg Lys Pro Leu Ser Thr Asp



435 440 445  
 Asp Asp Glu Phe Asp Pro His Val Asn Phe Tyr His Ser Thr Lys Pro  
 450 455 460  
 Leu Ile Lys Pro Gln Cys Thr Ala Tyr Gly Lys Ala Leu Asp Leu Ser  
 465 470 475 480  
 Leu Asn Asn Ile Phe Ile Ile Gly Lys Ser Gln Phe Glu Gly Phe Gln  
 485 490 495  
 Asp Ile Ala Cys Leu Asn Leu Ser Phe Asn Ala Asn Thr Gln Val Phe  
 500 505 510  
 Asn Gly Thr Glu Phe Ser Ser Met Pro His Ile Lys Tyr Leu Asp Leu  
 515 520 525  
 Thr Asn Asn Arg Leu Asp Phe Asp Asp Asn Asn Ala Phe Ser Asp Leu  
 530 535 540  
 His Asp Leu Glu Val Leu Asp Leu Ser His Asn Ala His Tyr Phe Ser  
 545 550 555 560  
 Ile Ala Gly Val Thr His Arg Leu Gly Phe Ile Gln Asn Leu Ile Asn  
 565 570 575  
 Leu Arg Val Leu Asn Leu Ser His Asn Gly Ile Tyr Thr Leu Thr Glu  
 580 585 590  
 Glu Ser Glu Leu Lys Ser Ile Ser Leu Lys Glu Leu Val Phe Ser Gly  
 595 600 605  
 Asn Arg Leu Asp His Leu Trp Asn Ala Asn Asp Gly Lys Tyr Trp Ser  
 610 615 620  
 Ile Phe Lys Ser Leu Gln Asn Leu Ile Arg Leu Asp Leu Ser Tyr Asn  
 625 630 635 640  
 Asn Leu Gln Gln Ile Pro Asn Gly Ala Phe Leu Asn Leu Pro Gln Ser  
 645 650 655  
 Leu Gln Glu Leu Leu Ile Ser Gly Asn Lys Leu Arg Phe Phe Asn Trp  
 660 665 670  
 Thr Leu Leu Gln Tyr Phe Pro His Leu His Leu Leu Asp Leu Ser Arg  
 675 680 685  
 Asn Glu Leu Tyr Phe Leu Pro Asn Cys Leu Ser Lys Phe Ala His Ser  
 690 695 700  
 Leu Glu Thr Leu Leu Leu Ser His Asn His Phe Ser His Leu Pro Ser  
 705 710 715 720  
 Gly Phe Leu Ser Glu Ala Arg Asn Leu Val His Leu Asp Leu Ser Phe  
 725 730 735  
 Asn Thr Ile Lys Met Ile Asn Lys Ser Ser Leu Gln Thr Lys Met Lys  
 740 745 750  
 Thr Asn Leu Ser Ile Leu Glu Leu His Gly Asn Tyr Phe Asp Cys Thr  
 755 760 765  
 Cys Asp Ile Ser Asp Phe Arg Ser Trp Leu Asp Glu Asn Leu Asn Ile

770 775 780  
 Thr Ile Pro Lys Leu Val Asn Val Ile Cys Ser Asn Pro Gly Asp Gln  
 785 790 795 800  
 Lys Ser Lys Ser Ile Met Ser Leu Asp Leu Thr Thr Cys Val Ser Asp  
 805 810 815  
 Thr Thr Ala Ala Val Leu Phe Phe Leu Thr Phe Leu Thr Thr Ser Met  
 820 825 830  
 Val Met Leu Ala Ala Leu Val His His Leu Phe Tyr Trp Asp Val Trp  
 835 840 845  
 Phe Ile Tyr His Met Cys Ser Ala Lys Leu Lys Gly Tyr Arg Thr Ser  
 850 855 860  
 Ser Thr Ser Gln Thr Phe Tyr Asp Ala Tyr Ile Ser Tyr Asp Thr Lys  
 865 870 875 880  
 Asp Ala Ser Val Thr Asp Trp Val Ile Asn Glu Leu Arg Tyr His Leu  
 885 890 895  
 Glu Glu Ser Glu Asp Lys Ser Val Leu Leu Cys Leu Glu Glu Arg Asp  
 900 905 910  
 Trp Asp Pro Gly Leu Pro Ile Ile Asp Asn Leu Met Gln Ser Ile Asn  
 915 920 925  
 Gln Ser Lys Lys Thr Ile Phe Val Leu Thr Lys Lys Tyr Ala Lys Ser  
 930 935 940  
 Trp Asn Phe Lys Thr Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp  
 945 950 955 960  
 Glu Asn Met Asp Val Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln  
 965 970 975  
 Tyr Ser Gln Tyr Leu Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile  
 980 985 990  
 Leu Gln Trp Pro Asn Asn Pro Lys Ala Glu Asn Leu Phe Trp Gln Ser  
 995 1000 1005  
 Leu Lys Asn Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asp Asp  
 1010 1015 1020  
 Leu Tyr Ile Asp Ser Ile Arg Gln Tyr  
 1025 1030

&lt;210&gt; 60

&lt;211&gt; 3352

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 60

aggctggtat aaaaatctta cttcctctat tctctgagcc gctgctgccc ctgtgggaag 60

ggacctcgag tgtgaagcat ccttcctgt agctgctgtc cagtctgccc gccagacct 120

ctggagaagc ccctgcccc cagcatgggt ttctgccgca gcgccctgca cccgctgtct 180

ctcctgggtgc aggccatcat gctggccatg accctggccc tgggtacctt gcctgccttc	240
ctaccctgtg agctccagcc ccacggcctg gtgaactgca actggctgtt cctgaagtct	300
gtgccccact totccatggc agcaccctcg ggcaatgtca ccagcctttc cttgtcctcc	360
aaccgcatcc accacctcca tgattctgac tttgcccacc tgcccagcct gcggcatctc	420
aacctcaagt ggaactgccc gccggttggc ctcagcccca tgcacttccc ctgccacatg	480
accatcgagc ccagcacctt cttggctgtg cccaccctgg aagagctaaa cctgagctac	540
aacaacatca tgactgtgcc tgcgctgccc aaatccctca tatccctgtc cctcagccat	600
accaacatcc tgatgctaga ctctgccagc ctcgcgggcc tgcattgccct gcgtctccta	660
ttcatggacg gcaactgtta ttacaagaac ccctgcaggc aggcactgga ggtggccccg	720
ggtgccctcc ttggcctggg caacctcacc cacctgtcac tcaagtacaa caacctcact	780
gtggtgcccc gcaacctgcc ttccagcctg gagtatctgc tgttgtccta caaccgcac	840
gtcaaaactg cgctgagga cctggccaat ctgaccgcc tgcgtgtgct cgatgtgggc	900
ggaaattgcc gccgctgcca ccacgtccc aaccctgca tggagtgcc tcgtcacttc	960
ccccagctac atcccatac cttcagccac ctgagccgtc ttgaaggcct ggtgttgaag	1020
gacagttctc tctcctggct gaatgccagt tggttccgtg ggctgggaaa cctccgagtg	1080
ctggacctga gtgagaactt cctctacaaa tgcatacta aaaccaaggc cttccagggc	1140
ctaacacagc tgcgcaagct taacctgtcc ttcaattacc aaaagagggg gtcctttgcc	1200
cacctgtctc tggccccctc cttcgggagc ctggctgccc tgaaggagct ggacatgcac	1260
ggcatcttct tccgctcact cgatgagacc acgtccggc cactggcccg cctgcccattg	1320
ctccagactc tgcgtctgca gatgaacttc atcaaccagg ccagctcgg catcttcagg	1380
gccttccctg gcctgcgcta cgtggacctg tcggacaacc gcatcagcgg agcttcggag	1440
ctgacagcca ccatggggga ggcagatgga ggggagaagg tctggctgca gcctggggac	1500
cttgctccgg cccagtgga cactcccagc tctgaagact tcaggcccaa ctgcagcacc	1560
ctcaacttca ccttgatct gtcacggaac aacctgggtg ccgtgcagcc ggagatgttt	1620
gccagctct cgacactgca gtgcctgccc ctgagccaca actgcatctc gcaggcagtc	1680
aatggctccc agttcctgcc gctgaccggg ctgcagggtg tagacctgtc ccgcaataag	1740
ctggacctct accacgagca ctcatcacg gagctaccgc gactggaggc cctggacctc	1800
agctacaaca gccagccctt tggcatgcag ggcgtggggc acaacttcag cttcgtggct	1860
cacctgcgca ccctgcgcca cctcagcctg gccacaaca acatccacag ccaagtgtcc	1920
cagcagctct gcagtacgtc gctgcggggc ctggacttca gcggcaatgc actgggccat	1980
atgtggggcg agggagacct ctatctgcac ttcttccaag gcctgagcgg tttgatctgg	2040
ctggacttgt cccagaaccg cctgcacacc ctctgcccc aaacctgcg caacctcccc	2100

aagagcctac aggtgctgcg tctccgtgac aattacctgg ccttctttaa gtggtggagc 2160  
ctccacttcc tgcccaaact ggaagtccctc gacctggcag gaaaccggct gaaggccctg 2220  
accaatggca gcctgcctgc tggcaccocg ctccggaggc tggatgtcag ctgcaacagc 2280  
atcagcttcg tggcccccgg cttcttttcc aaggccaagg agctgcgaga gctcaacctt 2340  
agcgccaacg ccctcaagac agtggaccac tcctggtttg gggccctggc gagtgccttg 2400  
caaatactag atgtaagcgc caaccctctg cactgcgctt gtggggcggc ctttatggac 2460  
ttcctgctgg aggtgcaggc tgccgtgccc ggtctgcccc gccgggtgaa gtgtggcagt 2520  
ccggggccagc tccagggcct cagcatcttt gcacaggacc tgcgcctctg cctggatgag 2580  
gccctctcct gggactgttt cggcctctcg ctgctggttg tggctctggg cctgggtgtg 2640  
cccatgctgc atcacctctg tggctgggac ctctggtact gcttccacct gtgcctggcc 2700  
tggtctccct ggcgggggcg gcaaagtggg cgagatgagg atgccctgcc ctacgatgcc 2760  
ttcgtggtct tcgacaaaac gcagagcgca gtggcagact ggggtgtacaa cgagcttcgg 2820  
gggcagctgg aggagtgcg tgggcgctgg gactccgcc tgtgcctgga ggaacgcgac 2880  
tggtgcctg gcaaaacct ctttgagaac ctgtgggcct cggctctatg cagccgcaag 2940  
acgctgtttg tgctggcccc caccggaccg gtcagtggtc tcttgcgcg cagcttctctg 3000  
ctggcccagc agcgctgct ggaggaccgc aaggacgtcg tggctgctgt gatcctgagc 3060  
cctgacggcc gcgctcccg ctacgtgcgg ctgcgccagc gcctctgccc ccagagtgtc 3120  
ctcctctggc cccaccagcc cagtggtcag cgcagcttct gggcccagct gggcatggcc 3180  
ctgaccaggg acaaccacca cttctataac cggaacttct gccagggacc caccggccgaa 3240  
tagccgtgag ccggaatcct gcacggtgcc acctccacac tcacctcacc tctgcttgcc 3300  
tggtctgacc ctccccgtct cgcctccctc accccacacc tgacacagag ca 3352

<210> 61

<211> 3257

<212> DNA

<213> Homo sapiens

<400> 61

ccgctgctgc ccctgtggga agggacctcg agtgtgaagc atccttccct gtagctgctg 60  
tccagtctgc ccgccagacc ctctggagaa gcccctgccc cccagcatgg gtttctgccc 120  
cagcgccctg caccgcctgt ctctcctggg gcaggccatc atgctggcca tgacctggc 180  
cctgggtacc ttgcctgctt tcctacctg tgagctccag cccacggcc tggatgaactg 240  
caactggctg ttctgaagt ctgtgcccc cttctccatg gcagcaccac gtggcaatgt 300  
caccagcctt tccttgctct ccaaccgcat ccaccacctc catgattctg actttgcccc 360

cctgcccagc	ctgcggcac	tcaacctcaa	gtggaactgc	ccgccggttg	gcctcagccc	420
catgcacttc	ccctgccaca	tgaccatcga	gcccagcacc	ttcttggttg	tgcccaccct	480
ggaagagcta	aacctgagct	acaacaacat	catgactgtg	cctgcgctgc	ccaaatccct	540
catatccctg	tccctcagcc	ataccaacat	cctgatgcta	gactctgcca	gcctcgccgg	600
cctgcatgcc	ctgcgcttcc	tattcatgga	cggcaactgt	tattacaaga	accctgcag	660
gcaggcactg	gaggtggccc	cgggtgccct	ccttggcctg	ggcaacctca	cccacctgtc	720
actcaagtac	aacaacctca	ctgtggtgcc	ccgcaacctg	ccttccagcc	tggagtatct	780
gctgttgctc	tacaaccgca	tcgtcaaact	ggcgctgag	gacctggcca	atctgaccgc	840
cctgcgtgtg	ctcgatgtgg	gcggaaattg	ccgccgctgc	gaccacgctc	ccaacccctg	900
catggagtgc	cctcgtcact	ttccccagct	acatcccgat	accttcagcc	acctgagccg	960
tcttgaaggc	ctggtgttga	aggacagttc	tctctcctgg	ctgaatgcca	gttggttccg	1020
tgggctggga	aacctccgag	tgctggacct	gagtgagaac	ttcctctaca	aatgcatcac	1080
taaaaccaag	gccttccagg	gcctaacaca	gctgcgcaag	cttaacctgt	ccttcaatta	1140
ccaaaagagg	gtgtcctttg	cccacctgtc	tctggcccct	tccttcggga	gcctggtcgc	1200
cctgaaggag	ctggacatgc	acggcatctt	cttccgctca	ctcgatgaga	ccacgctccg	1260
gccactggcc	cgctgccc	tgctccagac	tctgcgtctg	cagatgaact	tcacaaacca	1320
ggcccagctc	ggcatcttca	gggccttccc	tggcctgcgc	tacgtggacc	tgctggacaa	1380
ccgcatcagc	ggagcttcgg	agctgacagc	caccatgggg	gaggcagatg	gaggggagaa	1440
ggtctggctg	cagcctgggg	accttgctcc	ggccccagtg	gacactccca	gctctgaaga	1500
cttcaggccc	aactgcagca	ccctcaactt	caccttggat	ctgtcacgga	acaacctggg	1560
gacctgtcag	ccggagatgt	ttgcccagct	ctcgacactg	cagtgcctgc	gcctgagcca	1620
caactgcac	tcgaggcag	tcaatggctc	ccagttcctg	ccgctgaccg	gtctgcagg	1680
gctagacctg	ttccacaata	agctggacct	ctaccacgag	cactcattca	cggagctacc	1740
acgactggag	gccttgacc	tcagctacaa	cagccagccc	tttggcatgc	agggcggtgg	1800
ccacaacttc	agcttcgtgg	ctcacctgcg	caccctgcgc	cacctcagcc	tgggccacaa	1860
caacatccac	agccaagtgt	cccagcagct	ctgcagtaag	tcgctgcggg	ccctggactt	1920
cagcggcaat	gcactggggc	atatgtgggc	cgaggagagc	ctctatctgc	acttcttcca	1980
aggcctgagc	ggtttgatct	ggctggactt	gtcccagaac	cgctgcaca	ccctcctgcc	2040
ccaaaccctg	cgcaacctcc	ccaagagcct	acaggtgctg	cgtctccgtg	acaattacct	2100
ggccttcttt	aagtgggtga	gcctccactt	cctgcccaca	ctggaagtcc	tcgacctggc	2160
aggaaaccag	ctgaaggccc	tgaccaatgg	cagcctgcct	gctggcacc	ggctccggag	2220
gctggatgtc	agctgcaaca	gcacagctt	cgtggccccc	ggcttctttt	ccaaggccaa	2280

ggagctgcga gagctcaacc ttagcgccaa cgccctcaag acagtggacc actcctgggt 2340  
 tgggcccctg gcgagtgcc tgcaaatact agatgtaagc gccaacctc tgcactgcgc 2400  
 ctgtggggcg gcctttatgg acttctctgt ggaggtgcag gctgccgtgc ccggctctgcc 2460  
 cagccgggtg aagtgtggca gtccgggcca gctccagggc ctcagcatct ttgcacagga 2520  
 cctgcgcctc tgcttggatg aggcctctc ctgggactgt ttgcctctc cgctgctggc 2580  
 tgttgctctg ggctgggtg tgcccatgct gcacacctc tgtggctggg acctctggta 2640  
 ctgcttccac ctgtgcctgg cctggcttcc ctggcggggg cggcaaagtg ggcgagatga 2700  
 ggatgccttg ccctacgatg ccttcgtggt cttcgacaaa acgcagagcg cagtggcaga 2760  
 ctgggtgtac aacgagcttc gggggcagct ggaggagtgc cgtgggcgct gggcactccg 2820  
 cctgtgcctg gaggaacgcg actggctgcc tggcaaaacc ctctttgaga acctgtgggc 2880  
 ctcggtctat ggcagccgca agacgctgtt tgtgtgtggc cacacggacc gggtcagtgg 2940  
 tctcttgccg gccagcttcc tgetggccca gcagcgctg ctggaggacc gcaaggacgt 3000  
 cgtggtgctg gtgacctga gccctgacgg ccgccgctcc cgctacgtgc ggctgcgcca 3060  
 gcgcctctgc cgccagagtg tctcctctg gcccaccag ccagtggtc agcgcagctt 3120  
 ctggggccag ctgggcatgg ccctgaccag ggacaaccac cacttctata accggaactt 3180  
 ctgccagga cccacggccg aatagccgtg agccggaatc ctgcacggtg ccacctccac 3240  
 actcacctca cctctgc 3257

<210> 62  
 <211> 1032  
 <212> PRT  
 <213> Homo sapiens

<400> 62

Met Gly Phe Cys Arg Ser Ala Leu His Pro Leu Ser Leu Leu Val Gln  
 1 5 10 15  
 Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe  
 20 25 30  
 Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu  
 35 40 45  
 Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly Asn  
 50 55 60  
 Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His Asp  
 65 70 75 80  
 Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys Trp  
 85 90 95  
 Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met

Thr	Ile	Glu	Pro	Ser	Thr	Phe	Leu	Ala	Val	Pro	Thr	Leu	Glu	Glu	Leu
		100					105					110			
		115					120					125			
Asn	Leu	Ser	Tyr	Asn	Asn	Ile	Met	Thr	Val	Pro	Ala	Leu	Pro	Lys	Ser
		130				135					140				
Leu	Ile	Ser	Leu	Ser	Leu	Ser	His	Thr	Asn	Ile	Leu	Met	Leu	Asp	Ser
		145			150				155					160	
Ala	Ser	Leu	Ala	Gly	Leu	His	Ala	Leu	Arg	Phe	Leu	Phe	Met	Asp	Gly
				165					170					175	
Asn	Cys	Tyr	Tyr	Lys	Asn	Pro	Cys	Arg	Gln	Ala	Leu	Glu	Val	Ala	Pro
			180					185					190		
Gly	Ala	Leu	Leu	Gly	Leu	Gly	Asn	Leu	Thr	His	Leu	Ser	Leu	Lys	Tyr
		195					200					205			
Asn	Asn	Leu	Thr	Val	Val	Pro	Arg	Asn	Leu	Pro	Ser	Ser	Leu	Glu	Tyr
		210					215					220			
Leu	Leu	Leu	Ser	Tyr	Asn	Arg	Ile	Val	Lys	Leu	Ala	Pro	Glu	Asp	Leu
		225			230					235					240
Ala	Asn	Leu	Thr	Ala	Leu	Arg	Val	Leu	Asp	Val	Gly	Gly	Asn	Cys	Arg
				245					250					255	
Arg	Cys	Asp	His	Ala	Pro	Asn	Pro	Cys	Met	Glu	Cys	Pro	Arg	His	Phe
			260					265					270		
Pro	Gln	Leu	His	Pro	Asp	Thr	Phe	Ser	His	Leu	Ser	Arg	Leu	Glu	Gly
		275					280					285			
Leu	Val	Leu	Lys	Asp	Ser	Ser	Leu	Ser	Trp	Leu	Asn	Ala	Ser	Trp	Phe
		290					295				300				
Arg	Gly	Leu	Gly	Asn	Leu	Arg	Val	Leu	Asp	Leu	Ser	Glu	Asn	Phe	Leu
		305			310					315					320
Tyr	Lys	Cys	Ile	Thr	Lys	Thr	Lys	Ala	Phe	Gln	Gly	Leu	Thr	Gln	Leu
			325						330					335	
Arg	Lys	Leu	Asn	Leu	Ser	Phe	Asn	Tyr	Gln	Lys	Arg	Val	Ser	Phe	Ala
			340					345					350		
His	Leu	Ser	Leu	Ala	Pro	Ser	Phe	Gly	Ser	Leu	Val	Ala	Leu	Lys	Glu
		355					360					365			
Leu	Asp	Met	His	Gly	Ile	Phe	Phe	Arg	Ser	Leu	Asp	Glu	Thr	Thr	Leu
		370				375					380				
Arg	Pro	Leu	Ala	Arg	Leu	Pro	Met	Leu	Gln	Thr	Leu	Arg	Leu	Gln	Met
		385			390					395					400
Asn	Phe	Ile	Asn	Gln	Ala	Gln	Leu	Gly	Ile	Phe	Arg	Ala	Phe	Pro	Gly
			405						410					415	
Leu	Arg	Tyr	Val	Asp	Leu	Ser	Asp	Asn	Arg	Ile	Ser	Gly	Ala	Ser	Glu
			420					425					430		
Leu	Thr	Ala	Thr	Met	Gly	Glu	Ala	Asp	Gly	Gly	Glu	Lys	Val	Trp	Leu

435 440 445  
 Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu  
 450 455 460  
 Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser  
 465 470 475 480  
 Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser  
 485 490 495  
 His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val  
 500 505 510  
 Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu  
 515 520 525  
 Ser Arg Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu  
 530 535 540  
 Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly  
 545 550 555 560  
 Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr  
 565 570 575  
 Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser  
 580 585 590  
 Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn  
 595 600 605  
 Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe  
 610 615 620  
 Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp Leu Ser Gln Asn Arg Leu  
 625 630 635 640  
 His Thr Leu Leu Pro Gln Thr Leu Arg Asn Leu Pro Lys Ser Leu Gln  
 645 650 655  
 Val Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser  
 660 665 670  
 Leu His Phe Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Arg  
 675 680 685  
 Leu Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg  
 690 695 700  
 Arg Leu Asp Val Ser Cys Asn Ser Ile Ser Phe Val Ala Pro Gly Phe  
 705 710 715 720  
 Phe Ser Lys Ala Lys Glu Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala  
 725 730 735  
 Leu Lys Thr Val Asp His Ser Trp Phe Gly Pro Leu Ala Ser Ala Leu  
 740 745 750  
 Gln Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala  
 755 760 765  
 Ala Phe Met Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu



```

      770              775              780
Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Leu Ser
785              790              795              800

Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp
      805              810              815

Asp Cys Phe Ala Leu Ser Leu Leu Ala Val Ala Leu Gly Leu Gly Val
      820              825              830

Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His
      835              840              845

Leu Cys Leu Ala Trp Leu Pro Trp Arg Gly Arg Gln Ser Gly Arg Asp
      850              855              860

Glu Asp Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Thr Gln
865              870              875              880

Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Gly Gln Leu Glu
      885              890              895

Glu Cys Arg Gly Arg Trp Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp
      900              905              910

Trp Leu Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr
      915              920              925

Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser
      930              935              940

Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu
945              950              955              960

Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Ser Pro Asp Gly Arg
      965              970              975

Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val
      980              985              990

Leu Leu Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln
      995              1000              1005

Leu Gly Met Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg
      1010              1015              1020

Asn Phe Cys Gln Gly Pro Thr Ala Glu
      1025              1030

```

<210> 63  
 <211> 1032  
 <212> PRT  
 <213> Homo sapiens

<400> 63

```

Met Gly Phe Cys Arg Ser Ala Leu His Pro Leu Ser Leu Leu Val Gln
1          5          10          15

```

```

Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe
20          25          30

```

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu  
 35 40 45  
 Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly Asn  
 50 55 60  
 Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His Asp  
 65 70 75 80  
 Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys Trp  
 85 90 95  
 Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met  
 100 105 110  
 Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu  
 115 120 125  
 Asn Leu Ser Tyr Asn Asn Ile Met Thr Val Pro Ala Leu Pro Lys Ser  
 130 135 140  
 Leu Ile Ser Leu Ser Leu Ser His Thr Asn Ile Leu Met Leu Asp Ser  
 145 150 155 160  
 Ala Ser Leu Ala Gly Leu His Ala Leu Arg Phe Leu Phe Met Asp Gly  
 165 170 175  
 Asn Cys Tyr Tyr Lys Asn Pro Cys Arg Gln Ala Leu Glu Val Ala Pro  
 180 185 190  
 Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr  
 195 200 205  
 Asn Asn Leu Thr Val Val Pro Arg Asn Leu Pro Ser Ser Leu Glu Tyr  
 210 215 220  
 Leu Leu Leu Ser Tyr Asn Arg Ile Val Lys Leu Ala Pro Glu Asp Leu  
 225 230 235 240  
 Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg  
 245 250 255  
 Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys Pro Arg His Phe  
 260 265 270  
 Pro Gln Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly  
 275 280 285  
 Leu Val Leu Lys Asp Ser Ser Leu Ser Trp Leu Asn Ala Ser Trp Phe  
 290 295 300  
 Arg Gly Leu Gly Asn Leu Arg Val Leu Asp Leu Ser Glu Asn Phe Leu  
 305 310 315 320  
 Tyr Lys Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Thr Gln Leu  
 325 330 335  
 Arg Lys Leu Asn Leu Ser Phe Asn Tyr Gln Lys Arg Val Ser Phe Ala  
 340 345 350  
 His Leu Ser Leu Ala Pro Ser Phe Gly Ser Leu Val Ala Leu Lys Glu

355	360	365
Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Asp Glu Thr Thr Leu		
370	375	380
Arg Pro Leu Ala Arg Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met		
385	390	395
Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Arg Ala Phe Pro Gly		
	405	410
		415
Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ser Glu		
	420	425
		430
Leu Thr Ala Thr Met Gly Glu Ala Asp Gly Gly Glu Lys Val Trp Leu		
	435	440
		445
Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu		
	450	455
		460
Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser		
465	470	475
		480
Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser		
	485	490
		495
His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val		
	500	505
		510
Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu		
	515	520
		525
Ser His Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu		
	530	535
		540
Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly		
545	550	555
		560
Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr		
	565	570
		575
Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser		
	580	585
		590
Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn		
	595	600
		605
Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe		
	610	615
		620
Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp Leu Ser Gln Asn Arg Leu		
625	630	635
		640
His Thr Leu Leu Pro Gln Thr Leu Arg Asn Leu Pro Lys Ser Leu Gln		
	645	650
		655
Val Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser		
	660	665
		670
Leu His Phe Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Gln		
	675	680
		685
Leu Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg		

```

        690                695                700
Arg Leu Asp Val Ser Cys Asn Ser Ile Ser Phe Val Ala Pro Gly Phe
705                710                715                720

Phe Ser Lys Ala Lys Glu Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala
                725                730                735

Leu Lys Thr Val Asp His Ser Trp Phe Gly Pro Leu Ala Ser Ala Leu
                740                745                750

Gln Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala
                755                760                765

Ala Phe Met Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu
                770                775                780

Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Leu Ser
785                790                795                800

Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp
                805                810                815

Asp Cys Phe Ala Leu Ser Leu Leu Ala Val Ala Leu Gly Leu Gly Val
                820                825                830

Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His
                835                840                845

Leu Cys Leu Ala Trp Leu Pro Trp Arg Gly Arg Gln Ser Gly Arg Asp
                850                855                860

Glu Asp Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Thr Gln
865                870                875                880

Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Gly Gln Leu Glu
                885                890                895

Glu Cys Arg Gly Arg Trp Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp
                900                905                910

Trp Leu Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr
                915                920                925

Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser
                930                935                940

Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu
945                950                955                960

Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Ser Pro Asp Gly Arg
                965                970                975

Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val
                980                985                990

Leu Leu Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln
                995                1000                1005

Leu Gly Met Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg
                1010                1015                1020

Asn Phe Cys Gln Gly Pro Thr Ala Glu

```

1025                      1030  
 <210> 64  
 <211> 333  
 <212> PRT  
 <213> Homo sapiens  
 <400> 64  
  
 Met Pro Met Lys Trp Ser Gly Trp Arg Trp Ser Trp Gly Pro Ala Thr  
 1                      5                      10                      15  
  
 His Thr Ala Leu Pro Pro Pro Gln Gly Phe Cys Arg Ser Ala Leu His  
                     20                      25                      30  
  
 Pro Leu Ser Leu Leu Val Gln Ala Ile Met Leu Ala Met Thr Leu Ala  
                     35                      40                      45  
  
 Leu Gly Thr Leu Pro Ala Phe Leu Pro Cys Glu Leu Gln Pro His Gly  
                     50                      55                      60  
  
 Leu Val Asn Cys Asn Trp Leu Phe Leu Lys Ser Val Pro His Phe Ser  
 65                      70                      75                      80  
  
 Met Ala Ala Pro Arg Gly Asn Val Thr Ser Leu Ser Leu Ser Ser Asn  
                     85                      90                      95  
  
 Arg Ile His His Leu His Asp Ser Asp Phe Ala His Leu Pro Ser Leu  
                     100                      105                      110  
  
 Arg His Leu Asn Leu Lys Trp Asn Cys Pro Pro Val Gly Leu Ser Pro  
                     115                      120                      125  
  
 Met His Phe Pro Cys His Met Thr Ile Glu Pro Ser Thr Phe Leu Ala  
                     130                      135                      140  
  
 Val Pro Thr Leu Glu Glu Leu Asn Leu Ser Tyr Asn Asn Ile Met Thr  
 145                      150                      155                      160  
  
 Val Pro Ala Leu Pro Lys Ser Leu Ile Ser Leu Ser Leu Ser His Thr  
                     165                      170                      175  
  
 Asn Ile Leu Met Leu Asp Ser Ala Ser Leu Ala Gly Leu His Ala Leu  
                     180                      185                      190  
  
 Arg Phe Leu Phe Met Asp Gly Asn Cys Tyr Tyr Lys Asn Pro Cys Arg  
                     195                      200                      205  
  
 Gln Ala Leu Glu Val Ala Pro Gly Ala Leu Leu Gly Leu Gly Asn Leu  
                     210                      215                      220  
  
 Thr His Leu Ser Leu Lys Tyr Asn Asn Leu Thr Val Val Pro Arg Asn  
 225                      230                      235                      240  
  
 Leu Pro Ser Ser Leu Glu Tyr Leu Leu Leu Ser Tyr Asn Arg Ile Val  
                     245                      250                      255  
  
 Lys Leu Ala Pro Glu Asp Leu Ala Asn Leu Thr Ala Leu Arg Val Leu  
                     260                      265                      270  
  
 Asp Val Gly Gly Asn Cys Arg Arg Cys Asp His Ala Pro Asn Pro Cys  
                     275                      280                      285

Met Glu Cys Pro Arg His Phe Pro Gln Leu His Pro Asp Thr Phe Ser  
 290 295 300

His Leu Ser Arg Leu Glu Gly Leu Val Leu Lys Asp Ser Ser Leu Ser  
 305 310 315 320

Trp Leu Asn Ala Ser Trp Phe Arg Gly Leu Gly Asn Leu  
 325 330

<210> 65

<211> 216

<212> PRT

<213> Homo sapiens

<400> 65

Met Leu Tyr Ser Ser Cys Lys Ser Arg Leu Leu Asp Ser Val Glu Gln  
 1 5 10 15

Asp Phe His Leu Glu Ile Ala Lys Lys Gly Phe Cys Arg Ser Ala Leu  
 20 25 30

His Pro Leu Ser Leu Leu Val Gln Ala Ile Met Leu Ala Met Thr Leu  
 35 40 45

Ala Leu Gly Thr Leu Pro Ala Phe Leu Pro Cys Glu Leu Gln Pro His  
 50 55 60

Gly Leu Val Asn Cys Asn Trp Leu Phe Leu Lys Ser Val Pro His Phe  
 65 70 75 80

Ser Met Ala Ala Pro Arg Gly Asn Val Thr Ser Leu Ser Leu Ser Ser  
 85 90 95

Asn Arg Ile His His Leu His Asp Ser Asp Phe Ala His Leu Pro Ser  
 100 105 110

Leu Arg His Leu Asn Leu Lys Trp Asn Cys Pro Pro Val Gly Leu Ser  
 115 120 125

Pro Met His Phe Pro Cys His Met Thr Ile Glu Pro Ser Thr Phe Leu  
 130 135 140

Ala Val Pro Thr Leu Glu Glu Leu Asn Leu Ser Tyr Asn Asn Ile Met  
 145 150 155 160

Thr Val Pro Ala Leu Pro Lys Ser Leu Ile Ser Leu Ser Leu Ser His  
 165 170 175

Thr Asn Ile Leu Met Leu Asp Ser Ala Ser Leu Ala Gly Leu His Ala  
 180 185 190

Leu Arg Phe Leu Phe Met Asp Gly Asn Cys Tyr Tyr Lys Asn Pro Cys  
 195 200 205

Arg Gln Ala Leu Glu Val Ala Pro  
 210 215

<210> 66

<211> 117  
<212> PRT  
<213> Homo sapiens

<400> 66

Met Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala  
1 5 10 15  
Phe Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp  
20 25 30  
Leu Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly  
35 40 45  
Asn Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His  
50 55 60  
Asp Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys  
65 70 75 80  
Trp Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His  
85 90 95  
Met Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu  
100 105 110  
Leu Asn Leu Ser Tyr  
115

<210> 67  
<211> 1032  
<212> PRT  
<213> Homo sapiens

<400> 67

Met Gly Phe Cys Arg Ser Ala Leu His Pro Leu Ser Leu Leu Val Gln  
1 5 10 15  
Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe  
20 25 30  
Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu  
35 40 45  
Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly Asn  
50 55 60  
Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His Asp  
65 70 75 80  
Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys Trp  
85 90 95  
Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met  
100 105 110  
Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu  
115 120 125

Asn Leu Ser Tyr Asn Asn Ile Met Thr Val Pro Ala Leu Pro Lys Ser  
 130 135 140  
 Leu Ile Ser Leu Ser Leu Ser His Thr Asn Ile Leu Met Leu Asp Ser  
 145 150 155 160  
 Ala Ser Leu Ala Gly Leu His Ala Leu Arg Phe Leu Phe Met Asp Gly  
 165 170 175  
 Asn Cys Tyr Tyr Lys Asn Pro Cys Arg Gln Ala Leu Glu Val Ala Pro  
 180 185 190  
 Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr  
 195 200 205  
 Asn Asn Leu Thr Val Val Pro Arg Asn Leu Pro Ser Ser Leu Glu Tyr  
 210 215 220  
 Leu Leu Leu Ser Tyr Asn Arg Ile Val Lys Leu Ala Pro Glu Asp Leu  
 225 230 235 240  
 Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg  
 245 250 255  
 Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys Pro Arg His Phe  
 260 265 270  
 Pro Gln Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly  
 275 280 285  
 Leu Val Leu Lys Asp Ser Ser Leu Ser Trp Leu Asn Ala Ser Trp Phe  
 290 295 300  
 Arg Gly Leu Gly Asn Leu Arg Val Leu Asp Leu Ser Glu Asn Phe Leu  
 305 310 315 320  
 Tyr Lys Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Thr Gln Leu  
 325 330 335  
 Arg Lys Leu Asn Leu Ser Phe Asn Tyr Gln Lys Arg Val Ser Phe Ala  
 340 345 350  
 His Leu Ser Leu Ala Pro Ser Phe Gly Ser Leu Val Ala Leu Lys Glu  
 355 360 365  
 Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Asp Glu Thr Thr Leu  
 370 375 380  
 Arg Pro Leu Ala Arg Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met  
 385 390 395 400  
 Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Arg Ala Phe Pro Gly  
 405 410 415  
 Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ser Glu  
 420 425 430  
 Leu Thr Ala Thr Met Gly Glu Ala Asp Gly Gly Glu Lys Val Trp Leu  
 435 440 445  
 Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu



450	455	460
Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser		
465	470	475
Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser		
485	490	495
His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val		
500	505	510
Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu		
515	520	525
Ser His Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu		
530	535	540
Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly		
545	550	555
Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr		
565	570	575
Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser		
580	585	590
Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn		
595	600	605
Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe		
610	615	620
Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp Leu Ser Gln Asn Arg Leu		
625	630	635
His Thr Leu Leu Pro Gln Thr Leu Arg Asn Leu Pro Lys Ser Leu Gln		
645	650	655
Val Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser		
660	665	670
Leu His Phe Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Gln		
675	680	685
Leu Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg		
690	695	700
Arg Leu Asp Val Ser Cys Asn Ser Ile Ser Phe Val Ala Pro Gly Phe		
705	710	715
Phe Ser Lys Ala Lys Glu Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala		
725	730	735
Leu Lys Thr Val Asp His Ser Trp Phe Gly Pro Leu Ala Ser Ala Leu		
740	745	750
Gln Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala		
755	760	765
Ala Phe Met Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu		
770	775	780
Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Leu Ser		

785                      790                      795                      800  
 Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp  
                                  805                      810                      815  
  
 Asp Cys Phe Ala Leu Ser Leu Leu Ala Val Ala Leu Gly Leu Gly Val  
                                  820                      825                      830  
  
 Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His  
                                  835                      840                      845  
  
 Leu Cys Leu Ala Trp Leu Pro Trp Arg Gly Arg Gln Ser Gly Arg Asp  
                                  850                      855                      860  
  
 Glu Asp Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Thr Gln  
                                  865                      870                      875                      880  
  
 Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Gly Gln Leu Glu  
                                  885                      890                      895  
  
 Glu Cys Arg Gly Arg Trp Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp  
                                  900                      905                      910  
  
 Trp Leu Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr  
                                  915                      920                      925  
  
 Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser  
                                  930                      935                      940  
  
 Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu  
                                  945                      950                      955                      960  
  
 Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Ser Pro Asp Gly Arg  
                                  965                      970                      975  
  
 Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val  
                                  980                      985                      990  
  
 Leu Leu Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln  
                                  995                      1000                      1005  
  
 Leu Gly Met Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg  
                                  1010                      1015                      1020  
  
 Asn Phe Cys Gln Gly Pro Thr Ala Glu  
                                  1025                      1030

&lt;210&gt; 68

&lt;211&gt; 3200

&lt;212&gt; DNA

&lt;213&gt; murine

&lt;400&gt; 68

tgtcagaggg agcctcggga gaatcctcca tctcccaaca tggttctccg tcgaaggact 60

ctgcaccctt tgtcctctct ggtacaggct gcagtgtctgg ctgagactct ggccctgggt 120

accctgcctg ccttctctacc ctgtgagctg aagcctcatg gcctggtgga ctgcaattgg 180

ctgttctctga agtctgtacc ccgtttctct gcggcagcat cctgtctccaa catcaccgcg 240

ctctccttga tctccaaccg tatccaccac ctgcacaact ccgacttcgt ccacctgtcc 300

aacctgcggc agctgaacct caagtggaac tgtccacca ctggccttag cccctgcac 360  
ttctcttgcc acatgaccat tgagcccaga accttcctgg ctatgcgtac actggaggag 420  
ctgaacctga gctataatgg tatcaccact gtgccccgac tgcccagctc cctggtgaat 480  
ctgagcctga gccacaccaa catcctgggt ctatgtgcta acagcctcgc cggcctatac 540  
agcctgcgcg ttctcttcat ggacgggaac tgctactaca agaaccctg cacaggagcg 600  
gtgaaggtga cccagggcg cctcctgggc ctgagcaatc tcacccatct gtctctgaag 660  
tataacaacc tcacaaagggt gccccgccaa ctgcccccca gcctggagta cctcctgggtg 720  
tcctataacc tcattgtcaa gctggggcct gaagacctgg ccaatctgac ctcccttcga 780  
gtacttgatg tgggtgggaa ttgccgtcgc tgcgaccatg cccccaatcc ctgtatagaa 840  
tgtggccaaa agtccctcca cctgcaccct gagaccttcc atcacctgag ccatctggaa 900  
ggcctggtgc tgaaggacag ctctctccat aactgaact cttcctgggt ccaaggctctg 960  
gtcaacctct cgggtgctgga cctaagcgag aactttctct atgaaagcat caaccacacc 1020  
aatgcctttc agaacctaac ccgcctgcgc aagctcaacc tgccttcaa ttaccgcaag 1080  
aaggatcct ttgcccgcct ccacctggca agttccttca agaacctgggt gtactgcag 1140  
gagctgaaca tgaacggcat cttcttcgcg tcgctcaaca agtacacgct cagatggctg 1200  
gccgatctgc caaaactcca cactctgcat cttcaaata acttcatcaa ccaggcacag 1260  
ctcagcatct ttggtacctt ccgagccctt cgctttgtgg acttgtcaga caatcgcatc 1320  
agtgggcctt caacgctgtc agaagccacc cctgaaggag cagatgatgc agagcaggag 1380  
gagctgttgt ctgcggatcc tcacccagct ccactgagca cccctgcttc taagaacttc 1440  
atggacagggt gtaagaactt caagttcacc atggacctgt ctcggaacaa cctggtgact 1500  
atcaagccag agatgtttgt caatctctca cgcctccagt gtcttagcct gagccacaac 1560  
tcattgcac aggtgtcaa tggctctcag ttctgcgcg tgactaatct gcagggtgtg 1620  
gacctgtccc ataacaaact ggacttgtac cactggaaat cgttcagtga gctaccacag 1680  
ttgcaggccc tggacctgag ctacaacagc cagcccttta gcatgaaggg tataggccac 1740  
aatttcagtt ttgtggccca tctgtccatg ctacacagcc ttagcctggc acacaatgac 1800  
attcataccc gtgtgtcctc acatctcaac agcaactcag tgaggtttct tgacttcagc 1860  
ggcaacggta tgggccgcat gtgggatgag gggggccttt atctccattt cttccaaggc 1920  
ctgagtggcc tgctgaagct ggacctgtct caaaataacc tgcatatcct ccggccccag 1980  
aaccttgaca acctcccaa gagcctgaag ctgctgagcc tccgagacaa ctacctatct 2040  
ttctttaact ggaccagtct gtccttctg cccaacctgg aagtcctaga cctggcaggc 2100  
aaccagctaa aggcctgac caatggcacc ctgcctaata gcacctcct ccagaaactg 2160

gatgtcagca gcaacagtat cgtctctgtg gtcccagcct tcttcgctct ggcggtcgag 2220  
ctgaaagagg tcaacctcag ccacaacatt ctcaagacgg tggatcgctc ctggtttggg 2280  
cccattgtga tgaacctgac agttctagac gtgagaagca accctctgca ctgtgcctgt 2340  
ggggcagcct tcgtagactt actgttgag gtgcagacca aggtgcctgg cctggctaata 2400  
ggtgtgaagt gtggcagccc cggccagctg cagggccgta gcattctgc acaggacctg 2460  
cggctgtgcc tggatgaggt cctctcttg gactgctttg gcctttcact cttggctgtg 2520  
gcgctgggca tgggtgtgcc tatactgcac catctctcg gctgggacgt ctggtactgt 2580  
tttcatctgt gcctggcatg gctacctttg ctggcccga gccagcgcag cgccaagct 2640  
ctcccctatg atgccttcgt ggtgttcgat aaggcacaga gcgcagttgc ggactgggtg 2700  
tataacgagc tgcgggtgcg gctggaggag cggcgcggtc gccgagccct acgcttgtgt 2760  
ctggaggacc gagattggct gcctggccag acgctcttcg agaacctctg ggcttccatc 2820  
tatgggagcc gcaagactct atttgtgctg gccacacgg accgcgtcag tggcctcctg 2880  
cgcaccagct tcctgctggc tcagcagcgc ctgttgaag accgcaagga cgtgggtgtg 2940  
ttggtgatcc tgcgtccgga tgcccaccgc tcccgctatg tgcgactgc ccagcgtctc 3000  
tgccgccaga gtgtgctctt ctggccccag cagcccaacg ggagggggg cttctggggc 3060  
cagctgagta cagccctgac tagggacaac cgccacttct ataaccagaa cttctgccgg 3120  
ggacctacag cagaatagct cagagcaaca gctggaaaca gctgcatctt catgcctgg 3180  
tcccgagttg ctctgcctgc 3200

<210> 69  
<211> 3471  
<212> DNA  
<213> murine

<400> 69  
tgaaagtgtc acttcctcaa ttctctgaga gacctgggtg tggaacatca ttctctgccg 60  
cccagtttgt cagagggagc ctcgggagaa tcctccatct cccaacatgg ttctccgtcg 120  
aaggactctg cacccttgt ccctcctgg acaggtgca gtgtggctg agactctggc 180  
cctgggtacc ctgcctgcct tcctaccctg tgagctgaag cctcatggcc tgggtggactg 240  
caattggctg ttctgaagt ctgtaccccg tttctctgcg gcagcatcct gctccaacat 300  
caccgcctc tccttgatct ccaaccgtat ccaccacctg cacaactccg acttcgtcca 360  
cctgtccaac ctgcggcagc tgaacctcaa gtggaactgt ccaccactg gccttagccc 420  
cctgcacttc tcttgccaca tgaccattga gcccagaacc ttctggcta tgcgtacact 480  
ggaggagctg aacctgagct ataattggat caccactgtg ccccgactgc ccagctccct 540

ggatgaatctg agcctgagcc acaccaacat cctgggttcta gatgctaaca gcctcgccgg	600
cctatacagc ctgcgcgttc tcttcatgga cgggaactgc tactacaaga acccctgcac	660
aggagcgggtg aaggtgaccc caggcgccct cctgggcctg agcaatctca cccatctgtc	720
tctgaagtat aacaacctca caaagggtgcc ccgccaactg ccccccagcc tggagtacct	780
cctgggtgtcc tataacctca ttgtcaagct ggggcctgaa gacctggcca atctgacctc	840
ccttcgagta cttgatgtgg gtgggaattg ccgtcgctgc gaccatgccc ccaatccctg	900
tatagaatgt ggccaaaagt ccctccacct gcacctgag accttccatc acctgagcca	960
tctggaaggc ctggtgctga aggacagctc tctccataca ctgaactctt cctgggtcca	1020
aggctctggc aacctctcgg tgctggacct aagcgagaac tttctctatg aaagcatcaa	1080
ccacaccaat gcctttcaga acctaaccg cctgcgcaag ctcaacctgt ccttcaatta	1140
ccgcaagaag gtatcctttg ccgcctcca cctggcaagt tccttcaaga acctggtgtc	1200
actgcaggag ctgaacatga acggcatctt cttccgctcg ctcaacaagt acacgctcag	1260
atggctggcc gatctgcca aactccacac tctgcatctt caaatgaact tcatcaacca	1320
ggcacagctc agcatctttg gtaccttcg agcccttcgc tttgtggact tgtcagacaa	1380
tcgcatcagt gggccttcaa cgctgtcaga agccaccct gaagaggcag atgatgcaga	1440
gcaggaggag ctgttgtctg cggatcctca cccagctcca ctgagcacc ctgcttctaa	1500
gaacttcatg gacagggtga agaacttcaa gttcaccatg gacctgtctc ggaacaacct	1560
ggtgactatc aagccagaga tgtttgtcaa tctctcacgc ctccagtgtc ttagcctgag	1620
ccacaactcc attgcacagg ctgtcaatgg ctctcagttc ctgccgctga ctaatctgca	1680
ggtgctggac ctgtcccata acaaactgga cttgtaccac tggaaatcgt tcagtgaagt	1740
accacagttg caggccctgg acctgagcta caacagccag cccttttagca tgaagggtat	1800
aggccacaat ttcagttttg tgacctatct gtccatgcta cagagcctta gcctggcaca	1860
caatgacatt cataccctg tgctctcaca tctcaacagc aactcagtga ggtttcttga	1920
cttcagcggc aacgggtatgg gccgcatgtg ggatgagggg ggcctttatc tccatttctt	1980
ccaaggcctg agtggcctgc tgaagctgga cctgtctcaa aataacctgc atatcctccg	2040
gccccagAAC cttgacaacc tccccaagag cctgaagctg ctgagcctcc gagacaacta	2100
cctatctttc tttaactgga ccagtctgtc cttcctaccc aacctggaag tcctagacct	2160
ggcaggcaac cagctaaagg ccctgaccaa tggcaccctg cctaattggca ccctcctcca	2220
gaaactcgat gtcagtagca acagtatcgt ctctgtggtc ccagccttct tcgctctggc	2280
ggtcgagctg aaagagggtca acctcagcca caacattctc aagacgggtg atcgctcctg	2340
gtttgggccc atttgtatga acctgacagt tctagacgtg agaagcaacc ctctgcactg	2400
tgctgtggg gcagccttcg tagacttact gttggagggt cagaccaagg tgctggcct	2460

ggctaattggt gtgaagtgtg gcagccccgg ccagctgcag ggccgtagca tcttcgcgca 2520  
 ggacctgcgg ctgtgcctgg atgaggtcct ctcttgggac tgctttggcc tttcaactctt 2580  
 ggctgtggcc gtgggcatgg tgggtgcctat actgcaccat ctctgcggct gggacgtctg 2640  
 gtactgtttt catctgtgcc tggcatggct acctttgctg gcccgcagcc gacgcagcgc 2700  
 ccaaactctc ccttatgatg ccttcgtggg gttcgataag gcacagagcg cagttgccga 2760  
 ctgggtgtat aacgagctgc ggggtgcggct ggaggagcgg cgcggtcgcc gagccctacg 2820  
 cttgtgtctg gaggaccgag attggctgcc tggccagacg ctcttcgaga acctctgggc 2880  
 ttccatctat gggagccgca agactctatt tgtgctggcc cacacggacc gcgtcagtgg 2940  
 cctcctgcgc accagcttcc tgctggctca gcagcgctg ttggaagacc gcaaggacgt 3000  
 ggtggtgttg gtgatcctgc gtccggatgc ccaccgctcc cgctatgtgc gactgcgcca 3060  
 gcgtctctgc cgccagagtg tgctcttctg gcccagcag cccaacgggc aggggggctt 3120  
 ctggggccag ctgagtacag ccctgactag ggacaaccgc cacttctata accagaactt 3180  
 ctgccgggga cctacagcag aatagctcag agcaacagct ggaaacagct gcatcttcat 3240  
 gcctggttcc cgagttgtgc tgcttgcctt gctctgtctt actacaccgc tatttggcaa 3300  
 gtgcgcaata tatgtacca agccaccagg cccacggagc aaagggtggc agtaaagggt 3360  
 agttttcttc ccatgcatct ttcaggagag tgaagataga caccagacc acacagaaca 3420  
 ggactggagt tcattctctg cccctccacc ccactttgcc tgtctctgta t 3471

<210> 70  
 <211> 3340  
 <212> DNA  
 <213> murine

<400> 70  
 tctctgagag accctggtgt ggaacatcat tctctgccgc ccagtttgct agaggagacc 60  
 tcgggagaat cctccatctc ccaacatggt tctccgtcga aggactctgc accccttgct 120  
 cctcctggta caggctgcag tgctggctga gactctggcc ctgggtacct tgctgcctt 180  
 cctaccctgt gagctgaagc ctcatggcct ggtggactgc aattggctgt tcctgaagtc 240  
 tgtacccctg ttctctgcgg cagcatcctg ctccaacatc acccgctct ccttgatctc 300  
 caaccgtatc caccacctgc acaactccga ctttgtccac ctgtccaacc tgccgcagct 360  
 gaacctcaag tggaactgtc caccactgg ccttagcccc ctgcacttct cttgccacat 420  
 gaccattgag ccagaaacct tcctggctat gcgtacactg gaggagctga acctgagcta 480  
 taatggatc accactgtgc cccgactgcc cagctccctg gtgaatctga gcctgagcca 540  
 caccaacatc ctggttctag atgctaacag cctcgccggc ctatacagcc tgcgcgttct 600

cttcatggac	gggaactgct	actacaagaa	cccctgcaca	ggagcgggtga	aggtgacccc	660
aggcgccctc	ctgggcctga	gcaatctcac	ccatctgtct	ctgaagtata	acaacctcac	720
aaagggtgcc	cgccaactgc	ccccagcct	ggagtacctc	ctggtgtcct	ataacctcat	780
tgtcaagctg	gggcctgaag	acctggccaa	tctgacctcc	cttcgagtac	ttgatgtggg	840
tgggaattgc	cgctcgtcgc	accatgcccc	caatccctgt	atagaatgtg	gccaaaagtc	900
cctccacctg	cacctgaga	ccttccatca	cctgagccat	ctggaaggcc	tgggtgctgaa	960
ggacagctct	ctccatacac	tgaactcttc	ctggttccaa	ggtctggtca	acctctcggg	1020
gctggacctc	agcgagaact	ttctctatga	aagcatcaac	cacaccaatg	cctttcagaa	1080
cctaaccgcg	ctgcgcaagc	tcaacctgtc	cttcaattac	cgcaagaagg	tatcctttgc	1140
ccgcctccac	ctggcaagtt	ccttcaagaa	cctgggtgtca	ctgcaggagc	tgaacatgaa	1200
cgcatcttcc	ttccgctcgc	tcaacaagta	cacgctcaga	tggctggccg	atctgccccaa	1260
actccacact	ctgcatcttc	aatgaacttt	catcaaccag	gcacagctca	gcattcttgg	1320
taccttccga	gcccttcgct	ttgtggactt	gtcagacaat	cgcatcagtg	ggccttcaac	1380
gctgtcagaa	gccaccctg	aagaggcaga	tgatgcagag	caggaggagc	tgttgtctgc	1440
ggatcctcac	ccagctccac	tgagcaccoc	tgcttctaag	aacttcatgg	acagggtgtaa	1500
gaacttcaag	ttcaccatgg	acctgtctcg	gaacaacctg	gtgactatca	agccagagat	1560
gtttgtcaat	ctctcacgcc	tccagtgtct	tagcctgagc	cacaactcca	ttgcacaggc	1620
tgtcaatggc	tctcagttcc	tgccgctgac	taatctgcag	gtgctggacc	tgtcccataa	1680
caaactggac	ttgtaccact	ggaaatcggt	cagtgcagta	ccacagttgc	aggccctgga	1740
cctgggctac	aacagccagc	ccttttagcat	aaaggggtata	ggccacaatt	tcagttttgt	1800
ggcccatctg	tccatgctac	acagccttag	cctggcacac	aatgacattc	ataccctgtg	1860
gtcctcacat	ctcaacagca	actcagtgcg	gtttcttgac	ttcagcggca	acgggtatggg	1920
ccgcatgtgg	gatgaggggg	gcctttatct	ccatttcttc	caaggcctga	gtggcctgct	1980
gaagctggac	ctgtctcaaa	ataacctgca	tatcctccgg	cccagaacc	ttgacaacct	2040
ccccagagc	ctgaagctgc	tgagcctccg	agacaactac	ctatctttct	ttaactggac	2100
cagtctgtcc	ttcctgcccc	acctggaagt	cctagacctg	gcaggcaacc	agctaaaggc	2160
cctgaccaat	ggcaccctgc	ctaatggcac	cctcctccag	aaactggatg	tcagcagcaa	2220
cagtatcgtc	tctgtgggtc	cagccttctt	cgctctggcg	gtcgagctga	aagagggtcaa	2280
cctcagccac	aacattctca	agacgggtgga	tgcctcctgg	tttggggcca	ttgtgatgaa	2340
cctgacagtt	ctagacgtga	gaagcaaccc	tctgcactgt	gcctgtgggg	cagccttcgt	2400
agacttactg	ttggagggtg	agaccaagggt	gcctggcctg	gctaattggtg	tgaagtgtgg	2460
cagccccggc	cagctgcagg	gccgtagcat	cttcgcacag	gacctgcggc	tgtgcctgga	2520

tgaggtcctc tcttgggact gctttggcct ttcactcttg gctgtggccg tgggcatggg	2580
ggtgcctata ctgcaccatc tctgcggctg ggacgtctgg tactgttttc atctgtgcct	2640
ggcatggcta cctttgctgg ccgcagccg acgcagcgcc caagctctcc cctatgatgc	2700
cttcgtgggtg ttcgataagg cacagagcgc agttgcggac tgggtgtata acgagctgcg	2760
ggtgcggctg gaggggcggc gcggtcggc agccctacgc ttgtgtctgg aggaccgaga	2820
ttggctgcct ggccagacgc tcttcgagaa cctctgggct tccatctatg ggagccgcaa	2880
gactctatct gtgctggccc acacggaccg cgtcagtggc ctcttgcgca ccagcttcct	2940
gctggctcag cagcgctgt tggaagaccg caaggacgtg gtggtgttg tgatcctgcg	3000
tccggatgcc caccgctccc gctatgtgcg actgcgccag cgtctctgcc gccagagtgt	3060
gctcttttgg cccagcagc ccaacgggca ggggggcttc tgggccagc tgagtacagc	3120
cctgactagg gacaaccgcc acttctataa ccagaacttc tgccggggac ctacagcaga	3180
atagctcaga gcaacagctg gaaacagctg catcttcatg cctgggtccc gagttgctct	3240
gcctgccttg ctctgtctta ctacaccgct atttggcaag tgcgcaatat atgctaccaa	3300
gccaccgggc ccacggagca aagggtggct gtaaagggtg	3340

<210> 71  
 <211> 3471  
 <212> DNA  
 <213> murine

<400> 71	
tgaaagtgtc acttcctcaa ttctctgaga gaccctgggtg tggaacatca ttctctgccg	60
cccagtttgt cagagggagc ctcgggagaa tcctccatct cccaacatgg ttctccgtcg	120
aaggactctg cacccttgt cctcctgggt acaggctgca gtgctggctg agactctggc	180
cctgggtacc ctgcctgcct tcctaccctg tgagctgaag cctcatggcc tgggtggactg	240
caattggctg ttctgaagt ctgtaccccg tttctctgcg gcagcatcct gctccaacat	300
caccgcctc tccttgatct ccaaccgtat ccaccacctg cacaactccg acttcgtcca	360
cctgtccaac ctgcggcagc tgaacctcaa gtggaactgt ccaccactg gccttagccc	420
cctgcacttc tcttgccaca tgaccattga gcccagaacc ttcttggtta tgcgtacact	480
ggaggagctg aacctgagct ataattggtat caccactgtg ccccgactgc ccagctccct	540
ggtgaatctg agcctgagcc acaccaacat cctgggttcta gatgctaaca gcctcgccgg	600
cctatacagc ctgcgcgttc tcttcatgga cgggaactgc tactacaaga acccctgcac	660
aggagcgggtg aagggtgacc caggcgccct cctgggcctg agcaatctca cccatctgtc	720
tctgaagtat aacaacctca caaagggtgcc ccgccaactg ccccccagcc tggagtacct	780



cctgggtgtcc tataacctca ttgtcaagct ggggcctgaa gacctggcca atctgacctc	840
ccttcgagta cttgatgtgg gtgggaattg ccgtcgtgc gaccatgccc ccaatccctg	900
tatagaatgt ggccaaaagt ccctccacct gcacctgag accttccatc acctgagcca	960
tctggaaggc ctgggtgctga aggacagctc tctccataca ctgaactctt cctgggtcca	1020
aggtctggtc aacctctcgg tgctggacct aagcgagaac tttctctatg aaagcatcaa	1080
ccacaccaat gcctttcaga acctaaccgg cctgcgcaag ctcaacctgt ccttcaatta	1140
ccgcaagaag gtatcctttg ccgcctcca cctggcaagt tccttcaaga acctggtgtc	1200
actgcaggag ctgaacatga acggcatctt cttccgctcg ctcaacaagt acacgctcag	1260
atggctggcc gatctgccc aactccacac tctgcatctt caaatgaact tcatcaacca	1320
ggcacagctc agcatctttg gtaccttccg agcccttcgc tttgtggact tgtcagacaa	1380
tcgcatcagt gggccttcaa cgctgtcaga agccaccct gaagaggcag atgatgcaga	1440
gcaggaggag ctggtgtctg cggatcctca ccagctcca ctgagcacc ctgcttctaa	1500
gaacttcatg gacaggtgta agaacttcaa gttcaccatg gacctgtctc ggaacaacct	1560
ggtgactatc aagccagaga tgtttgtcaa tctctcacgc ctccagtgtc ttagcctgag	1620
ccacaactcc attgcacagg ctgtcaatgg ctctcagttc ctgccgctga ctaatctgca	1680
ggtgctggac ctgtcccata aaaaactgga cttgtaccac tggaaatcgt tcagttagct	1740
accacagttg caggccctgg acctgagcta caacagccag cccttttagca tgaagggtat	1800
agggcacaat ttcagttttg tgacctctt gtccatgcta cagagcctta gcctggcaca	1860
caatgacatt cataccctg tgctctcaca tctcaacagc aactcagtga ggtttcttga	1920
cttcagcggc aacggtatgg gccgcatgtg ggatgagggg ggccctttatc tccatttctt	1980
ccaaggcctg agtggcctgc tgaagctgga cctgtctcaa aataacctgc atatcctccg	2040
gccccagaac cttgacaacc tccccagag cctgaagctg ctgagcctcc gagacaacta	2100
cctatctttc tttaactgga ccagtctgtc ctctctacct aacctggaag tcctagacct	2160
ggcaggcaac cagctaaagg ccctgaccaa tggcaccctg cctaatggca ccctcctcca	2220
gaaactcgat gtcagtagca acagtatcgt ctctgtggtc ccagccttct tcgctctggc	2280
ggtcgagctg aaagaggtca acctcagcca caacattctc aagacgggtg atcgctcctg	2340
gtttgggccc atttgtatga acctgacagt tctagacgtg agaagcaacc ctctgcactg	2400
tgctgtggg gcagccttcg tagacttact gttggaggtg cagaccaagg tgctggcct	2460
ggctaattgg gtgaagtgtg gcagccccgg ccagctgcag ggccgtagca tcttcgcgca	2520
ggacctgcgg ctgtgcctgg atgaggtcct ctcttgggac tgctttggcc tttcactctt	2580
ggctgtggcc gtgggcatgg tgggtgcctat actgcaccat ctctgaggct gggacgtctg	2640
gtactgtttt catctgtgcc tggcatggct acctttgctg gcccgagcc gacgcagcgc	2700

ccaaaactctc ccttatgatg ccttcgtggg gtctcgataag gcacagagcg cagttgccga 2760  
 ctgggtgtat aacgagctgc gggtgccggc ggaggagcgg cgcggtcgcc gagccctacg 2820  
 cttgtgtctg gaggaccgag attggctgcc tggccagacg ctcttcgaga acctctgggc 2880  
 ttccatctat gggagccgca agactctatt tgtgctggcc cacacggacc gcgtcagtgg 2940  
 cctcctgcgc accagcttcc tgctggctca gcagcgctg ttggaagacc gcaaggacgt 3000  
 ggtggtgttg gtgatcctgc gtccggatgc ccaccgctcc cgctatgtgc gactgcgcca 3060  
 gcgtctctgc cgccagagtg tgctcttctg gcccagcag cccaacgggc aggggggctt 3120  
 ctggggccag ctgagtacag ccctgactag ggacaaccgc cacttctata accagaactt 3180  
 ctgccgggga cctacagcag aatagctcag agcaacagct ggaaacagct gcattctcat 3240  
 gcctggttcc cgagttgctc tgcctgcctt gtctgtctt actacaccgc tatttgga 3300  
 gtgcgcaata tatgctacca agccaccagg ccacaggagc aaaggttggc agtaaagggt 3360  
 agttttcttc ccatgcatct ttcaggagag tgaagataga caccagacc acacagaaca 3420  
 ggactggagt tcattctctg ccctocacc ccactttgcc tgtctctgta t 3471

<210> 72  
 <211> 1032  
 <212> PRT  
 <213> murine

<400> 72

Met Val Leu Arg Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln  
 1 5 10 15  
 Ala Ala Val Leu Ala Glu Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe  
 20 25 30  
 Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu  
 35 40 45  
 Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ala Ser Cys Ser Asn  
 50 55 60  
 Ile Thr Arg Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asn  
 65 70 75 80  
 Ser Asp Phe Val His Leu Ser Asn Leu Arg Gln Leu Asn Leu Lys Trp  
 85 90 95  
 Asn Cys Pro Pro Thr Gly Leu Ser Pro Leu His Phe Ser Cys His Met  
 100 105 110  
 Thr Ile Glu Pro Arg Thr Phe Leu Ala Met Arg Thr Leu Glu Glu Leu  
 115 120 125  
 Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser  
 130 135 140

Leu Val Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala  
 145 150 155 160  
 Asn Ser Leu Ala Gly Leu Tyr Ser Leu Arg Val Leu Phe Met Asp Gly  
 165 170 175  
 Asn Cys Tyr Tyr Lys Asn Pro Cys Thr Gly Ala Val Lys Val Thr Pro  
 180 185 190  
 Gly Ala Leu Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr  
 195 200 205  
 Asn Asn Leu Thr Lys Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr  
 210 215 220  
 Leu Leu Val Ser Tyr Asn Leu Ile Val Lys Leu Gly Pro Glu Asp Leu  
 225 230 235 240  
 Ala Asn Leu Thr Ser Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg  
 245 250 255  
 Arg Cys Asp His Ala Pro Asn Pro Cys Ile Glu Cys Gly Gln Lys Ser  
 260 265 270  
 Leu His Leu His Pro Glu Thr Phe His His Leu Ser His Leu Glu Gly  
 275 280 285  
 Leu Val Leu Lys Asp Ser Ser Leu His Thr Leu Asn Ser Ser Trp Phe  
 290 295 300  
 Gln Gly Leu Val Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu  
 305 310 315 320  
 Tyr Glu Ser Ile Asn His Thr Asn Ala Phe Gln Asn Leu Thr Arg Leu  
 325 330 335  
 Arg Lys Leu Asn Leu Ser Phe Asn Tyr Arg Lys Lys Val Ser Phe Ala  
 340 345 350  
 Arg Leu His Leu Ala Ser Ser Phe Lys Asn Leu Val Ser Leu Gln Glu  
 355 360 365  
 Leu Asn Met Asn Gly Ile Phe Phe Arg Ser Leu Asn Lys Tyr Thr Leu  
 370 375 380  
 Arg Trp Leu Ala Asp Leu Pro Lys Leu His Thr Leu His Leu Gln Met  
 385 390 395 400  
 Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala  
 405 410 415  
 Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr  
 420 425 430  
 Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Gln Glu Glu  
 435 440 445  
 Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser  
 450 455 460  
 Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu

465	470										475				480		
Ser	Arg	Asn	Asn	Leu	Val	Thr	Ile	Lys	Pro	Glu	Met	Phe	Val	Asn	Leu		
				485					490					495			
Ser	Arg	Leu	Gln	Cys	Leu	Ser	Leu	Ser	His	Asn	Ser	Ile	Ala	Gln	Ala		
			500					505					510				
Val	Asn	Gly	Ser	Gln	Phe	Leu	Pro	Leu	Thr	Asn	Leu	Gln	Val	Leu	Asp		
		515					520					525					
Leu	Ser	His	Asn	Lys	Leu	Asp	Leu	Tyr	His	Trp	Lys	Ser	Phe	Ser	Glu		
	530					535					540						
Leu	Pro	Gln	Leu	Gln	Ala	Leu	Asp	Leu	Ser	Tyr	Asn	Ser	Gln	Pro	Phe		
545					550					555					560		
Ser	Met	Lys	Gly	Ile	Gly	His	Asn	Phe	Ser	Phe	Val	Ala	His	Leu	Ser		
				565					570					575			
Met	Leu	His	Ser	Leu	Ser	Leu	Ala	His	Asn	Asp	Ile	His	Thr	Arg	Val		
			580					585					590				
Ser	Ser	His	Leu	Asn	Ser	Asn	Ser	Val	Arg	Phe	Leu	Asp	Phe	Ser	Gly		
		595					600					605					
Asn	Gly	Met	Gly	Arg	Met	Trp	Asp	Glu	Gly	Gly	Leu	Tyr	Leu	His	Phe		
	610					615					620						
Phe	Gln	Gly	Leu	Ser	Gly	Leu	Leu	Lys	Leu	Asp	Leu	Ser	Gln	Asn	Asn		
625					630					635					640		
Leu	His	Ile	Leu	Arg	Pro	Gln	Asn	Leu	Asp	Asn	Leu	Pro	Lys	Ser	Leu		
				645					650					655			
Lys	Leu	Leu	Ser	Leu	Arg	Asp	Asn	Tyr	Leu	Ser	Phe	Phe	Asn	Trp	Thr		
			660					665					670				
Ser	Leu	Ser	Phe	Leu	Pro	Asn	Leu	Glu	Val	Leu	Asp	Leu	Ala	Gly	Asn		
		675					680					685					
Gln	Leu	Lys	Ala	Leu	Thr	Asn	Gly	Thr	Leu	Pro	Asn	Gly	Thr	Leu	Leu		
	690					695					700						
Gln	Lys	Leu	Asp	Val	Ser	Ser	Asn	Ser	Ile	Val	Ser	Val	Val	Pro	Ala		
705					710					715					720		
Phe	Phe	Ala	Leu	Ala	Val	Glu	Leu	Lys	Glu	Val	Asn	Leu	Ser	His	Asn		
				725					730					735			
Ile	Leu	Lys	Thr	Val	Asp	Arg	Ser	Trp	Phe	Gly	Pro	Ile	Val	Met	Asn		
			740					745					750				
Leu	Thr	Val	Leu	Asp	Val	Arg	Ser	Asn	Pro	Leu	His	Cys	Ala	Cys	Gly		
	755						760					765					
Ala	Ala	Phe	Val	Asp	Leu	Leu	Leu	Glu	Val	Gln	Thr	Lys	Val	Pro	Gly		
	770					775					780						
Leu	Ala	Asn	Gly	Val	Lys	Cys	Gly	Ser	Pro	Gly	Gln	Leu	Gln	Gly	Arg		
785					790					795					800		
Ser	Ile	Phe	Ala	Gln	Asp	Leu	Arg	Leu	Cys	Leu	Asp	Glu	Val	Leu	Ser		

385					390					395					400
Asn	Phe	Ile	Asn	Gln	Ala	Gln	Leu	Ser	Ile	Phe	Gly	Thr	Phe	Arg	Ala
				405					410					415	
Leu	Arg	Phe	Val	Asp	Leu	Ser	Asp	Asn	Arg	Ile	Ser	Gly	Pro	Ser	Thr
			420					425					430		
Leu	Ser	Glu	Ala	Thr	Pro	Glu	Glu	Ala	Asp	Asp	Ala	Glu	Gln	Glu	Glu
		435					440					445			
Leu	Leu	Ser	Ala	Asp	Pro	His	Pro	Ala	Pro	Leu	Ser	Thr	Pro	Ala	Ser
		450				455						460			
Lys	Asn	Phe	Met	Asp	Arg	Cys	Lys	Asn	Phe	Lys	Phe	Thr	Met	Asp	Leu
465					470					475					480
Ser	Arg	Asn	Asn	Leu	Val	Thr	Ile	Lys	Pro	Glu	Met	Phe	Val	Asn	Leu
				485					490					495	
Ser	Arg	Leu	Gln	Cys	Leu	Ser	Leu	Ser	His	Asn	Ser	Ile	Ala	Gln	Ala
			500					505					510		
Val	Asn	Gly	Ser	Gln	Phe	Leu	Pro	Leu	Thr	Asn	Leu	Gln	Val	Leu	Asp
		515					520					525			
Leu	Ser	His	Asn	Lys	Leu	Asp	Leu	Tyr	His	Trp	Lys	Ser	Phe	Ser	Glu
		530				535					540				
Leu	Pro	Gln	Leu	Gln	Ala	Leu	Asp	Leu	Gly	Tyr	Asn	Ser	Gln	Pro	Phe
545					550					555					560
Ser	Ile	Lys	Gly	Ile	Gly	His	Asn	Phe	Ser	Phe	Val	Ala	His	Leu	Ser
				565					570					575	
Met	Leu	His	Ser	Leu	Ser	Leu	Ala	His	Asn	Asp	Ile	His	Thr	Arg	Val
			580					585					590		
Ser	Ser	His	Leu	Asn	Ser	Asn	Ser	Val	Arg	Phe	Leu	Asp	Phe	Ser	Gly
		595					600					605			
Asn	Gly	Met	Gly	Arg	Met	Trp	Asp	Glu	Gly	Gly	Leu	Tyr	Leu	His	Phe
	610					615					620				
Phe	Gln	Gly	Leu	Ser	Gly	Leu	Leu	Lys	Leu	Asp	Leu	Ser	Gln	Asn	Asn
625					630					635					640
Leu	His	Ile	Leu	Arg	Pro	Gln	Asn	Leu	Asp	Asn	Leu	Pro	Lys	Ser	Leu
				645					650					655	
Lys	Leu	Leu	Ser	Leu	Arg	Asp	Asn	Tyr	Leu	Ser	Phe	Phe	Asn	Trp	Thr
			660					665					670		
Ser	Leu	Ser	Phe	Leu	Pro	Asn	Leu	Glu	Val	Leu	Asp	Leu	Ala	Gly	Asn
		675					680					685			
Gln	Leu	Lys	Ala	Leu	Thr	Asn	Gly	Thr	Leu	Pro	Asn	Gly	Thr	Leu	Leu
		690				695					700				
Gln	Lys	Leu	Asp	Val	Ser	Ser	Asn	Ser	Ile	Val	Ser	Val	Val	Pro	Ala
705					710					715					720
Phe	Phe	Ala	Leu	Ala	Val	Glu	Leu	Lys	Glu	Val	Asn	Leu	Ser	His	Asn

```

              725              730              735
Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn
              740              745              750

Leu Thr Val Leu Asp Val Arg Ser Asn Pro Leu His Cys Ala Cys Gly
              755              760              765

Ala Ala Phe Val Asp Leu Leu Leu Glu Val Gln Thr Lys Val Pro Gly
              770              775              780

Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg
785              790              795              800

Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Val Leu Ser
              805              810              815

Trp Asp Cys Phe Gly Leu Ser Leu Leu Ala Val Ala Val Gly Met Val
              820              825              830

Val Pro Ile Leu His His Leu Cys Gly Trp Asp Val Trp Tyr Cys Phe
              835              840              845

His Leu Cys Leu Ala Trp Leu Pro Leu Leu Ala Arg Ser Arg Arg Ser
850              855              860

Ala Gln Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln
865              870              875              880

Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu
              885              890              895

Gly Arg Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Asp Arg Asp
              900              905              910

Trp Leu Pro Gly Gln Thr Leu Phe Glu Asn Leu Trp Ala Ser Ile Tyr
              915              920              925

Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser
930              935              940

Gly Leu Leu Arg Thr Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu
945              950              955              960

Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Arg Pro Asp Ala His
              965              970              975

Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val
              980              985              990

Leu Phe Trp Pro Gln Gln Pro Asn Gly Gln Gly Gly Phe Trp Ala Gln
995              1000              1005

Leu Ser Thr Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln
1010              1015              1020

Asn Phe Cys Arg Gly Pro Thr Ala Glu
1025              1030

```

<210> 74  
 <211> 1032  
 <212> PRT

&lt;213&gt; murine

&lt;400&gt; 74

```

Met Val Leu Arg Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln
1           5           10           15

Ala Ala Val Leu Ala Glu Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe
20           25           30

Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu
35           40           45

Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ala Ser Cys Ser Asn
50           55           60

Ile Thr Arg Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asn
65           70           75           80

Ser Asp Phe Val His Leu Ser Asn Leu Arg Gln Leu Asn Leu Lys Trp
85           90           95

Asn Cys Pro Pro Thr Gly Leu Ser Pro Leu His Phe Ser Cys His Met
100          105          110

Thr Ile Glu Pro Arg Thr Phe Leu Ala Met Arg Thr Leu Glu Glu Leu
115          120          125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser
130          135          140

Leu Val Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala
145          150          155          160

Asn Ser Leu Ala Gly Leu Tyr Ser Leu Arg Val Leu Phe Met Asp Gly
165          170          175

Asn Cys Tyr Tyr Lys Asn Pro Cys Thr Gly Ala Val Lys Val Thr Pro
180          185          190

Gly Ala Leu Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr
195          200          205

Asn Asn Leu Thr Lys Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr
210          215          220

Leu Leu Val Ser Tyr Asn Leu Ile Val Lys Leu Gly Pro Glu Asp Leu
225          230          235          240

Ala Asn Leu Thr Ser Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg
245          250          255

Arg Cys Asp His Ala Pro Asn Pro Cys Ile Glu Cys Gly Gln Lys Ser
260          265          270

Leu His Leu His Pro Glu Thr Phe His His Leu Ser His Leu Glu Gly
275          280          285

Leu Val Leu Lys Asp Ser Ser Leu His Thr Leu Asn Ser Ser Trp Phe
290          295          300

Gln Gly Leu Val Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu
305          310          315          320

```

Tyr Glu Ser Ile Asn His Thr Asn Ala Phe Gln Asn Leu Thr Arg Leu  
 325 330 335  
 Arg Lys Leu Asn Leu Ser Phe Asn Tyr Arg Lys Lys Val Ser Phe Ala  
 340 345 350  
 Arg Leu His Leu Ala Ser Ser Phe Lys Asn Leu Val Ser Leu Gln Glu  
 355 360 365  
 Leu Asn Met Asn Gly Ile Phe Phe Arg Ser Leu Asn Lys Tyr Thr Leu  
 370 375 380  
 Arg Trp Leu Ala Asp Leu Pro Lys Leu His Thr Leu His Leu Gln Met  
 385 390 395 400  
 Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala  
 405 410 415  
 Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr  
 420 425 430  
 Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Gln Glu Glu  
 435 440 445  
 Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser  
 450 455 460  
 Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu  
 465 470 475 480  
 Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu  
 485 490 495  
 Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala  
 500 505 510  
 Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp  
 515 520 525  
 Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu  
 530 535 540  
 Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe  
 545 550 555 560  
 Ser Met Lys Gly Ile Gly His Asn Phe Ser Phe Val Thr His Leu Ser  
 565 570 575  
 Met Leu Gln Ser Leu Ser Leu Ala His Asn Asp Ile His Thr Arg Val  
 580 585 590  
 Ser Ser His Leu Asn Ser Asn Ser Val Arg Phe Leu Asp Phe Ser Gly  
 595 600 605  
 Asn Gly Met Gly Arg Met Trp Asp Glu Gly Gly Leu Tyr Leu His Phe  
 610 615 620  
 Phe Gln Gly Leu Ser Gly Leu Leu Lys Leu Asp Leu Ser Gln Asn Asn  
 625 630 635 640  
 Leu His Ile Leu Arg Pro Gln Asn Leu Asp Asn Leu Pro Lys Ser Leu



[illegible]

980 985 990  
 Leu Phe Trp Pro Gln Gln Pro Asn Gly Gln Gly Gly Phe Trp Ala Gln  
 995 1000 1005  
 Leu Ser Thr Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln  
 1010 1015 1020  
 Asn Phe Cys Arg Gly Pro Thr Ala Glu  
 1025 1030  
  
 <210> 75  
 <211> 1032  
 <212> PRT  
 <213> murine  
  
 <400> 75  
 Met Val Leu Arg Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln  
 1 5 10 15  
 Ala Ala Val Leu Ala Glu Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe  
 20 25 30  
 Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu  
 35 40 45  
 Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ala Ser Cys Ser Asn  
 50 55 60  
 Ile Thr Arg Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asn  
 65 70 75 80  
 Ser Asp Phe Val His Leu Ser Asn Leu Arg Gln Leu Asn Leu Lys Trp  
 85 90 95  
 Asn Cys Pro Pro Thr Gly Leu Ser Pro Leu His Phe Ser Cys His Met  
 100 105 110  
 Thr Ile Glu Pro Arg Thr Phe Leu Ala Met Arg Thr Leu Glu Glu Leu  
 115 120 125  
 Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser  
 130 135 140  
 Leu Val Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala  
 145 150 155 160  
 Asn Ser Leu Ala Gly Leu Tyr Ser Leu Arg Val Leu Phe Met Asp Gly  
 165 170 175  
 Asn Cys Tyr Tyr Lys Asn Pro Cys Thr Gly Ala Val Lys Val Thr Pro  
 180 185 190  
 Gly Ala Leu Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr  
 195 200 205  
 Asn Asn Leu Thr Lys Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr  
 210 215 220  
 Leu Leu Val Ser Tyr Asn Leu Ile Val Lys Leu Gly Pro Glu Asp Leu  
 225 230 235 240

Ala Asn Leu Thr Ser Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg  
 245 250 255  
 Arg Cys Asp His Ala Pro Asn Pro Cys Ile Glu Cys Gly Gln Lys Ser  
 260 265 270  
 Leu His Leu His Pro Glu Thr Phe His His Leu Ser His Leu Glu Gly  
 275 280 285  
 Leu Val Leu Lys Asp Ser Ser Leu His Thr Leu Asn Ser Ser Trp Phe  
 290 295 300  
 Gln Gly Leu Val Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu  
 305 310 315 320  
 Tyr Glu Ser Ile Asn His Thr Asn Ala Phe Gln Asn Leu Thr Arg Leu  
 325 330 335  
 Arg Lys Leu Asn Leu Ser Phe Asn Tyr Arg Lys Lys Val Ser Phe Ala  
 340 345 350  
 Arg Leu His Leu Ala Ser Ser Phe Lys Asn Leu Val Ser Leu Gln Glu  
 355 360 365  
 Leu Asn Met Asn Gly Ile Phe Phe Arg Ser Leu Asn Lys Tyr Thr Leu  
 370 375 380  
 Arg Trp Leu Ala Asp Leu Pro Lys Leu His Thr Leu His Leu Gln Met  
 385 390 395 400  
 Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala  
 405 410 415  
 Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr  
 420 425 430  
 Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Gln Glu Glu  
 435 440 445  
 Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser  
 450 455 460  
 Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu  
 465 470 475 480  
 Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu  
 485 490 495  
 Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala  
 500 505 510  
 Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp  
 515 520 525  
 Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu  
 530 535 540  
 Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe  
 545 550 555 560  
 Ser Met Lys Gly Ile Gly His Asn Phe Ser Phe Val Thr His Leu Ser

[illegible]

	900		905		910
Trp Leu Pro Gly Gln Thr Leu Phe	Glu Asn Leu Trp Ala Ser Ile Tyr				
915	920		925		
Gly Ser Arg Lys Thr Leu Phe Val	Leu Ala His Thr Asp Arg Val Ser				
930	935		940		
Gly Leu Leu Arg Thr Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu					
945	950		955		960
Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Arg Pro Asp Ala His					
	965		970		975
Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val					
	980		985		990
Leu Phe Trp Pro Gln Gln Pro Asn Gly Gln Gly Gly Phe Trp Ala Gln					
	995		1000		1005
Leu Ser Thr Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln					
	1010		1015		1020
Asn Phe Cys Arg Gly Pro Thr Ala Glu					
	1025		1030		

<210> 76  
 <211> 3002  
 <212> DNA  
 <213> Homo sapiens

<400> 76  
 gtggcttggt attcactggc aggtttcaga catttagatc tttcttttaa tgactaacac 60  
 catgcctatc tgtggagaag ctggcaacat gtcacacctg gaaattgttt ttcaacatta 120  
 atactattat ttggcagtaa tccagattgc ttttccacc aacctgaaga catatagagg 180  
 cagaaggaca ggaataattc tatttgtttc ctgttttgaa acttccatct gtaaggctat 240  
 caaaaggaga tgtgagagag ggtattgagt ctggcctgac aatgcagttc ttaaaccaaa 300  
 ggtccattat gcttctctc tctgagaatc ctgaactacc tcaacaacgg agacatggca 360  
 cagtagccag cttggagact tctcagccaa tgctctgaga tcaagtcgaa gaccaatat 420  
 acagggtttt gagctcatct tcatcattca tatgaggaaa taagtggtaa aatccttgga 480  
 aatacaatga gactcatcag aaacatttac atattttgta gtattgttat gacagcagag 540  
 ggtgatgctc cagagctgcc agaagaaagg gaactgatga ccaactgctc caacatgtct 600  
 ctaagaaagg ttcccgaga cttgaccca gccacaacga cactggattt atcctataac 660  
 ctcttttttc aactccagag ttcagatttt cattctgtct ccaaactgag agttttgatt 720  
 ctatgccata acagaattca acagctggat ctcaaacct ttgaattcaa caaggagtta 780  
 agatatttag atttgtctaa taacagactg aagagtgtaa cttggtattt actggcaggt 840  
 ctcaggattt tagatcttct ttttaatgac ttgacacca tgcctatctg tgaggaagct 900

ggcaacatgt	cacacctgga	aatcctaggt	ttgagtgggg	caaaaataca	aaaatcagat	960
ttccagaaaa	ttgctcatct	gcatctaaat	actgtcttct	taggattcag	aactcttcct	1020
cattatgaag	aaggtagcct	gcccattctta	aacacaacaa	aactgcacat	tgtttttacca	1080
atggacacaa	attttctgggt	tcttttgcgt	gatggaatca	agacttcaaa	aatattagaa	1140
atgacaaata	tagatggcaa	aagccaatth	gtaagttatg	aaatgcaacg	aaatcttagt	1200
ttagaaaatg	ctaagacatc	ggttctattg	cttaataaag	ttgatttact	ctgggacgac	1260
cttttcttta	tcttacaatt	tgtttggcat	acatcagtgg	aacactttca	gatccgaaat	1320
gtgacttttg	gtggtaaggc	ttatcttgac	cacaattcat	ttgactactc	aaatactgta	1380
atgagaacta	taaaattgga	gcatgtacat	ttcagagtgt	tttacattca	acaggataaa	1440
atctattttgc	ttttgaccaa	aatggacata	gaaaacctga	caatatcaaa	tgcacaaatg	1500
ccacacatgc	ttttcccgaa	ttatcctacg	aaattccaat	atttaaattt	tgccaataat	1560
atcttaacag	acgagttggt	taaaagaact	atccaactgc	ctcacttgaa	aactctcatt	1620
ttgaatggca	ataaactgga	gacactttct	ttagtaagtt	gctttgctaa	caacacaccc	1680
ttggaacact	tggatctgag	tcaaaatcta	ttacaacata	aaaatgatga	aaattgctca	1740
tggccagaaa	ctgtgggtcaa	tatgaatctg	tcatacaata	aattgtctga	ttctgtcttc	1800
aggtgcttgc	ccaaaagtat	tcaaaacttt	gacctaaata	ataaccaaat	ccaaactgta	1860
cctaaagaga	ctattcatct	gatggcctta	cgagaactaa	atattgcatt	taattttcta	1920
actgatctcc	ctggatgcag	tcatttcagt	agactttcag	ttctgaacat	tgaaatgaac	1980
ttcattctca	gcccattctt	ggattttggt	cagagctgcc	aggaagttaa	aactctaaat	2040
gcgggaagaa	atccattccg	gtgtacctgt	gaattaaaaa	atttcattca	gcttgaaaca	2100
tattcagagg	tcattgatgt	tggatgggtca	gattcataca	cctgtgaata	ccctttaaac	2160
ctaaggggaa	ttaggttaaa	agacgttcat	ctccacgaat	tatcttgcaa	cacagctctg	2220
ttgattgtca	ccattgtgggt	tattatgcta	gttctgggggt	tggctgtggc	cttctgctgt	2280
ctccactttg	atctgccctg	gtatctcagg	atgctaggtc	aatgcacaca	aacatggcac	2340
agggttagga	aaacaaccca	agaacaactc	aagagaaatg	tccgattcca	cgcatthatt	2400
tcatacagt	aacatgatth	tctgtgggtg	agaatgaat	tgatcccaaa	tctagagaag	2460
gaagatgggt	ctatcttgat	ttgcctttat	gaaagctact	ttgacctggg	caaaagcatt	2520
agtgaataa	ttgtaagctt	cattgagaaa	agctataagt	ccatctttgt	tttgtctccc	2580
aactttgtcc	agaatgagt	gtgccattat	gaattttact	ttgccacca	caatctcttc	2640
catgaaaatt	ctgatcatat	aattcttato	ttactggaac	ccattccatt	ctattgcatt	2700
cccaccaggt	atcataaact	gaaagctctc	ctggaaaaaa	aagcatactt	ggaatggccc	2760
aaggataggc	gtaaatgtgg	gcttttctgg	gcaaaccttc	gagctgctat	taatgttaat	2820

gtattagcca ccagagaaat gtatgaactg cagacattca cagagttaaa tgaagagtct 2880  
 cgagggttcta caatctctct gatgagaaca gattgtctat aaaatcccac agtccttggg 2940  
 aagttgggga ccacatacac tgttgggatg tacattgata caacctttat gatggcaatt 3000  
 tg 3002

<210> 77  
 <211> 811  
 <212> PRT  
 <213> Homo sapiens

<400> 77

Met Arg Leu Ile Arg Asn Ile Tyr Ile Phe Cys Ser Ile Val Met Thr  
 1 5 10 15  
 Ala Glu Gly Asp Ala Pro Glu Leu Pro Glu Glu Arg Glu Leu Met Thr  
 20 25 30  
 Asn Cys Ser Asn Met Ser Leu Arg Lys Val Pro Ala Asp Leu Thr Pro  
 35 40 45  
 Ala Thr Thr Thr Leu Asp Leu Ser Tyr Asn Leu Leu Phe Gln Leu Gln  
 50 55 60  
 Ser Ser Asp Phe His Ser Val Ser Lys Leu Arg Val Leu Ile Leu Cys  
 65 70 75 80  
 His Asn Arg Ile Gln Gln Leu Asp Leu Lys Thr Phe Glu Phe Asn Lys  
 85 90 95  
 Glu Leu Arg Tyr Leu Asp Leu Ser Asn Asn Arg Leu Lys Ser Val Thr  
 100 105 110  
 Trp Tyr Leu Leu Ala Gly Leu Arg Tyr Leu Asp Leu Ser Phe Asn Asp  
 115 120 125  
 Phe Asp Thr Met Pro Ile Cys Glu Glu Ala Gly Asn Met Ser His Leu  
 130 135 140  
 Glu Ile Leu Gly Leu Ser Gly Ala Lys Ile Gln Lys Ser Asp Phe Gln  
 145 150 155 160  
 Lys Ile Ala His Leu His Leu Asn Thr Val Phe Leu Gly Phe Arg Thr  
 165 170 175  
 Leu Pro His Tyr Glu Glu Gly Ser Leu Pro Ile Leu Asn Thr Thr Lys  
 180 185 190  
 Leu His Ile Val Leu Pro Met Asp Thr Asn Phe Trp Val Leu Leu Arg  
 195 200 205  
 Asp Gly Ile Lys Thr Ser Lys Ile Leu Glu Met Thr Asn Ile Asp Gly  
 210 215 220  
 Lys Ser Gln Phe Val Ser Tyr Glu Met Gln Arg Asn Leu Ser Leu Glu  
 225 230 235 240

Asn	Ala	Lys	Thr	Ser	Val	Leu	Leu	Leu	Asn	Lys	Val	Asp	Leu	Leu	Trp	245	250	255
Asp	Asp	Leu	Phe	Leu	Ile	Leu	Gln	Phe	Val	Trp	His	Thr	Ser	Val	Glu	260	265	270
His	Phe	Gln	Ile	Arg	Asn	Val	Thr	Phe	Gly	Gly	Lys	Ala	Tyr	Leu	Asp	275	280	285
His	Asn	Ser	Phe	Asp	Tyr	Ser	Asn	Thr	Val	Met	Arg	Thr	Ile	Lys	Leu	290	295	300
Glu	His	Val	His	Phe	Arg	Val	Phe	Tyr	Ile	Gln	Gln	Asp	Lys	Ile	Tyr	305	310	315
Leu	Leu	Leu	Thr	Lys	Met	Asp	Ile	Glu	Asn	Leu	Thr	Ile	Ser	Asn	Ala	325	330	335
Gln	Met	Pro	His	Met	Leu	Phe	Pro	Asn	Tyr	Pro	Thr	Lys	Phe	Gln	Tyr	340	345	350
Leu	Asn	Phe	Ala	Asn	Asn	Ile	Leu	Thr	Asp	Glu	Leu	Phe	Lys	Arg	Thr	355	360	365
Ile	Gln	Leu	Pro	His	Leu	Lys	Thr	Leu	Ile	Leu	Asn	Gly	Asn	Lys	Leu	370	375	380
Glu	Thr	Leu	Ser	Leu	Val	Ser	Cys	Phe	Ala	Asn	Asn	Thr	Pro	Leu	Glu	385	390	395
His	Leu	Asp	Leu	Ser	Gln	Asn	Leu	Leu	Gln	His	Lys	Asn	Asp	Glu	Asn	405	410	415
Cys	Ser	Trp	Pro	Glu	Thr	Val	Val	Asn	Met	Asn	Leu	Ser	Tyr	Asn	Lys	420	425	430
Leu	Ser	Asp	Ser	Val	Phe	Arg	Cys	Leu	Pro	Lys	Ser	Ile	Gln	Ile	Leu	435	440	445
Asp	Leu	Asn	Asn	Asn	Gln	Ile	Gln	Thr	Val	Pro	Lys	Glu	Thr	Ile	His	450	455	460
Leu	Met	Ala	Leu	Arg	Glu	Leu	Asn	Ile	Ala	Phe	Asn	Phe	Leu	Thr	Asp	465	470	475
Leu	Pro	Gly	Cys	Ser	His	Phe	Ser	Arg	Leu	Ser	Val	Leu	Asn	Ile	Glu	485	490	495
Met	Asn	Phe	Ile	Leu	Ser	Pro	Ser	Leu	Asp	Phe	Val	Gln	Ser	Cys	Gln	500	505	510
Glu	Val	Lys	Thr	Leu	Asn	Ala	Gly	Arg	Asn	Pro	Phe	Arg	Cys	Thr	Cys	515	520	525
Glu	Leu	Lys	Asn	Phe	Ile	Gln	Leu	Glu	Thr	Tyr	Ser	Glu	Val	Met	Met	530	535	540
Val	Gly	Trp	Ser	Asp	Ser	Tyr	Thr	Cys	Glu	Tyr	Pro	Leu	Asn	Leu	Arg	545	550	555
Gly	Ile	Arg	Leu	Lys	Asp	Val	His	Leu	His	Glu	Leu	Ser	Cys	Asn	Thr			



565 570 575  
 Ala Leu Leu Ile Val Thr Ile Val Val Ile Met Leu Val Leu Gly Leu  
 580 585 590  
 Ala Val Ala Phe Cys Cys Leu His Phe Asp Leu Pro Trp Tyr Leu Arg  
 595 600 605  
 Met Leu Gly Gln Cys Thr Gln Thr Trp His Arg Val Arg Lys Thr Thr  
 610 615 620  
 Gln Glu Gln Leu Lys Arg Asn Val Arg Phe His Ala Phe Ile Ser Tyr  
 625 630 635 640  
 Ser Glu His Asp Ser Leu Trp Val Lys Asn Glu Leu Ile Pro Asn Leu  
 645 650 655  
 Glu Lys Glu Asp Gly Ser Ile Leu Ile Cys Leu Tyr Glu Ser Tyr Phe  
 660 665 670  
 Asp Pro Gly Lys Ser Ile Ser Glu Asn Ile Val Ser Phe Ile Glu Lys  
 675 680 685  
 Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro Asn Phe Val Gln Asn Glu  
 690 695 700  
 Trp Cys His Tyr Glu Phe Tyr Phe Ala His His Asn Leu Phe His Glu  
 705 710 715 720  
 Asn Ser Asp His Ile Ile Leu Ile Leu Leu Glu Pro Ile Pro Phe Tyr  
 725 730 735  
 Cys Ile Pro Thr Arg Tyr His Lys Leu Lys Ala Leu Leu Glu Lys Lys  
 740 745 750  
 Ala Tyr Leu Glu Trp Pro Lys Asp Arg Arg Lys Cys Gly Leu Phe Trp  
 755 760 765  
 Ala Asn Leu Arg Ala Ala Ile Asn Val Asn Val Leu Ala Thr Arg Glu  
 770 775 780  
 Met Tyr Glu Leu Gln Thr Phe Thr Glu Leu Asn Glu Glu Ser Arg Gly  
 785 790 795 800  
 Ser Thr Ile Ser Leu Met Arg Thr Asp Cys Leu  
 805 810

<210> 78  
 <211> 2760  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc feature  
 <222> (2529)..(2529)  
 <223> n is a, c, g, or t

<400> 78  
 aagaatttgg actcatatca agatgctctg aagaagaaca acccttttagg atagccactg 60  
 caacatcatg accaaagaca aagaacctat tgttaaaagc ttccattttg tttgccttat 120

gatcataata gttggaacca gaatccagtt ctccgacgga aatgaatttg cagtagacaa	180
gtcaaaaaga ggtcttattc atgttccaaa agacctaccg ctgaaaacca aagtcttaga	240
tatgtctcag aactacatcg ctgagcttca ggtctctgac atgagctttc tatcagagtt	300
gacagttttg agactttccc ataacagaat ccagctactt gattttaagtg ttttcaagtt	360
caaccaggat ttagaatatt tggattttatc tcataatcag ttgcaaaaga tatcctgcca	420
tcctattgtg agtttcaggc atttagatct ctcatccaat gatttcaagg ccctgccccat	480
ctgtaaggaa tttggcaact tatcacaact gaatttcttg ggattgagtg ctatgaagct	540
gcaaaaatta gatttgctgc caattgctca cttgcatcta agttatatcc ttctggattt	600
aagaaattat tatataaaag aaaatgagac agaaagtcta caaattctga atgcaaaaac	660
ccttcacctt gtttttcacc caactagttt attcgcctatc caagtgaaca tatcagttaa	720
tacttttaggg tgcttacaac tgactaatat taaattgaat gatgacaact gtcaagtttt	780
cattaaattt ttatcagaac tcaccagagg tccaacctta ctgaatttta ccctcaacca	840
catagaaacg acttggaat gcctggtcag agtctttcaa tttctttggc ccaaacctgt	900
ggaatatctc aatattttaca atttaacaat aattgaaagc attcgtgaag aagattttac	960
ttattctaaa acgacattga aagcattgac aatagaacat atcacgaacc aagtttttct	1020
gttttcacag acagctttgt acaccgtgtt ttctgagatg aacattatga tgttaaccat	1080
ttcagataca ctttttatac acatgctgtg tcctcatgca ccaagcacat tcaagttttt	1140
gaactttacc cagaacgttt tcacagatag tatttttgaa aaatgttcca cgttagttaa	1200
attggagaca cttatcttac aaaagaatgg attaaaagac cttttcaaag taggtctcat	1260
gacgaaggat atgccttctt tggaaatact ggatgttagc tggaaattctt tggaatctgg	1320
tagacataaa gaaaactgca cttgggttga gagtatagtg gtgttaaatt tgtcttcaaa	1380
tatgcttact gactctgttt tcagatgttt acctcccagg atcaaggtagc ttgatcttca	1440
cagcaataaa ataaagagcg ttcttaaaaca agtcgtaaaa ctggaagctt tgcaagaact	1500
caatgttgct ttcaattctt taactgacct tcctggatgt ggcagcttta gcagcctttc	1560
tgtattgac attgatcaca attcagtttc ccacctatcg gctgatttct tccagagctg	1620
ccagaagatg aggtcaataa aagcagggga caatccattc caatgtacct gtgagctaag	1680
agaatttgct aaaaatatag accaagtatc aagtgaagtg ttagagggct ggcctgattc	1740
ttataagtgt gactaccag aaagttatag aggaagccca cttaaaggact ttcacatgtc	1800
tgaattatcc tgcaacataa ctctgctgat cgtcaccatc ggtgccacca tgctggtgtt	1860
ggctgtgact gtgacctccc tctgcatcta cttggatctg ccctggtatc tcaggatggt	1920
gtgccagtgg acccagactc ggcgcagggc caggaacata cccttagaag aactccaaag	1980
aaacctccag tttcatgctt ttatttcata tagtgaacat gattctgcct gggtgaaaag	2040

tgaattggta ccttacctag aaaaagaaga tatacagatt tgtcttcatg agaggaactt 2100  
 tgtccctggc aagagcattg tggaaaatat catcaactgc attgagaaga gttacaagtc 2160  
 catctttggt ttgtctccca actttgtcca gagtgagtg tgccattacg aactctattt 2220  
 tgcccatcac aatctctttc atgaaggatc taataactta atcctcatct tactggaacc 2280  
 cattccacag aacagcattc ccaacaagta ccacaagctg aaggctctca tgacgcagcg 2340  
 gacttatttg cagtggccca aggagaaaag caaacgtggg ctcttttggg ctaacattag 2400  
 agccgctttt aatatgaaat taacactagt cactgaaaac aatgatgtga aatcttaaaa 2460  
 aaatttagga aattcaactt aagaaaccat tatttacttg gatgatggtg aatagtacag 2520  
 tcgtaagtna ctgtctggag gtgcctccat taccctcatg ccttcaggaa agacttaaca 2580  
 aaaacaatgt ttcattctggg gaactgagct aggcgtgag gttagcctgc cagttagaga 2640  
 cagcccagtc tcttctgggt taatcattat gtttcaaatt gaaacagtct cttttgagta 2700  
 aatgctcagt ttttcagctc ctctccactc tgctttccca aatggattct gttggtgaag 2760

<210> 79

<211> 2753

<212> DNA

<213> Homo sapiens

<400> 79

agaatttgga ctcatatcaa gatgctctga agaagaacaa cccttttagga tagccactgc 60  
 aacatcatga ccaaagacaa agaacctatt gttaaaagct tccattttgt ttgccttatg 120  
 atcataatag ttggaaccag aatccagttc tccgacggaa atgaatttgc agtagacaag 180  
 tcaaaaagag gtcttattca tgttccaaaa gacctaccgc tgaaaaccaa agtcttagat 240  
 atgtctcaga actacatgcg tgagcttcag gtctctgaca tgagctttct atcagagttg 300  
 acagttttga gactttccca taacagaatc cagctacttg atttaagtgt tttcaagttc 360  
 aaccaggatt tagaatattt ggatttatct cataatcagt tgcaaaagat atcctgccat 420  
 cctattgtga gtttcaggca tttagatctc tcattcaatg atttcaaggc cctgcccac 480  
 tgtaaggaat ttggcaactt atcacaaactg aatttcttgg gattgagtgc tatgaagctg 540  
 caaaaattag atttgctgcc aattgctcac ttgcatctaa gttatatcct tctggattta 600  
 agaaattatt atataaaaga aaatgagaca gaaagtctac aaattctgaa tgcaaaaacc 660  
 cttcaccttg tttttcacc cactagttaa ttcgctatcc aagtgaacat atcagttaat 720  
 actttagggt gcttacaact gactaatatt aaattgaatg atgacaactg tcaagttttc 780  
 attaaatttt tatcagaact caccagaggt tcaaccttac tgaattttac cctcaaccac 840  
 atagaaacga cttggaaatg cctggtcaga gtctttcaat ttctttggcc caaacctgtg 900

gaatatctca atatttacaa tttacaata attgaaagca ttcgtgaaga agatcttact	960
tattctaaaa cgacattgaa agcattgaca atagaacata tcacgaacca agtttttctg	1020
ttttcacaga cagctttgta caccgtgttt tctgagatga acattatgat gttaaccatt	1080
tcagatacac cttttataca catgctgtgt cctcatgcac caagcacatt caagtttttg	1140
aactttaccc agaacgtttt cacagatagt atttttgaaa aatgttccac gttagttaaa	1200
ttggagacac ttatcttaca aaaaaatgga ttaaaagacc ttttcaaagt aggtotcatg	1260
acgaaggata tgccttcttt ggaaatactg gatgttagct ggaattcttt ggaatctggt	1320
agacataaag aaaactgcac ttgggttgag agtatagtgg tgtaaattt gtcttcaa	1380
atgcttactg actctgtttt cagatgttta cctcccagga tcaaggctact tgatcttcac	1440
agcaataaaa taaagagcgt tcctaaacaa gtcgtaaac tggaagcttt gcaagaactc	1500
aatgttgctt tcaattcttt aactgacctt cctggatgtg gcagcttttag cagcctttct	1560
gtattgatca ttgatcacia ttcagtttcc caccatcgg ctgatttctt ccagagctgc	1620
cagaagatga ggtcaataaa agcaggggac aatccattcc aatgtacctg tgagctaaga	1680
gaatttgatca aaaatataga ccaagtatca agtgaagtgt tagagggtg gcctgattct	1740
tataagtgtg actaccaga aagttataga ggaagccac taaaggactt tcacatgtct	1800
gaattatcct gcaacataac tctgctgac gtcaccatcg gtgccaccat gctgggtgtg	1860
gctgtgactg tgacctccct ctgcatctac ttggatctgc cctggatatct caggatggtg	1920
tgccagtgga cccagactcg gcgcagggcc aggaacatac ccttagaaga actccaaaga	1980
aacctccagt ttcattgttt tatttcatat agtgaacatg attctgcctg ggtgaaaagt	2040
gaattggtac cttacctaga aaaagaagat atacagattt gtcttcatga gaggaacttt	2100
gtccctggca agagcattgt ggaaaatata atcaactgca ttgagaagag ttacaagtcc	2160
atctttgttt tgtctcccaa ctttgtccag agtgagtggg gccattacga actctatctt	2220
gcccatacaca atctctttca tgaaggatct aataacttaa tctcatctt actggaacct	2280
attccacaga acagcattcc caacaagtac cacaagctga aggtctcat gacgcagcgg	2340
acttatttgc agtggcccaa ggagaaaagc aaacgtgggc tcttttgggc taacattaga	2400
gccgctttta atatgaaatt aacactagtc actgaaaaca atgatgtgaa atcttaaaaa	2460
aatttaggaa attcaactta agaaaccatt atttacttgg atgatggtga atagtacagt	2520
cgtaagtaac tgtctggagg tgctccatt atctcatgc cttcaggaaa gacttaacaa	2580
aaacaatgtt tcatctgggg aactgagcta ggcggtgagg ttagcctgcc agttagagac	2640
agcccagtct cttctggttt aatcattatg tttcaaattg aaacagtctc ttttgagtaa	2700
atgctcagtt tttcagctcc tctccactct gctttcccaa atggattctg ttg	2753

<210> 80  
 <211> 796  
 <212> PRT  
 <213> Homo sapiens

<400> 80

Met Thr Lys Asp Lys Glu Pro Ile Val Lys Ser Phe His Phe Val Cys  
 1 5 10 15  
 Leu Met Ile Ile Ile Val Gly Thr Arg Ile Gln Phe Ser Asp Gly Asn  
 20 25 30  
 Glu Phe Ala Val Asp Lys Ser Lys Arg Gly Leu Ile His Val Pro Lys  
 35 40 45  
 Asp Leu Pro Leu Lys Thr Lys Val Leu Asp Met Ser Gln Asn Tyr Ile  
 50 55 60  
 Ala Glu Leu Gln Val Ser Asp Met Ser Phe Leu Ser Glu Leu Thr Val  
 65 70 75 80  
 Leu Arg Leu Ser His Asn Arg Ile Gln Leu Leu Asp Leu Ser Val Phe  
 85 90 95  
 Lys Phe Asn Gln Asp Leu Glu Tyr Leu Asp Leu Ser His Asn Gln Leu  
 100 105 110  
 Gln Lys Ile Ser Cys His Pro Ile Val Ser Phe Arg His Leu Asp Leu  
 115 120 125  
 Ser Phe Asn Asp Phe Lys Ala Leu Pro Ile Cys Lys Glu Phe Gly Asn  
 130 135 140  
 Leu Ser Gln Leu Asn Phe Leu Gly Leu Ser Ala Met Lys Leu Gln Lys  
 145 150 155 160  
 Leu Asp Leu Leu Pro Ile Ala His Leu His Leu Ser Tyr Ile Leu Leu  
 165 170 175  
 Asp Leu Arg Asn Tyr Tyr Ile Lys Glu Asn Glu Thr Glu Ser Leu Gln  
 180 185 190  
 Ile Leu Asn Ala Lys Thr Leu His Leu Val Phe His Pro Thr Ser Leu  
 195 200 205  
 Phe Ala Ile Gln Val Asn Ile Ser Val Asn Thr Leu Gly Cys Leu Gln  
 210 215 220  
 Leu Thr Asn Ile Lys Leu Asn Asp Asp Asn Cys Gln Val Phe Ile Lys  
 225 230 235 240  
 Phe Leu Ser Glu Leu Thr Arg Gly Pro Thr Leu Leu Asn Phe Thr Leu  
 245 250 255  
 Asn His Ile Glu Thr Thr Trp Lys Cys Leu Val Arg Val Phe Gln Phe  
 260 265 270  
 Leu Trp Pro Lys Pro Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile  
 275 280 285

Ile Glu Ser Ile Arg Glu Glu Asp Phe Thr Tyr Ser Lys Thr Thr Leu  
 290 295 300  
 Lys Ala Leu Thr Ile Glu His Ile Thr Asn Gln Val Phe Leu Phe Ser  
 305 310 315 320  
 Gln Thr Ala Leu Tyr Thr Val Phe Ser Glu Met Asn Ile Met Met Leu  
 325 330 335  
 Thr Ile Ser Asp Thr Pro Phe Ile His Met Leu Cys Pro His Ala Pro  
 340 345 350  
 Ser Thr Phe Lys Phe Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser  
 355 360 365  
 Ile Phe Glu Lys Cys Ser Thr Leu Val Lys Leu Glu Thr Leu Ile Leu  
 370 375 380  
 Gln Lys Asn Gly Leu Lys Asp Leu Phe Lys Val Gly Leu Met Thr Lys  
 385 390 395 400  
 Asp Met Pro Ser Leu Glu Ile Leu Asp Val Ser Trp Asn Ser Leu Glu  
 405 410 415  
 Ser Gly Arg His Lys Glu Asn Cys Thr Trp Val Glu Ser Ile Val Val  
 420 425 430  
 Leu Asn Leu Ser Ser Asn Met Leu Thr Asp Ser Val Phe Arg Cys Leu  
 435 440 445  
 Pro Pro Arg Ile Lys Val Leu Asp Leu His Ser Asn Lys Ile Lys Ser  
 450 455 460  
 Val Pro Lys Gln Val Val Lys Leu Glu Ala Leu Gln Glu Leu Asn Val  
 465 470 475 480  
 Ala Phe Asn Ser Leu Thr Asp Leu Pro Gly Cys Gly Ser Phe Ser Ser  
 485 490 495  
 Leu Ser Val Leu Ile Ile Asp His Asn Ser Val Ser His Pro Ser Ala  
 500 505 510  
 Asp Phe Phe Gln Ser Cys Gln Lys Met Arg Ser Ile Lys Ala Gly Asp  
 515 520 525  
 Asn Pro Phe Gln Cys Thr Cys Glu Leu Arg Glu Phe Val Lys Asn Ile  
 530 535 540  
 Asp Gln Val Ser Ser Glu Val Leu Glu Gly Trp Pro Asp Ser Tyr Lys  
 545 550 555 560  
 Cys Asp Tyr Pro Glu Ser Tyr Arg Gly Ser Pro Leu Lys Asp Phe His  
 565 570 575  
 Met Ser Glu Leu Ser Cys Asn Ile Thr Leu Leu Ile Val Thr Ile Gly  
 580 585 590  
 Ala Thr Met Leu Val Leu Ala Val Thr Val Thr Ser Leu Cys Ile Tyr  
 595 600 605  
 Leu Asp Leu Pro Trp Tyr Leu Arg Met Val Cys Gln Trp Thr Gln Thr

610 615 620  
 Arg Arg Arg Ala Arg Asn Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu  
 625 630 635 640  
 Gln Phe His Ala Phe Ile Ser Tyr Ser Glu His Asp Ser Ala Trp Val  
 645 650 655  
 Lys Ser Glu Leu Val Pro Tyr Leu Glu Lys Glu Asp Ile Gln Ile Cys  
 660 665 670  
 Leu His Glu Arg Asn Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile  
 675 680 685  
 Ile Asn Cys Ile Glu Lys Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro  
 690 695 700  
 Asn Phe Val Gln Ser Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His  
 705 710 715 720  
 His Asn Leu Phe His Glu Gly Ser Asn Asn Leu Ile Leu Ile Leu Leu  
 725 730 735  
 Glu Pro Ile Pro Gln Asn Ser Ile Pro Asn Lys Tyr His Lys Leu Lys  
 740 745 750  
 Ala Leu Met Thr Gln Arg Thr Tyr Leu Gln Trp Pro Lys Glu Lys Ser  
 755 760 765  
 Lys Arg Gly Leu Phe Trp Ala Asn Ile Arg Ala Ala Phe Asn Met Lys  
 770 775 780  
 Leu Thr Leu Val Thr Glu Asn Asn Asp Val Lys Ser  
 785 790 795

<210> 81  
 <211> 796  
 <212> PRT  
 <213> Homo sapiens

<400> 81

Met Thr Lys Asp Lys Glu Pro Ile Val Lys Ser Phe His Phe Val Cys  
 1 5 10 15  
 Leu Met Ile Ile Ile Val Gly Thr Arg Ile Gln Phe Ser Asp Gly Asn  
 20 25 30  
 Glu Phe Ala Val Asp Lys Ser Lys Arg Gly Leu Ile His Val Pro Lys  
 35 40 45  
 Asp Leu Pro Leu Lys Thr Lys Val Leu Asp Met Ser Gln Asn Tyr Ile  
 50 55 60  
 Ala Glu Leu Gln Val Ser Asp Met Ser Phe Leu Ser Glu Leu Thr Val  
 65 70 75 80  
 Leu Arg Leu Ser His Asn Arg Ile Gln Leu Leu Asp Leu Ser Val Phe  
 85 90 95  
 Lys Phe Asn Gln Asp Leu Glu Tyr Leu Asp Leu Ser His Asn Gln Leu  
 100 105 110

Gln Lys Ile Ser Cys His Pro Ile Val Ser Phe Arg His Leu Asp Leu  
 115 120 125  
 Ser Phe Asn Asp Phe Lys Ala Leu Pro Ile Cys Lys Glu Phe Gly Asn  
 130 135 140  
 Leu Ser Gln Leu Asn Phe Leu Gly Leu Ser Ala Met Lys Leu Gln Lys  
 145 150 155 160  
 Leu Asp Leu Leu Pro Ile Ala His Leu His Leu Ser Tyr Ile Leu Leu  
 165 170 175  
 Asp Leu Arg Asn Tyr Tyr Ile Lys Glu Asn Glu Thr Glu Ser Leu Gln  
 180 185 190  
 Ile Leu Asn Ala Lys Thr Leu His Leu Val Phe His Pro Thr Ser Leu  
 195 200 205  
 Phe Ala Ile Gln Val Asn Ile Ser Val Asn Thr Leu Gly Cys Leu Gln  
 210 215 220  
 Leu Thr Asn Ile Lys Leu Asn Asp Asp Asn Cys Gln Val Phe Ile Lys  
 225 230 235 240  
 Phe Leu Ser Glu Leu Thr Arg Gly Ser Thr Leu Leu Asn Phe Thr Leu  
 245 250 255  
 Asn His Ile Glu Thr Thr Trp Lys Cys Leu Val Arg Val Phe Gln Phe  
 260 265 270  
 Leu Trp Pro Lys Pro Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile  
 275 280 285  
 Ile Glu Ser Ile Arg Glu Glu Asp Phe Thr Tyr Ser Lys Thr Thr Leu  
 290 295 300  
 Lys Ala Leu Thr Ile Glu His Ile Thr Asn Gln Val Phe Leu Phe Ser  
 305 310 315 320  
 Gln Thr Ala Leu Tyr Thr Val Phe Ser Glu Met Asn Ile Met Met Leu  
 325 330 335  
 Thr Ile Ser Asp Thr Pro Phe Ile His Met Leu Cys Pro His Ala Pro  
 340 345 350  
 Ser Thr Phe Lys Phe Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser  
 355 360 365  
 Ile Phe Glu Lys Cys Ser Thr Leu Val Lys Leu Glu Thr Leu Ile Leu  
 370 375 380  
 Gln Lys Asn Gly Leu Lys Asp Leu Phe Lys Val Gly Leu Met Thr Lys  
 385 390 395 400  
 Asp Met Pro Ser Leu Glu Ile Leu Asp Val Ser Trp Asn Ser Leu Glu  
 405 410 415  
 Ser Gly Arg His Lys Glu Asn Cys Thr Trp Val Glu Ser Ile Val Val  
 420 425 430  
 Leu Asn Leu Ser Ser Asn Met Leu Thr Asp Ser Val Phe Arg Cys Leu



435	440	445
Pro Pro Arg Ile Lys Val	Leu Asp Leu His Ser Asn Lys Ile Lys Ser	
450	455	460
Val Pro Lys Gln Val Val Lys Leu Glu Ala Leu Gln Glu Leu Asn Val		
465	470	475
Ala Phe Asn Ser Leu Thr Asp Leu Pro Gly Cys Gly Ser Phe Ser Ser		
	485	490
Leu Ser Val Leu Ile Ile Asp His Asn Ser Val Ser His Pro Ser Ala		
	500	505
Asp Phe Phe Gln Ser Cys Gln Lys Met Arg Ser Ile Lys Ala Gly Asp		
	515	520
Asn Pro Phe Gln Cys Thr Cys Glu Leu Arg Glu Phe Val Lys Asn Ile		
	530	535
Asp Gln Val Ser Ser Glu Val Leu Glu Gly Trp Pro Asp Ser Tyr Lys		
	545	550
Cys Asp Tyr Pro Glu Ser Tyr Arg Gly Ser Pro Leu Lys Asp Phe His		
	565	570
Met Ser Glu Leu Ser Cys Asn Ile Thr Leu Leu Ile Val Thr Ile Gly		
	580	585
Ala Thr Met Leu Val Leu Ala Val Thr Val Thr Ser Leu Cys Ile Tyr		
	595	600
Leu Asp Leu Pro Trp Tyr Leu Arg Met Val Cys Gln Trp Thr Gln Thr		
	610	615
Arg Arg Arg Ala Arg Asn Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu		
	625	630
Gln Phe His Ala Phe Ile Ser Tyr Ser Glu His Asp Ser Ala Trp Val		
	645	650
Lys Ser Glu Leu Val Pro Tyr Leu Glu Lys Glu Asp Ile Gln Ile Cys		
	660	665
Leu His Glu Arg Asn Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile		
	675	680
Ile Asn Cys Ile Glu Lys Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro		
	690	695
Asn Phe Val Gln Ser Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His		
	705	710
His Asn Leu Phe His Glu Gly Ser Asn Asn Leu Ile Leu Ile Leu Leu		
	725	730
Glu Pro Ile Pro Gln Asn Ser Ile Pro Asn Lys Tyr His Lys Leu Lys		
	740	745
Ala Leu Met Thr Gln Arg Thr Tyr Leu Gln Trp Pro Lys Glu Lys Ser		
	755	760
Lys Arg Gly Leu Phe Trp Ala Asn Ile Arg Ala Ala Phe Asn Met Lys		

770                      775                      780  
 Leu Thr Leu Val Thr Glu Asn Asn Asp Val Lys Ser  
 785                      790                      795

<210> 82  
 <211> 796  
 <212> PRT  
 <213> Homo sapiens

<400> 82

Met Thr Lys Asp Lys Glu Pro Ile Val Lys Ser Phe His Phe Val Cys  
 1                      5                      10                      15

Leu Met Ile Ile Ile Val Gly Thr Arg Ile Gln Phe Ser Asp Gly Asn  
                     20                      25                      30

Glu Phe Ala Val Asp Lys Ser Lys Arg Gly Leu Ile His Val Pro Lys  
                     35                      40                      45

Asp Leu Pro Leu Lys Thr Lys Val Leu Asp Met Ser Gln Asn Tyr Ile  
                     50                      55                      60

Ala Glu Leu Gln Val Ser Asp Met Ser Phe Leu Ser Glu Leu Thr Val  
 65                      70                      75                      80

Leu Arg Leu Ser His Asn Arg Ile Gln Leu Leu Asp Leu Ser Val Phe  
                     85                      90                      95

Lys Phe Asn Gln Asp Leu Glu Tyr Leu Asp Leu Ser His Asn Gln Leu  
                     100                      105                      110

Gln Lys Ile Ser Cys His Pro Ile Val Ser Phe Arg His Leu Asp Leu  
                     115                      120                      125

Ser Phe Asn Asp Phe Lys Ala Leu Pro Ile Cys Lys Glu Phe Gly Asn  
 130                      135                      140

Leu Ser Gln Leu Asn Phe Leu Gly Leu Ser Ala Met Lys Leu Gln Lys  
 145                      150                      155                      160

Leu Asp Leu Leu Pro Ile Ala His Leu His Leu Ser Tyr Ile Leu Leu  
                     165                      170                      175

Asp Leu Arg Asn Tyr Tyr Ile Lys Glu Asn Glu Thr Glu Ser Leu Gln  
                     180                      185                      190

Ile Leu Asn Ala Lys Thr Leu His Leu Val Phe His Pro Thr Ser Leu  
                     195                      200                      205

Phe Ala Ile Gln Val Asn Ile Ser Val Asn Thr Leu Gly Cys Leu Gln  
 210                      215                      220

Leu Thr Asn Ile Lys Leu Asn Asp Asp Asn Cys Gln Val Phe Ile Lys  
 225                      230                      235                      240

Phe Leu Ser Glu Leu Thr Arg Gly Pro Thr Leu Leu Asn Phe Thr Leu  
                     245                      250                      255

Asn His Ile Glu Thr Thr Trp Lys Cys Leu Val Arg Val Phe Gln Phe  
                     260                      265                      270

Leu Trp Pro Lys Pro Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile  
 275 280 285  
 Ile Glu Ser Ile Arg Glu Glu Asp Phe Thr Tyr Ser Lys Thr Thr Leu  
 290 295 300  
 Lys Ala Leu Thr Ile Glu His Ile Thr Asn Gln Val Phe Leu Phe Ser  
 305 310 315 320  
 Gln Thr Ala Leu Tyr Thr Val Phe Ser Glu Met Asn Ile Met Met Leu  
 325 330 335  
 Thr Ile Ser Asp Thr Pro Phe Ile His Met Leu Cys Pro His Ala Pro  
 340 345 350  
 Ser Thr Phe Lys Phe Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser  
 355 360 365  
 Ile Phe Glu Lys Cys Ser Thr Leu Val Lys Leu Glu Thr Leu Ile Leu  
 370 375 380  
 Gln Lys Asn Gly Leu Lys Asp Leu Phe Lys Val Gly Leu Met Thr Lys  
 385 390 395 400  
 Asp Met Pro Ser Leu Glu Ile Leu Asp Val Ser Trp Asn Ser Leu Glu  
 405 410 415  
 Ser Gly Arg His Lys Glu Asn Cys Thr Trp Val Glu Ser Ile Val Val  
 420 425 430  
 Leu Asn Leu Ser Ser Asn Met Leu Thr Asp Ser Val Phe Arg Cys Leu  
 435 440 445  
 Pro Pro Arg Ile Lys Val Leu Asp Leu His Ser Asn Lys Ile Lys Ser  
 450 455 460  
 Val Pro Lys Gln Val Val Lys Leu Glu Ala Leu Gln Glu Leu Asn Val  
 465 470 475 480  
 Ala Phe Asn Ser Leu Thr Asp Leu Pro Gly Cys Gly Ser Phe Ser Ser  
 485 490 495  
 Leu Ser Val Leu Ile Ile Asp His Asn Ser Val Ser His Pro Ser Ala  
 500 505 510  
 Asp Phe Phe Gln Ser Cys Gln Lys Met Arg Ser Ile Lys Ala Gly Asp  
 515 520 525  
 Asn Pro Phe Gln Cys Thr Cys Glu Leu Arg Glu Phe Val Lys Asn Ile  
 530 535 540  
 Asp Gln Val Ser Ser Glu Val Leu Glu Gly Trp Pro Asp Ser Tyr Lys  
 545 550 555 560  
 Cys Asp Tyr Pro Glu Ser Tyr Arg Gly Ser Pro Leu Lys Asp Phe His  
 565 570 575  
 Met Ser Glu Leu Ser Cys Asn Ile Thr Leu Leu Ile Val Thr Ile Gly  
 580 585 590  
 Ala Thr Met Leu Val Leu Ala Val Thr Val Thr Ser Leu Cys Ile Tyr

595                      600                      605  
 Leu Asp Leu Pro Trp Tyr Leu Arg Met Val Cys Gln Trp Thr Gln Thr  
 610                      615                      620  
 Arg Arg Arg Ala Arg Asn Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu  
 625                      630                      635                      640  
 Gln Phe His Ala Phe Ile Ser Tyr Ser Glu His Asp Ser Ala Trp Val  
 645                      650                      655  
 Lys Ser Glu Leu Val Pro Tyr Leu Glu Lys Glu Asp Ile Gln Ile Cys  
 660                      665                      670  
 Leu His Glu Arg Asn Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile  
 675                      680                      685  
 Ile Asn Cys Ile Glu Lys Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro  
 690                      695                      700  
 Asn Phe Val Gln Ser Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His  
 705                      710                      715                      720  
 His Asn Leu Phe His Glu Gly Ser Asn Asn Leu Ile Leu Ile Leu Leu  
 725                      730                      735  
 Glu Pro Ile Pro Gln Asn Ser Ile Pro Asn Lys Tyr His Lys Leu Lys  
 740                      745                      750  
 Ala Leu Met Thr Gln Arg Thr Tyr Leu Gln Trp Pro Lys Glu Lys Ser  
 755                      760                      765  
 Lys Arg Gly Leu Phe Trp Ala Asn Ile Arg Ala Ala Phe Asn Met Lys  
 770                      775                      780  
 Leu Thr Leu Val Thr Glu Asn Asn Asp Val Lys Ser  
 785                      790                      795

<210> 83  
 <211> 2604  
 <212> DNA  
 <213> murine

<400> 83  
 aagtaaaaat gctgtgaaga atggtaaagt ccctctggga tagcctctgc aacatgagcc 60  
 aagacagaaa acccatcgtg gggagtttcc actttgtttg cgccctggcc ttaatagtcg 120  
 gaagcatgac cccgttctct aatgaacttg agtctatggt agactattca aacaggaacc 180  
 ttactcatgt ccccaaagac ctgccaccaa gaacaaaagc cctgagtctg tctcaaaact 240  
 ctatatctga gcttcggatg cctgatatca gctttctgtc agagctgaga gttctgagac 300  
 tctcccacaa caggatacgg agccttgatt tccatgtatt cttgttcaat caggacttag 360  
 aatacctgga tgtctcacac aatcgggtgc aaaacatctc ttgctgccct atggcgagcc 420  
 tgaggcatct agacctctca ttcaatgact ttgatgtact gcctgtgtgt aaggaatttg 480  
 gcaacctgac gaagctgact ttctgggat taagtgtgc caagttccga caactggatc 540

tgctcccagt tgctcacttg catctaagct gcattcttct ggacttagtg agtcatcata	600
taaaaggcgg ggaaacagaa agtcttcaga ttcccaatac caccgttctc catttggtct	660
ttcatccaaa tagcttggtc tctgttcaag tgaacatgtc tgtaaagct ttaggacatt	720
tacaactgag taatattaaa ttgaatgatg aaaactgtca aagggttaatg acatttttat	780
cagaactcac cagaggtcca accttattga atgtgaccct ccagcacata gaaacaacct	840
ggaagtgtc gggtaaactt ttccaattct tttggccccg accggtggag tacctcaata	900
tttacaactt aacgataact gagagaatcg acagggaaga atttacttac tcggagacag	960
actgaagtc actgatgata gagcacgtca aaaaccaagt gtccctcttt tcaaaggagg	1020
cgctatactc ggtgtttgct gagatgaaca tcaagatgct ctctatctca gacaccctt	1080
tcatccacat ggtgtgcccc ccatcccaa gctcatttac atttctgaac ttaccacaga	1140
atgtttttac tgacagtgtt tttcaaggct gtccacctt aaagagattg cagacactta	1200
tcttacaag gaatggtttg aagaactttt ttaaagtagc tctcatgact aagaatatgt	1260
cctctctgga aactttggat gttagtttga attctttgaa ctctcatgca tatgacagga	1320
catgcgcctg ggctgagagc atattggtgt tgaatttgtc ttcgaatatg cttacaggct	1380
ctgtcttcag atgcttacct cccaaggta aggtccttga ccttcacaac aacaggataa	1440
tgagcatccc taaagatgtc acccacctgc aggtcttgca ggaactcaat gtagcatcca	1500
actccttaac tgaccttct ggggtgtggg ccttcagcag ctttctgtg ctggtcatcg	1560
accataactc agtttcccat ccctctgagg atttcttcca gagctgtcag aatattagat	1620
ccctaacagc gggaaacaac ccattccaat gcacatgtga gctgagggac tttgtcaaga	1680
acataggctg ggtagcaaga gaagtgggtg agggctggcc tgactcttac aggtgtgact	1740
accagaaaag ctctaaggga actgcactga gggacttcca catgtctcca ctgtcctgtg	1800
atactgttct gctgactgtc accatcgggg ccactatgct ggtgctggct gtcactgggg	1860
ctttctctg tctctacttt gacctgccct ggtatgtgag gatgctgtgt cagtggacac	1920
agaccaggca cagggccagg cacatcccct tagaggaact ccagagaaac ctccagttcc	1980
atgcttttgt ctcatacagt gagcatgatt ctgcctgggt gaagaacgaa ttactacca	2040
acctagagaa agatgacatc cgggtttgcc tccatgagag gaactttgtc cctggcaaga	2100
gcattgtgga gaacatcatc aatttcattg agaagagtta caaggccatc tttgtgctgt	2160
ctccccactt catccagagt gagtgggtgcc attatgaact ctattttgcc catcataatc	2220
tcttccatga aggtctgat aacttaatcc tcatcttgct ggaaccatt ctacagaaca	2280
acattcccag tagataccac aagctgcggg ctctcatggc acagcggact tacttggaat	2340
ggcctactga gaagggcaaa cgtgggctgt tttgggcca ccttagagct tcatttatta	2400
tgaagttagc cttagtcaat gaggatgatg tgaaaacttg aaacttgggt ttctaactta	2460

ataaactgtc aacctgggct ctcatgaaca ctgtggtttt cagttcctac ctggagggtac 2520  
ttctgttggtg gtgtcttagt ttgctctgtg cttatgataa ataacatgtt tagaagtagt 2580  
ttatgaaggt gctaagttca ttaa 2604

<210> 84  
<211> 2604  
<212> DNA  
<213> murine

<400> 84  
aagtaaaaat gctgtgaaga atggtaaagt ccctctggga tagcctctgc aacatgagcc 60  
aagacagaaa acccatcgtg gggagtttcc actttgtttg cgccctggcc ttaatagtcg 120  
gaagcatgac cccgttctct aatgaacttg agtctatggg agactattca aacaggaacc 180  
ttactcatgt ccccaaagac ctgccaccaa gaacaaagc cctgagtctg tctcaaaact 240  
ctatatctga gcttcggatg cctgatatca gctttctgtc agagctgaga gttctgagac 300  
tctcccacaa caggatacgg agccttgatt tccatgtatt cttgttcaat caggacttag 360  
aatacctgga tgtctcacac aatcggttgc aaaacatctc ttgctgcctc atggcgagcc 420  
tgaggcatct agacctctca ttcaatgact ttgatgtact gcctgtgtgt aaggaatttg 480  
gcaacctgac gaagctgact ttcctgggat taagtgtctc caagttccga caactggatc 540  
tgctcccagt tgctcacttg catctaagct gcattcttct ggacttagtg agtcatcata 600  
taaaaggcgg ggaaacagaa agtcttcaga ttcccaatac caccgttctc catttggtct 660  
ttcatccaaa tagcttggtc tctgttcaag tgaacatgtc tgtaaagct ttaggacatt 720  
tacaactgag taatattaaa ttgaatgatg aaaactgtca aaggttaatg acatttttat 780  
cagaactcac cagaggtcca accttattga atgtgacct ccagcacata gaaacaacct 840  
ggaagtgtc gggttaaactt ttccaattct tttggccccg accggtggag tacctcaata 900  
tttacaactt aacgataact gagagaatcg acaggaaga atttacttac tcggagacag 960  
cactgaagtc actgatgata gagcacgtca aaaaccaagt gttcctcttt tcaaaggagg 1020  
cgctatactc ggtgtttgct gagatgaaca tcaagatgct ctctatctca gacaccctt 1080  
tcatccacat ggtgtgcccg ccatcccaa gctcatttac atttctgaac ttaccacaga 1140  
atgtttttac tgacagtgtt tttcaaggct gttccacctt aaagagattg cagacactta 1200  
tcttaciaag gaatggttg aagaactttt ttaaagtagc tctcatgact aagaatatgt 1260  
cctctctgga aactttggat gttagtttga attccttgaa ctctcatgca tatgacagga 1320  
catgcgcctg ggctgagagc atattggtgt tgaatttgtc ttcgaatatg cttacaggct 1380  
ctgtcttcag atgcttacct cccaagggtc aggtccttga ccttcacaac aacaggataa 1440

tgagcatccc	taaagatgtc	acccacctgc	aggttttgca	ggaactcaat	gtagcatcca	1500
actccttaac	tgaccttcc	gggtgtggg	ccttcagcag	cctttctgtg	ctggcatcg	1560
accataactc	agtttcccat	ccctctgagg	atttcttcca	gagctgtcag	aatattagat	1620
ccctaacagc	gggaaacaac	ccattccaat	gcacatgtga	gctgagggac	tttgtcaaga	1680
acataggctg	ggtagcaaga	gaagtgggtg	agggctggcc	tgactcttac	aggtgtgact	1740
acccagaaag	ctctaaggga	actgcactga	gggacttcca	catgtctcca	ctgtcctgtg	1800
atactgttct	gctgactgtc	accatcgggg	ccactatgct	ggtgctggct	gtcactgggg	1860
ccttcctctg	tctctaactt	gacctgccct	ggtatgtgag	gatgctgtgt	cagtggacac	1920
agaccaggca	cagggccagg	cacatcccct	tagaggaaat	ccagagaaac	ctccagttcc	1980
atgcttttgt	ctcatacagt	gagcatgatt	ctgcctgggt	gaagaacgaa	ttactaccca	2040
acctagagaa	agatgacatc	cgggtttgcc	tccatgagag	gaactttgtc	cctggcaaga	2100
gcattgtgga	gaacatcatc	aatttcattg	agaagagtta	caaggccatc	tttgtgctgt	2160
ctccccactt	catccagagt	gagtgggtgc	attatgaact	ctattttgcc	catcataatc	2220
tcttccatga	aggctctgat	aacttaatcc	tcactcttgc	ggaacccatt	ctacagaaca	2280
acattcccag	tagataccac	aagctgcggg	ctctcatggc	acagcggact	tacttggaat	2340
ggcctactga	gaagggcaaa	cgtgggctgt	tttgggccaa	ccttagagct	tcatttatta	2400
tgaagtttag	cttagtcaat	gaggatgatg	tgaaaacttg	aaacttgggt	ttctaactta	2460
ataaactgtc	aacctgggct	ctcatgaaca	ctgtggtttt	cagttcctac	ctggaggtac	2520
ttctgttgtg	gtgtcttagt	ttgctctgtg	cttatgataa	ataacatgtt	tagaagtagt	2580
ttatgaagg	gctaagttca	ttaa				2604

&lt;210&gt; 85

&lt;211&gt; 2421

&lt;212&gt; DNA

&lt;213&gt; murine

&lt;400&gt; 85

atggtaaagt	ccctctggga	tagcctctgc	aacatgagcc	aagacagaaa	acccatcgtg	60
gggagtttcc	actttgtttg	cgccctggcc	ttaatagtgc	gaagcatgac	cccgttctct	120
aatgaacttg	agtctatgg	agactattca	aacaggaacc	ttactcatgt	ccccaaagac	180
ctgccaccaa	gaacaaaagc	cctgagtctg	tctcaaaact	ctatatctga	gcttcggatg	240
cctgatatca	gctttctgtc	agagctgaga	gttctgagac	tctcccacaa	caggatacgg	300
agccttgatt	tccatgtatt	cttgttcaat	caggacttag	aatacctgga	tgtctcacac	360
aatcggttgc	aaaacatctc	ttgctgccct	atggcgagcc	tgaggcatct	agacctctca	420
ttcaatgact	ttgatgtact	gcctgtgtgt	aaggaatttg	gcaacctgac	gaagctgact	480

ttcctgggat	taagtgetgc	aaagtccga	caactggatc	tgctcccagt	tgctcacttg	540
catctaagct	gcattcttct	ggacttagtg	agttatcata	taaaaggcgg	ggaaacagaa	600
agtcttcaga	ttcccaatac	caccgttctc	catttggtct	ttcatccaaa	tagcttggtc	660
tctgttcaag	tgaacatgtc	tgtaaacgct	ttaggacatt	tacaactgag	taatattaaa	720
ttgaatgatg	aaaactgtca	aagggttaatg	acatttttat	cagaactcac	cagaggtcca	780
accttattga	atgtgaccct	ccagcacata	gaaacaacct	ggaagtgtc	ggttaaactt	840
ttccaattct	tttggccccg	accggtggag	tacctcaata	tttacaactt	aacgataact	900
gagagaatcg	acaggaaga	atttacttac	tcggagacag	cactgaagtc	actgatgata	960
gagcacgtca	aaaaccaagt	gttcctcttt	tcaaaggagg	cgctatactc	ggtgtttgct	1020
gagatgaaca	tcaagatgct	ctctatctca	gacaccctt	tcattccacat	ggtgtgccccg	1080
ccatcccaa	gtcattttac	atttctgaac	tttaccaga	atgtttttac	tgacagtgtt	1140
tttcaaggct	gttccacctt	aaagagattg	cagacactta	tcttacaag	gaatggtttg	1200
aagaactttt	ttaaagtagc	tctcatgact	aagaatatgt	cctctctgga	aactttggat	1260
gttagtttga	attctttgaa	ctctcatgca	tatgacagga	catgcgcctg	ggctgagagc	1320
atattggtgt	tgaatttgtc	ttcgaatatg	cttacaggct	ctgtcttcag	atgcttacct	1380
cccaaggctca	aggctcctga	ccttcacaac	aacaggataa	tgagcatccc	taaagatgtc	1440
accacactgc	aggctttgca	ggaactcaat	gtagcatcca	actccttaac	tgaccttcct	1500
gggtgtgggg	ccttcagcag	cctttctgtg	ctggtcacg	accataactc	agtttcccat	1560
ccctctgagg	atttcttcca	gagctgtcag	aatattagat	ccctaacagc	gggaaacaac	1620
ccattccaat	gcacatgtga	gctgaggggac	tttgtcaaga	acataggctg	ggtagcaaga	1680
gaagtgggtg	agggtggcc	tgactcttac	aggtgtgact	accagaaaag	ctctaaggga	1740
actgcactga	gggacttcca	catgtctcca	ctgtcctgtg	atactgttct	gctgactgtc	1800
accatcgggg	ccactatgct	ggtgctggct	gtcactgggg	ctttcctctg	tctctacttt	1860
gacctgccct	ggtatgtgag	gatgctgtgt	cagtggacac	agaccaggca	cagggccagg	1920
cacatcccct	tagaggaact	ccagagaaac	ctccagttcc	atgcttttgt	ctcatacagt	1980
gagcatgatt	ctgcctgggt	gaagaacgaa	ttactacca	acctagagaa	agatgacatc	2040
cgggtttgcc	tccatgagag	gaactttgtc	cctggcaaga	gcattgtgga	gaacatcatc	2100
aatttcattg	agaagagtta	caaggccatc	tttgtgtgt	ctccccactt	catccagagt	2160
gagtgggtgc	attatgaact	ctattttgcc	catcataatc	tcttccatga	aggctctgat	2220
aacttaatcc	tcattcttgc	ggaaccatt	ctacagaaca	acattcccag	tagataccac	2280
aagctgcggg	ctctcatggc	acagcggact	tacttggaat	ggcctactga	gaagggcaaa	2340
cgtgggctgt	tttgggcaa	ccttagagct	tcatttatta	tgaagttagc	cttagtcaat	2400



gaggatgatg tgaaaacttg a

2421

&lt;210&gt; 86

&lt;211&gt; 806

&lt;212&gt; PRT

&lt;213&gt; murine

&lt;400&gt; 86

Met Val Lys Ser Leu Trp Asp Ser Leu Cys Asn Met Ser Gln Asp Arg  
 1 5 10 15

Lys Pro Ile Val Gly Ser Phe His Phe Val Cys Ala Leu Ala Leu Ile  
 20 25 30

Val Gly Ser Met Thr Pro Phe Ser Asn Glu Leu Glu Ser Met Val Asp  
 35 40 45

Tyr Ser Asn Arg Asn Leu Thr His Val Pro Lys Asp Leu Pro Pro Arg  
 50 55 60

Thr Lys Ala Leu Ser Leu Ser Gln Asn Ser Ile Ser Glu Leu Arg Met  
 65 70 75 80

Pro Asp Ile Ser Phe Leu Ser Glu Leu Arg Val Leu Arg Leu Ser His  
 85 90 95

Asn Arg Ile Arg Ser Leu Asp Phe His Val Phe Leu Phe Asn Gln Asp  
 100 105 110

Leu Glu Tyr Leu Asp Val Ser His Asn Arg Leu Gln Asn Ile Ser Cys  
 115 120 125

Cys Pro Met Ala Ser Leu Arg His Leu Asp Leu Ser Phe Asn Asp Phe  
 130 135 140

Asp Val Leu Pro Val Cys Lys Glu Phe Gly Asn Leu Thr Lys Leu Thr  
 145 150 155 160

Phe Leu Gly Leu Ser Ala Ala Lys Phe Arg Gln Leu Asp Leu Leu Pro  
 165 170 175

Val Ala His Leu His Leu Ser Cys Ile Leu Leu Asp Leu Val Ser His  
 180 185 190

His Ile Lys Gly Gly Glu Thr Glu Ser Leu Gln Ile Pro Asn Thr Thr  
 195 200 205

Val Leu His Leu Val Phe His Pro Asn Ser Leu Phe Ser Val Gln Val  
 210 215 220

Asn Met Ser Val Asn Ala Leu Gly His Leu Gln Leu Ser Asn Ile Lys  
 225 230 235 240

Leu Asn Asp Glu Asn Cys Gln Arg Leu Met Thr Phe Leu Ser Glu Leu  
 245 250 255

Thr Arg Gly Pro Thr Leu Leu Asn Val Thr Leu Gln His Ile Glu Thr  
 260 265 270

Thr	Trp	Lys	Cys	Ser	Val	Lys	Leu	Phe	Gln	Phe	Phe	Trp	Pro	Arg	Pro		
		275					280					285					
Val	Glu	Tyr	Leu	Asn	Ile	Tyr	Asn	Leu	Thr	Ile	Thr	Glu	Arg	Ile	Asp		
	290					295					300						
Arg	Glu	Glu	Phe	Thr	Tyr	Ser	Glu	Thr	Ala	Leu	Lys	Ser	Leu	Met	Ile		
305					310					315					320		
Glu	His	Val	Lys	Asn	Gln	Val	Phe	Leu	Phe	Ser	Lys	Glu	Ala	Leu	Tyr		
				325					330					335			
Ser	Val	Phe	Ala	Glu	Met	Asn	Ile	Lys	Met	Leu	Ser	Ile	Ser	Asp	Thr		
			340					345					350				
Pro	Phe	Ile	His	Met	Val	Cys	Pro	Pro	Ser	Pro	Ser	Ser	Phe	Thr	Phe		
		355					360					365					
Leu	Asn	Phe	Thr	Gln	Asn	Val	Phe	Thr	Asp	Ser	Val	Phe	Gln	Gly	Cys		
	370					375					380						
Ser	Thr	Leu	Lys	Arg	Leu	Gln	Thr	Leu	Ile	Leu	Gln	Arg	Asn	Gly	Leu		
385					390					395					400		
Lys	Asn	Phe	Phe	Lys	Val	Ala	Leu	Met	Thr	Lys	Asn	Met	Ser	Ser	Leu		
				405					410						415		
Glu	Thr	Leu	Asp	Val	Ser	Leu	Asn	Ser	Leu	Asn	Ser	His	Ala	Tyr	Asp		
			420					425					430				
Arg	Thr	Cys	Ala	Trp	Ala	Glu	Ser	Ile	Leu	Val	Leu	Asn	Leu	Ser	Ser		
		435					440					445					
Asn	Met	Leu	Thr	Gly	Ser	Val	Phe	Arg	Cys	Leu	Pro	Pro	Lys	Val	Lys		
	450					455					460						
Val	Leu	Asp	Leu	His	Asn	Asn	Arg	Ile	Met	Ser	Ile	Pro	Lys	Asp	Val		
465					470					475					480		
Thr	His	Leu	Gln	Ala	Leu	Gln	Glu	Leu	Asn	Val	Ala	Ser	Asn	Ser	Leu		
				485					490						495		
Thr	Asp	Leu	Pro	Gly	Cys	Gly	Ala	Phe	Ser	Ser	Leu	Ser	Val	Leu	Val		
			500					505					510				
Ile	Asp	His	Asn	Ser	Val	Ser	His	Pro	Ser	Glu	Asp	Phe	Phe	Gln	Ser		
		515					520					525					
Cys	Gln	Asn	Ile	Arg	Ser	Leu	Thr	Ala	Gly	Asn	Asn	Pro	Phe	Gln	Cys		
	530					535					540						
Thr	Cys	Glu	Leu	Arg	Asp	Phe	Val	Lys	Asn	Ile	Gly	Trp	Val	Ala	Arg		
545					550					555					560		
Glu	Val	Val	Glu	Gly	Trp	Pro	Asp	Ser	Tyr	Arg	Cys	Asp	Tyr	Pro	Glu		
				565					570					575			
Ser	Ser	Lys	Gly	Thr	Ala	Leu	Arg	Asp	Phe	His	Met	Ser	Pro	Leu	Ser		
			580					585					590				
Cys	Asp	Thr	Val	Leu	Leu	Thr	Val	Thr	Ile	Gly	Ala	Thr	Met	Leu	Val		

595                      600                      605  
 Leu Ala Val Thr Gly Ala Phe Leu Cys Leu Tyr Phe Asp Leu Pro Trp  
 610                      615                      620  
 Tyr Val Arg Met Leu Cys Gln Trp Thr Gln Thr Arg His Arg Ala Arg  
 625                      630                      635                      640  
 His Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu Gln Phe His Ala Phe  
 645                      650                      655  
 Val Ser Tyr Ser Glu His Asp Ser Ala Trp Val Lys Asn Glu Leu Leu  
 660                      665                      670  
 Pro Asn Leu Glu Lys Asp Asp Ile Arg Val Cys Leu His Glu Arg Asn  
 675                      680                      685  
 Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile Ile Asn Phe Ile Glu  
 690                      695                      700  
 Lys Ser Tyr Lys Ala Ile Phe Val Leu Ser Pro His Phe Ile Gln Ser  
 705                      710                      715                      720  
 Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His His Asn Leu Phe His  
 725                      730                      735  
 Glu Gly Ser Asp Asn Leu Ile Leu Ile Leu Leu Glu Pro Ile Leu Gln  
 740                      745                      750  
 Asn Asn Ile Pro Ser Arg Tyr His Lys Leu Arg Ala Leu Met Ala Gln  
 755                      760                      765  
 Arg Thr Tyr Leu Glu Trp Pro Thr Glu Lys Gly Lys Arg Gly Leu Phe  
 770                      775                      780  
 Trp Ala Asn Leu Arg Ala Ser Phe Ile Met Lys Leu Ala Leu Val Asn  
 785                      790                      795                      800  
 Glu Asp Asp Val Lys Thr  
 805

<210> 87  
 <211> 806  
 <212> PRT  
 <213> murine

<400> 87

Met Val Lys Ser Leu Trp Asp Ser Leu Cys Asn Met Ser Gln Asp Arg  
 1                      5                      10                      15  
 Lys Pro Ile Val Gly Ser Phe His Phe Val Cys Ala Leu Ala Leu Ile  
 20                      25                      30  
 Val Gly Ser Met Thr Pro Phe Ser Asn Glu Leu Glu Ser Met Val Asp  
 35                      40                      45  
 Tyr Ser Asn Arg Asn Leu Thr His Val Pro Lys Asp Leu Pro Pro Arg  
 50                      55                      60  
 Thr Lys Ala Leu Ser Leu Ser Gln Asn Ser Ile Ser Glu Leu Arg Met  
 65                      70                      75                      80

Pro Asp Ile Ser Phe Leu Ser Glu Leu Arg Val Leu Arg Leu Ser His  
                             85                            90                            95  
 Asn Arg Ile Arg Ser Leu Asp Phe His Val Phe Leu Phe Asn Gln Asp  
                             100                            105                            110  
 Leu Glu Tyr Leu Asp Val Ser His Asn Arg Leu Gln Asn Ile Ser Cys  
                             115                            120                            125  
 Cys Pro Met Ala Ser Leu Arg His Leu Asp Leu Ser Phe Asn Asp Phe  
                             130                            135                            140  
 Asp Val Leu Pro Val Cys Lys Glu Phe Gly Asn Leu Thr Lys Leu Thr  
                             145                            150                            155                            160  
 Phe Leu Gly Leu Ser Ala Ala Lys Phe Arg Gln Leu Asp Leu Leu Pro  
                             165                            170                            175  
 Val Ala His Leu His Leu Ser Cys Ile Leu Leu Asp Leu Val Ser Tyr  
                             180                            185                            190  
 His Ile Lys Gly Gly Glu Thr Glu Ser Leu Gln Ile Pro Asn Thr Thr  
                             195                            200                            205  
 Val Leu His Leu Val Phe His Pro Asn Ser Leu Phe Ser Val Gln Val  
                             210                            215                            220  
 Asn Met Ser Val Asn Ala Leu Gly His Leu Gln Leu Ser Asn Ile Lys  
                             225                            230                            235                            240  
 Leu Asn Asp Glu Asn Cys Gln Arg Leu Met Thr Phe Leu Ser Glu Leu  
                             245                            250                            255  
 Thr Arg Gly Pro Thr Leu Leu Asn Val Thr Leu Gln His Ile Glu Thr  
                             260                            265                            270  
 Thr Trp Lys Cys Ser Val Lys Leu Phe Gln Phe Phe Trp Pro Arg Pro  
                             275                            280                            285  
 Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile Thr Glu Arg Ile Asp  
                             290                            295                            300  
 Arg Glu Glu Phe Thr Tyr Ser Glu Thr Ala Leu Lys Ser Leu Met Ile  
                             305                            310                            315                            320  
 Glu His Val Lys Asn Gln Val Phe Leu Phe Ser Lys Glu Ala Leu Tyr  
                             325                            330                            335  
 Ser Val Phe Ala Glu Met Asn Ile Lys Met Leu Ser Ile Ser Asp Thr  
                             340                            345                            350  
 Pro Phe Ile His Met Val Cys Pro Pro Ser Pro Ser Ser Phe Thr Phe  
                             355                            360                            365  
 Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser Val Phe Gln Gly Cys  
                             370                            375                            380  
 Ser Thr Leu Lys Arg Leu Gln Thr Leu Ile Leu Gln Arg Asn Gly Leu  
                             385                            390                            395                            400  
 Lys Asn Phe Phe Lys Val Ala Leu Met Thr Lys Asn Met Ser Ser Leu

405 410 415  
 Glu Thr Leu Asp Val Ser Leu Asn Ser Leu Asn Ser His Ala Tyr Asp  
 420 425 430  
 Arg Thr Cys Ala Trp Ala Glu Ser Ile Leu Val Leu Asn Leu Ser Ser  
 435 440 445  
 Asn Met Leu Thr Gly Ser Val Phe Arg Cys Leu Pro Pro Lys Val Lys  
 450 455 460  
 Val Leu Asp Leu His Asn Asn Arg Ile Met Ser Ile Pro Lys Asp Val  
 465 470 475 480  
 Thr His Leu Gln Ala Leu Gln Glu Leu Asn Val Ala Ser Asn Ser Leu  
 485 490 495  
 Thr Asp Leu Pro Gly Cys Gly Ala Phe Ser Ser Leu Ser Val Leu Val  
 500 505 510  
 Ile Asp His Asn Ser Val Ser His Pro Ser Glu Asp Phe Phe Gln Ser  
 515 520 525  
 Cys Gln Asn Ile Arg Ser Leu Thr Ala Gly Asn Asn Pro Phe Gln Cys  
 530 535 540  
 Thr Cys Glu Leu Arg Asp Phe Val Lys Asn Ile Gly Trp Val Ala Arg  
 545 550 555 560  
 Glu Val Val Glu Gly Trp Pro Asp Ser Tyr Arg Cys Asp Tyr Pro Glu  
 565 570 575  
 Ser Ser Lys Gly Thr Ala Leu Arg Asp Phe His Met Ser Pro Leu Ser  
 580 585 590  
 Cys Asp Thr Val Leu Leu Thr Val Thr Ile Gly Ala Thr Met Leu Val  
 595 600 605  
 Leu Ala Val Thr Gly Ala Phe Leu Cys Leu Tyr Phe Asp Leu Pro Trp  
 610 615 620  
 Tyr Val Arg Met Leu Cys Gln Trp Thr Gln Thr Arg His Arg Ala Arg  
 625 630 635 640  
 His Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu Gln Phe His Ala Phe  
 645 650 655  
 Val Ser Tyr Ser Glu His Asp Ser Ala Trp Val Lys Asn Glu Leu Leu  
 660 665 670  
 Pro Asn Leu Glu Lys Asp Asp Ile Arg Val Cys Leu His Glu Arg Asn  
 675 680 685  
 Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile Ile Asn Phe Ile Glu  
 690 695 700  
 Lys Ser Tyr Lys Ala Ile Phe Val Leu Ser Pro His Phe Ile Gln Ser  
 705 710 715 720  
 Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His His Asn Leu Phe His  
 725 730 735  
 Glu Gly Ser Asp Asn Leu Ile Leu Ile Leu Leu Glu Pro Ile Leu Gln

740 745 750  
 Asn Asn Ile Pro Ser Arg Tyr His Lys Leu Arg Ala Leu Met Ala Gln  
 755 760 765  
 Arg Thr Tyr Leu Glu Trp Pro Thr Glu Lys Gly Lys Arg Gly Leu Phe  
 770 775 780  
 Trp Ala Asn Leu Arg Ala Ser Phe Ile Met Lys Leu Ala Leu Val Asn  
 785 790 795 800  
 Glu Asp Asp Val Lys Thr  
 805

<210> 88  
 <211> 806  
 <212> PRT  
 <213> murine

<400> 88

Met Val Lys Ser Leu Trp Asp Ser Leu Cys Asn Met Ser Gln Asp Arg  
 1 5 10 15  
 Lys Pro Ile Val Gly Ser Phe His Phe Val Cys Ala Leu Ala Leu Ile  
 20 25 30  
 Val Gly Ser Met Thr Pro Phe Ser Asn Glu Leu Glu Ser Met Val Asp  
 35 40 45  
 Tyr Ser Asn Arg Asn Leu Thr His Val Pro Lys Asp Leu Pro Pro Arg  
 50 55 60  
 Thr Lys Ala Leu Ser Leu Ser Gln Asn Ser Ile Ser Glu Leu Arg Met  
 65 70 75 80  
 Pro Asp Ile Ser Phe Leu Ser Glu Leu Arg Val Leu Arg Leu Ser His  
 85 90 95  
 Asn Arg Ile Arg Ser Leu Asp Phe His Val Phe Leu Phe Asn Gln Asp  
 100 105 110  
 Leu Glu Tyr Leu Asp Val Ser His Asn Arg Leu Gln Asn Ile Ser Cys  
 115 120 125  
 Cys Pro Met Ala Ser Leu Arg His Leu Asp Leu Ser Phe Asn Asp Phe  
 130 135 140  
 Asp Val Leu Pro Val Cys Lys Glu Phe Gly Asn Leu Thr Lys Leu Thr  
 145 150 155 160  
 Phe Leu Gly Leu Ser Ala Ala Lys Phe Arg Gln Leu Asp Leu Leu Pro  
 165 170 175  
 Val Ala His Leu His Leu Ser Cys Ile Leu Leu Asp Leu Val Ser His  
 180 185 190  
 His Ile Lys Gly Gly Glu Thr Glu Ser Leu Gln Ile Pro Asn Thr Thr  
 195 200 205  
 Val Leu His Leu Val Phe His Pro Asn Ser Leu Phe Ser Val Gln Val  
 210 215 220

Asn Met Ser Val Asn Ala Leu Gly His Leu Gln Leu Ser Asn Ile Lys  
 225 230 235 240  
 Leu Asn Asp Glu Asn Cys Gln Arg Leu Met Thr Phe Leu Ser Glu Leu  
 245 250 255  
 Thr Arg Gly Pro Thr Leu Leu Asn Val Thr Leu Gln His Ile Glu Thr  
 260 265 270  
 Thr Trp Lys Cys Ser Val Lys Leu Phe Gln Phe Phe Trp Pro Arg Pro  
 275 280 285  
 Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile Thr Glu Arg Ile Asp  
 290 295 300  
 Arg Glu Glu Phe Thr Tyr Ser Glu Thr Ala Leu Lys Ser Leu Met Ile  
 305 310 315 320  
 Glu His Val Lys Asn Gln Val Phe Leu Phe Ser Lys Glu Ala Leu Tyr  
 325 330 335  
 Ser Val Phe Ala Glu Met Asn Ile Lys Met Leu Ser Ile Ser Asp Thr  
 340 345 350  
 Pro Phe Ile His Met Val Cys Pro Pro Ser Pro Ser Ser Phe Thr Phe  
 355 360 365  
 Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser Val Phe Gln Gly Cys  
 370 375 380  
 Ser Thr Leu Lys Arg Leu Gln Thr Leu Ile Leu Gln Arg Asn Gly Leu  
 385 390 395 400  
 Lys Asn Phe Phe Lys Val Ala Leu Met Thr Lys Asn Met Ser Ser Leu  
 405 410 415  
 Glu Thr Leu Asp Val Ser Leu Asn Ser Leu Asn Ser His Ala Tyr Asp  
 420 425 430  
 Arg Thr Cys Ala Trp Ala Glu Ser Ile Leu Val Leu Asn Leu Ser Ser  
 435 440 445  
 Asn Met Leu Thr Gly Ser Val Phe Arg Cys Leu Pro Pro Lys Val Lys  
 450 455 460  
 Val Leu Asp Leu His Asn Asn Arg Ile Met Ser Ile Pro Lys Asp Val  
 465 470 475 480  
 Thr His Leu Gln Ala Leu Gln Glu Leu Asn Val Ala Ser Asn Ser Leu  
 485 490 495  
 Thr Asp Leu Pro Gly Cys Gly Ala Phe Ser Ser Leu Ser Val Leu Val  
 500 505 510  
 Ile Asp His Asn Ser Val Ser His Pro Ser Glu Asp Phe Phe Gln Ser  
 515 520 525  
 Cys Gln Asn Ile Arg Ser Leu Thr Ala Gly Asn Asn Pro Phe Gln Cys  
 530 535 540  
 Thr Cys Glu Leu Arg Asp Phe Val Lys Asn Ile Gly Trp Val Ala Arg

545                      550                      555                      560  
 Glu Val Val Glu Gly Trp Pro Asp Ser Tyr Arg Cys Asp Tyr Pro Glu  
                                  565                      570                      575  
  
 Ser Ser Lys Gly Thr Ala Leu Arg Asp Phe His Met Ser Pro Leu Ser  
                                  580                      585                      590  
  
 Cys Asp Thr Val Leu Leu Thr Val Thr Ile Gly Ala Thr Met Leu Val  
                                  595                      600                      605  
  
 Leu Ala Val Thr Gly Ala Phe Leu Cys Leu Tyr Phe Asp Leu Pro Trp  
                                  610                      615                      620  
  
 Tyr Val Arg Met Leu Cys Gln Trp Thr Gln Thr Arg His Arg Ala Arg  
                                  625                      630                      635                      640  
  
 His Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu Gln Phe His Ala Phe  
                                  645                      650                      655  
  
 Val Ser Tyr Ser Glu His Asp Ser Ala Trp Val Lys Asn Glu Leu Leu  
                                  660                      665                      670  
  
 Pro Asn Leu Glu Lys Asp Asp Ile Arg Val Cys Leu His Glu Arg Asn  
                                  675                      680                      685  
  
 Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile Ile Asn Phe Ile Glu  
                                  690                      695                      700  
  
 Lys Ser Tyr Lys Ala Ile Phe Val Leu Ser Pro His Phe Ile Gln Ser  
                                  705                      710                      715                      720  
  
 Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His His Asn Leu Phe His  
                                  725                      730                      735  
  
 Glu Gly Ser Asp Asn Leu Ile Leu Ile Leu Leu Glu Pro Ile Leu Gln  
                                  740                      745                      750  
  
 Asn Asn Ile Pro Ser Arg Tyr His Lys Leu Arg Ala Leu Met Ala Gln  
                                  755                      760                      765  
  
 Arg Thr Tyr Leu Glu Trp Pro Thr Glu Lys Gly Lys Arg Gly Leu Phe  
                                  770                      775                      780  
  
 Trp Ala Asn Leu Arg Ala Ser Phe Ile Met Lys Leu Ala Leu Val Asn  
                                  785                      790                      795                      800  
  
 Glu Asp Asp Val Lys Thr  
                                  805

<210> 89  
 <211> 795  
 <212> PRT  
 <213> murine

<400> 89

Met Ser Gln Asp Arg Lys Pro Ile Val Gly Ser Phe His Phe Val Cys  
 1                      5                      10                      15  
  
 Ala Leu Ala Leu Ile Val Gly Ser Met Thr Pro Phe Ser Asn Glu Leu  
                                  20                      25                      30



Glu Ser Met Val Asp Tyr Ser Asn Arg Asn Leu Thr His Val Pro Lys  
           35                                  40                                  45  
 Asp Leu Pro Pro Arg Thr Lys Ala Leu Ser Leu Ser Gln Asn Ser Ile  
       50                                  55                                  60  
 Ser Glu Leu Arg Met Pro Asp Ile Ser Phe Leu Ser Glu Leu Arg Val  
       65                                  70                                  75                                  80  
 Leu Arg Leu Ser His Asn Arg Ile Arg Ser Leu Asp Phe His Val Phe  
                                   85                                  90                                  95  
 Leu Phe Asn Gln Asp Leu Glu Tyr Leu Asp Val Ser His Asn Arg Leu  
                                   100                                  105                                  110  
 Gln Asn Ile Ser Cys Cys Pro Met Ala Ser Leu Arg His Leu Asp Leu  
           115                                  120                                  125  
 Ser Phe Asn Asp Phe Asp Val Leu Pro Val Cys Lys Glu Phe Gly Asn  
       130                                  135                                  140  
 Leu Thr Lys Leu Thr Phe Leu Gly Leu Ser Ala Ala Lys Phe Arg Gln  
       145                                  150                                  155                                  160  
 Leu Asp Leu Leu Pro Val Ala His Leu His Leu Ser Cys Ile Leu Leu  
                                   165                                  170                                  175  
 Asp Leu Val Ser Tyr His Ile Lys Gly Gly Glu Thr Glu Ser Leu Gln  
                                   180                                  185                                  190  
 Ile Pro Asn Thr Thr Val Leu His Leu Val Phe His Pro Asn Ser Leu  
           195                                  200                                  205  
 Phe Ser Val Gln Val Asn Met Ser Val Asn Ala Leu Gly His Leu Gln  
       210                                  215                                  220  
 Leu Ser Asn Ile Lys Leu Asn Asp Glu Asn Cys Gln Arg Leu Met Thr  
       225                                  230                                  235                                  240  
 Phe Leu Ser Glu Leu Thr Arg Gly Pro Thr Leu Leu Asn Val Thr Leu  
                                   245                                  250                                  255  
 Gln His Ile Glu Thr Thr Trp Lys Cys Ser Val Lys Leu Phe Gln Phe  
                                   260                                  265                                  270  
 Phe Trp Pro Arg Pro Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile  
       275                                  280                                  285  
 Thr Glu Arg Ile Asp Arg Glu Glu Phe Thr Tyr Ser Glu Thr Ala Leu  
       290                                  295                                  300  
 Lys Ser Leu Met Ile Glu His Val Lys Asn Gln Val Phe Leu Phe Ser  
       305                                  310                                  315                                  320  
 Lys Glu Ala Leu Tyr Ser Val Phe Ala Glu Met Asn Ile Lys Met Leu  
                                   325                                  330                                  335  
 Ser Ile Ser Asp Thr Pro Phe Ile His Met Val Cys Pro Pro Ser Pro  
           340                                  345                                  350  
 Ser Ser Phe Thr Phe Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser

```

      355      360      365
Val Phe Gln Gly Cys Ser Thr Leu Lys Arg Leu Gln Thr Leu Ile Leu
  370      375      380

Gln Arg Asn Gly Leu Lys Asn Phe Phe Lys Val Ala Leu Met Thr Lys
385      390      395      400

Asn Met Ser Ser Leu Glu Thr Leu Asp Val Ser Leu Asn Ser Leu Asn
      405      410      415

Ser His Ala Tyr Asp Arg Thr Cys Ala Trp Ala Glu Ser Ile Leu Val
      420      425      430

Leu Asn Leu Ser Ser Asn Met Leu Thr Gly Ser Val Phe Arg Cys Leu
      435      440      445

Pro Pro Lys Val Lys Val Leu Asp Leu His Asn Asn Arg Ile Met Ser
      450      455      460

Ile Pro Lys Asp Val Thr His Leu Gln Ala Leu Gln Glu Leu Asn Val
465      470      475      480

Ala Ser Asn Ser Leu Thr Asp Leu Pro Gly Cys Gly Ala Phe Ser Ser
      485      490      495

Leu Ser Val Leu Val Ile Asp His Asn Ser Val Ser His Pro Ser Glu
      500      505      510

Asp Phe Phe Gln Ser Cys Gln Asn Ile Arg Ser Leu Thr Ala Gly Asn
      515      520      525

Asn Pro Phe Gln Cys Thr Cys Glu Leu Arg Asp Phe Val Lys Asn Ile
      530      535      540

Gly Trp Val Ala Arg Glu Val Val Glu Gly Trp Pro Asp Ser Tyr Arg
545      550      555      560

Cys Asp Tyr Pro Glu Ser Ser Lys Gly Thr Ala Leu Arg Asp Phe His
      565      570      575

Met Ser Pro Leu Ser Cys Asp Thr Val Leu Leu Thr Val Thr Ile Gly
      580      585      590

Ala Thr Met Leu Val Leu Ala Val Thr Gly Ala Phe Leu Cys Leu Tyr
      595      600      605

Phe Asp Leu Pro Trp Tyr Val Arg Met Leu Cys Gln Trp Thr Gln Thr
      610      615      620

Arg His Arg Ala Arg His Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu
625      630      635      640

Gln Phe His Ala Phe Val Ser Tyr Ser Glu His Asp Ser Ala Trp Val
      645      650      655

Lys Asn Glu Leu Leu Pro Asn Leu Glu Lys Asp Asp Ile Arg Val Cys
      660      665      670

Leu His Glu Arg Asn Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile
      675      680      685

Ile Asn Phe Ile Glu Lys Ser Tyr Lys Ala Ile Phe Val Leu Ser Pro

```

690	695	700
His Phe Ile Gln Ser Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His		
705	710	715 720
His Asn Leu Phe His Glu Gly Ser Asp Asn Leu Ile Leu Ile Leu Leu		
725	730	735
Glu Pro Ile Leu Gln Asn Asn Ile Pro Ser Arg Tyr His Lys Leu Arg		
740	745	750
Ala Leu Met Ala Gln Arg Thr Tyr Leu Glu Trp Pro Thr Glu Lys Gly		
755	760	765
Lys Arg Gly Leu Phe Trp Ala Asn Leu Arg Ala Ser Phe Ile Met Lys		
770	775	780
Leu Ala Leu Val Asn Glu Asp Asp Val Lys Thr		
785	790	795

<210> 90  
 <211> 10  
 <212> DNA  
 <213> artificial sequence

<220>

<223> consensus p50 subunit

<220>  
 <221> misc\_feature  
 <222> (7)..(7)  
 <223> N = c or t

<400> 90  
 ggggatnccc

10

<210> 91  
 <211> 10  
 <212> DNA  
 <213> artificial sequence

<220>

<223> consensus p65 subunit

<220>  
 <221> misc\_feature  
 <222> (4)..(4)  
 <223> N = a or g

<220>  
 <221> misc\_feature  
 <222> (5)..(5)  
 <223> N = a, c, g, or t

<400> 91  
 gggntttccc

10

<210> 92

<211> 22  
<212> DNA  
<213> artificial sequence

<220>

<223> consensus subunit

<400> 92  
agttgagggg actttcccag gc

22

<210> 93  
<211> 27  
<212> DNA  
<213> artificial sequence

<220>

<223> CREB binding site

<400> 93  
agagattgcc tgacgtcaga gagctag

27

<210> 94  
<211> 21  
<212> DNA  
<213> artificial sequence

<220>

<223> AP-1 binding site

<400> 94  
cgcttgatga gtcagccgga a

21

<210> 95  
<211> 15  
<212> DNA  
<213> artificial sequence

<220>

<223> AP-1 binding site

<400> 95  
cgcatgagtc agaca

15

<210> 96  
<211> 19  
<212> DNA  
<213> artificial sequence

<220>

<223> ISRE

<400> 96

tgcagaagtg aaactgagg

19

<210> . 97

<211> 11

<212> DNA

<213> artificial sequence

<220>

<223> ISRE

<400> 97

agaacgaaac a

11

<210> 98

<211> 15

<212> DNA

<213> artificial sequence

<220>

<223> ISRE

<400> 98

gagaagtgaa agtgg

15

<210> 99

<211> 18

<212> DNA

<213> artificial sequence

<220>

<223> ISRE

<400> 99

taagaacatg aaactgaa

18

<210> 100

<211> 15

<212> DNA

<213> artificial sequence

<220>

<223> ISRE

<400> 100

atgaaactga aagta

15

<210> 101

<211> 16

<212> DNA

<213> artificial sequence

<220>

<223> ISRE

<400> 101  
tgaaaaccga aagcgc

16

<210> 102  
<211> 13  
<212> DNA  
<213> artificial sequence

<220>

<223> ISRE

<400> 102  
agaaatggaa agt

13

<210> 103  
<211> 9  
<212> DNA  
<213> artificial sequence

<220>

<223> SRE

<400> 103  
tcacccac

9

<210> 104  
<211> 10  
<212> DNA  
<213> artificial sequence

<220>

<223> SRE

<400> 104  
ctcacccac

10

<210> 105  
<211> 10  
<212> DNA  
<213> artificial sequence

<220>

<223> SRE

<400> 105  
gccaccctac

10

<210> 106  
<211> 17  
<212> DNA  
<213> artificial sequence

<220>  
<223> NFAT

<400> 106  
tatgaaacag tttttcc

17

<210> 107  
<211> 9  
<212> DNA  
<213> artificial sequence

<220>

<223> NFAT

<400> 107  
aggaaactc

9

<210> 108  
<211> 10  
<212> DNA  
<213> artificial sequence

<220>

<223> NFAT

<220>  
<221> misc\_feature  
<222> (2)..(2)  
<223> N = a or g

<220>  
<221> misc\_feature  
<222> (5)..(5)  
<223> N = a or g

<400> 108  
anganattcc

10

<210> 109  
<211> 16  
<212> DNA  
<213> artificial sequence

<220>

<223> NFAT

<400> 109  
ccagttgagc cagaga

16

<210> 110  
<211> 30  
<212> DNA  
<213> artificial sequence

<220>

<223> GAS

<400> 110

ctttcagttt catattactc taaatccatt

30

<210> 111

<211> 10

<212> DNA

<213> artificial sequence

<220>

<223> p53 consensus site

<220>

<221> misc\_feature

<222> (1)..(3)

<223> N = a or g

<220>

<221> misc\_feature

<222> (5)..(6)

<223> N = a or t

<220>

<221> misc\_feature

<222> (8)..(10)

<223> N = c or t

<400> 111

nnncnngnnn

10

<210> 112

<211> 10

<212> DNA

<213> artificial sequence

<220>

<223> p53 consensus site

<400> 112

aggcatgcct

10

<210> 113

<211> 10

<212> DNA

<213> artificial sequence

<220>

<223> p53 consensus site

<400> 113

gggcttgccc

10

<210> 114



<211> 10  
<212> DNA  
<213> artificial sequence

<220>

<223> p53 consensus site

<400> 114  
gggcttgctt

10

<210> 115  
<211> 13  
<212> DNA  
<213> artificial sequence

<220>

<223> p53 consensus site

<400> 115  
gcctggactt gcc

13

<210> 116  
<211> 20  
<212> DNA  
<213> artificial sequence

<220>

<223> p53 consensus site

<400> 116  
ggacatgccc gggcatgtcc

20

<210> 117  
<211> 23  
<212> DNA  
<213> artificial sequence

<220>

<223> p53 consensus site

<400> 117  
gtagcattag cccagacatg tcc

23

<210> 118  
<211> 36  
<212> DNA  
<213> artificial sequence

<220>

<223> TARE

<400> 118  
gaggtagtgc gacaagagtc agagtttccc cttgaa

36

<210> 119  
 <211> 10  
 <212> DNA  
 <213> artificial sequence

<220>

<223> SRF

<220>  
 <221> misc\_feature  
 <222> (3)..(8)  
 <223> N = a or t

<400> 119  
 ccnnnnnnngg

10

<210> 120  
 <211> 11  
 <212> DNA  
 <213> artificial sequence

<220>

<223> SRF

<400> 120  
 ccaaataagg c

11

<210> 121  
 <211> 670  
 <212> DNA  
 <213> Homo sapiens

<400> 121  
 agaaaaattt taaaaaatta ttcattcata tttttaggag ttttgaatga ttggatatgt 60  
 aattatatct atattattaa tgtgtatcta tatagatttt tattttgcat atgtactttg 120  
 atacaaaatt tacatgaaca aattacacta aaagttattc cacaaatata cttatcaaatt 180  
 taagttaaatt gtcaatagct tttaaactta aatttttagtt taacttttct gtcattcttt 240  
 actttgaata aaaagagcaa actttgtagt ttttatctgt gaagtagagg tatacgtaat 300  
 atacataaat agatatgcca aatctgtgtt attaaaattt catgaagatt tcaattagaa 360  
 aaaaatacca taaaaggctt tgagtgcagg tgaaaaatag gcaatgatga aaaaaaatga 420  
 aaaacttttt aaacacatgt agagagtgcg taaagaaagc aaaaacagag atagaaagta 480  
 caactaggga atttagaaaa tggaaattag tatgttcact atttaagacc tatgcacaga 540  
 gcaaagtctt cagaaaacct agaggccgaa gttcaagggt atccatctca agtagcctag 600  
 caatatttgc aacatcccaa tggccctgtc cttttcttta ctgatggccg tgctgggtgct 660  
 cagctacaaa 670

<210> 122  
<211> 207  
<212> DNA  
<213> Homo sapiens

<400> 122  
aggttctctg aaggccttgc ttcttcgaga tgccttaa at agggaaacata ctgatttcca 60  
ctttctta at gcttctggac catttccatt tctgtttttg ctttccttct taactcttta 120  
catgagttta gagccgtgtt tctcaaatga tgggctagca cgcgtaagag ctcggtacct 180  
atcgatagag aaatgttctg gcacctg 207

<210> 123  
<211> 161  
<212> DNA  
<213> Homo sapiens

<400> 123  
aggttctctg aaggctttgc ttcttcgaga tgccttaa at agggaaacata ctgatttcca 60  
ctttctta at gcttctggac cactttccat ttctgttttt gctttccttc ttgaactctt 120  
tacatgagtt tagagccgtg tttctcaacc attttgtttt t 161

<210> 124  
<211> 300  
<212> DNA  
<213> Homo sapiens

<400> 124  
ttctcaggtc gtttgctttc ctttgctttc tcccaagtct tgttttacaa tttgctttag 60  
tcattcactg aaactttaaa aaacattaga aaacctcaca gtttgtaaat ctttttcctt 120  
attatatata tcataagata ggagcttaaa taaagagttt tagaaactac taaaatgtaa 180  
atgacatagg aaaactgaaa gggagaagtg aaagtgggaa attcctctga atagagagag 240  
gaccatctca tataaatagg ccatacccac ggagaaagga cattctaact gcaacctttc 300

<210> 125  
<211> 401  
<212> DNA  
<213> Homo sapiens

<400> 125  
gatctgta at gaataagcag gaactttgaa gactcagtga ctcagtgagt aataaagact 60  
cagtgacttc tgatcctgtc ctaactgcc a ctccttggtg tcccaagaaa gcggcttcct 120  
gctctctgag gaggaccctt tccctggaag gtaaaactaa ggatgtcagc agagaaatth 180  
ttccaccatt ggtgcttggt caaagaggaa actgatgagc tcactctaga tgagagagca 240  
gtgagggaga gacagagact cgaatttccg gagctatttc agttttcttt tccgttttgt 300

gcaatttcac ttatgatacc ggccaatgct tggttgctat tttggaaact ccccttaggg 360  
gatgcccctc aactggccct ataaagggcc agcctgagct g 401

<210> 126  
<211> 781  
<212> DNA  
<213> Homo sapiens

<400> 126  
ggttgctctgt atgcctccct gagggatatt cactttctgc tcccatccgc ccctatgagc 60  
gagtacctat gagcacagga tgtgcacata tttgagtctt attagtggta cacgcagttt 120  
tatcatctcc ccaggtctgt gtctgtatga aatgtgcatg ggtgtgtgtg tgcacgcgtg 180  
tgttcccact cggggaatgt ggggagaggt gcatggagcc aagatgggtg gtaaatagta 240  
tgtttctgaa attaaaggac taatgtggag gaaggcgccc cagatgtact aaaccctttg 300  
ccttcactctc atcctctctg acttggaag aaccaggatt ttgtttttaa gcccttgggc 360  
atacagttgt tccatcccga catgaactca gcctcccgtc tgaccgcccc ttggccttcc 420  
ttcttcctcg atctgtggaa cccagggat ctgcctagtg ctgtctccaa gcaccttggc 480  
catgatgtaa acccagagaa attagcatct ccatctcctt ccttattccc caccctaaaag 540  
tcatttctctc ttagttcatt acctgggatt ttgatgtcta tgttccctcc tcgttattga 600  
tacacacaca gagagagaca aacaaaaaag gaacttcttg aaattccccc agaaggtttt 660  
gagagttggt ttcaatgttg caacaagtca gtttctagtt taagtttcca tcagaaagga 720  
gtagagtata taagttccag taccagcaac agcagcagaa gaaacaacat ctgtttcagg 780  
g 781

<210> 127  
<211> 277  
<212> DNA  
<213> Homo sapiens

<400> 127  
gcatctccat ctcttctctt attccccacc caaaagtcatt ttcctcttag ttcattacct 60  
gggattttga tgtctatggt ccctcctcgt tattgataca cacacagaga gagacaaaca 120  
aaaaaggaac ttcttgaaat tccccagaa ggttttgaga gttgttttca atgttgcaac 180  
aagtcagttt ctagtttaag tttccatcag aaaggagtag agtatataag ttccagtacc 240  
agcaacagca gcagaagaaa caacatctgt ttcaggg 277

<210> 128  
<211> 305  
<212> DNA  
<213> Homo sapiens

<400> 128

caagacatgc caagtgctga gtcactaata aagaaaaaag aagtaaagga agagtgggtc 60  
tgcttcttag cgctagcctc aatgacgacc taagctgcac ttttccccct agttgtgtct 120  
  
tgcgatgcta aaggacgtca ttgcacaatc ttaataaggt ttccaatcag cccacccgc 180  
tctggcccca ccctcaccct ccaacaaaga tttatcaaat gtgggatttt cccatgagtc 240  
tcaatattag agtctcaacc cccaataaat ataggactgg agatgtctct gaggtcatt 300  
ctgcc 305

<210> 129  
<211> 1181  
<212> DNA  
<213> Homo sapiens

<400> 129  
cctgcaagag acaccatcct gaggggaaga gggcttctga accagcttga cccaataaga 60  
aattcttggg tgcgcagcggg gacagcagat tcagagccta gagccgtgcc tgcgtccgta 120  
gtttccttct agcttctttt tgatttcaaa tcaagactta caggagagg gagcgataaa 180  
cacaaactct gcaagatgcc acaaggctcct cctttgacat cccaacaaa gaaggtagt 240  
agtaatctcc ccctttctgc cctgaaccaa gtggcttcag taagtttcag ggctccagga 300  
gacctgggca tgcaggtgcc gatgaaacag tggatgaag actcagtgcc agtggcagtg 360  
gggagagcac tcgcagcaca ggcaaacctc tggcacaaga gcaaagtcct cactggagga 420  
ttccaaggg tcaactggga gagggcaggc agcagccaac ctctctaag tgggctgaag 480  
caggtgaaga aatggcagaa gacgcggtgg tggcaaaaag gagtcacaca ctccacctgg 540  
agacgccttg aagtaactgc acgaaatttg agggtaggcca ggcagttcta caacagccgc 600  
ctcacaggga gagccagaac acagcaagaa ctcatagac tggtagtatt accttcttca 660  
taatcccagg cttggggggc tgcgatggag tcagaggaaa ctcatgagc aacatctttg 720  
gtttttacaa tacaaattaa ctggaacgct aaattctagc ctgttaatct ggtcactgaa 780  
aaaaaaaaa tttttttttt ttcaaaaaac atagcttttag cttatttttt ttttctcttt 840  
gtaaaacttc gtgcatgact tcagctttac tcttgtcaag acatgccaag tgctgagtca 900  
ctaataaaga aaaaagaagt aaaggaagag tggttctgct tcttagcgct agcctcaatg 960  
acgacctag ctgcactttt cccctagtt gtgtcttgcg atgctaaagg acgtcattgc 1020  
acaatcttaa taaggtttcc aatcagcccc acccgctctg gccccacct caccctccaa 1080  
caaagattta tcaaatgtgg gatcttccca tgagtctcaa tattagagtc tcaaccccca 1140  
ataaatatag gactggagat gtctctgagg ctcatctgac c 1181

<210> 130  
<211> 778  
<212> DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 130

```

ctaccacttg tctattctgc tatatagtca gtccttacat tgctttcttc ttctgataga      60
ccaaactctt taaggacaag tacctagtct tatctatttc tagatcccc acattactca      120
gaaagttact ccataaatgt ttgtggaact gatttctatg tgaagacatg tgcccccttca      180
ctctgttaac tagcattaga aaaacaaatc ttttgaaaag ttgtagtatg cccctaagag      240
cagtaacagt tcctagaaac tctctaaaat gcttagaaaa agatttattt taaattacct      300
ccccataaaa atgattggct ggcttatctt caccatcatg atagcatctg taattaactg      360
aaaaaaaaata attatgccat taaaagaaaa tcatccatga tcttggtcta acacctgcca      420
ctctagtact atatctgtca catgggtctat gataaagtta tctagaaata aaaaagcata      480
caattgataa ttcaccaaatt tgtggagctt cagtatttta aatgtatatt aaaattaaat      540
tattttaaag atcaaagaaa actttcgtca tactccgtat ttgataagga acaaatagga      600
agtgtgatga ctcaggtttg ccctgagggg atgggccatc agttgcaaat cgtggaattt      660
cctctgacat aatgaaaaga tgagggtgca taagttctct agtagggtga tgatataaaa      720
agccaccgga gcactccata aggcacaaac tttcagagac agcagagcac acaagctt      778

```

&lt;210&gt; 131

&lt;211&gt; 207

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 131

```

actccgtatt tgataaggaa caaataggaa gtgtgatgac tcaggtttgc cctgagggga      60
tgggccatca gttgcaaata gtggaatttc ctctgacata atgaaaagat gaggggtgcat      120
aagttctcta gtaggggtgat gatataaaaa gccaccggag cactccataa ggcacaaact      180
ttcagagaca gcagagcaca caagctt      207

```

&lt;210&gt; 132

&lt;211&gt; 645

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 132

```

gggggtgatt tcactccccg gggctgtccc aggcttgtcc ctgctaccgc caccagcct      60
ttcctgaggc ctcaagcctg ccaccaagcc ccagctcct tctccccgca gggcccaaac      120
acaggcctca ggactcaaca cagcttttcc ctccaacccc gttttctctc cctcaacgga      180
ctcagctttc tgaagccctt ccagttcta gttctatctt tttcctgcat cctgtctgga      240
agttagaagg aaacagacca cagacctggt ccccaaaaga aatggaggca atagggtttg      300
aggggcatgg ggacgggggt cagcctccag ggtcctacac acaaatcagt cagtggccca      360

```

gaagaccccc ctcggaatcg gagcagggag gatggggagt gtgaggggta tccttgatgc 420  
 ttgtgtgtcc ccaactttcc aaatccccgc ccccgcatg gagaagaaac cgagacagaa 480

gggtgcagggc ccactaccgc ttctccaga tgagctcatg ggtttctcca ccaaggaagt 540

tttccgctgg ttgaatgatt ctttccccgc cctcctctcg cccagggac atataaaggc 600

agttgttggc acaccagcc agcagacgct cctcagcaa ggaca 645

<210> 133  
 <211> 457  
 <212> DNA  
 <213> Homo sapiens

<400> 133  
 gcctgtactc agccaagggt gcagagatgt tatatatgat tgctcttcag ggaaccgggc 60

ctccagctca caccacagct gctcaaccac ctcctctctg aattgactgt cccttctttg 120

gaactctagg cctgacccca ctccttgcc ctcacagccc acgattcccc tgacccgact 180

ccctttccca gaactcagtc gcctgaaccc ccagcctgtg gttctctcct aggccctcagc 240

ctttcctgcc ttgactgaa acagcagtat cttctaagcc ctgggggctt ccccgggccc 300

cagccccgac ctagaaccgc ccgctgcct gccacgctgc cactgccgct tcctctataa 360

agggaccta ggcgtccggc ccaggggctc cgcacagcag gtgaggctct cctgccccat 420

ctccttgggc tgcccgctgct tcgtgctttg gactacc 457

<210> 134  
 <211> 973  
 <212> DNA  
 <213> Homo sapiens

<400> 134  
 gcagcaaadc agaatggcag ttgattcat ggtgctgaga ctggagggtc ctctgctgta 60

ggctcagaat atgtctaagc aattgaggaa tgtctcagaa aacgtggggc tagtgtgcca 120

tatttatctg caaagccatt ttccctccct aattctgatt ggataagggc attacagttg 180

acttagcaaa acctgctggc tgctcctggg gaagtcccat gttgcagact cgaaggattt 240

atttattgta gcctccaagt tacggaattt cctctgctc ctcttttttt ggtaatagtg 300

aattagggtt cactttccaa aacatgaact gtttcttgaa aaaaagaact tcattgcata 360

tagaaaaaaa caaagggtgc aatccattct aactataatg ctttttctca acacttaaac 420

ttttacagtt actttcagag gttatttttc aaaatatccc cagtaataga aatttttcat 480

cctttatagg taaacctaatt tttttgtaa cagcaagttg tgccctgatta ttagaacagt 540

gatttacctg gacagtcctc cttgatcaaa tactataaag taataggact ggcctgcttt 600

gacagggcca aagatctgga actggcaagt tttaaataat tcaataaatg ctttgatcat 660

tcataacacc attagattaa gtaaatagcc tccaacataa ctattttgag ggaaaacatt 720

gctcatttgg gtatctgatt tgtggtgtgt taaaacaagt ttcacgtctt atagcagtcc 780  
 ctgaatgaaa acatcataag atggtatcta gaatggtgtg agaaaaggat tcatagctat 840  
 cctaggggta ttgtaaaaaa caaaggggtgc tttttgagga aatgaattta aaagcggggg 900  
 ggcacgcata gagacagacc ttgggaaagt agcttgagac agaagggaaa caggttgatt 960  
 tacgatgggg ttc 973

<210> 135  
 <211> 333  
 <212> DNA  
 <213> Homo sapiens

<400> 135  
 gctaccttaa gaaggctggt taccatctgg gttttcacag tgctttcaca ttcttatcac 60  
 tttcaacact actgcaaata ggaagggaca gtaacattta gaagagaaca aaacagaaac 120  
 tcttgaagc aggaaagggtg catgactcaa agagggaaat tcctgtgcca taaaaggatt 180  
 gctggtgtat aaaatgctct atatatgcca attatcaatt tcctttcatg ttcagcattt 240  
 ctactccttc caagaagagc agcaaagctg aagttagcag cagcagcacc agcagcaaca 300  
 gcaaaaaaca aacatgagtg tgaagggcac gcc 333

<210> 136  
 <211> 1048  
 <212> DNA  
 <213> Homo sapiens

<400> 136  
 ggtgaccaag aatgtgagca agcccaggca cagccactgt gggcgccctga ccaaacagca 60  
 ctaaatttgt gtgggacatg atcccagagg tgtgtggctt caccctcaa cgagtggcgt 120  
 ggcattggagt tactgaatct ccaagggtcaa acaggccctc aaattcatca agaaaagggt 180  
 agggacaaac atctgtacca agagaaggca ggaggagctg agcaacgtcc tgctgccatg 240  
 aggaaagcag ctgccaagaa ggactgagcc cctgccatct gcctataatg aaagctttgc 300  
 aaaataaaat aaatataaaa taaagtaata aaattaaatt aaatttaaaa ataaaataaa 360  
 gcaaaaacaa ataaaatata taaagtaaaa attgttaaaa tgcaaaaaca tatggacata 420  
 aatacagaaa cacagggaaa cttcttttagg cactcattta caggtaaaaa tatgaaattg 480  
 aataaaggtc atctggtgtc aaataatata ggccttatct attataagag tttggactga 540  
 aaagcaaaag tgagataaca aaaaaagct tttcagaata ttattttgta tagatatgtg 600  
 aaggatgaag ggtgggtgaa aggacaaaa acagaaacac agtcttcctg aatgaatgac 660  
 aatcagaatt ccgctgcccc aagtagtccg acaattaaat ggatttctag gaaaagctac 720  
 cttaagaagg ctggttacca tctgggtttt cacagtgtct tcacattctt atcactttca 780



acactactgc aaataggaag ggacagtaac atttagaaga gaacaaaaca gaaactcttg 840  
gaagcaggaa aggtgcatga ctcaaagagg gaaattcctg tgccataaaa ggattgctgg 900  
tgtataaaat gctctatata tgccaattat caatttcctt tcatgttcag cattttotact 960  
ccttccaaga agagcagcaa agctgaagtt agcagcagca gcaccagcag caacagcaaa 1020  
aaacaaacat gagtgtgaag ggcatggc 1048

<210> 137  
<211> 504  
<212> DNA  
<213> Homo sapiens

<400> 137  
agggggcccc gcagcagccc cttggcttcc cttctccctt gcctccccctc cggggctccg 60  
gttcagaggc actctgggcg cctgctacag cttccaaact gcgccgcttc cttcttcggc 120  
agaaaaggac ttctagatgc ggcggcggcg gcggcgcgga ctcaggacag cgccccctcc 180  
cctaacggcc gcctctccct ctccccctcg ccgccccgg ctccccacc tctgggaagg 240  
cgctgggggt gtggccaggg accggtataa agtccggggg agccggtccc gggcagccgc 300  
tcagccccct gcccctcgcc gccgcgccgc tgccctgggccc gggccgagga tgcggcgag 360  
cgcctcggcg gccaggcttg ctccctccgg cagcctgct aacttcccc gctacgtccc 420  
cgttcgcccg ccgggccgcc ccgtctcccc gcgcctccg ggtcgggtcc tccaggagcg 480  
ccaggcgctg ccgccgtgtg ccct 504

<210> 138  
<211> 1042  
<212> DNA  
<213> Homo sapiens

<400> 138  
gatcacaaca gctctacaaa tacacaatga ttacaaggaa tgggtgcccc ctggagtgtg 60  
tcaacgcaaa acttgacacat tgcaagtggc aatctcccag gcctgcctcc ctccacgagt 120  
gggtctgaat gggcctgaga ggcaaacatc caagaaggag gaagaggctc ggcggcacct 180  
ccctccccgg gagttctgct gattocatct tggggaagca gggtagacca gggcccaaat 240  
gcgcctggg gagattgcgg gggcgggaga ggttgcaagg ggcaagtggc aagagcctgt 300  
taacgtctta gggcctccag gcctttctgt gccctagct gtgcctgtac gctttacccc 360  
acctcaggag gcttggtctc cagcggttga ggctggaagc accgggggtgc ggtggaaagg 420  
gctctgtcca ggaagaccgg atccgcagag ccgggagtcg gggctaggaa gtccctttct 480  
cggtagggaga ctgaggccgc cttggcgggg cgggacgaga ctctccgag gtcgggaaag 540  
ggggccccgc agcagcccct tggcttccct tctcccttgc ctccccctcg gggctccggt 600

tcagaggcac tctgggcgcc tgctacagct tccaaactgc gccgcttcct tcttcggcag 660  
aaaaggactt tcagatgcgg cggcggcgcc ggcggcgact caggacagcg cccctcccc 720  
taacggccgc ctctccctct cccctcgcc cgcccggt cccccacctc tgggaaggcg 780  
ctgggggtgt ggccaggac cggtataaag tccgggggag ccggtcccgg gcagccgctc 840  
agccccctgc cctcgccgc ccgccgctg cctgggcccgg gccgaggatg cggcgagcg 900  
cctcggcggc caggcttgct ccctcggca cgcctgctaa cttccccgc tacgtccccg 960  
ttcgccgcc gggccgcccc gtctccccgc gccctccggg tcgggtcctc caggagcgcc 1020  
aggcgctgcc gccgtgtgcc ct 1042

<210> 139  
<211> 24  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 139  
tcgtcgtttt gacgttttgc cgtt 24

<210> 140  
<211> 24  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 140  
tcgtcgtttt gtcgtttttt tcga 24

<210> 141  
<211> 24  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 141  
tcgtcgtttc gtcgtttcgt cgtt 24

<210> 142  
<211> 24  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

&lt;223&gt; Immunostimulatory nucleic acid

&lt;400&gt; 142

tcgctcgtttc gtcgttttgt cggt

24

&lt;210&gt; 143

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; artificial sequence

&lt;220&gt;

&lt;223&gt; Immunostimulatory nucleic acid

&lt;400&gt; 143

tcgctcgtttt tcggtcgttt t

21

&lt;210&gt; 144

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; artificial sequence

&lt;220&gt;

&lt;223&gt; Immunostimulatory nucleic acid

&lt;400&gt; 144

tcgctcgtttt tcgtgcgttt tt

22

&lt;210&gt; 145

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; artificial sequence

&lt;220&gt;

&lt;223&gt; Immunostimulatory nucleic acid

&lt;400&gt; 145

tcgctcgtttt cggcggccgc cg

22

&lt;210&gt; 146

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; artificial sequence

&lt;220&gt;

&lt;223&gt; Immunostimulatory nucleic acid

&lt;400&gt; 146

tcgctcgtttt acggcgccgt gccg

24

&lt;210&gt; 147

&lt;211&gt; 24

&lt;212&gt; DNA

<213> artificial sequence  
<220>

<223> Immunostimulatory nucleic acid

<220>

<221> misc\_feature

<222> (2)..(2)

<223> N = 5-methylcytosine

<220>

<221> misc\_feature

<222> (5)..(5)

<223> N = 5-methylcytosine

<220>

<221> misc\_feature

<222> (13)..(13)

<223> N = 5-methylcytosine

<220>

<221> misc\_feature

<222> (21)..(21)

<223> N = 5-methylcytosine

<400> 147

tngtngtttt gtngttttgt ngtt

24

<210> 148

<211> 27

<212> DNA

<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<220>

<221> misc\_feature

<222> (2)..(2)

<223> N = 5-methylcytosine

<220>

<221> misc\_feature

<222> (5)..(5)

<223> N = 5-methylcytosine

<220>

<221> misc\_feature

<222> (7)..(7)

<223> N = 5-methylcytosine

<220>

<221> misc\_feature

<222> (11)..(11)

<223> N = 5-methylcytosine

<220>

<221> misc\_feature

<222> (13)..(14)

<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (16)..(16)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (19)..(19)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (22)..(22)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (26)..(27)  
<223> N = 5-methylcytosine

<400> 148  
tngtngtgt ntnngnttnt tnttggn

27

<210> 149  
<211> 21  
<212> DNA  
<213> artificial sequence

<220>  
<223> Immunostimulatory nucleic acid

<220>  
<221> misc\_feature  
<222> (2)..(2)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (8)..(8)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (10)..(10)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (13)..(13)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (16)..(16)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (20)..(20)

<223> N = 5-methylcytosine  
<400> 149  
gngtttgntn ttnttnttgn g

21

<210> 150  
<211> 20  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<220>  
<221> misc\_feature  
<222> (2)..(4)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (8)..(8)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (12)..(12)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (15)..(16)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (19)..(19)  
<223> N = 5-methylcytosine

<400> 150  
gnnnaagntg gnatnngtna

20

<210> 151  
<211> 15  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 151  
tcctggcggg gaagt

15

<210> 152  
<211> 42  
<212> DNA  
<213> artificial sequence

<220>

WO 2004/094671

PCT/US2004/012788

<400> 152  
gaaactcgag ccaccatgag acagactttg ccttgatatct ac 42

<210> 153  
<211> 37  
<212> DNA  
<213> artificial sequence

<220>

<223> Oligonucleotide

<400> 153  
gaaagaattc ttaatgtaca gagtttttgg atccaag 37

<210> 154  
<211> 24  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 154  
tgctgctttt gtgcttttgt gctt 24

<210> 155  
<211> 20  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 155  
tccatgacgt tcctgatgct 20

<210> 156  
<211> 20  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 156  
tccatgagct tcctgatgct 20

<210> 157  
<211> 20  
<212> DNA  
<213> artificial sequence

WO 2004/094671

PCT/US2004/012788

<223> Immunostimulatory nucleic acid

<220>

<221> misc\_feature

<222> (8)..(8)

<223> N = 5-methylcytosine

<400> 157

tccatgangt tcctgatgct

20

<210> 158

<211> 22

<212> DNA

<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 158

tcgtcggtttt cggcgcgcgcg cg

22

<210> 159

<211> 21

<212> DNA

<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 159

gggggacgacg tcgtgggggg g

21

<210> 160

<211> 22

<212> DNA

<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 160

tgctgctttt cggcggccgc cg

22

<210> 161

<211> 21

<212> DNA

<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 161

gggggacgacg tgctgggggg g

21